0	pseudomona aeruginosa infect cystic fibrosi occurr precipit antibodi pseudomona aeruginosa relat concentr sixteen serum protein clinic radiograph statu lung signific pseudomona aeruginosa infect respiratori tract 9 cystic fibrosi patient studi mean immunoelectrophoret analysi patient sera number precipitin pseudomona aeruginosa concentr 16 serum protein addit clinic radiograph statu lung evalu use 2 score system precipitin pseudomona aeruginosa demonstr sera maximum number one serum 22 concentr 12 serum protein significantli chang compar match control person notabl igg iga elev acut phase protein chang latter suggest activ tissu damag concentr 3 acut phase protein notabl haptoglobin correl number precipitin suggest respiratori tract infect patient mani precipitin accompani tissu damag infect patient precipitin result indic protect valu mani precipitin tissu respiratori tract
1	amylas content mix saliva children salivari amylas level determin normal subject birth adult life children condit sometim associ low pancreat amylas malnutrit coeliac diseas cystic fibrosi mix saliva collect care standardis condit amylas measur method dahlqvist wide scatter valu 84 normal subject concentr rose low level birth reach adult level age 6 month 1 year salivari amylas activ rose normal ten week one prematur infant fed milk gastrostomi thirteen children coeliac diseas 9 children cystic fibrosi mostli normal salivari amylas concentr six 12 malnourish children jejun villou atrophi uncertain aetiolog low level rose normal recoveri began
2	clinic studi diagnosi cystic fibrosi instrument neutron activ analysi sodium nail clip articl report possibl use instrument neutron activ analysi inaa sodium nail clip diagnos cystic fibrosi cf children adult detect heterozygot screen neonat period nail clip 1322 newborn 22 cf patient two newborn 52 healthi control 22 heterozygot analyz discrimin cf patient control found precis individu one year age inaa nail clip accept diagnost test cf age heterozygot could detect method first five day life big overlap valu normal newborn cf children make method invalu earli screen cf
3	methodolog studi diagnosi cystic fibrosi instrument neutron activ analysi sodium nail clip instrument neutron activ analysi inaa nail clip use develop diagnost method cystic fibrosi cf cf patient control three year old nail clip sampl test differ error result studi precis collect routin outlin sodium easili wash nail clip risk sodium contamin nail seem small sodium distribut nail inhomogen sodium content vari also nail nail person good evid increas sodium nail cf patient come sweat seem basic intrins sodium level nail cf patient control precis accuraci inaa determin sodium nail consid satisfactori conclud inaa sodium concentr nail clip suitabl method aid diagnosi cf precis collect routin use
4	proteolyt activ duoden juic infant children adult capac duoden juic hydrolys casein trichloroacet acidsolubl peptid investig control group 11 infant children 7 adult 5 children pancreat diseas 10 children enterogen malabsorpt coeliac diseas cow milk protein intoler proteolyt activ per ml duoden juic fast condit great healthi infant children healthi adult 500600 mg caseinmlhour good correl trypsin content proteolyt activ duoden juic pancreat insuffici proteolyt activ extrem low measur 3 patient trypsin activ wherea enterogen malabsorpt within rang control
5	pseudomona aeruginosa infect cystic fibrosi distribut b lymphocyt relat humor immun respons influenc chronic ps aeruginosa infect occurr bone marrowderiv lymphocyt b cell thymusderiv lymphocyt cell peripher blood studi 2 group patient cystic fibrosi one group 9 patient suffer chronic ps aeruginosa infect respiratori tract produc multipl ps aeruginosa precipitin demonstr mean cross immunoelectrophoresi group 9 patient never harbour ps aeruginosa respiratori tract present demonstr precipitin bacteria lymphocyt examin presenc 2 surfac marker b cell receptor c3 complement compon eac rosetteform surfac immunoglobulin immunofluoresc stain presenc 1 surfac marker cell spontan bind sheep red blood cell e rosetteform bt cell ratio nearli ident 2 group patient wherea total number b cell signific higher patient chronic ps aeruginosa infect number ps aeruginosa precipitin per serum significantli posit correl total number cell whera correl total number b cell insignific
6	pseudomona aeruginosa infect cystic fibrosi relationship mucoid strain pseudomona aeruginosa humor immun respons occurr pseudomona aeruginosa respiratori tract 70 cystic fibrosi patient occurr precipitin ps aeruginosa sera patient investig one year mean monthli bacteriolog examin tracheal secret mean cross immunoelectrophoresi polyval ps aeruginosa antigen sera patient oneyear period preval rate patient harbour ps aeruginosa 64 per cent newli colon patient intermitt colon patient nonmucoid strain predomin wherea mucoid strain predomin chronic colon patient occurr mucoid strain especi chronic colon patient associ significantli higher number precipitin ps aeruginosa occurr nonmucoid strain male chronic colon mucoid strain present significantli higher number precipitin femal chronic colon mucoid strain number precipitin correl durat chronic colon ps aeruginosa male contrast femal result accord hypothesi mucoid substanc could virul factor might inhibit opson effect precipitin mucoid cell complement depend lysi cell herebi favour mucoid strain expens nonmucoid strain respiratori tract cystic fibrosi patient
7	epidemiolog investig respiratori tract bacteriolog patient cystic fibrosi seventi patient cystic fibrosi treat outpati cystic fibrosi clinic follow one year monthli bacteriolog examin tracheal secret daili impress obtain laboratori express mean point preval rate pseudomona aeruginosa 44 per cent staphylococcu aureu 39 per cent haemophilu influenza 17 per cent diplococcu pneumonia 8 per cent miscellan bacteria mainli enterobacteriacea 8 per cent fluctuat bacteriolog describ addit epidemiolog term one examin studi period preval rate 90 per cent patient harbour st aureu 64 per cent ps aeruginosa mainli mucoid strain 64 per cent h influenza 37 per cent pneumonia 30 per cent miscellan bacteria mainli enterobacteriacea pattern found age group minor agedepend modif especi regard enterobacteriacea ps aeruginosa predomin regard chronic colon reflect difficult therapeut problem period preval rate 39 per cent contrast st aureu 10 per cent h influenza 1 per cent st aureu predomin regard new colon recolon reflect problem prevent incid rate new colon recolon per risk group 84 per cent follow h influenza 62 per cent ps aeruginosa 43 per cent pneumonia 30 per cent result show bacteriolog problem cystic fibrosi still consider regard therapi well prevent although mani speci may colon respiratori tract patient main clinic problem concern ps aeruginosa st aureu reason discuss
8	occurr cystic fibrosi celiac sprue within singl sibship famili present celiac sprue cystic fibrosi occur within sibship cousin index case also discov celiac sprue genet incid condit review estim likelihood associ occur basi chanc famili 1 50000
9	cystic fibrosi patient kartagen syndrom patient exhibit featur kartagen syndrom cystic fibrosi author knowledg repres third report combin cystic fibrosi exclud diagnosi kartagen syndrom made
10	coexist respiratori allergi cystic fibrosi preval respiratori allergi effect cours cystic fibrosi cf studi 63 patient fifteen patient 24 respiratori allergi defin histori physic examin posit allergi skin test nasal peripher eosinophilia revers airway obstruct serum immunoglobulin 15 allerg cf 22 nonallerg cf patient elev compar normal agematch control allerg cf patient significantli higher ige level mean 598 intern unit iu compar 281 iu igg igm iga level similar two cf group clinic condit allerg cf patient shwachman score better nonallerg suggest modul effect respiratori allergi sever diseas
11	letter silverrussel dwarfism cystic fibrosi taussig et al report case 6yearold boy russel variant silverrussel syndrom concomit cystic fibrosi would like describ anoth patient combin diseas pattern clinic find patient accord silverrussel syndrom cours possibl develop cystic fibrosi patient entir accident although coincid would statist rare event establish possibl relationship two condit would depend report similar case
12	cystic fibrosi black washington dc incid characterist intens search black cystic fibrosi cf washington dc period 1962 1971 disclos 16 black patient eight born district columbia decad calcul incid cf least one 17033 black newborn clinic cours patholog chang black cf similar white genet consider point autosom recess inherit black gener accept white diseas
13	present statu intrauterin diagnosi genet defect prenat diagnosi genet disord receiv increas attent past sever year rapid expans knowledg basi genet diseas develop reliabl diagnost method led rapid advanc intrauterin diagnosi larg number inherit disord prenat diagnosi initi use determin presenc down syndrom chromosom abnorm determin fetal sex pregnanc risk number sever xlink recess disord shortli thereaft becam clear techniqu could appli prenat diagnosi number inborn error metabol recent number new techniqu develop may prove great valu prenat diagnosi number sever congenit malform could diagnos prior birth goal review defin past achiev futur goal present limit intrauterin diagnosi first section deal gener approach use prenat diagnosi genet disord follow discuss specif applic basic techniqu intrauterin diagnosi chromosom abnorm inborn error metabol approach prenat diagnosi genet disord includ amniocentesi direct indirect visual fetu analysi matern blood urin sampl fetal tissu applic prenat genet diagnosi includ xlink recess disord chromosom abnorm inborn error metabol disord lipid metabol disord carbohydr metabol disord mucopolysaccharid metabol disord amino acid metabol miscellan disord cystic fibrosi techniqu provid parent method children without fear child specif deform addit develop approach increas number disord detect utero potenti treatment genet disord unlimit
14	polypoid cervic cystic fibrosi patient receiv oral contracept three 4 women cystic fibrosi clinic use combin form oral contracept develop acut polypoid cervic one woman polyp recur reinstitut medic resolut polyp instanc discontinu drug 2 3 affect women coincident deterior respiratori statu therefor suggest cystic fibrosi patient use oral contracept observ close regard pulmonari gynecolog statu
15	ataxiatelangiectasia chronic pneumonia sinus adenoid hypoplasia syndrom ataxiatelangiectasia character ataxia progress neurolog degener cutan conjunctiv telangiectasi immunolog defici roentgenolog evid chronic pulmonari sinu infect decreas lymphoid tissu usual present sinopulmonari abnorm resembl cystic fibrosi small adenoid mass may differenti aid
16	pulmonari involv adult cystic fibrosi cystic fibrosi longer rare adult lung main target organ basic lesion bronchial obstruct lead bronchiectasi interstiti infiltr cystlik chang characterist roentgenographi complic includ pulmonari hypertens pneumon hemorrhag pneumothorax littl correl exist respiratori tract pancreat gastrointestin involv despit similar pathogenesi pulmonari cystic fibrosi adult alway resembl condit children must differenti chronic interstiti diseas
17	letter select inhibit phagocyt activ rabbit alveolar macrophag cystic fibrosi serum far rabbit alveolar macrophag concern concentr homozyg cf serum use experi even greater fourfold concentr biggar associ state requir normal phagocytosi increas dilut homozyg cf sera either hank balanc salt solut normal human serum thu decreas concentr increas capac rabbit alveolar macrophag phagocyt kill pseudomona aeruginosa increas concentr opposit effect suspens rabbit alveolar macrophag human serum reduc phagocyt activ activ reduc human cf serum human normal serum unexpect high human serum concentr like toxic rabbit alveolar macrophag inhibit phagocytosi absent homozyg cf serum 24 hour old previous heat frozen use observ dilut increas macrophag phagocyt abil feel data demonstr presenc labil inhibitor rather defici sinc well known cf patient normal elev concentr immunoglobulin includ iga sera pulmonari secret respond infect iga shown essenti alveolar macrophag phagocytosi pseudomona aeruginosa cannot agre inhibit due iga defici also note sera use experi biggar associ store 70 degre c perhap may account differ result
18	letter plasma arginin esteras activ cystic fibrosi assay serum group cystic fibrosi patient oral arginin therapi group cystic fibrosi patient receiv treatment total arginin esteras activ untreat cystic fibrosi patient significantli lower serum arginin esteras activ normal control cystic fibrosi carrier cystic fibrosi patient receiv oral arginin therapi signific differ arginin esteras activ normal control cystic fibrosi carrier cystic fibrosi patient treat arginin recent observ differ arginin esteras plasma control patient electrofus polyacrylamid gel six activ band could detect plasma control wherea five could detect plasma patient work defici trypsinlik activ mix saliva patient cystic fibrosi reproduc anoth laboratori coburn recent confirm work defici arginin esteras serum patient cystic fibrosi present defici arginin esteras cystic fibrosi work hypothesi understand basic defect variat ph sodium chlorid content employ test 6 patient without diagnosi cystic fibrosi found alter level arginineesteras activ major differ two studi result control subject dr rao neglect mention laboratori unabl confirm find
19	rel sensit close volum children asthma cystic fibrosi abil detect abnorm lung function children asthma cystic fibrosi measur close volum studi 205 children flow volum characterist routin spirometri bodi plethysmographi arteri oxygen tension studi comparison close volum close volum less sensit detect diseas residu volum total lung capac ratio maximum expiratori flow volum curv arteri blood gase
20	bronchial asthma allerg rhiniti associ inhal pancreat extract five parent children cystic fibrosi develop allerg bronchospasm inhal pancreat extract sprinkl children food posit histori allergi past histori asthma 5 parent asthma respond bronchodil use face mask prepar meal prevent recurr date asthma precipit inhal pancreat extract seen patient cystic fibrosi
21	specif airway resist perinat period adulthood alter childhood pulmonari diseas airway resist lung volum measur modif plethysmograph method brisco duboi 1 calcul specif airway resist sraw 263 control subject rang age newborn 54 year mean sraw lowest newborn period increas rapidli adult level first year life age group mean sraw lower femal male control subject sraw greater 8 sec cm h2o decreas mean sraw 42 sec cm h2o femal 5 9 year age 35 sec cm h2o 18 year age parallel sexual matur similar chang observ male direct correl sraw clinic observ found young patient variou degre pulmonari involv cystic fibrosi
22	human respiratori tract secret 1 mucou glycoprotein secret cultur nasal polyp epithelium subject allerg rhiniti cystic fibrosi ciliat nasal polyp epithelium patient allerg rhiniti patient cystic fibrosi maintain organ cultur 168 hour explant epithelium retain morpholog characterist incorpor 35so4 3h blood group specif glycoprotein secret medium throughout cultur period label mucou glycoprotein solubil reduct alkyl purifi gel filtrat chromatographi purifi glycoprotein separ diethylaminoethyl deae cellulos column 3 blood group activ fraction fraction similar amino acid composit differ nacetyl neuramin acid fucos content rel incorpor 35so4 3hglucosamin blood group glycoprotein polyp epithelium patient allerg rhiniti cystic fibrosi indistinguish mani respect howev 35so4 per 3h ratio 3 glycoprotein fraction patient cystic fibrosi exceed correspond fraction secret patient allerg rhiniti
23	lung elast recoil cystic fibrosi pressurevolum behavior lung studi 24 patient cystic fibrosi isovolum flowpressur relationship measur 7 patient modif flowvolum test evalu detect flow reduct separ group 63 patient rel result control group 31 normal subject 13 24 patient grossli abnorm pressurevolum curv excess stiff lung near maximum volum loss recoil lower volum close volum patient often high enough caus signific disturb ga exchang elev close volum quantit explain low valu elast recoil modifi flowvolum test detect mild flow reduct mani patient otherwis normal pulmonari function test loss recoil per se account low maximum expiratori flow sinc upstream resist high howev pressureflow curv effortdepend high lung volum even patient sever airway obstruct show time constant empti vari wide patient conclud deterior lung function cystic fibrosi involv airway obstruct worsen ga trap explain progress loss lung elast recoil
24	use water vapor treatment lower respiratori diseas use bland aerosol particularli mist tent treatment lower respiratori diseas review convinc evid efficaci found surpris evid mist tent deposit littl water lower respiratori tract mist tent may detriment case bacteri contamin caus bronchospasm
25	plasma arginin esteras activ cystic fibrosi plasma arginin esteras activ measur 13 young adult patient cystic fibrosi 36 control subject enzym activ treat plasma chloroform ellag acid manner describ rao associ 1 differ found either arginin esteras activ patient cystic fibrosi control subject degre activ inhibit soybean trypsin inhibitor thu find rao associ defici arginin esteras activ plasma patient cystic fibrosi confirm
26	pulmonari physiotherapi pediatr age group spite widespread clinic impress pulmonari physic therapi includ breath exercis help pediatr age group object demonstr valu variou maneuv part lack evid volum sputum produc short period time patient cystic fibrosi increas cough accompani postur drainag pulmonari physic therapi longterm effect variou maneuv cours chronic pulmonari diseas remain unknown
27	studi neutron activ analysi measur sodium nail screen test cystic fibrosi present studi point simplic eas use fingernail toenail measur electrolyt level test cystic fibrosi procedur variou effect rang valu differ categori healthi diseas subject discuss limit method indic
28	upper respiratori tract cystic fibrosi earnosethroat survey 50 children earnosethroat survey carri 50 children age 4 10 year cystic fibrosi 10 shown transient deaf associ eustachian tube dysfunct confirm case secretori otiti media 10 children 20 found nasal polyp gave histori polypectomi though high incid middl ear problem children cystic fibrosi report usa neither deaf secretori otiti media found problem group studi
29	letter muscular perform vitamin e cystic fibrosi patient cystic fibrosi tocopherol defici presum result steatorrhoea evid possibl muscular involv cystic fibrosi patient clinic muscular weak wast mani patient biochem creatinuria creatinepoor diet revers find ingest tocopherol ester accompani decreas creatin plasma increas creatin muscl patholog focal lesion skelet muscl resembl nutrit muscular dystrophi ceroid pigment smooth muscl muscl strength measur bulb ergograph 45 patient cystic fibrosi attend clinic babi hospit columbia presbyterian medic center new york doubleblind studi half case receiv tocopherol oral remaind placebo signific increas muscl strength found patient receiv tocopherol period 6 month compar placebo group blood tocopherol level treat group return normal
30	influenc mist tent therapi sputum viscos water content cystic fibrosi hypothesi mist tent therapi decreas viscos sputum direct liquefact sputum lower respiratori tract test 6 patient cystic fibrosi cf first night patient slept without mist tent first morn sputum collect analysi follow 2 night patient randomli alloc tent suppli either jet ultrason nebul earli morn sputum analys volum viscos water content dna content index purul relat sputum viscos dna content water content volum furthermor consist relat sputum viscos volum expector presenc absenc 8hour stay tent either method water nebul result therefor suggest mist therapi consist influenc sputum viscos volum patient cf sputum water content 90 increas water content influenc viscos
31	chronic suppur lung diseas sister mimick cystic fibrosi two sister describ fatal chronic obstruct lung diseas unknown origin lung condit clinic histolog indistinguish cystic fibrosi salivari gland show patholog chang expect cystic fibrosi neither child abnorm sweat electrolyt bowel symptom pancrea normal necropsi
32	plasma protein meconium normal infant babi cystic fibrosi cellulos acet strip electrophoresi found suffici reliabl differenti normal cf meconium mark differ obtain quantit immunoelectrophoret method employ normal meconium shown contain alpha1antitrypsin alpha1antichymotrypsin sampl contain low concentr albumin measur amount varieti plasma protein suggest quantit immunoelectrophoresi could use mean confirm diagnosi cf posit result obtain meconium specimen screen test strip
33	letter cystic fibrosi coeliac diseas coexist cystic fibrosi coeliac diseas recent report suggest cystic fibrosi may predispos later develop coeliac diseas diagnosi coeliac diseas larg depend upon demonstr histolog chang small intestin jejun biopsi may distress small child suggest food protein antibodi studi may valu investig children cystic fibrosi gluten sensit suspect follow case decis perform jejun biopsi made studi posit food protein antibodi cereal antigen wheat oatmeal gluten rumin antigen cow milk calf serum persist detect patient blood jejun biopsi show partial villou atrophi shorten broaden branch villi satisfactori clinic improv gluten restrict
34	immunochem method detect albumin human meconium simpl immunochem techniqu util singl radial immunodiffus demonstr albumin human meconium describ comparison techniqu wide use sulphosalicyl acid precipit method report also attempt determin normal level albumin meconium
35	proceed neonat periton neonat periton remain danger condit factor complic diagnosi manag includ low incid divers aetiolog factor found sever underli associ diseas 28 case present sinc 1957 southmead gener hospit review thirteen aetiolog factor relat mother babi found 13 infant prematur 10 sever respiratori problem birth matern hydramnio present 7 6 babi exchang transfus commonest find gangren volvulu cystic fibrosi combin factor often present usual present biliou vomit abdomin distens failur pass normal meconium 4 case distend abdomen birth plain abdomin xray great diagnost valu pneumoperitoneum diagnost absent earli film treatment surgic close liaison paediatrician see babi first essenti assess result point mani babi small andor suffer seriou condit haemolyt diseas cystic fibrosi gangren volvulu 8 case consid unfit surgeri 20 submit surgeri 12 surviv mostli latter part seri
36	proceed experi ionspecif electrod measur sweat chlorid orion skin chlorid measur system evalu children variou age method found give reproduc result nearli case failur obtain reproduc relat inadequ sweat subject like occur first week life gener clear distinct healthi children patient cystic fibrosi method simpl reliabl provid oper reason experi instrument one distinct advantag method compar use filter paper speed result obtain design instrument made method complet safe patient notic slight tingl iontophoresi mean sweat chlorid normal 269 meql compar 1023 meql patient cystic fibrosi
37	screen cystic fibrosi examin meconium valu detect albumin meconium screen procedur cystic fibrosi cf assess 34228 sampl south wale north staffordshir 4year period simultan four method detect albumin evalu 12 case cf detect detect rate 60 incid diseas popul screen 1 1850 confirm clinic test procedur case cf without impair pancreat function like miss screen method depend presenc albumin meconium
38	cystic fibrosi 3 pakistani children caucasian european origin cystic fibrosi cf remain commonest recogn autosom recess disord appear rariti among colour race time record may suggest associ cf white recent year howev instanc cf children describ whose racial origin negroid mongoloid noneuropean caucasoid present case report concern 3 pakistani children born birmingham cf confirm 2 3 case 1 2 brother sister present incid diseas among asian immigr west midland approxim 110000
39	ultrastructur vitro format hydroxyapatit submandibular saliva children cystic fibrosi calcium phosphat precipit submandibular saliva patient cystic fibrosi elev calcium concentr shown electron microscopi transform stand vitro amorph calcium phosphat globul stellar cluster hydroxyapatit crystal amorph globul appear form regular nucleat point fine network unknown natur hydroxyapatit crystal format confirm electron diffract pattern chemic solubl zymogengranul spherul inclus bodi present greatli increas number cystic fibrosi submandibular saliva disintegr stand homogen appear bead hollow sphere
40	paneth cell metaplasia diseas colon rectum paneth cell metaplasia variabl featur divers diseas colon rectum paneth cell numer atroph mucosa chronic ulcer coliti juvenil polyp around colloid mucin carcinoma moder number paneth cell found cystic fibrosi pancrea ambeic coliti villou adenoma paneth cell spars diverticul adenomat polyp around nonmucin carcinoma studi paneth cell metaplasia associ mucu hypersecret mucin deposit suggest one function paneth cell control gastrointestin mucin viscos
41	anosm hypogonadotrop hypogonad kallman syndromea case histori complic cystic fibrosi associ anomasia hypogonad report increas frequenc past sever year case report kallman syndrom emphas import test anomasia patient manifest abnorm sexual develop
42	famili respons cystic fibrosi effect cystic fibrosi 50 victorian famili one affect children examin studi carri august 1972 februari 1973 social emot problem experienc famili member particularli patient mother report age social embarrass symptom awar differ creat major problem patient uncertainti prognosi doubt prospect employ special relev teenag suggest patient given ampl opportun earli adolesc onward discuss aspect diseas appropri provis made total care adult patient mani problem depress feel isol physic demand constant treatment parent children cystic fibrosi experi probabl similar confront parent chronic ill handicap children special difficulti stem genet basi cystic fibrosi knowledg eventu fatal outcom role profession member medic team touch particularli relat genet counsel provis practic emot support parent comment made establish lay organis financi strain associ obtain regular medic attent look suggest made minim econom problem certain vulner famili
43	cystic fibrosi effect media cultur cystic fibrosi fibroblast atpas activ membran associ atpas activ human red blood cell examin follow addit spent fibroblast cultur media normal cystic fibrosi cell line comparison normal unspent media cystic fibrosi media consist depress atpas activ
44	cystic fibrosi demonstr abnorm mucopolysaccharid cultur lymphoid line cultur lymphoid cell homozygot heterozygot cystic fibrosi could distinguish normal 1 growth pattern gross clump 2 rel increas dermatan sulfat normal total mucopolysaccharid content line deriv genet mucopolysaccharidos also characterist total mucopolysaccharid content markedli increas observ support hypothesi cellular disturb cystic fibrosi resid cellular region whose function would alter mucopolysaccharid composit
45	hereditari disord intestin transport hereditari abnorm intestin transport rare condit disproportion import inform give regard mechan intestin absorpt man main disabl usual diarrhoea may abnorm lack absorpt essenti nutrient occasion absorpt compound excess due failur normal control mechan diseas experi natur cannot exactli simul laboratori anim thu may occas give inform unobtain sourc often howev confirm mechan absorpt studi detail smaller mammal probabl applic man diseas associ defect transport proxim renal tubul well gut furnish evid therefor transport process close relat gut kidney least import step transport ident two site disord includ disord carbohydr absorpt hereditari defect amino acid absorpt hereditari defect absorpt fat hereditari disord intestin absorpt electrolyt hereditari defect vitamin b12 absorpt
46	elast sputum low shear rate elast sputum elast sputum determin use weissenberg rheogoniomet oscillatori test frequenc 001 08 cs sputum patient either asthma chronic bronchiti cystic fibrosi bronchiectasi macroscop mucoid mucopurul purul viscos plot shear rate rang two zone junction region distinguish zone 1 lowest shear rate elast increas slowli chang littl plateau region zone 2 increas sharpli contrast viscos plot plateau show noth 08 cs sampl show decreas elast although varianc sampl wide level elast characterist diseas one macroscop appear elast viscos correl significantli lowest shear rate asthmat bronchiectat sputa resembl correl still signific higher shear rate cystic fibrosi chronic bronchit sputum sinc last two mucou gland hypertrophi present may sputum higher mucu compon
47	immunolog studi children cystic fibrosi cf concentr immunoglobulin determin use mancini method standard 108 sera taken long term treatment 45 children cf 2 month 16 year old shown depend markedli clinic state children particularli presenc pulmonari tract infecti process infect caus rise immunoglobulin concentr predomin igm cf children age 3 yr predomin igg older children mean titer isohemagglutinin children cf higher healthi children low titer diphtheri stapholococc antibodi found case anti diphtheria antibodi attribut fact children regularli vaccin owe poor clinic condit low titer antistaphylococc antibodi well known find cours chronic staphylococc infect appropri bacteriolog test cf children furthermor lymphocyt show increas blastic transform stimul staphylococc filtrat transform phastimul lymphocyt normal ct 1 lieberman j rev respir di 116 1047 977
48	compar trial pancrex v fort nutrizym treatment malabsorpt cystic fibrosi crossov trial pancreat enzym replac therapi conduct 12 children cystic fibrosi use pancrex v fort nutrizym tablet equival dosag differ found effect product measur stool volum number bowel action faecal fat excret urin urea excret neither product elimin steatorrhoea though laboratori evid support choic nine patient express prefer nutrizym conclus trial prefer base partli smaller number tablet requir
49	failur bronchopulmonari lavag cystic fibrosi attempt retard deterior pulmonari function young man cystic fibrosi underw bronchopulmonari lavag entir lung spite theoret advantag lavag produc acut deterior patient clinic physiolog statu recov one month later conclud bronchopulmonari lavag cystic fibrosi may hazard reserv case convent method improv tracheobronchi clearanc fail
50	level galactosyltransferas activ sera normal children patient cystic fibrosi level galactosyltransferas studi sera obtain 59 normal individu vari age 5 19 year 29 cystic fibrosi patient vari age 5 33 year enzym level found children lower adult level sera cystic fibrosi patient found half normal sera correspond age group cystic fibrosi patient 20 year age normal level found
51	erythrocyt membran properti cystic fibrosi biochem properti erythrocyt membran studi cystic fibrosi patient agematch control signific differ could observ either concentr composit princip membran constitu contrari previou report found normal level mg2depend ca2 mg2depend atpas activ cf prepar howev qualit differ observ ca2depend atpas sinc enzym rel greater activ lower calcium concentr cystic prepar effect membranebound ca2atpas unlik repres genet defect enzym may connect mechan pathogenesi cystic fibrosi
52	properti microsom glycoprotein galactosyltransferas cultur human fibroblast relat cystic fibrosi level properti microsom glycoprotein galactosyltransferas cultur skin fibroblast control cystic fibrosi patient investig use bovin submaxillari gland mucin exogen acceptor although mean specif activ enzym higher tin cystic fibrosi fibroblast differ signific properti enzym regard ph optimum metal ion triton x100 requir appar km heat stabil nucleotidesugarnucleotid respons similar control cystic fibrosi fibroblast
53	ca2 uptak bind isol erythrocyt membran cystic fibrosi control subject ca2atpas activ high affin ca2 bind presenc absenc atp low affin ca2 bind ad cacl2 concentr 1 microm 100 microm 10 mm measur isol erythrocyt membran cystic fibrosi control subject signific differ detect two group measur
54	aspect immun patient cystic fibrosi variou aspect immun statu examin patient cystic fibrosi cf follow observ made ten per cent cf patient elev reduc serum igg concentr seem transient low serum iga concentr number serum igm concentr normal cf patient normal level three serum immunoglobulin igg iga igm detect sibl heterozygot serum ige concentr elev 32 patient cf normal concentr detect heterozygot sibl precipit antibodi variou antigen allergen detect sputum patient cf sera contain lower undetect titr antibodi precipit antibodi cf sputum bacteria agar semin fluid urin human serum may relat common antigen determin glycoprotein present fluid total protein concentr sputum cf patient seem reflect extent lung damag third compon c3 serum complement concentr normal moder elev cf patient test serum transferrin concentr normal cf patient prealbumin level depress suggest margin undernutrit peripher blood lymphocyt transform pha pwm appear normal cf patient
55	differenti diagnosi wheez children remark base postgradu lectur order differenti asthma disord resembl one attempt defin clearli mean asthma wheez simplist statement would defin asthma recur form dyspnea mark wheez breath sound incomplet definit appar asthma realli symptom complex labor wheez breath character hyperreact bronchi variou stimuli result gener narrow airway variabl scope often revers sympathomimet theophyllin deriv corticosteroid varieti condit must consid studi wheez child includ asthmat bronchiti acut bronchiti spasmod croup allerg cough habit cough foreign bodi cystic fibrosi mucoviscidosi right middl lobe syndrom upper lower respiratori tract condit simul asthma
56	glucos intoler threeyearold child cystic fibrosi glucos intoler preced pulmonari diseas child cystic fibrosi describ glucos intoler control tolbutamid pulmonari infect resolv earli recognit treatment diabet children cystic fibrosi emphas
57	chronic sinus children comment pathogenesi manag chronic sinus young children often invok sinu complaint full discomfort pain affect sinu older child verbal complaint rather secondari sign symptom lead physician suspect entiti children common chronic nasal discharg chronic nasal obstruct care nasal examin essenti recognit chronic sinus common predecessor chronic sinus allerg rhiniti probabl second common background acut chronic sinus chronic sinus children cystic fibrosi characterist find sinus common cleft lip cleft palat children infant children clinic sign chronic infect radiograph chang nose cultur sensit studi plan appropri antibiot therapi surgic therapi indic symptom chronic pain chronic otiti media chronic bronchiti orbit infect intracrani complic occur
58	serum alkalin phosphatas cystic fibrosi interpret elev valu base electrophoret isoenzym analys sera 31 146 patient cystic fibrosi cf contain level serum alkalin phosphatas ap elev agerel criteria promin liver isoenzym band present polyacrylamid gel electrophoresi 31 abnorm sera larger normal amount bone intestin ap present sera find indic liver abnorm consist respons elev total ap sera patient cf sever caus high liver ap level cf patient identifi chronic hepat congest drug hepatotox overt biliari cirrhosi commonli subclin focal biliari cirrhosi
59	differenti diagnosi childhood asthma asthma accord unit state nation tuberculosi associ diseas character increas respons trachea bronchi variou stimuli made manifest difficulti breath due gener narrow airway narrow dynam chang degre either spontan therapi basic defect appear alter state host maxim wheez asthma justifi reinforc import differenti diagnosi inde characterist featur asthma may found degre wide varieti chest condit gener system diseas purpos monograph review condit may confus asthma focu attent specif point import histori physic examin laboratori test result might provid clue final diagnosi
60	tobramycin therapi pulmonari infect patient cystic fibrosi six patient exacerb chronic pulmonari infect associ cystic fibrosi treat intramuscular tobramycin 5 mgkgday 3 divid dose eight treatment cours last 9 30 day mean serum level 25 microgml 1 3 hour 02 microgml 7 12 8 hour dose tobramycin mean tobramycin concentr sputum 03 microgml eightytwo percent 66 pathogen bacteri isol sputum either pseudomona sp 64 staphylococcu aureu 18 ninetyseven percent pseudomona sp 83 percent staphylococcu aureu inhibit 31 microg tobramycin per ml organ isol therapi observ becom resist tobramycin although 3 occas colon new resist gramneg bacilli occur 6 8 cours therapi patient show clinic improv elimin bacteri pathogen sputum rare achiev necessari produc clinic improv colon resist flora uncommon find tobramycin side effect limit local discomfort inject site nausea vomit
61	serum protein paper electrophoresi cystic fibrosi correl bacteriolog lung find serum protein studi mean paper electrophoresi 88 patient cystic fibrosi cf correl bacteriolog lung find increas serum globulin fraction cf patient found wherea albumin albuminglobulin ratio decreas chang serum protein fraction significantli greater patient constant pseudomona aeruginosa infect lung patient without constant infect p 0005 wherea patient intermitt pseudomona infect sever chang patient without pseudomona infect chang gammaglobulin total globulin significantli greater patient frequent staphylococcu aureu infect patient rare staphylococcu aureu infect p 0005 p 005 respect regard serum protein fraction signific differ patient frequent rare staphylococcu infect found judg simpl score system lung diseas patient constant pseudomona infect significantli progress clinic radiolog patient without constant pseudomona infect p 000005 wherea signific differ found patient group
62	serum protein paper electrophoresi cystic fibrosi correl clinic radiolog find studi serum protein mean paper electrophoresi patient cystic fibrosi cf publish studi alter serum protein fraction found significantli correl clinic radiolog sever diseas present studi serum protein determin paper electrophoresi 95 patient cf studi correl clinic radiolog find serum protein electrophoret pattern 95 patient cf follow 1 6 year patient cf patient whole total serum protein unchang wherea albumin albuminglobulin ratio decreas globulin fraction increas total serum protein increas patient sever pulmonari diseas chang total serum protein protein fraction significantli correl clinic radiolog sever lung diseas termin patient sever chang patient complic liver cirrhosi electrophoret pattern differ cf patient conclud main caus serum protein alter cf lung affect wherea liver involv malabsorpt probabl much less import
63	lung function children young adult cystic fibrosi main characterist patient cystic fibrosi lung involv fatal outcom diseas often due pulmonari complic sinc paper west et al 1954 pulmonari function cystic fibrosi import lung function studi disord stress sever public studi lung function number children young adult cystic fibrosi result correl clinic radiolog bacteriolog find
64	screen cystic fibrosi chlorid electrod investig sweat chlorid chlorid electrod orion 417 normal person patient cystic fibrosi investig sweat chlorid chlorid electrod orion 417 normal person patient cystic fibrosi sweat chlorid valu examin orion 417 directread skin electrod collect group 811 normal person group 91 patient cystic fibrosi evalu differ attribut age sex normal group signific differ found two sex normal group valu among newborn found consider higher rest childhood first month life valu decreas steadi level maintain age 1 month 15 year age 15 steadi increas take place data gather normal group propos follow upper limit normal sweat chlorid test 1 month 15 year chlorid 40 meql 16 25 year chlorid 55 meql upon examin cystic fibrosi group sweat chlorid valu age group found upper limit normal method found valuabl larg scale screen purpos cystic fibrosi
65	diminish excret bicarbon singl sweat gland patient cystic fibrosi pancrea use phmicroelectrod excret hydrogenion bicarbon relat flow rate investig singl sweat gland cystic fibrosi children result show decreas excret hydrogenion increas excret bicarbon evid present due reduc secret hydrogenion duct reabsorpt sodium secret potassium may impair reduc flux proton across lumin membran epitheli cell propos gener featur exocrin gland defect possibl describ cation transport defect sweat gland duct anion bicarbonatesecretori defect one term
66	express inherit metabol diseas cultur cell sinc 1900 improv gener hygien develop antibiot therapi enabl mani epidem infecti diseas particularli infanc earli childhood increasingli control contrast morbid mortal diseas genet origin littl affect ration use cell cultur investig techniqu inherit metabol diseas root simpl biolog truth sinc full complement chromosom present somat cell possibl detect specif biochem consequ gene activ cultur fibroblast unless process differenti gene irrevers inactiv use tissu cultur investig inherit metabol diseas rest biochem identif primari defect cell cultur provid model system diseas use test possibl effect therapeut agent tissu cultur techniqu indic cell deriv patient cystic fibrosi show metachromasia although isol character cystic fibrosi cystic fibrosi serum accomplish number properti describ
67	hematolog find greek children cystic fibrosi 43 children cystic fibrosi 16 receiv pancreat extract investig hematolog differ observ mean hemoglobin serum iron level bone marrow non hemoglobin iron patient receiv receiv pancreat enzym signific proport children group found mild iron defici find agreement view pancreat insuffici increas iron absorpt
68	clinic variat cystic fibrosi estim cystic fibrosi affect approxim one everi 2000 white children born unit state gener regard commonest seriou metabol disord white children except diabet mellitu occurr children afroamerican quit rare exceedingli orient extract sinc cystic fibrosi genet determin autosom recess trait sinc oblig heterozygot parent entir asymptomat diseas first occurr given famili suspect manifest patient present test avail detect cystic fibrosi appli simpl practic screen test avail phenylketonuria diagnost test therefor use confirm refut diagnosi cystic fibrosi suggest symptom aris sibl rel known diseas ct 1 pearson rd pediatr re 13 834 979 2 jakel hp biol zentralbl 98 55 979
69	use semisynthet amino acid 3methoxyphenyllalanin measur amino acid absorpt pp 3046 paper describ investig absorpt 3methoxyphenyllalanin anisylalanin normal subject children cystic fibrosi one child hartnup diseas anisylalanin slowli metabolis mainli acetyl anisylalanin pmethoxyphenylpyruv acid lactic acid excret normal adult subject anisylalanin 25 mgkg bodi weight rapidli absorb maximum plasma concentr obtain 0510 hour ingest thereaft plasma concentr declin exponenti group eight children cystic fibrosi maximum plasma concentr lower observ control group delay poor respons observ infant hartnup disord
70	studi alpha1antitrypsin amniot fluid meconium cord serum homozygot newborn infant pp 10722 cord serum amniot fluid meconium newborn heterozygot pizz mother investig newborn infant diagnosi homozygot pizz defici alpha1antitrypsin could establish cord serum time deliveri trypsin inhibitori capac tic alpha1antitrypsin cord serum rang adult homozygot mean cross immunoelectrophoresi exclus phenotyp allel zz demonstr exclud possibl maternofet transfer alpha1antitrypsin infant amniot fluid extrem low antiproteaseact substanti alpha1antitrypsin found wherea normal sampl tic 3 6 cord serum valu 12 4 cord serum concentr data suggest major compon tic normal amniot fluid deriv fetu normal meconium detect tic concentr increas proport total protein content inhibitori capac meconium express mg trypsin inhibit per mg alpha1antitrypsin howev 80 less serum alpha1antitrypsin correl exist free tryptic activ meconium pizz infant clearli diminish refer fresh weight wherea meconia three cystic fibrosi newborn screen bm test extrem high concentr estim tic meconium regard use approach screen homozygot alpha1antitrypsin defici exact diagnosi howev establish phenotyp allel cystic fibrosi high protein content meconium accompani increas alpha1antitrypsin level
71	advanc diagnosi human genet disord pp 297317 purpos commun discuss applic one methodolog studi cultur human cell ad insight understand genet reason dispar clinic phenotyp mutant genotyp recogniz andor understand vivo often recogn vitro studi metabol morpholog characterist cultur cell two syndrom use illustr principl genet mucopolysaccharidos cystic fibrosi patient describ select demonstr use cell cultur add insight diagnosi human genet disord studi cultur human cell aid advanc abil diagnos human genet disord
72	preval coeliac diseas cystic fibrosi ireland scotland england wale admiss hospit republ ireland scotland england wale coeliac diseas cystic fibrosi compar admiss hospit 1972 coeliac diseas republ ireland yet full return hospit admiss approxim three time greater number expect base upon rate england wale 196971 scotland admiss rate coeliac diseas twice expect number base upon english rate contrast admiss cystic fibrosi slightli higher ireland scotland england wale evid high admiss rate coeliac diseas repres genuin high rate commun admiss rate coeliac diseas high east south ireland west ireland potato wheaten bread stapl diet great famin 1840 nineteenthcenturi scotland less wheaten bread eaten england wale past therefor coeliac diseas would disadvantag ireland less extent scotland england wale
73	cytoplasm metachromasia cultur skin fibroblast parent children cystic fibrosi cytoplasm metachromasia phenomenon toluidin blue 0 cultur skin fibroblast studi 12 parent children cystic fibrosi 12 control posit find record 10 cf parent one control averag cultur time requir develop maximum metachromasia posit case six week possibl signific ametachromat cf patient relat suggest genet heterogen cystic fibrosi discuss
74	predict tetracyclineinduc tooth discolor fortysix decidu teeth 17 children cystic fibrosi record histori tetracyclin therapi section vertic horizont teeth three repres stain categori mild moder sever photograph visibl ultraviolet illumin determin extent tetracyclin incorpor tooth enamel dentin tetracyclin incorpor enamel minim nonexist wherea tetracyclin incorpor dentin alway observ sever gener surfac discolor directli relat proxim tetracyclin incorpor dentinoenamel junction depend dosag durat period initi tetracyclin therapi relat odontogenesi critic period avoid tetracyclin therapi therebi minim potenti tooth discolor determin
75	problem affect commun popul screen screen appar healthi popul metabol disord rais mani ethic problem necessari differenti clearli screen programm servic natur realli research project screen phenylketonuria histidinaemia galactosaemia cystic fibrosi tayand sach diseas discuss disord demonstr advantag undoubtedli difficult problem screen present essenti one lose sight fact aim screen help individu commun psycholog aspect screen import continu thought must given fact biochem abnorm necessarili equat diseas
76	standard new minor salivari gland collect procedur diagnosi cystic fibrosi object investig refin techniqu develop serv new test procedur diagnosi cystic fibrosi pancrea util quantit approach measur standard fashion volum secret minor salivari gland lower labial mucosa collect fix period time also hope standard would facilit accur studi aspect studi minor salivari gland secret collect fashion find obviou less minor salivari gland secret collect cystic fibrosi patient normal control subject use capillari tube test may due part increas viscos minorsalivarygland saliva cystic fibrosi unfortun viscos studi beyond scope investig result indic rel differ volum minor salivari secret collect standard test site collect total lower labial mucosa similar volumetr differ minor salivari secret found distinct enough suggest studi continu area refin diagnost test procedur cystic fibrosi pancrea present time studi progress measur volum minor salivari secret standard test site employ electron techniqu hope approach may permit elimin viscos variabl
77	intracistern inclus bodi induc anim transform signific intracistern granul palad 1956 inclus bodi occur within cisterna roughsurfac endoplasm reticulum observ normal condit also experiment condit paper intracistern inclus bodi induc found varieti anim follow chemic administr artifici hibern cold exposur also cystic fibrosi inclus bodi tent classifi 6 type base upon morpholog aspect format fate signific bodi also discuss
78	pyocin type pseudomona aeruginosa last 10 year pyocin type use tool epidemiolog fingerprint pseudomona aeruginosa wide use scrapeandstreak method gilli govan although simpl perform sensit enough differenti strain use addit indic strain might correct defici growthinbroth method type shown promis easili autom may becom method choic sensit result requir valu pyocin type appear well establish studi nosocomi infect howev situat may give mislead result studi requir demonstr rel valu relationship serolog pyocin bacteriophag type
79	pseudomona aeruginosa infect humor antibodi respons patient cystic fibrosi studi humor antibodi respons patient cystic fibrosi heatstabl possibl k antigen pseudomona aeruginosa reveal antibodi signific titer lead erad microorgan respiratori tract three six patient antibodi direct strain isol sputum lung autopsi present elev titer antibodi respons p aeruginosa strikingli affect condit host differ patient cystic fibrosi one anoth kind malign
80	role antibodi infect due pseudomona aeruginosa variou techniqu util measur antibodi pseudomona aeruginosa gener result measur tend parallel princip function antibodi pseudomona appear opsonin igg igm immunoglobulin class antibodi potenti complement system activ either classic altern pathway suscept fatal infect pseudomona associ antibodi defici defect usual correl data regard state host underli diseas immunosuppress therapi function leukopenia addit inform need rel protect role igg igm antibodi affin antibodi viabl bacteria role antibodi nonlipopolysaccharid antigen protein compon cell wall pseudomona exotoxin
81	preliminari investig pseudomona aeruginosa vaccin patient leukemia cystic fibrosi heptaval lipopolysaccharid vaccin pseudomona develop clinic trial reveal decreas incid sepsi mortal due pseudomona vaccin patient burn vaccin certain group immunosuppress patient cancer may also decreas incid death associ pseudomona trial parenter vaccin patient cystic fibrosi show littl benefit advers reaction vaccin frequent often limit dose given
82	letter cellular metachromasia toluidin blue cultur white cell cystic fibrosi heterozygot examin white cell cultur 45 parent cf patient ie compulsori heterozygot confirm possibl exist ametachromat group class iii0 quantit class relat number heterozygot show vesicular cytoplasm metachromasia class i0 gener metachromasia class ii leucocyt cultur 45 cf carrier set parallel similar cultur 45 normal healthi control result confirm valu toluidin blue metachromasia phenomenon white cell cultur method heterozygot detect cystic fibrosi suggest may justifi replac tediou expens timeconsum fibroblast techniqu much simpler rapid leukocyt cultur procedur simplic appar reliabl leukocyt cultur procedur outlin facilit intrafamili investig coordin metachromasia class paramet sweat electrolyt ciliari dyskinet factor clinic manifest studi reveal distinct consist phenotyp correl might furnish valuabl addit evid genet heterogen cystic fibrosi
83	cystic fibrosi current concept brief review emphas paradox cystic fibrosi plethora abnorm disclos yet none accord pride place primari inherit abnorm nevertheless hope near futur result collabor integr highli special area research meaning signific data obtain ultim valu identifi heterozygot condit also handl treatment patient common disabl inherit diseas
84	effect cystic fibrosi sera proteu vulgari motil suspens proteu vulgari rapidli agglutin serum cystic fibrosi patient serum oblig heterozygot exhibit mean agglutin time significantli less observ 128 control agglutin properti observ transmit sever gener matern patern branch pedigre qualit differ note cf sera induc format clump two 10fold larger observ heterozygot serum factor respons p vulgari agglutin heat sensit destroy pronas neutral antihuman whole serum cf serum retain agglutin activ follow preincub antihuman igg iga b1e b1ab1c
85	evolut plasmid vivo strain staphylococcu aureu strain staphylococcu aureu far4 isol patient frequent interv 18 month strain previous shown lose resist sever antibodi lacey et al 1973 last 6 month chang occur vivo lincomycin resist appear patient treat clindamycin due mutat constitut resist lincomycin erythromycin locu adjac determin induc resist erythromycin loci probabl carri extrachromosom element three type variat pf plasmid observ alter product penicillinas macroconstitut microconstitut associ detect chang plasmid size chang gave cell advantag vitro associ faster growth rate probabl also vivo microconstitut variant isol increas number flucloxacillin therapi ceas complet loss determin penicillinas product resist cadmium ion pf plasmid associ decreas plasmid size 4 x 10 6 dalton chang also associ increas growth rate vitro loss resist fusid acid pf plasmid associ decreas plasmid size 1 x 10 6 dalton
86	radionuclid evalu region lung function children method suitabl studi region lung function children describ method simpl perform take 2 min provid pictori numer inform region ventil perfus scale factor measur rebreath account region variat lung size shield although avail comput system one describ text essenti precis rapid numer evalu nuclear medicin laboratori lack facil gamma camera could use method obtain scintigraph inform alon
87	staphylococcu aureu empyema cystic fibrosi staphylococc empyema rare occurr patient cystic fibrosi occur mani 45 per cent patient recent experi patient may present ill infanc cystic fibrosi patient empyema constitut signific percentag approxim 3 7 per cent total number patient hospit empyema sinc empyema occur infanc staphylococc origin sweat test done infant admit staphylococc pneumonia without empyema particularli recoveri adequ treatment unduli prolong
88	steatorrhea azotorrhea relat growth nutrit adolesc young adult cystic fibrosi fecal fat nitrogen excret determin 20 patient 12 17 year age cystic fibrosi cf pancreat defici current clinic nutrit statu growth achiev relat fecal nutrient loss age diagnosi adequaci treatment evalu steatorrhea azotorrhea present variabl extent time massiv patient studi bore littl relat exist intestin symptom state nutrit growth achiev age diagnosi mani patient better growth nutrit prognost score diagnos rel late life presum receiv adequ optim treatment addit pancreat supplement result signific dramat decreas fecal loss fat nitrogen conclud despit pancreat defici older patient cf need littl dietari restrict although treatment individu growth failur state nutrit seem correl close pulmonari state pancreat defici ultim prognosi natur variat sever lung involv least import earli diagnosi adequ optim treatment
89	editori mist aerosol new studi new thought recent data suggest longer use mist tent intermitt aerosol therapi cystic fibrosi patient abandon previous employ cannot accept therapi prove effect formerli believ aerosol mist could littl harm know harm treatment use patient close monitor clinic sensit pulmonari function test maximum expiratori flow volum curv obviou much learn confirm disprov respect rational benefit mist aerosol therapi
90	letter effect antibiot sweat chlorid level cystic fibrosi recent studi 11yearold child prove cystic fibrosi rais sweat sodium normal sweat chlorid level obtain receiv cloxacillin peripher edema hypoproteinemia although necropsi evid biliari cirrhosi although sweat abnorm might due yet unknown factor tempor associ cloxacillin administr suggest caus relationship tempt specul anomali produc instanc substitut cloxacillin radic chlorid ion sweat period therapi light find would interest know whether infant report maclean tripp receiv drug time initi sweat chlorid estim whether sodium estim also perform
91	endocrin function pancrea cystic fibrosi evid impair glucagon insulin respons follow arginin infus pancreat glucagon insulin determin 10 children cystic fibrosi cf control group follow stimul arginin infus control infus arginin induc prompt threefold elev plasma pancreat glucagon sixfold increas plasma immunoreact insulin patient cf averag respons hormon consider less baselin concentr glucagon lower data support hypothesi cf alpha betacel function affect result underli process
92	pulmonari deposit aerosol children cystic fibrosi effici deliveri aerosol 22 children cystic fibrosi age 8 month 17 year investig use standard ultrason nebul studi design simul clinic condit close possibl retent aerosol monitor scintil camera interfac small digit comput children also ventil studi xenon133 allow comparison distribut aerosol region ventil aerosol visual within lung 22 patient 08 65 per cent initi activ deposit lung repres averag 027 ml per therapi session 00131 ml per kilogram bodi weight posit correl r 089 p 001 increas age greater pulmonari deposit aerosol decreas aerosol entri region poorli ventil effici aerosol deposit variabl children cystic fibrosi depend primarili age patient wherea distribut within lung relat region variat sever pulmonari diseas
93	letter cystic fibrosi edema fals neg sweat test recent interest report cystic fibrosi edema fals neg sweat test prompt us report similar case previous report similar case one suggest cystic fibrosi suspect edemat infant sweat chlorid sodium concentr within normal rang test repeat edema disappear
94	abdomin complaint appendic chang lead diagnosi cystic fibrosi twelv patient abdomin complaint oper includ incident appendectomi later diagnos cystic fibrosi four group present sign symptom right lower quadrant mass chronic abdomin pain intestin obstruct hepatomegali case symptom precipit oper due underli unrecogn condit cystic fibrosi review histolog appendix reveal classic chang hypersecret mucou gland present appendix share gener intestin mucou gland involv peculiar cystic fibrosi awar fact widespread perhap usual emphasi pulmonari pancreat aspect diseas greater appreci clinic symptom cystic fibrosi liber use sweat test could diminish number exploratori celiotomi recognit histoloc chang remov appendic also suggest proper diagnosi lead earlier institut treatment improv prognosi
95	famili meconium ileu associ cystic fibrosi rare except patient meconium ileu cystic fibrosi pancrea pancreat achylia elev salt content sweat characterist pulmonari manifest wish report occurr meconium ileu two fullterm sibl normal pancreat function evid cystic fibrosi histori physic find normal sweat electrolyt knowledg first report famili meconium ileu without associ cystic fibrosi pancrea pancreat insuffici
96	hypoproteinemia anemia infant cystic fibrosi present symptom complex often misdiagnos infant cystic fibrosi occasion may present symptom complex anemia hypoproteinemia edema case report seven infant age 1 4 month develop abnorm indic sever instanc children condit misdiagnos milksensit milkallergi furthermor case histori verifi hypoalbuminemia anemia nutrit correct readili absorb diet pancreaticenzym supplement given retrospect review feed histori 100 infant cystic fibrosi well case report indic affect children breastf fed soybas formula like develop syndrom
97	letter idiopath hypoproteinemia twin sinc report edemaanemiahypoproteinemia symptom complex infant cystic fibrosi sever articl publish also particip care ident male twin interest symptom complex twin offer two exampl edemaanemiahypoproteinemia symptom complex infant cystic fibrosi presenc transsupplement absenc hemolysi normal serum iron increas peripher marrow iron valu suggest anemia result defect level hemoglobin synthesi iron transport remain suffici face protein deplet possibl rel iron defici occur increas nutrit intak due increas util lee suggest hypoproteinemia due loss protein stool twin suggest problem lie loss urin stool rather failur protein synthesi possibl hypoproteinemia secondari liver dysfunct attract although liver function test biopsi find normal often case patient cystic fibrosi anemia associ increas serum marrow iron valu like due decreas hemoglobin synthesi routin cystic fibrosi therapi appear suffici clinic recoveri compon symptom complex
98	cystic fibrosi manifest focal biliari cirrhosi newborn infant congenit heart diseas 3dayold infant meconium stain birth present respiratori distress hypoplast left heart syndrom diagnos clinic document autopsi unsuspect cystic fibrosi demonstr histolog presenc sever focal biliari cirrhosi spread fibrosi liver minim lesion pancrea intestin compat diagnosi cystic fibrosi abund hepat fibrosi unusu infant age indic utero origin case also unusu fortuit associ cystic fibrosi congenit cardiac malform
99	medic mucoid lesion pulmonari arteri cystic fibrosi pulmonari hypertens disord alter pulmonari vascular bed review autopsi materi 35 patient cystic fibrosi pancrea cor pulmonal hypertrophi media intim prolifer small muscular arteri arteriol note eight patient intim prolifer larger calib arteri seen seven patient unexpect chang howev presenc interstiti hyalin materi media pulmonari arteri major branch onethird specimen elast fiber distort disrupt find unrel presenc sever vascular chang intim deposit materi also present seven patient intim prolifer major pulmonari arteri ident medial lesion found pulmonari arteri seven 35 children pulmonari hypertens seven patient disord similar lesion media aorta found group patient materi schiffreact histochem characterist connect tissu acid mucopolysaccharid
100	letter treatment cystic fibrosi letter prompt recent report favour result use artifici diet consist protein hydrolys glucos polym mediumchain glycerid treatment cystic fibrosi pancrea observ children often find prepar unpleas unpalat loos motion nausea vomit quit common compar experi use malabsorpt state advanc proteincalori malnutrit whether untoward effect result excess flood gut andor exceedingli high bloodamino acid level matter specul
101	letter complement compon cystic fibrosi dr conov colleagu report differ haemolyt activ serum complement compon c1c9 cystic fibrosi cf patient oblig heterozygot normal control also measur individu complement compon radial immunodiffus found signific rise c3 signific differ c5 level group use immunodiffus kit manufactur freshli obtain sera observ quit differ find c5 mildli elev 20 highli elev 25 56 cf patient 2 29 year age c5 also elev 24 51 parent cf patient 15 show mild 9 higher elev 4 24 control show mild elev correl observ serumc5 level age sex clinic sever diseas judg shwachmankulczyki score sputum bacteri colonis mode treatment cf patient elev c3 c5 major patient cf oblig heterozygot interest suggest certain genet defect complement activ system autosom recess disord
102	letter skin wrinkl cystic fibrosi letter professor elliott appear first record skin wrinkl cystic fibrosi may observ import di sant agnes note high salt concentr sweat seem parent well awar respons repeat professor elliott observ soak hand six infant cystic fibrosi hot water show mark wrinkl present five minut often two minut occur control children similar nutrit state except case twin one cystic fibrosi one without unaffect child finger began wrinkl slightli five minut wrinkl appear associ wast due malnutrit sinc occur equal plump thin infant cystic fibrosi present children sever wast respiratori diseas due cystic fibrosi
103	letter frequenc cysticfibrosi gene unsolv problem human popul genet high frequenc gene cystic fibrosi cf caucasian wherea gene frequenc probabl low enough noncaucasian maintain recur mutat case caucasian carrier frequenc approxim 1 25 order establish stabl genet polymorph gene homozyg state lethal degre heterozygot advantag must exist suggest cf heterozygot higher reproduct fit normal individu possibl cours know exactli stabl cf polymorph one cannot exclud possibl form heterozygot advantag exist time past longer exist today like suggest possibl explan much common gener accept explan high frequenc sicklecel gene certain popul latter case heterozygot increas resist particular type malaria patient cf heterozyg carrier found serum substanc probabl protein agglutin proteu vulgari immunolog crossreact certain strain proteu eg ox 19 rickettsia prowazeki long provid basi serolog test typhu weilfelix reaction thu conceiv cf heterozygot might increas innat abil counter infect r prowazeki although typhu known mani part world seem predominantli endem epidem temper region inhabit caucasian peopl area endem south america first experienc diseas introduc european would seem compat observ higher cf gene frequenc caucasian group
104	letter skin wrinkl cystic fibrosi dr economoumavr colleagu appear misunderstood previou note concern skin wrinkl cystic fibrosi rang normal vari differ climat condit aukland wrinkl appear cool tapwat 1822 c 3 minut normal skin wrinkl immers appear agerel difficult detect reliabl newborn prior wash hand immers seawat even day acceler skin wrinkl warm weather would suggest normal need redefin athen 6 17 normal abnorm
105	letter sulphat incorpor leucocyt patient cystic fibrosi preliminari studi shortterm leukocyt cultur use na235so4 incorpor cetylpyridiniumchlorid cpcprecipit materi presum glycosaminoglycan gag found signific variat among cf patient parent oblig heterozygot biochem heterogen compar report fibroblast cultur serum amount na235so4 incorpor gag materi found incub medium cell cf patient significantli increas normal similar analysi normal heterozygot show signific differ na235so4 incorpor gag materi cell howev 4 6 heterozygot appear show pattern increas incorpor materi found incub medium indic higher mean normal donor result suggest yet anoth system studi effect cf gene incorpor na235so4 gag materi cf leukocyt cultur give addit evid genet heterogen disord
106	letter complement compon cystic fibrosi freshli obtain sera assay 14 cf young adult patient age 18 33 7 men 7 women 15 control patient bronchiectasi chronic bronchiti cf rule addit blood 2 mother heterozygot cf patient assay mean c3 level cf men slightli lower male control wherea cf women significantli higher mean level c3 femal control c3 level cf women also significantli higher cf men p 001 3855 student test femal control slightli higher c3 level male control differ signific comparison c3 level cf subject control show consider overlap valu especi men studi suggest assay serumc3 effect distinguish cf subject patient type chronic lung diseas howev differ cf women cf men interest deserv attent data cf young adult fulli confirm report conov et al possibl experiment effect carboxypeptidas b observ conov might result action enzym cf factor serum although ident like c3a
107	increas uptak 35sheparin lymphocyt patient cystic fibrosi previou studi cystic fibrosi cf shown increas mucopolysaccharid synthesi cf cell uptak 35sheparin sulphon purifi lymphocyt examin 3 day cultur medium 199 supplement 20 autochthon plasma fourteen cf homozygot seven sibl nine parent show significantli greater uptak p 0001 35sheparin cultur twentythre normal control partial overlap heparinuptak valu cf patient famili procedur thu differenti cf famili normal popul differenti cf homozygot heterozygot hope either variat cultur method combin procedur measur cf ciliari dyskinesi cellular metachromasia permit unequivoc identif cf carrier
108	letter wrinkl skin cystic fibrosi observ skin children cystic fibrosi wrinkl excess earli soak tap water physic sign highli reliabl irrespect degre nutrit patient sometim seen infant marasmu normal skin wrinkl eventu exposur water except dead sea possibl disord salt flux cystic fibrosi connect appar excess hyperton reactiv skin three minut bowl water might provid cheap screen test condit ct 1 bull c br med j 1 551 977 2 braham j arch neurol 36 113 979
109	letter cystic fibrosi 1972 may herrick thompson question classic hypothesi cystic fibrosi cf suggest cf children fact abnorm suscept fo respiratori pathogen birth perhap bit prematur chang classic hypothesi bacteriolog cf sinc predomin flora hospit nurseri staph aureu rather gramneg bacteria may initi exposur cf patient organ staph aureu addit organ becom resist antibodi ps aeruginosa organ could perhap present termin sputum flora agre data
110	letter nitrobluetetrazolium test cystic fibrosi claim nitroblu tetrazolium nbt test valu surveil children cystic fibrosi posit test give evid activ bacteri infect may appar clinic made evid investig whitebloodcel count sputum cultur chest xray test therefor includ routin assess patient attend clinic total 269 nbt test 110 posit 57 case evid infect 57 treat antibiot remain 53 left untreat 41 remain complet free infect standard criteria subsequ review 12 case howev patient develop obviou infect next clinic visit could argu case nbt test given earli evid infect otherwis appar mean certain sinc onset infect could time fourweek interv experi nbt littl help manag cystic fibrosi seri 27 falseneg least 37 falseposit high count possibl howev 12 ie 4 test carri nbt gave earli indic infect otherwis suspect
111	letter bioassay cysticfibrosi factor wish respond letter dr wood dr di santagnes regard studi reliabl ciliari assay cysticfibrosi screen investig conclud result studi rule possibl reliabl conclus could obtain ciliari assay feel conclus far accur although never intent research group utilis ciliari prepar massiv heterozygot screen prenat diagnosi ciliari assay provid valuabl scientif progress cystic fibrosi research exist assay suitabl massiv screen cystic fibrosi clinic detect cysticfibrosi carrier nevertheless techniqu offer promis method studi purifi characteris molecul molecul directli indirectli relat pathogenesi cystic fibrosi
112	intellig malnutrit caus neonat resect ileum assess intellig drawaman test school report shown despit sever earli malnutrit children neonat resect ileum frequenc mental retard higher normal popul score patient cystic fibrosi also similar control group
113	invertebr model studi macromolecular regul mucu secret larg molecul consist stimul hypersecret individu mucussecretori sell anim system marin invertebr sipunculu found human serum urin activ heatevok serum heatlabil urin heatstabl heatevok factor also found respect saliva tear serum urin factor withstood freezethaw activ factor destroy pronas activ urin factor destroy trypsin incub alphaamylas factor urin induc product aberr type secret
114	letter skin wrinkl nerv function interest professor elliott descript earli skin wrinkl children cystic fibrosi although phenomenon may well relat osmot differ skin water observ skin wrinkl seen finger pulp fulli depend intact peripher nervesuppli use sign peripher nerv lesion help follow recoveri wrinkl return furthermor impress normal individu wrinkl appar left hand righthand individu howev preliminari studi use fingerprint densiti measur photometri signific differ found side
115	letter skin wrinkl cystic fibrosi professor elliott dr norman colleagu suggest excess wrinkl skin soak tap water might provid easi cheap probabl reliabl screen test cystic fibrosi result show true mark wrinkl immers finger warm tap water 5 minut observ randomli select children wide varieti condit includ cystic fibrosi also malnutrit renal heart endocrin collagen diseas elicit even appar healthi individu young adult
116	fetal malform abnorm prevent fetal malform abnorm long hope obstetrician paediatrician geneticist sinc caus human malform spontan gene chromosom mutat unknown must remain dream present howev introduct midtrimest amniocentesi possibl detect abnorm earli enough select abort abnorm fetus though consid temporari expedi abnorm amen approach chromosom aberr down syndrom neuraltub malform includ spina bifida cystica recess inherit xlink metabol disord
117	letter whitecel glutathion reductas cystic fibrosi report redcel glutathion reductas gr activ increas cysticfibrosi cf patient comparison age sex match control also demonstr serumgr activ significantli greater cf control oblig heterozygot patient varieti respiratori immunolog diseas moreov serumgr cf patient carrier respond differ control storag incub heparin examin gr white bloodcel wbc cf patient day collect sampl mean wbcgr activ significantli less cf group carrier control differ gr activ group appar 4 6 day whitecel gr activ appar lower cf patient control cannot rationalis decreas increas activ found cf red cell serum nevertheless differ cf control greater interest appar direct contradict basi quantatit enzym differ difficult determin simplest explan initi whitecel gr differ cf patient one hand control carrier secondari aspect diseas treatment evid support conclus result reflect alter behaviour gr cf patient suggest us gr involv cf
118	letter skin wrinkl cystic fibrosi waterbind capac protein minim isoelectr point ph 35 5 keratin make horni layer increas increas diverg isoelectr point reason normal palmar skin wrinkl moder immers warm water especi soapi ph 8 howev patient cystic fibrosi increas salt content sweat rather ph differ increas waterbind capac keratin respons wrinkl patient
119	inherit metabol diseas present extrem doubt masspopul screen inherit metabol diseas phenylketonuria establish beyond pilot studi present progress mani diseas although earli detect clearli desir technic mean screen avail even establish pilot survey yet indic instead method screen limit popul risk particular disord within nation coordin administr structur establish experi mass screen one inherit metabol diseas must sure convinc new programm launch prematur harm caus incomplet detect case recognit disord whose manag uncertain unavail far outweigh benefit
120	letter uptak 35sheparin lymphocyt cysticfibrosi patient 1969 dane bearn propos metachromasia note shortterm whitebloodcel cultur cystic fibrosi cf homozygot heterozygot probabl reflect uptak heparin culturemedium pinocytosi genet mucopolysaccharidos store mucopolysaccharid hypothesi recent confirm robertson et al use 35sheparin demonstr increas uptak heparin shortterm cf whitebloodcel cultur correspond observ made basi stain howev mention 1971 bafalluy et al white bloodcel cultur overload heparin process involv endocytosi exocytosi probabl inconst within one cell certainli differ cell type standardis cytoplasm retent heparin may possibl order elimin partial overlap normal cf homozygot obligatori heterozygot observ robertson et al report 35sheparin rais question signific cellular mucopolysaccharid cystic fibrosi relev mucopolysaccharid cf cultur cell still unclear 1968 1970 mucopolysaccharid content cultur fibroblast report normal variabl
121	studi ciliari dyskinesia factor cystic fibrosi iv possibl identif anaphylatoxin c3aigg complex presumpt evid indic substanc respons pathophysiolog condit cystic fibrosi cf complement compon c3a also known anaphylatoxin known biochem physiolog properti c3a togeth behavior purifi substanc associ igg tracheal bioassay compar favor molecular speci separ sera cell cultur cf homozygot heterozygot sera normal healthi subject previous inact bioassay ciliari dyskinesia factor cdf convert cdf posit state incub epsilonaminocaproicacid eaca eaca known inhibitor carboxypeptidaseblik anaphylatoxin inactiv method choic accumul anaphylatoxin normal blood incub eacatr normal sera two fresh cdfposit cf sera carboxypeptidaseb produc revers instanc cdf neg normal state propos anaphylatoxin inactiv carboxypeptidaseblik enzym defect deficientin cystic fibrosi defici primari gene defect
122	inhibit pseudomona aeruginosa ascorb acid act singli combin antimicrobi invitro invivo studi ascorb acid act found exert bacteriostat action vitro 16 strain pseudomona aeruginosa test action attribut oxid ascorb acid depend individu strain inoculum size combin sulphamethoxazol trimethoprim septrin ampicillin erythromycin chloramphenicol colistin sulphat ascorb acid act synergist pseudomona aeruginosa vitro experi mice erythromycinascorb acid combin show curv dose 50 ascorb acid act alon 1122 milligramm per kilogram bodi weight significantli lower p 0001 691 mgkg administ combin erythromycin 10 mgkg human patient cystic fibrosi combin administr ascorb acid sulphamethoxazol trimethoprim bactrim roch pseudomona infect could control viabl number organ significantli diminish therapi
123	number ouabainbind site fibroblast normal subject patient cystic fibrosi autosom recess diseas defect net sodium transport eccrin gland result increas concentr sodium sweat possibl complic erythrocyt cf patient sinc activ observ cell homogen may express situat intact cell look differ bind 3houabain cultur normal cf human diploid fibroblast observ appreci differ number ouabainbind site normal cf cell strain also unabl observ differ kinet ouabainbind normal cf fibroblast kfree phosphatebuff salin solut result essenti seen hela cell observ alter kinet bind ouabain alter total number bind site
124	letter na transport defect cystic fibrosi use techniqu 3houabain bind isol cell quissel pitot conclud nak atpas function normal fibroblast cystic fibrosi patient howev find may relev na transport defect occur genet diseas na transport abnorm cystic fibrosi seem confin exocrin gland unknown present whether defect resid activ passiv transport step cation least isol sweat gland tissu erythrocyt cystic fibrosi patient nak atpas activ found normal howev decreas ethacryn acidsensit efflux na exchang mechan report cystic fibrosi erythrocyt find suggest fundament abnorm nak atpas enzym diseas may defect ethacryn acidsensit transport step therefor order obtain better understand cation transport defect one measur bind label ethacrynicacid rather ouabain
125	essenti fatti acid cystic fibrosi natur metabol defect cystic fibrosi cf date elucid elliott report intraven administr soybean oil lecithin children suffer cf caus sweat sodium concentr decreas toward normal valu prompt us investig fatti acid spectra variou serum lipid class children cf found affect children defici essenti fatti acid data suggest anoth approach studi metabol defect cystic fibrosi appar defici essenti fatti acid mark reduct serum vitamin e level also report cf condit might partial correct intraven inject possibl feed lipid contain essenti fatti acid concomit administr vitamin e observ defici essenti fatti acid may produc reduc abil absorb acid diet turn may result defect membran structur stabil reduc level vitamin e cf may reflect reduc requir vitamin lower level essenti fatti acid also possibl observ defici serum level essenti fatti acid may lead less normal product prostaglandin
126	screen tool detect psychosoci adjust children cystic fibrosi tool assess psychosoci adjust schoolag children cystic fibrosi develop use three instrument standard openend parent interview selfadminist teacher questionnair selfadminist parent demograph data form three instrument enabl pediatr nurs practition make clinic assess child psychosoci adjust assess check valid mean social worker interview implic research discuss
127	home care cf patient
128	cystic fibrosi black popul studi report high number black cystic fibrosi patient brooklyn new york descript patient popul area resid total 70 case cystic fibrosi follow long island colleg hospit ten 142 per cent 70 case cystic fibrosi black equal divid 5 femal 5 male
129	rapid semiquantit test trypsin chymotrypsin applic screen cystic fibrosi enterokinas defici pancreat hypoplasia neonat method rapid semiquantit analys trypsin chymotrypsin faec sampl develop faecal sampl shaken ph 82 buffer solut contain enzym substrat buffer indic ad sampl incub 37 degre c period depend amount faecal materi present colour note chang colour violet yellow trypsin green rose chymotrypsin indic presenc enzym screen trial use test carri st helen matern hospit auckland
130	use mediumchain triglycerid children intestin malabsorpt mediumchain triglycerid mct fat chain length six twelv carbon atom contrast usual dietari sourc fat longchain triglycerid lct contain 14 carbon atom atom chain differ chemic structur lct mct import relat major differ characterist absorpt metabol two class lipid physiolog differ lct mct led use mct variou disord malabsorpt lct occur mct absorb bypass sever step necessari absorpt long chain fat includ pancreat diseas chronic liver diseas disord biliari tract diseas small intestin epithelium lymphat vessel comment follow brief summari therapeut place mct children malabsorpt follow remark potenti valu mct countri like indonesia commonest caus chronic diarrhoea malabsorpt children malnutrit chronic repeat gastrointestin infect infest mct use wide
131	chronic diarrhea childhood new look old problem diarrhea defin excess loss water electrolyt fece excess physician fecal loss may excess caus patient ill parent stool pattern differ neighbor infant even singl wateri stool may much new knowledg normal gut function patholog process may afflict child alimentari tract improv one capabl diagnos manag certain specif diseas caus diarrhea although great interest academician mani diseas extraordinarili rare practic substanti perplex pool pooper specif diseas found fortun patient latter group rare serious ill articl attempt help practition understand diagnos treat children specif diseas known caus chronic diarrhea specul also mechan manag idiopath chronic diarrhea
132	cystic fibrosi notsofat diseas cystic fibrosi intric vexati diseas involv whole patient yet abl treat sign symptom done complet possibl treatment gear erad staphylococcu aureu lung prevent reinfect gramneg organ particularli pseudomona aeruginosa treat becom pathogen condit atopia respiratori tract gastrointestin system may detriment patient cystic fibrosi condit must control pancreat insuffici requir adequ enzym replac therapi prevent steatorrhea azotorrhea fatti acid play role membran oxygen transport abnorm composit cystic fibrosi may requir specif chang type fat intak salt deplet look correct screen test cystic fibrosi need prefer one done small blood specimen
133	chronic ill adolesc chronic ill age unfortun tax strength resourc individu associ chronic ill teenag face difficulti differ child adult ill burden adolesc chronic ill even greater burden task matur must success complet adolesc made difficult chronic ill health impact upon patient educ need sexual need life expect impact upon famili impact upon societi examin specif ill diabet mellitu fibrocyst diseas discuss
134	standard assay sodium reabsorpt inhibitori effect studi salivari gland distribut patient cystic fibrosi retrograd perfus assay mago sodium reabsorpt inhibitori effect sweat mix saliva patient cystic fibrosi cf modifi 1 use second parotid gland rat control 2 care control quantiti saliva perfus rat parotid gland ratio millilit perfus gram dri gland weight fell 18 28 3 report inhibitori effect percentag inhibit rate sodium reabsorpt rna perfus gland calcul differ rna two gland use modifi assay abl confirm signific differ exist percentag inhibit rna caus cf normal mix saliva 470 plu minu 248 180 plu minu 83 mean plu minu sd addit similar signific differ percentag inhibit rna submandibular gland secret 397 plu minu 135 160 plu minu 118 sublingu gland secret 395 plu minu 60 197 plu minu 143 submucos gland secret 340 plu minu 117 217 plu minu 127 cf normal subject observ howev parotid gland secret cf subject show increas inhibitori effect 125 plu minu 79 125 plu minu 66 find demonstr sodium reabsorpt inhibitori effect produc secret salivari gland patient cf
135	evalu differenti methyl ribonucl acid cystic fibrosi differ found methyl total nucleic acid total rna dna trna rrna lymphocyt fibroblast obtain normal subject oblig heterozygot individu cystic fibrosi similar result obtain use four method isol nucleic acid reason failur two laboratori discern report variat methyl rna normal carrier cystic fibrosi state may obscur differ cultur condit condit extract
136	purif properti calciumprecipit protein submaxillari saliva normal cystic fibrosi subject calciumprecipit protein capp previous shown caus turbid submaxilliari saliva sm patient cystic fibrosi cf purifi normal cfsm nh42so4 precipit gel filtrat prepar polyacrylamid gel electrophoresi protein molecular weight 12000 contain larg number serin glycin glutam acid residu 085 phosphoru phosphat monoest small amount carbohydr precipit aggreg capp occur basic ph valu presenc ionic calcium enhanc increas calcium concentr capp concentr ph aggreg capp bind calcium molar quantiti equal number phosphat prosthet group alkalin phosphatas remov phosphat capp elimin calciuminduc precipit studi capp cf saliva demonstr electrophoret composit differ normal capp higher normal ph valu elev capp concentr present sm patient cf contribut format turbid sm aggreg precipit capp saliva patient cf seem induc primarili elev level calcium saliva precipit may entir part respons focal obstruct submaxillari gland duct patient cf howev littl capp secret lower gastrointestin tracheobronchi tract therefor capp play gener role obstruct process character cf
137	erythrocyt transport function cystic fibrosi atpas activ monoval cation transport examin erythrocyt rbc subject cystic fibrosi cf rbc membran ca2atpas activ homozyg patient oblig heterozygot indistinguish normal control subject true similarli total ouabainsensit ouabaininsensit nakatpas total ouabainsensit ouabaininsensit 24na transport normal cf cell ouabaininduc na accumul similar cf normal rbc measur k transport cf rbc likewis normal conclud intrins atpas monoval transport function normal cf rbc unabl confirm sever abnorm cell report previous cf rbc help defin transport abnorm entiti studi document normal intrins transport function rbc patient cf report abnorm serum factor patient cf factor might involv product transport defect cf studi indic determin whether cf plasma contain factor capabl alter membran transport function normal rbc
138	arginin esteras cystic fibrosi pancrea arginin esteras activ chloroformellag acidtr plasma 11 patient cystic fibrosiscf 12 agematch control subject resolv compon fraction ion exchang chromatographi deaesephadex electrofocus polyacrylamid gel activ resolv two fraction chromatographi one inhibit soybean trypsin inhibitor sti inhibit sti plasma cf patient fraction activ inhibit sti reduc approxim 30 correspond fraction control plasma contrast fraction activ resist inhibit sti show signific quantit differ control cf plasma sampl analysi plasma sampl electrofocus 5 polyacrylamid gel rang ph 5080 subsequ stain arginin esteras activ show qualit differ control cf plasma sampl six activ band could detect control sampl wherea five band detect cf sampl eight sampl one type band miss two anoth type band miss one yet anoth type band miss band restrict narrow ph zone center gel data consist extend earlier report differ arginin esteras activ plasma sampl cf patient control subject demonstr absenc singl band arginin esteras activ consist absenc specif arginin esteras isoenzym patient cf defici arginin esteras patient cystic fibrosi may account presenc factor saliva plasma fibroblast patient consequ clinic manifest diseas
139	letter cystic fibrosi ciliari inhibitor fact amniot cell fetus high risk cf gene well cell deriv heterozyg individu produc ciliari inhibitor suggest close relat genet defect necessit identif character respons molecul
140	methyl transfer ribosom ribonucl acid human fibroblast normal methyl ribonucl acid cystic fibrosi comprehens studi trna 18 28 rrna methyl human fibroblast present cell normal volunt patient cystic fibrosi cf examin exponenti growth incub lmethyl14cmethionin 3huridin ratio 14c 3h count per minut isol rna serv measur extent methyl found similar normal cf fibroblast trna 18 rrna 28 rrna hydrolyz sampl 14cmethyllabel rna speci analyz two dimension chromatographi autoradiographi methyl base nucleosid composit trna rrna agre well data hela cell eurkaryot cell yeast mous chicken rna methyl pattern cf fibroblast qualit quantit similar observ normal cell 4 18 28 rna evid rna speci patient cystic fibrosi defici methyl compon methyl rna tissuecultur cell cystic fibrosi qualit quantit normal prove use marker identif carrier cystic fibrosi
141	helium flowvolum curv detect earli small airway diseas assess small airway diseas cystic fibrosi cf patient minim pulmonari involv maxim expiratori flow volum mefv curv obtain patient breath first air 80 helium20 oxygen ga mixtur fifteen cf patient 24 control studi flow rate 50 25 vital capac vc calcul air heliummixtur mefv curv compar give flow ratio lung volum 50 vc heliumair flow ratio similar cf patient normal subject 25 vc flow ratio significantli lower p 005 cf patient air helium mefv curv superimpos point curv cross point ident flow pif determin express vc cf patient mean pif 18 control 5 p 001 nine 15 cf patient pif valu greater 2 standard deviat sd normal mean none follow test abnorm three patient fev1fvc mmef rvtlc vmax 50 tlc tlcsec vmax 25 vc tlcsec arteri oxygen tension 86 mm hg four patient close volum 100 helium bolu techniqu normal patient determin pif appear simpl noninvas sensit test detect earli small airway involv
142	intellectu develop sever malnutrit infanc intellectu perform sensori motor abil social adapt studi 41 subject 2 21 year age sever malnutrit infanc control group consist 41 sibl mean iq 31 parent ws 108 sd plu minu 113 socioeconom depriv present result merrillpalm test malnourish group control reveal signific differ favor control differ found older popul wisc wai use lincolnoseretski test motor develop vineland scale social matur show signific differ result consist hypothesi malnutrit infanc affect intellectu develop first five year life beyond age given adequ socioeconom support signific differ observ
143	outpati intraven medic manag cystic fibrosi manag cystic fibrosi continu present constant therapeut problem pediatrician internist hospit patient use butterfli scalp vein needl attach plastic tube seal rubber cap heparin lock offer mani advantag report relat experi method use indwel intraven infus set home administr potent antibiot quit success therapi chronic bronchopulmonari infect associ cystic fibrosi
144	letter rate calcium concentr sweat relat cystic fibrosi author recent articl fail show signific differ sweat calcium concentr cf patient control subject suggest find refut hyperperm hypothesi found sweat ca 032 167 meqlit 26 control subject 042 203 meqlit 16 cf patient tremend rang mani subject would requir prove disprov differ differ undetect moder number subject probabl pathophysiolog signific ca realli vari unpredict sweat ca howev gener believ vari rate sweat much higher lower rate measur made compar rate might well show signific differ author attempt control rate inappropri manner measur constant rate took averag rate 30 minut immedi iontophoresi give littl inform concern rate sweat actual produc
145	sever respiratori diseas infant cystic fibrosi diagnosi manag prognosi 17 infant cystic fibrosi cf sever respiratori diseas review period 1968 1972 clinic cours infant character bronchiolitislik syndrom failur thrive malnutrit arteri blood gase demonstr mark hypoxemia mean pao2 365 mm hg tracheal cultur show predomin gramneg microorgan pseudomona aeruginosa klebsiella pneumonia escherichia coli predomin corticosteroid use patient despit vigor therapi includ antibiot 60 mortal delay diagnosi cf onset respiratori symptom mean six week consid import factor affect surviv data support need develop reliabl screen test cf birth
146	liverspleen scan pediatr liverspleen scan 254 children review retrospect regard accuraci yield examin scan predict abnorm correctli 95 time normal correctli 86 time pitfal interpret includ nonspecif abnorm present scan confus extrins intrins defect normal anatom variat patholog technetium99msulfur colloid scan found help diagnos splenic abnorm work abdomin mass evalu tumor patient baselin scan found least use patient fever unknown origin abdomin pain diffus liver diseas inflammatori condit liver abscess found febril otherwis healthi children iodine131ros bengal liver scan found use differenti potenti curabl lesion eg choledoch cyst surgic treatabl
147	use serum amylas isoenzym evalu pancreat function amylas isoenzym pattern evalu serum urin duoden fluid 19 patient cystic fibrosi cf normal subject two third cf patient absent pancreat enzym lack serum pancreat isoamylas band remaind markedli diminish pancreat band compar salivari isoamylas normal sera pancreat band equal greater salivari band patient absent enzym diagnosi abnorm pancreat function could made evalu serum isoamylas pattern therebi avoid duoden intub collect 72hour stool proteolyt enzym activ patient normal pancreat enzym activ normal serum zymogram cf patient low total serum amylas concentr total duoden fluid amylas level may mislead evalu pancreat function sinc amylas may salivari origin advantag isoamylas method includ 1 simplic noninvas requir small blood sampl 2 specif pancreat function 3 independ pancreat enzym medic
148	electron microscop appear presecret gastric mucu cystic fibrosi gastric mucos biopsi eight new untreat patient cystic fibrosi cf two normal subject studi quantit techniqu electron microscopi em determin whether presecret gastric mucu compact viscid normal analysi varianc techniqu show differ mean group studi observ suggest mucu may viscid prior secret electron microscopi gastric mucu appear diagnost valu cf
149	gentamicin paediatr gentamicin broadspectrum bactericid aminoglycosid antibiot tenth year use uk leagu tabl antibiot rank disc sensit test urinari tract pathogen staph aureu confirm remark effect 1973 bacteriod sp streptococci major omiss spectrum mic sensit strain usual less equal 2 microgml although pseudomona may requir greater equal 4 microgml therapeut rang aim 212 microgml serum peak level measur 1 hr intramuscular 20 min intraven inject worker regard level 12 microgml potenti toxic tri avoid exceed
150	therapeut special diet aim therapeut diet provid nutrit adequ diet varieti natur andor special prepar artifici food substitut treatment specif clinic disord role dietitian work member medic team paediatr dietet requir rather detail advic help parent particularli diet involv calcul restrict specif nutrient dietari consider obes diabet mellitu coeliac diseas cystic fibrosi carbohydr intoler galactosaemia phenylketonuria discuss
151	defect cell cycl fibroblast obtain patient cystic fibrosi paper analyz cell cycl cystic fibrosisderiv fibroblast statist demonstr failur support normal popul doubl time vitro indic due larg failur cystic fibrosisderiv cell enter cell cycl normal number explan signific differ behavior cell patient cystic fibrosi visavi either normal diseas control fibroblast save conclud proce intrins properti cell
152	quantit assess region ventil perfus children cystic fibrosi twentyf children age 8 month 17 year studi determin use computerassist ventilationperfus vp scan analysi region pulmonari function cystic fibrosi ventil perfus scintiphotograph compar patient radiograph region fraction exchang air rel region vp ratio obtain wholelung airexchang significantli correl standard pulmonari function test radiograph score ventilationperfus ratio gradient revers pat predominantli upper zone diseas region vp ratio uneven distribut quantit assess region ventil perfus use techniqu assess sever pulmonari diseas children cystic fibrosi
153	endoscop pancreatographi analysi radiolog find pancreat endoscop pancreaticograph find 46 prove case pancreat analyz patholog ductogram demonstr approxim 60 signific inform obtain mani case allow proper diagnosi primari diseas process complic thereof latter procedur prove quit help isol patient could benefit surgeri
154	vitamin e need section consid signific vitamin e tocopherol defici varieti diseas state effect vitamin lack unclear caus vitamin e defici includ dietari lack intestin malabsorpt case histori involv cystic fibrosi examin
155	analysi albumin meconium earli detect cystic fibrosi methodolog studi albumin meconium quantit mean singl radial immunodiffus techniqu describ detail method show good precis accuraci materi certain condit associ collect prepar analysi observ method discrimin healthi newborn newborn cystic fibrosi
156	tobramycin treatment pseudomona aeruginosa infect cystic fibrosi tobramycin treatment chronic pulmonari infect caus pseudomona aeruginosa 13 children cystic fibrosi evalu initi patient receiv recommend dose 125 mgm224 hour dose increas 250 mgm224 hour approxim 10 mgkg24 hour higher dosag administ intramuscularli 9 patient eight receiv addit therapi aerosol contain tobramycin therapi possibl erad ps aeruginosa respiratori tract 5 patient discontinu therapi ps aeruginosa reoccur patient within one month patient show clinic improv relat therapi toxic allerg side effect observ
157	pattern infect cystic fibrosi thirtyf patient cystic fibrosi age 11 month 135 year investig regard respiratori symptom respiratori tract pathogen serum immunoglobulin serum precipitin haemophilu influenza commonest pathogen supplant advanc diseas pseudomona aeruginosa patient respiratori infect level igg significantli lower normal children compar age children sever respiratori infect immunoglobulin rais precipitin predomin respiratori organ present find differ preval view patient cystic fibrosi normal respons infect common infect organ staphylococcu aureu
158	suscept mucoid pseudomona aeruginosa gentamicin disk compar vitro suscept mucoid nonmucoid pseudomona aeruginosa gentamicin 144 isol mucoid nonmucoid p aeruginosa cultur throat swab sputum specimen 29 patient diagnos cystic fibrosi mucoid form p aeruginosa throat swab cultur suscept gentamicin wherea 855 mucoid strain sputum cultur suscept nonmucoid strain throat swab sputum cultur 851 778 suscept respect sinc differ suscept four group organ signific p 005 conclud data show real differ suscept gentamicin mucoid nonmucoid strain
159	materi genet mucoviscidosi purpos present work studi type inherit involv mucoviscidosi analysi genet relat mucoviscidosi perform 26 famili bear wit monomer autosom mechan transmiss charact contrast recess diseas parent consanguin play secondari role mucoviscidosi appar explain wide distribut mucoviscidosi gene among popul observ describ may util medicogenet consult given member famili children suffer mucoviscidosi
160	abnorm thyroid function respons iodid patient cystic fibrosi suggest develop goiter hypothyroid patient receiv chronic iodid therapi indic underli thyroid diseas 1971 dolan gibson retrospect studi review record children cystic fibrosi receiv chronic expector therapi iodid report approxim 85 percent goiter 15 percent suggest clinic find hypothyroid studi togeth fact thyroid like lung pancrea endoderm origin rais possibl patient cystic fibrosi might underli defect thyroid function thyroid function patient cystic fibrosi evalu systemat fashion present studi undertaken evalu basal thyroid function larg group patient cystic fibrosi addit observ effect chronic iodid administr present studi strongli suggest often occur patient cystic fibrosi derang thyroid hormon economi frequenc iodid increas serum thyrotropin decreas serum thyroxin concentr induc goiter without hypothyroid patient cystic fibrosi point strongli presenc intrins abnorm thyroid diseas natur abnorm remain unclear
161	whole cell heatkil gramneg bacilli vaccin preliminari clinic studi abil multival heatkil whole cell gramneg bacilli vaccin toler evok antibodi respons group patient manifest need increas resist gramneg bacilli three group patient studi 35 burn patient seven small children cystic fibrosi 35 patient undergo coronari vein graft result vaccin differ three group patient vaccin
162	determin vitamin aspect distribut mobil transport health diseas author attempt evalu methodolog current use suggest routin determin vitamin blood tissu special consider given extran factor caus erron result fluorometr analys review older current literatur distribut vitamin tissu present special consider given uptak vitamin liver storag hepatocyt kupffer cell subcellular organel data concentr vitamin liver victim accident death effect diseas sever etiolog present mechan liver store retinyl ester mobil releas plasma remain obscur consider inform gain recent mechan retinol transport blood studi lead isol character retinol transport protein summar metabol retinol bind protein health diseas especi cystic fibrosi discuss final factor import interpret plasma level term vitamin review special attent given effect plasma level retinol retinol transport protein period rapid growth correl age influenc dietari adequaci distribut plasma level vitamin
163	histochem observ pulmonari macrophag cystic fibrosi pulmonari macrophag collect bronchial mucu patient cystic fibrosi chronic lung diseas investig histochem acid phosphatas betaglucuronidas betaglucosaminidas activ also mucopolysaccharid content macrophag patient cystic fibrosi decreas betaglucuronidas activ observ togeth larg cytoplasm vacuol suggest storag partial digest materi thu seem like apart increas synthesi mucopolysaccharid describ cystic fibrosi sever author degrad mucosubst produc impair
164	hla antigen cystic fibrosi hla frequenc 28 patient cystic fibrosi 240 unrel control compar statist signific differ hla frequenc could observ group slightli increas hla 2 frequenc consid chanc phenomenon accord previous demonstr lack associ abh blood group substanc correl certain hla antigen demonstr
165	fight cystic fibrosi cystic fibrosi gener hereditari disord children adolesc young adult widespread dysfunct mucussecret gland patient condit may character one follow chronic pulmonari diseas pancreat enzym defici abnorm high sweat electrolyt henc patient treat individu basi parent tie rigid regim impos diseas must help volunt need support assist home school cystic fibrosi still need lot help knowledg understand part nurs profess help great deal
166	conjunctiv goblet cell patient cystic fibrosi five patient cystic fibrosi pancrea mucou glandular system conjunctiva studi chang conjunctiv goblet cell might applic diagnost test question case wholemount techniqu use special develop studi conjunctiv goblet cell five case qualit well quantit gobletcel find accord previous report normal materi particular sign stagnat secret
167	plasma tocopherol infant children studi made plasma tocopherol concentr normal children children intestin abnorm posit correl plasma tocopherol age shown age 4 month 10 year patient cystic fibrosi coeliac diseas found markedli reduc plasma tocopherol concentr comparison normal children similar age
168	glycosidas human skin fibroblast cultur alphafucosidas alphagalactosidas alphaglucosidas betamannosidas nacetylalphaglucosaminidas five glycosidas alphafucosidas alphagalactosidas alpha glucosidas betamannosidas nacetylalphaglucosaminidas studi human skin fibroblast cultur phdepend kinet properti enzym result isoelectr focus ion exchang chromatographi present techniqu suitabl diagnos inborn lysosom diseas skin fibroblast cultur defin
169	electr polar rectal mucosa excret tetrahydroaldosteron patient cystic fibrosi pancrea normal subject electr potenti differ pd across rectal wall measur 26 patient cystic fibrosi pancrea cfp 18 healthi subject pd obtain normal children ident previous obtain normal adult significantli greater dispers valu observ cfp patient divid group accord metachromasia fibroblast cultur mean pd increas ametachromat group true enough observ suggest differ variou form cfp distinguish metachromasia thu indic heterogen diseas greater abnorm metachromasia neg patient may howev due sole fact patient sever affect diseas urinari excret tetrahydroaldosteron patient within rang obtain control exclud possibl secondari hyperaldosteron sourc increas pd evid provid favour basic defect intestin transport na cl minu k concentr faecal fluid patient significantli lower control equilibrium concentr k could account simpl passiv diffus suggest epithelium behav inertli respect ion cfp
170	letter measur electr potenti differ across colon mucosa cystic fibrosi patient measur potenti differ rectal mucosa perian skin use refer electrod place forearm demonstr alter potenti differ cystic children compar control adult normal children suggest might due alter rectal mucosa potenti alter skin potenti cystic fibrosi measur skin rectal charg directli connect refer electrod blood stream intraven line use techniqu show cystic fibrosi patient cf abnorm perian skin potenti differ compar read obtain normal children littl differ transmur rectal potenti differ cystic patient previous report valu normal adult thu recent paper confirm find normal polar rectal mucosa surfac increas skin polaris cystic fibrosi
171	addit data hepat function test cystic fibrosi fifti cystic fibrosi cf patient 9 multilobular cirrhosi observ regularli period 3 year variou liver function test indic cytolysi cholestasi cellular insuffici perform immunoglobulin prothrombin assay 9 patient cirrhosi test gener abnorm two distinct biochem pattern cirrhosi distinguish one clearli cholestat cellular type distinct made basi iga transferrin ratio gammaglutamyltranspeptidas level noncirrhot patient temporari increas cytolysi cholestasi observ 50 case
172	screen cystic fibrosi analysi albumin meconium clinic studi albumin content meconium perform two categori newborn infant screen seri 8830 infant highrisk group cystic fibrosi cf 70 infant singl radial immunodiffus techniqu test strip use three cf infant detect screen seri 13000 16 highrisk group diagnost accuraci cf fairli good specif 998 immunodiffus techniqu 992 test strip high concentr albumin meconium found cf also preterm babi infant gastrointestin disturb atresia malaena neonatorum malabsorpt syndrom sensit 90 immunodiffus techniqu 78 test strip falseneg result probabl due proteolyt activ might avoid sampl store low temperatur analysi cf screen meconium use test strip follow analysi posit test immunodiffus techniqu suggest
173	epidemiolog marker pseudomona aeruginosa 6 relationship concomit nonmucoid mucoid strain respiratori tract cystic fibrosi simultan occur mucoid nonmucoid nm variant pseudomona aeruginosa frequent observ cultur respiratori tract chronic infect cystic fibrosi patient studi cultur vitro unstabl easili dissoci nm coloni larg proport case nm variant occur simultan cultur one clinic specimen pyocin type phage type serogroup remain case small differ nm variant ident variant one specimen possibl although definit nm dissoci strain type variant possibl role crossinfect interact bacteria host respons factor continu tend select unstabl variant vivo discuss
174	preval mucoid strain pseudomona aeruginosa bacteriolog specimen patient cystic fibrosi patient diseas rel preval mucoid strain compar nonmucoid strain pseudomona aeruginosa investig routin bacteriolog specimen receiv depart clinic microbiolog 1973 pseudomona aeruginosa isol 1054 specimen 57 per cent repres 53 patient cystic fibrosi 551 isol 169 patient diseas 503 isol rel preval mucoid strain significantli higher specimen patient cystic fibrosi 80 per cent specimen patient diseas 3 per cent consid patient without cystic fibrosi rel preval mucoid strain low specimen anatom region special prefer strain respiratori tract could demonstr patient contrast situat patient cystic fibrosi altern mucoid strain nonmucoid strain subsequ specimen observ 33 patient
175	serolog pseudomona aeruginosa analys mean quantit immunoelectrophoret method ii comparison antibodi respons man thirteen group ps aeruginosa occurr antibodi antigen prepar strain repres 13 group pseudomona aeruginosa polyval ps aeruginosa antigen stag investig sera 100 patient mean fuse rocket immunoelectrophoresi intermedi gel found humor immun respons ps aeruginosa result precipit antibodi detect stag well antigen sampl investig six sera contain groupspecif antibodi reveal one antigen sampl use stag six sera studi mean variou quantit immunoelectrophoret method use stag well antigen prepar infect ps aeruginosa strain patient concern six sera one extra precipitin could detect use antigen prepar homolog strain instead stag extra precipitin correspond presum groupspecif oantigen includ stag sera patient groupspecif antibodi alway accompani antibodi antigen common strain ps aeruginosa
176	staphylococcu aureu cystic fibrosi antibiot sensit phage type latest decad investig occurr protein properti recent isol strain relat occurr precipit antibodi recent decad 1651 isol staphylococcu aureu 111 patient cystic fibrosi test antibiot sensit half isol phage type patient follow one clinic polici antibiot treatment consist period result show dynam situat epidem phage type recent year gradual replac type period preval strain resist one antibiot decreas multiresist strain includ strain resist methicillin infrequ patient 23 per cent patient strain repeatedli isol 1 year despit appar success chemotherapi recent isol strain found produc cellbound well extracellular protein ninetyon per cent strain produc extracellular lipas 8 per cent resist mercuri chlorid eightyon per cent patient produc precipit antibodi aureu judg cross immunoelectrophoresi investig properti aureu significantli correl occurr precipit antibodi bacteria possibl signific protein patholog respiratori tract infect discuss
177	effect malnutrit matur central nervou system recent year data accumul implic earli malnutrit subsequ small statur behavior abnorm studi divid two larg categori one deal cellular biochem chang tissu level one deal function chang within nervou system measur chang variou mode behavior chapter attempt review studi broad categori led present concept malnutrit grow period perman retard growth result stunt individu markedli retard psycholog develop result individu perman alter behavior shall first consid normal cellular biochem develop central nervou system second shall examin malnutrit alter cellular biochem process final shall review evid implic earli malnutrit alter later behavior abil learn
178	dietari supplement nutrit children cystic fibrosi assess nutrit statu patient cystic fibrosi pancrea cfp show poor growth associ low concentr albumin urea nitrogen cholesterol serum elev white blood cell wbc count patient cfp maintain weight approxim 1 standard deviat mean 8 year progress declin growth rate compar normal complet dietari supplement consist beef serum hydrolys glucos polym mediumchain triglycerid given 15 patient year patient receiv diet show signific gain weight signific increas clinic score signific increas serum albumin level signific drop wbc count compar control patient receiv supplement
179	pneumatosi coli cystic fibrosi clinic radiolog patholog featur patient cystic fibrosi found pneumatosi coli associt rectal prolaps cystic fibrosi sever factor predispos pneumatosi yet rare report symptom nonspecif diagnosi consid patient cystic fibrosi chronic lung diseas vagu abdomin complaint
180	cystic fibrosi hypertroph osteoarthropathi children report three case three patient cystic fibrosi note swell knee ankl joint exacerb lung diseas synovi fluid analyz one patient synovium underw biopsi anoth studi exclud caus arthriti contribut new inform natur secondari hypertroph osteoarthropathi radiolog examin long bone confirm diagnosi hypertroph osteoarthropathi three patient sinc mani patient cystic fibrosi surviv longer instanc hypertroph osteoarthropathi expect futur
181	complianc selfmed cystic fibrosi sixtyon patient cystic fibrosi studi determin relationship degre complianc take antibiot sever diseas complianc rate high patient suggest percept sever diseas potenti consequ discontinu medic princip factor
182	letter nutrit supplement cystic fibrosi duke medic center nation institut health analyz maximum achiev height weight 60 person cf 20 year old paramet markedli skew toward lower percentil band signific differ found among patient whose condit diagnos earli life sever pulmonari gastrointestin impair among pancreat enzym andor nutrit supplement employ nutrit supplement yet proven signific longterm influenc morbid mortal cf lober report data 60 person cystic fibrosi cf 20 year age popul 63 individu contain three 15 year old median age death patient cf 12 year realist compar patient surviv adulthood younger group state type nutrit supplement signific among patient experi nutrit supplement amino acidglucos polym mixtur equal poor data growth rate similar lober height weight skew toward lower end height less affect weight increas rate linear growth observ eight 13 children 12 year age time dietari supplement begun patient continu take nutrit supplement shown deterior pulmonari statu
183	nonop treatment meconium ileu equival intralumin bowel obstruct secondari inspiss fece known complic cystic fibrosi seen older child term meconium ileu equival studi case nonsurg resolut obstruct obtain n acetylcystein enema pancreat replac enzym given oral enema pathogenesi disord basi treatment describ recognit complic familiar medic manag import care older child cystic fibrosi
184	aspergillu antibodi patient cystic fibrosi respiratori flora patient cystic fibrosi cf frequent includ aspergillu 30 serum sampl observ contain precipit antibodi fungu serum 61 cf patient 60 healthi person three patient cf allerg bronchopulmonari aspergillosi studi use quantit assay antibodi fumigatu although cf patient significantli higher level aspergillu antibodi antibodi found serum sampl normal individu bind immunolog specif fumigatu serum ige level dermal reactiv aspergillu similar cf normal subject increas level aspergillu antibodi cf patient probabl reflect pulmonari colon rare caus infect sensit
185	use pseudomona aeruginosa vaccin pateint acut leukemia cystic fibrosi heptaval lipopolysaccharid pseudomona vaccin evalu 22 patient acut leukemia 12 patient cystic fibrosi 18 month interv clinic center nation institut health 34 patient 32 excel serum hemagglutin ha antibodi respons immun comparison patient cystic fibrosi patient leukemia smaller ha antibodi respons last shorter period time alsoi experienc greater toxic vaccin mix adren corticosteroid vaccin greatli decreas side reaction among patient leukemia without significantli inhibit antibodi product previou antineoplast chemotherapi littl influenc antibodi respons patient leukemia except methortrex vaccin patient leukemia 1 pseudomona infect 14 bacteri fungal infect wherea 2 pseudomona infect 5 bacteri fungal infect occur control group 20 patient acut leukemia 12 patient cystic fibrosi 4 pseudomona infect vaccin
186	famili adjust cystic fibrosi nurs mother describ clinic effect cystic fibrosi patient longterm demand diseas place children famili diagnosi mainli accomplish analysi sweat sodium chlorid ion cf transmit mendelian recess trait gener dysfunct endocrin gland abnorm seemingli unrel appear loss electrolyt sweat salivari gland unusu thick sticki mucu secret obstruct damag patient pancrea lung gallbladd intestin liver object pulmonari therapi decreas viscos pulmonari secret improv maintain pulmonari hygien financi cost one mani burden famili
187	studi synthesi plasma membran protein fibroblast patient cystic fibrosi characterist increas salin sweat abnorm exocrin secret patient cystic fibrosi cf suggest possibl disturb function plasma membran diseas sever line evid indic fibroblast express presenc cf genotyp therefor cell use vitro studi direct determin whether manifest cf might relat alter one protein compon plasma membran order evalu synthesi compon grow fibrosblast patient cf normal subject briefli expos either 14c 3hleucin plasma membran isol subject analysi nondeterg acrylamid gel system coelectrophoresi differenti label prepar reveal absenc detect abnorm synthet rate 30 resolv protein speci
188	carboxypeptidas blike activ c3 cystic fibrosi assay carboxypeptidas blike activ c3 serum patient cystic fibrosi appropri control subject fail demonstr defici carboxypeptidas blike activ consist increas c3 suggest conov associ differ men women cystic fibrosi appar women cystic fibrosi higher concentr serum carboxypeptidas blike activ c3 either men cystic fibrosi control subject
189	relationship arterialalveolar nitrogen tension alveolararteri oxygen tension lung volum flow measur diffus capac cystic fibrosi pulmonari function children cystic fibrosi assess arterialalveolar pn2 differ adjust sublingu temperatur result valu compar alveolar arteri po2 differ arteri pco2 standard measur lung volum flow diffus capac arterialalveolar pn2 differ nearli one half po2 differ earli diseas advanc stage analysi take account o2 dissoci curv possibl alveolar temperatur higher sublingu temperatur suggest po2 differ could explain term ventil perfus imbal gasfil unit lung reduct fraction co uptak increas pn2 differ suggest decreas diffus capac cystic fibrosi may explain ventilationperfus inequ signific relationship arteri pco2 pn2 differ support view ventilationperfus inequ caus co2 retent present pn2 po2 differ abnorm standard test lung volum flow gener correl excel pn2 differ superior po2 differ detect earli diseas technic problem measur consider recommend routin measur
190	open thoracotomi pneumothorax cystic fibrosi result open thoractomi pleurectomi pleural abras 17 episod pneumothorax patient cystic fibrosi compar result observ close thoracostomi close thoracostomi scleros agent open thoracotomi advantag insur prompt resolut pneumothorax small incis minim postop morbid averag hospit stay 15 day open thoracotomi 19 day close thoracostomi without scleros agent complic treatment infrequ limit symptomat recurr observ 2 17 pneumothorac success treat open thoracotomi recurr also occur 1 8 treat observ 3 9 treat close thoracostomi 1 14 treat close thoracostomi scleros agent loss vital capac usual note 4 18 month resolut regardless treatment forti per cent patient oper nonop group surviv 3 year experi open thoracotomi use safe treatment unresolv recurr pneumothorax warrant evalu primari therapi pneumothorax patient cystic fibrosi
191	contribut inhomogen lung unit maxim expiratori flowvolum curv children asthma cystic fibrosi normal children well asthma cystic fibrosi studi assess contribut lung zone empti differ rate curvilinear maxim expiratori flow volum curv lung volum maxim expiratori flowvolum curv breath air breath heliumoxygen mixtur singl breath nitrogen washout measur forc expiratori maneuv lung volum near function residu capac perform produc transient flow exceed maxim flow defin full flowvolum curv normal children asthma mild cystic fibrosi small transient sever cystic fibrosi larg transient well increas phase nitrogen washout curv larg transient associ increas curvilinear maxim expiratori flowvolum curv smaller normal flow respons breath helium sever cystic fibrosi larg transient suggest sequenti empti fast slow space influenc shape maxim expiratori flowvolum curv fast space could due compress enlarg anatom dead space time constant inequ parenchym unit present asthma mild cystic fibrosi appear contribut significantli shape maxim expiratori flowvolum curv
192	tracheal mucociliari transport patient cystic fibrosi stimul terbutalin tracheal mucou veloc measur observ motion teflon disc across tracheal mucosa fiberopt bronchoscop averag rate movement 14 adult patient cystic fibrosi 26 mm per min plu minu 33 sd compar 201 mm per min plu minu 63 20 normal subject age p less 0001 failur mucociliari transport may play role pathogenesi pulmonari diseas cystic fibrosi administr betaadrenerg agent terbutalin increas averag mucou veloc patient cystic fibrosi 55 mm per min plu minu 36 sd p less 0001 control subject observ potenti therapeut signific
193	mucociliari clearanc mucociliari clearanc data obtain group rel healthi cystic fibrosi subject affect cough major subject mention origin articl cough studi inde chosen rel healthi time possibl studi fairli long period without interfer cough thu rel normal clearanc time demonstr presum due mucociliari transport refer made nasal mucociliari clearanc studi patient cystic fibrosi normal subject indic clearanc similar group mild inflamm nasal mucosa produc would like point work perform laboratori sinc refer given discuss
194	congenit metabol diseas pediatr patient anesthet implic larg number congenit metabol disord make complet discuss biochem problem hazard pharmacolog implic anesthet recommend imposs review confin discuss certain aspect sever genet acquir diseas metabol anaesthesiologist may call upon manag pediatr patient everi genet metabol diseas result specif enzym defect defect function amount review diseas defect known eg homocystinuria suspect eg myotonia congenita unknown eg cystic fibrosi discuss therapeut approach genet metabol diseas includ suppli miss product prevent substrat accumul prevent altern product synthesi enzym induct enzym replac increas defici function cofactor administr compensatori therapi obvious ideal way treat consequ genet diseas normal patient biochem diseas pathophysiolog clear goal approach condit pathophysiolog unknown compensatori therapi possibl
195	data hla linkag group lod score studi 229 famili linkag relat hlapgm3 19 marker loci cystic fibrosi report data exclud ada belong linkag group give weak support inclus p weak evid linkag cystic fibrosi pgm3 none linkag hla new suggest linkag appear
196	low blood pressur young adult cystic fibrosi effect chronic salt loss sweat young adult cystic fibrosi lower blood pressur control subject similar age sex low blood pressur may relat excess loss salt sweat patient benefici effect cystic fibrosi gene may protect develop hypertens homozyg heterozyg state especi heterozygot borderlin elev sweat electrolyt
197	ciliari inhibit axonem microtubul alter freshwat mussel phenomenon associ genet diseas cystic fibrosi cf presenc serum factor stop discoordin ciliari beat effect demonstr expos freshwat mussel oyster gill cilia rabbit tracheal cilia sera homozyg heterozyg cystic fibrosi subject assay reproduc unsatisfactori howev mechan effect understood know may consider differ activ test heterozygot homozygot ciliari assay caprici need understand ciliari beat disturb stop sinc microtubul import mechan ciliari motion could conceiv show alter respons inhibitori substanc ultrastructur studi howev effect ciliari inhibit axonem compon therefor studi design examin ciliari structur differ stage ciliari inhibit rapid microtubular disappear reappear occur termin cilia freshwat mussel unio exposur cf serum caus shockstop reaction return water allow resumpt normal ciliari beat contrast slowstop reaction caus distort cilia asynchron beat eject cell distal gill filament ciliari axonem structur preserv slowstop cilia resum beat water saliva reserpinetr rat caus ciliari inhibit similar induc cf serum
198	primari periton infanc childhood primari periton rare diagnos preoper uncommon diseas account 21 pediatr abdomin emerg often associ urinari hepat patholog former sourc infect organ major case present characterist symptom depend upon whether occur infanc childhood symptom sign allow posit prospect diagnosi illustr compar diseas entiti often confus eg diffus periton etiolog includ short durat symptom associ urinari tract infect absenc free air abdomin roentgenogram past gram posit organ common infect agent howev seri gram neg bacteria account 69 organ antibiot gram neg spectrum exploratori laparotomi appendectomi hallmark therapi latter replac abdomin tap patient satisfi criteria primari periton associ diseas make risk surgeri prohibit
199	genet screen recent prolifer genet knowledg accompani specul use pursuit medic social goal well fear concern possibl misus specul appear proceed numer symposia mani book paper review literatur reveal nonmed particip debat preoccupi aim genet might benefit threaten societi physician concern accomplish standard medic mission social aim figur incident mission diagnosi manag prevent diseas specif use genet knowledg frequent mention advanc taxonomi diseas lead improv diagnosi treatment individu patient rel genet counsel genet screen latter two particularli screen prevent repres interfac medic genet especi popul genet societi review focus develop genet screen defin search popul gener medic reason individu possess particular genotyp
200	liver scan cystic fibrosi liver scan perform 16 cystic fibrosi patient scan consid abnorm patient result serolog liver function test normal liver scan cystic fibrosi unlik make signific contribut assess prognosi
201	aspect bile acid metabol cystic fibrosi previou report indic cystic fibrosi cf patient pancreat enzym insuffici rais faecal bile acid output studi 18 29 cf patient 2 4 noncf patient pancreat enzym insuffici rais faecal bile acid level cf patient correl found faecal bile acid faecal fat excret invers relat shown faecal bile acid valu age cf patient overt liver diseas tend lowest faecal bile acid valu duoden spirat 5 cf patient one noncf patient pancreat enzym insuffici shwachmandiamond syndrom produc small fluid volum duoden fluid mean total bile acid concentr within normal limit estim serum bile acid 6 patient show 3 patient rais serum bile acid valu suggest excess faecal bile acid loss may produc contract bile acid pool lead eventu reduct intraduoden bile acid concentr measur curtail faecal bile acid loss may particular signific manag cf
202	letter bronchial labil cystic fibrosi alway seem use exercis labil index eli distort result may mislead fals high valu labil obtain pef rest low incorrect compar percentag valu patient percentag valu figur rest near normal jone liabil index avoid distort suggest proport cf patient abnorm labil would maintain eli introduc inaccuraci may blur distinct cf respiratori condit may lead postul problem concern labil cf necessarili exist failur use bronchodil agent reinforc brief exercis may also caus distort opposit direct
203	unusu clinic cours child cystic fibrosi treat fat emuls child diagnos cystic fibrosi customari criteria given regular parenter soya oil emuls near birth sweat test improv pancreat achylia reliev child present remain entir well correct essenti fatti acid defici found cystic fibrosi may prevent manifest diseas
204	letter essenti fatti acid cystic fibrosi read interest report elliott robinson concern appar benefici effect intraven fat infus child cystic fibrosi question whether increas essenti fatti acid brought soya oil account favour cours diseas patient observ confirm essenti fatti acid level often normal cystic fibrosi correl clinic condit patient seem unlik minor degre essenti fatti acid defici would impair prostaglandin synthesi give rise usual clinic featur cystic fibrosi recent research platelet aggreg prostaglandin cyclic nucleotid product make us awar simpl efa defici per se cannot origin symptom cf possibl agent infus mixtur exampl contain 12 tocopherol may contribut factor also investig howev invalid possibl therapeut effect efa diseas particular partial correl possibl disord prostaglandin synthesi
205	insulin releas cystic fibrosi earli insulin respons rapid intraven inject glucos studi 7 case cystic fibrosi age 8 month 9 12 year plasma insulin measur radioimmunolog method blood glucos valu determin glucos disappear rate kg calcul children except youngest one earli insulin respons valu low compar normal children kgvalu normal correl neither durat clinic symptom patient actual clinic condit measur mean shwachman score explan decreas insulin respons probabl progress fibrosi pancrea may also explain report increas incid diabet mellitu cystic fibrosi comparison made condit pancreat fibrosi rabbit produc duct ligat
206	neg sweat test cystic fibrosi two brother describ chronic suppur pulmonari diseas one classic cystic fibrosi complet pancreat involv abnorm sweat test incomplet pancreat diseas repeatedli normal sweat test implic neg sweat test patient cystic fibrosi discuss
207	preval atopi exerciseinduc bronchial labil rel patient cystic fibrosi skin test exercis test perform children cystic fibrosi cf firstdegre rel cf children posit skin test found 56 patient 19 rel preval atopi cf patient bore relationship preval rel increas 0ronchial labil mainli due bronchoconstrict present 54 patient 27 rel result show increas preval bronchial labil atopi found firstdegre rel cf children abnorm labil atopi found cf children indic famili allerg background
208	trial artifici diet treatment cystic fibrosi pancrea twelv patient cystic fibrosi start artifici diet albumaid caloreen togeth supplement medium chain triglycerid oil vitamin miner growth veloc gener health assess period full year child patient mildli affect diseas show improv stool frequenc growth rate diet repres major part nutrit intak patient sever affect show improv growth gener clinic statu frequenc respiratori infect
209	cystic fibrosi ciliari inhibitor small polypeptid associ immunoglobulin g small polypeptid within molecular weight rang 6000 11000 found immunoglobulin fraction sera cystic fibrosi homozygot heterozygot factor appear respons interf ciliari activ oyster gill sinc dissoci igg without reduct cleavag must bound noncoval manner dissoci igg fraction cystic fibrosi sera longer inhibit ciliari activ find explain differ previous observ molecular weight ciliari inhibitor synthes cultur cell sera cystic fibrosi genotyp
210	classif hereditari disord sexual develop recent propos classif disord sexual develop base upon presum site action abnorm gene embryogenesi disord may either genet nongenet natur result disturb physiolog sexual differenti embryogenesi purpos review summar current physiolog concept normal sexual differenti review known hereditari disord sexual develop consid briefli implic mutat understand normal sexual differenti translat genet sex phenotyp sex complex process sinc 19 hereditari singlegen determin disord sexual develop current recogn involv loci autosom x chromosom infer minimum 19 gene henc 19 discret biochem step involv process least 10 mutat result male pseudohermaphrodit wherea 2 mutat known caus femal pseudohermaphrodit predomin male type mutat result fact format male phenotyp activ induc secret fetal testi wherea format femal phenotyp requir secret fetal ovari end result mutat involv format action testosteron similar requir anatom endocrinolog genet studi individu patient identifi mutant gene involv undoubtedli mani yet unidentifi gene must particip sexual differenti identif gene depend continu delin new simpli inherit clinic syndrom fundament understand program event phenotyp differenti requir identif gene involv elucid molecular mechan gene express
211	letter serum alphafetoprotein cystic fibrosi professor r k chandra other suggest estim serum alphafetoprotein afp might help detect carrier famili risk cystic fibrosi observ uk unabl confirm find wherea dr j smith new york support perhap crux matter lie techniqu estim serum afp small number famili analys proport affect individu may differ expect chanc famili may normal children wherea may affect children exampl nowaday sinc famili tend small appear autosom recess condit often sporad one affect person famili could well appli cystic fibrosi
212	letter serum alphafetoprotein cystic fibrosi professor r k chandra other found rais serum level alphafetoprotein afp heterozygot carrier gene cystic fibrosi patient diseas sibl result show signific differ afp level patient sibl parent control children probabl discrep find explain detail examin techniqu use
213	letter serum alphafetoprotein cystic fibrosi professor r k chandra other report significantli increas level alphafetoprotein afp serum patient cystic fibrosi cf parent patient sibl newfoundland canada serum afp level 38 patient cf differ healthi adult opinion genet differ cannot explain differ result concern serum afp level patient cf
214	letter essenti fatti acid defici due artifici diet cystic fibrosi wish draw attent reader possibl hazard feed infant element diet consider interest current shown use artifici diet cystic fibrosi may use supplement ordinari food suppli nutrit need child latter event believ particularli import emphas parent need addit sourc dietari fat clinic evid anim experi suggest infant rapid growth rate particularli risk absenc dietari efa develop defici symptom two month
215	serum alpha fetoprotein level patient cystic fibrosi parent sibl patient cystic fibrosi cf show rais serum level alphafetoprotein afp moder signific increas serum afp present parent sibl correl clinic sever diseas serum afp concentr sampl control group gluteninduc malabsorpt bronchiectasi normal level persist synthesi afp may associ marker cf gene estim serum afp might help detect heterozygot carrier famili risk
216	letter serum alphafetoprotein cystic fibrosi sera 40 wellconfirm cystic fibrosi patient 60 parent obtain two canadian chicoutimi quebec one unit state san diego cystic fibrosi clinic afp measur two method doubl antibodi enzym immunoassay sodium sulphat precipit radioimmunoassay result thu confirm serum afp level normal cystic fibrosi
217	immun complex cystic fibrosi circul immun complex detect serum sputum patient cystic fibrosi cf extens deposit immunoglobulin complement immun complex sever cf organ especi respiratori gastrointestin tract kidney signific concentr igg complement complex could elut lung cf patient control studi involv immunoabsorpt autoradiographi molecular siev sephadex g200 column identifi bovin serum albumin staphylococc alphahaemolysin two antigen present immun complex sediment constant immun complex 8s 11 clinic signific immun complex wide varieti antibodi detect cf patient discuss
218	anaesthet manag volum control unilater lung lavag convent mean facilit clearanc inspiss materi obstruct ga exchang alveoli finer airway patient alveolar proteinosi asthma mucoviscidosi often effect mechan remov materi volum control unilater lung lavag salin benefit select patient refractori convent therapi particularli alveolar proteinosi accident inhal radioact particl report describ anaesthet lavag techniqu current use manag patient alveolar proteinosi mucoviscidosi lung lavag repeat approxim sixmonth interv result subject object improv 14 lavag four differ patient 10 lavag two patient alveolar proteinosi four lavag two patient mucoviscidosi certain physiolog respons lung lavag particularli relat oxygen transport measur quantit attempt evalu optim anaesthet lavag techniqu mainten anaesthet lavag select randomli patient receiv light anaesthesia ketaminediazepam one lavag light halothan anaesthesia lavag contralater lung
219	cystic fibrosi present statu futur prospect detect patient carrier develop sensit easili perform reliabl test would import advanc detect cystic fibrosi improv genet counsel provid earli effect treatment sweat chlorid test reliabl diagnosi technic difficult screen program reliabl detect homozygot contrast meconium test detect homozygot newborn simpl inexpens reason specif gener applic yet evalu detect serum compon basi two new test distinguish patient cystic fibrosi carrier effect serum compon ciliari activ principl one test extrem difficult procedur subject lack suffici specif routin use second test serum compon separ isoelectr focus may provid object biochem mean detect homozygot heterozygot
220	cystic fibrosi cystic fibrosi whether call fibrocyst diseas pancrea mucoviscidosi simpli cf condit current afflict one everi 2500 children glimps diseas gain experi amelia one victim
221	volumecontrol lung lavag woman cystic fibrosi 22yearold woman cystic fibrosi treat volum control lavag lung two occas follow first lavag patient vital capac increas 103 liter 1sec forc expiratori volum increas 070 literssecond similar improv although less pronounc note lung lavag second time conclud volumecontrol lung lavag benefit adjunct treatment patient cystic fibrosi
222	cystic fibrosisimmunolog reaction fumigatu common allergen immunolog studi fortythre patient cystic fibrosi show posit prick test least one common allergen obtain 70 multipl allergen 28 fumigatu 50 specif ige antibodi allergen found appropri subject spite evid type 1 ige sensit none patient histori infantil eczema intracutan test fumigatu extract gave type 1 3 reaction sixteen patient 37 seven among sixteen 37 gave posit precipitin test rais level total serum igg iga found compar healthi control asthmat subject differ found total serum igm igd level high incid allergi fumigatu cystic fibrosi confirm
223	immedi hypersensit patient cystic fibrosi twentythre thirti patient cystic fibrosi gave strong immedi skin hypersensit reaction wide varieti allergen seventyf per cent markedli elev serum ige concentr wherea patient neg type 1 immedi skin reaction also normal level serum ige sputum patient immedi skin reactiv also posit precipitin varieti antigen
224	polyamin alter blood male homozygot heterozygot cystic fibrosi polyamin spermidin spermin measur whole blood extract control volunt patient cystic fibrosi oblig cystic fibrosi heterozygot male homo heterozygot cystic fibrosi exhibit consist signific decreas blood spermin result elev spermidinespermin ratio compar control male contrast control femal exhibit reduc spermidin spermin level compar control male blood femal cystic fibrosi homo heterozygot show similar result sex differ probabl due fluctuat blood polyamin menstrual cycl abnorm polyamin level first observ alter low molecular weight metabolit characterist male homo heterozygot cystic fibrosi
225	copper analysi nail clip attempt differenti normal children patient suffer cystic fibrosi 39 normal children 36 patient suffer cystic fibrosi cf copper content finger nail clip toe nail clip determin studi conclud although patient cystic fibrosi cf higher copper content determin copper nail sampl cannot use order differenti normal children patient also higher mean copper concentr found finger nail clip comparison toe nail differ signific patient cystic fibrosi
226	alpha1antitrypsin duoden fluid gallbladd bile use immunoelectrophoret method alpha1antitrypsin detect 6 26 sampl duoden fluid obtain 16 patient variou gastroenterolog problem concentr mg100 ml alpha1antitrypsin duoden aspir children liver diseas 732 plu minu 61 less children cystic fibrosi shwachman diamond syndrom hirschsprung diseas 167 plu minu 119 p smaller 002 alpha1antitrypsin detect one 6 sampl gallbladd bile except patient extrahepat biliari atresia signific correl found alpha1antitrypsin concentr sampl studi correspond total antitrypsin activ
227	simpl method quantit determin stool trypsin chymotrypsin simpl method determin activ trypsin chymotrypsin stool duoden aspir describ method base describ barbero et al j di child 112 1966 536 1 util time drop 01 ph unit solut instead constant ph titrat determin enzym activ result number cystic fibrosi patient normal compar favor literatur
228	screen cystic fibrosi analysi meconium albumin proteas inhibitor qualit method detect elev meconium protein concentr compar method determin meconium albumin concentr electroimmunoassay sinc elev meconium protein level indic pancreat insuffici caus cystic fibrosi 5 10 per 1000 healthi infant pass meconium specimen gave fals posit reaction boehring mannheim test strip contain greater expect concentr albumin possibl exclud pancreat insuffici children determin ratio albumin alpha1antitrypsin meconium subsequ faecal specimen sinc found valu ratio excess 20 suggest pancreat insuffici type associ cystic fibrosi three 14 neonat subsequ proven cystic fibrosi yield meconium specimen give neg test strip result low albumin concentr two patient ratio albumin alpha1antitrypsin meconium within normal limit within two month birth albumin alpha1 antitrypsin ratio faec children greater 30 suggest pancreat insuffici develop
229	cystic fibrosi heterozygot detect studi normal popul detect cystic fibrosi cf heterozygot test cystic fibrosi factor activ cffa serum sampl use bioassay report give unreli result present studi undertaken find whether use medium short term white blood cell skin fibroblast cultur rather serum test sampl would elimin inconsist short term white blood cell cultur establish 107 normal healthi individu cultur 97 cffa six 16 show variabl result four 710 activ four test done singl sampl assay repeat 3 month later new cultur four posit cffa individu two show activ no 7 9 two no 8 10 10 individu whose cultur show cffa histori allergi associ cffa cultur medium deriv individu allergi intermitt presenc activ suggest environment factor induc cfflike activ white blood cell cultur oyster ciliari assay use medium white blood cell cultur cannot use screen cf heterozygot sinc substitut cultur medium serum elimin inconsist result cffa specif assay cf gene fibroblast line establish four person whose initi white blood cell cultur consist show cffa one 7 show cf cultur phenotyp cffa posit metachromasia
230	cystic fibrosi heterozygot detect famili studi famili studi done determin phenotyp describ cystic fibrosi cf cultur cell reliabl detect cf gene two cultur phenotyp studi cultur deriv consecut gener four cf famili 1 cystic fibrosi factor cff medium shortterm white blood cell cultur assay modifi oyster ciliari test 2 three characterist cultur skin fibroblast metachromasia without alcianophilia 03 mgcl2 cff cultur medium metabol cooper normal fibroblast cf autosom recess disord famili offer test unit determin specif cell phenotyp cf gene basi detect cf cultur phenotyp homozygot obligatori heterozygot parent segreg consecut gener detect cf gene possibl white blood cell cultur possibl skin fibroblast cultur
231	pulmonari diseas childhood mani type lung diseas seen pediatr age group rang way disord neonat close relat parturit acut infecti diseas seen infanc earli childhood chronic disord cystic fibrosi bronchial asthma manag condit describ involv cooper primari care physician specialist varieti organ offer aid physician patient famili
232	manag cystic fibrosi observ gentamycin use antibiot pulmonari infect associ cystic fibrosi 1971 1973 hospit 41 symptomat patient cystic fibrosi intens pulmonari therapi sever ill patient admit period studi includ 100 cours intens treatment garamycin pediatr inject contain 10 mgml activ ingredi administ intraven patient divid dose 30 50 mgkgday purpos studi evalu toler pharmacokinet efficaci garamycin administ parenter cystic fibrosi patient seriou infect 100 cours treatment clinic improv rate follow signific definit improv 39 moder improv 50 slight improv 9 chang 2 use garamycin pediatr inject safe help manag pulmonari infecti complic cystic fibrosi employ along wellestablish modal therapi
233	psychosoci approach medic manag patient cystic fibrosi import deal feel child famili regard cystic fibrosi genuin recognit feel pediatr staff go long way toward reassur famili member longstand burden suffer valid understood famili manifest earli sign difficulti cope emot physic stress impos cystic fibrosi help refer child psychiatrist consult primarili famili high risk breakdown requir earli prevent intervent role pediatrician primari clinician crucial must provid support understand integr part primari prevent emot decompens disord
234	mild cystic fibrosi present asymptomat distend appendic mass case report case cystic fibrosi present right lower quadrant mass fiveyearold white femal present laparotomi mucoid impact appendix found microscop suggest diagnosi cystic fibrosi cystic fibrosi must ad condit present abdomin mass
235	cor pulmonal children accord world health organ chronic cor pulmonal defin hypertrophi right ventricl result diseas affect function andor structur lung except pulmonari alter result diseas primarili affect left side heart congenit heart diseas cor pulmonal extens studi report adult receiv rel littl attent pediatr age group although part knowledg gain adult studi use chronic cor pulmonal children infant quit differ entiti usual seen adult review primarili attempt clarifi confus surround subject focu pediatr aspect pathophysiolog etiolog diagnosi treatment discuss
236	class skin fibroblast metachromasia cystic fibrosi correl lung function test lung function test conduct 35 patient cystic fibrosi correl class skin fibroblast metachromasia seven patient belong class vesticular metachromasia 16 class ii gener metachromasia 12 class iii metachromasia class patient significantli lower vital capac vc class ii patient regard lung function test gener trend found class patient compar two class class iii patient lung function test reflect seriou lung chang class ii patient statist signific differ found regard residu volumetot lung capac onesecond forc expiratori volum fev1 fev1vc differ due vari intens treatment result accord find previou studi clinic radiolog lung symptom serum protein valu cf correl metachromat class
237	class skin fibroblast metachromasia cystic fibrosi correl growth paramet metachromasia cultur skin fibroblast patient cystic fibrosi cf assign fibroblast one three class morpholog distribut metachromat stain describ dane bearn 1968 1969 dane 1969 two previou studi hospit lykkegaard jacobsen 1975 lykkegaard thuesen pedersen 1975 clinic radiolog function sever lung diseas serum protein pattern cf patient studi relat class skin fibroblast metachromasia found class iii patient tend sever affect class ii patient class ii patient possibl class patient also sever affect class ii patient sproul huang 1964 studi growth pattern cystic fibrosi found signific correl sever respiratori diseas height weight retard present studi height weight develop 98 cf patient correl class skin fibroblast metachromasia
238	class skin fibroblast metachromasia cystic fibrosi correl clinic paramet retrospect studi clinic radiolog lung symptom intens treatment 98 patient cystic fibrosi conduct result correl class skin fibroblast metachromasia fourteen patient belong class vesicular metachromasia 52 class ii gener metachromasia 32 class iii metachromasia patient 16 year age six patient class ii simpl score system clinic lung symptom treatment lung diseas develop compar age class iii patient sever affect judg clinic lung symptom class ii patient intens treat compar class ii patient metachromat fibroblast class iii patient ametachromat fibroblast found class iii patient sever affect intens treat class ii patient regard chest radiograph judg norman system similar pattern seen statist signific differ found 68 patient 9 class 35 class ii 24 class iii serum protein electrophoret fraction studi found class iii patient sever alter class ii patient class ii patient proport femal patient class iii greater two class could explain differ small number patient class differ class class ii patient doubt differ class iii class ii patient class iii class ii patient
239	immunoperoxidas demonstr human serum globulin bind islet tissu sera juvenil diabet nondiabet control test use immunoperoxidas method presenc isletbind immunoglobulin diabet sera test contain isletbind protein averag sera posit age match control normal adult sera undifferenti juvenil diabet sera sera children less two year age bind islet tissu sera cystic fibrosi patient markedli diminish abil bind islet tissu bind protein appear immunoglobulin select react element islet beta cell
240	excret trypsinlik activ electrolyt protein mix parotid saliva patient cystic fibrosi pancrea esterolyt activ mix parotid saliva cystic fibrosi cf patient normal subject determin use baee alphabenzoyl1arginineethylest substrat use soybean trypsininhibitor trypsinlik activ tla measur plot function parotid flow rate addit calcium protein ph determin trypsinlik activ mix parotid saliva show larg individu variat cf normal children parotid saliva could find signific differ wherea reduct tla mix saliva cf patient observ fact normal valu fell within rang heterozygot report rao et al 19 make hypothesi close relationship reduc tla genet defect doubt protein calcium ph increas augment saliv differ cf patient normal age match children could found except ph flow rate 075 mlmin per m2 bodi surfac significantli lower ph valu result relev reduc tla pathogenesi cystic fibrosi discuss
241	screen genet disord past 50 year develop countri seen steadi declin infant mortal diseas associ infect malnutrit period contribut genet diseas congenit malform risen significantli genet orient screen program high potenti contribut overal improv health develop underdevelop countri review procedur screen hereditari biochem disord consid criteria select genet trait screen schedul screen specimen screen screen newborn infant test older infant test highrisk infant children screen famili genet diseas screen carrier select popul discuss
242	parathenar palmar pattern dermatoglyph sign possibl clinic signific frequenc doubl proxim axial triradiu dpat result palmar parathenar pattern report increas ventricular septal defect bsd score presenc pattern 313 patient congenit heart defect includ 86 isol vsd 176 cystic fibrosi cf rel cf 333 known clinic diseas unrel individu cf frequenc three group 16 23 06 respect none isol vsd defect dpat five individu heart defect group dpat pulmon stenosi total eleven individu seri dpat pattern eight affect right hand frequenc dpat individu known diseas seri 440610 doubl frequenc control seri publish previous david 5112904 73 rel cf exclud control group frequenc dpat group 06 closer result david control seri
243	demonstr factor serum homozygot heterozygot cystic fibrosi nonbiolog techniqu factor isol serum homozygot oblig heterozygot cystic fibrosi use isoelectr focus disc electrophoresi analyt method factor focus within iggfract isoelectr point ph 8 9 differ igg lower molecular weight thu similar ident ciliari dyskinesia factor
244	cystic fibrosi involv ear nose paranas sinus twentysix patient cystic fibrosi exhibit diseas paranas sinus consist opacif maxillari sinus either alon part parasinus symptom sinus seldom occur treatment gener requir agenesi delay develop frontal sinus also seen major patient nasal polyp occur 27 patient five year age exclud patient five year age none polyp incid 36 gener polyp observ patient sever diseas mild degre conduct hear loss note younger age group especi instanc sever hear loss nerv conduct disturb encount mild degre hear loss may mere reflect applic standard stringent age group throat nose cultur 26 patient reveal pseudomona aeruginosa eighteen case reflect flora tracheobronchi tree organ encount unpredict basi find consist anticip age group patient
245	clinic aspect iron absorpt turnov pp 3461 diagnost 10 micromol 056 mg 59fe2 absorpt whole bodi retent test fig 1 use 10 year detect deplet iron store subject iron defici heinrich et al 1966 heinrich bartel 1967 studi necessari investig clinic reliabl increas 59fe2 absorpt patient erythroblast hyperplasia may control regul iron absorpt iron store relationship iron absorpt iron store studi pancreat insuffici reinvestig effect pancreat secret iron absorpt iron absorpt patient glutensensit enteropathi investig order correl impair iron absorpt degre villou atrophi studi recoveri glutenfre diet dietari iron absorpt measur patient gastric mucos atrophi partial gastrectomi investig extent iron malabsorpt respons high incid iron defici patient combin diagnost 59fe2 absorpt test measur whole bodi 59fe2 elimin rate use routin procedur detect quantif gastrointestin urogenit blood loss caus iron defici
246	alphafetoprotein serum amniot fluid diagnosi neonat hepat syndrom indian childhood cirrhosi cystic fibrosi ataxia telangiectasia spina bifida alphafetoprotein afp detect quantit method immunodiffus agaros counterimmunoelectrophoresi radioimmunoassay serum afp level rais patient sibl indian childhood cirrhosi cystic fibrosi homozygot heterozygot neonat hepat ataxia telangiectasia mildli elev biliari atresia women previou histori child sever neural tube defect rais amniot fluid level afp associ anencephali spina bifida diagnost util afp pediatr especi genet counsel discuss
247	concentr gentamicin bronchial secret children cystic fibrosi tracheostomi comparison intramuscular rout endotrach instil aerosol level gentamicin blood secret tracheobronchi tree measur 14 children 8 cystic fibrosi 6 tracheostomi cross fashion administr 40 mg gentamicin aerosol endotrach inject high level gentamicin greater 20 mugml within bronchial secret observ 7 children aerosol 11 children endotrach instil correspond blood level low less 3 mugml patient detect level found 10 children aerosol 6 children endotrach instil signific differ observ children cystic fibrosi tracheostomi sinc intramuscular inject gentamicin singl dose 15 mgkg result low level gentamicin within bronchial secret less 2 mugml 10 patient among 4 undetect level conclud administr antibiot gentamicin directli trachea endotrach inject aerosol might prove help infect confin mainli tracheobronchi tree
248	applic cilia dyskinesi test diagnosi cystic fibrosi adolesc certain case obscur chronic lung diseas possibl genet disord cystic fibrosi pancrea consid genet defect fail caus pancreat involv partial express cystic fibrosi encount elev sweat electrolyt level suffici confirm diagnosi cystic fibrosi adult sinc normal level vari wide adolesc adult test therefor util cilia dyskinesi test posit homozyg heterozyg patient cystic fibrosi util techniqu famili studi confirm diagnosi partial express cystic fibrosi adolesc femal
249	absorpt two antibacteri drug cephalexin cotrimoxazol malabsorpt syndrom plasma concentr urinari excret cephalexin trimethoprim sulphamethoxazol cotrimoxazol measur normal subject patient coeliac diseas small bowel diverticulosi crohn diseas cystic fibrosi cephalexin administr cholestyramin absorpt cephalexin improv coeliac diseas diverticulosi cystic fibrosi crohn diseas peak plasma level reduc delay absorpt trimethoprim sulphamethoxazol increas three condit howev disproportion increas plasma level trimethoprim coeliac diseas diverticulosi compar sulphamethoxazol crohn diseas threefold increas peak plasma level sulphamethoxazol cholestyramin administr malabsorpt three drug
250	heterogen carbohydr chain sulfat bronchial glycoprotein isol patient suffer cystic fibrosi sulfat glycoprotein blood group h activ isol sputum child suffer cystic fibrosi reduct fibrillar mucu chromatographi ecteola cellulos gel filtrat sepharos 4b sulfat glycoprotein degrad alkalin borohydrid degrad product fraction chromatographi ion exchang resin gel filtrat carbohydr chain thu obtain wide heterogen regard acid molecular size neutral chain contain blood group h activ oligosaccharid incomplet chain short 1 residu 2 acetamido2deoxydgalactos minim size neuramin acidcontain chain less sulfat chain increas degre sulfat sulfat group link c6 dgalactos residu
251	tropomyosin antibodi specif local tropomyosin nonmuscl cell antibodi purifi chicken skelet muscl tropomyosin use indirect immunofluoresc visual local tropomyosin varieti nonmuscl cell antibodi produc fluoresc pattern similar obtain actinspecif antibodi pattern compos fluoresc fiber shown coincid fiber seen phasecontrast optic high resolut epifluoresc microscopi reveal fiber stain actin antibodi show continu fluoresc fiber react tropomyosin antibodi show period fluoresc measur indic length fluoresc segment variabl averag 12 mum space segment approxim 04 mum
252	surviv pattern cyctic fibrosi paper describ data registri system cystic fibrosi foundat system annual updat correct data base prepar cystic fibrosi patient seen usa center 1966 1972 data base larg number life tabl studi calcul studi specifi data base observ period analysi age age year year sinc diagnosi center includ condit patient birth possibl addit factor sex age diagnosi race annual rate mortal measur forc mortal techniqu two techniqu use apprais mortal particular group graph cumul surviv function group togeth cumul surviv function compar group calcul mortal ratio actual expect death applic standard mortal tabl latter approach lend readili test signific purpos calcul mortal ratio two standard tabl prepar basi 1972 data base 19661972 observ first standard tabl use age year studi second year sinc diagnosi studi paper comment number mortal studi calendar year sex condit birth age diagnosi surviv diagnosi patient diagnos 19661972 calendar year studi indic improv trend surviv experi 1966 1972 chang may occur studi sex exhibit higher femal mortal 7 patient meconium ileu birth show significantli higher firstyear mortal somewhat lower surviv rate thereaft even first year life experi exclud mortal data group specifi age diagnosi given patient diagnos 19661972 indic better surviv patient diagnos prior 1966 continu mortal studi annual basi understand surviv pattern cystic fibrosi patient
253	urinari excret adenosin 35monophosph guanosin 35monophosph normal children cystic fibrosi urinari excret adenosin 35monophosph cyclic amp guanosin 35monophosph cyclic gmp examin 98 normal children 46 children cystic fibrosi age 9 month 18 yr diurnal variat cyclic amp cyclic gmp excret observ subject either group peak level cyclic nucleotid excret gener observ period 0700 2100 h excret rate mumolday cyclic amp cyclic gmp increas significantli age cyclic amp cyclic gmp excret rate normal urinari creatin bodi weight valu declin significantli age group patient cyclic gmp excret normal bodi surfac area also decreas age valu cyclic amp 286 plu minu 008 mumoldaym2 mean plu minu se constant age normal cystic fibrosi children comparison age group signific differ cyclic nucleotid excret normal subject children cystic fibrosi differ note depend upon method use normal excret rate urinari creatin bodi weight surfac area ratio cyclic amp cyclic gmp excret gener patient cystic fibrosi excret greater amount cyclic gmp normal strike comparison ratio cyclic amp cyclic gmp excret 909 plu minu 050 normal children 441 plu minu 032 children cystic fibrosi p smaller 0001
254	serotyp pseudomona aeruginosa isol patient cystic fibrosi pancrea pseudomona aeruginosa isol 173 144 patient cystic fibrosi cf pancrea seven hospit serotyp agglutin system homma 1974 fisher et al 1969 two system complementari strain cf patient much less like furnish stabl type repetit type test strain patient relat frequent occurr mucoid p aeruginosa strain 173 strain divid among 11 homma serotyp singl homma type type 8 capabl mucoid growth compris 104 60 cf strain eight serotyp detect 77 strain 48 cf patient one hospit three strain detect one hospit cf unit two strain detect five hospit cf unit cf serotyp compris 50 93 cf strain seven hospit p aeruginosa strain dissoci vivo judg mucoid nonmucoid coloni primari cultur plate continu dissoci subcultur coloni type serotyp tendenc regard coloni phenotyp mucoid nonmucoid rough separ strain erron repetit type two system gave better result singl system mucoid p aeruginosa strain probabl spread patient patient rather acquir mucoid characterist de novo cf patient known mucoid cf strain peculiar predilect cf patient gener lose qualiti cultur retain indefinit patient
255	sourc na cl activ skin surfac experi electrod measur children use ionspecif electrod attempt map sodium chlorid activ skin differ surfac condit rang valu standard deviat wide baselin untreat dri skin preclud patient cystic fibrosi wide rang valu also found group measur dri skin taken immedi wash low rang healthi subject rang measur dri skin newborn infant similar fullterm infant reactiv sweat gland prematur infant fail show sweat respons natur reflex stimul well local glandular stimul sudorif drug two condit measur sodium chlorid activ surfac skin valu 1 sweatcov skin detect high valu encount cystic fibrosi 2 dri skin surfac depriv autonom innerv spinal paraplegia extrem low sodium chlorid activ reflect absent gland activ
256	fibrocyst diseas pancrea case report autopsi case cystic fibrosi pancrea 2monthold thai male infant report patient suffer chronic repeat lung infect die lung diseas case seem first report case thailand
257	alphafetoprotein develop diseas alphafetoprotein afp present mani mammal bird shark develop afp present differ speci similar physicochem properti often common antigen determin studi health diseas provid use model understand phasespecif antigen activ gene control synthesi human fetu level afp fall increas matur sensit method detect disclos fetal protein persist trace amount throughout life level increas matern blood pregnanc princip site synthesi fetal liver mammal yolk sac splanchnopleur human well mice cow notabl synthesi afp increas liver cancer cell high level protein present serum elev valu afp also detect human subject undifferenti tumour testi ovari fall normal level note case complet remiss surgeri return high level patient develop metastas patient hepat temporari rise level afp also observ recent year detect high level afp amniot fluid prove great valu prenat diagnosi neuraltub defect abnorm level also found amniot fluid matern serum case spontan abort measur assess method monitor abnorm pregnanc
258	search relev cell cultur research cystic fibrosi one research opinion recent plethora research approach use cell cultur studi cystic fibrosi although effort laud attempt understand one common genet disord affect caucasian popul research relev clinic entiti known cystic fibrosi ultim object research determin yet unknown basic defect develop assay heterozygot detect
259	mucoid strain pseudomona aeruginosa influenc cultur medium stabil mucu product mucoid strain pseudomona aeruginosa isol respiratori tract patient cystic fibrosi cf obtain noncf patient obtain vitro action phage found stabl mucoid coloni form serial subcultur deoxycholatecitr agar abil anion cation neutral surfact stabilis mucu product describ possibl import dipalmitoyl lecithin stabilis agent mucu product vivo consid particular refer role mucoid p aeruginosa cf diseas
260	hepat chang young infant cystic fibrosi possibl relat focal biliari cirrhosi focal biliari cirrhosi uncommon find infant cystic fibrosi present fifth surviv children adolesc found postmortem examin five 47 infant cf younger 3 month five 32 infant 3 12 month 18 67 children older 1 year infant 3 month excess mucu intrahepat bile duct seen 11 necropsi 15 other nonspecif periport chang cholestasi found liver 18 26 infant excess mucu biliari tree occasion associ periport chang cholestasi older infant periport chang regard nonspecif never found infant 1 year age
261	letter vocal cord paralysi cystic fibrosi mani condit report caus vocal cord paralysi knowledg cystic fibrosi describ one condit 15yearold white male cystic fibrosi treat hospit report hoars two week durat routin clinic visit march 1973 march 1974 mirror laryngoscopi reveal paralysi left vocal cord paramedian posit consist paralysi left recurr laryng nerv felt vocal cord paralysi patient cystic fibrosi due compress left recurr laryng nerv enlarg pulmonari arteri
262	tast correl diseas state cystic fibrosi purpos test gener abnorm sensit extern chemorecept system use standard method separ sensori activ bias factor known affect measur sensit frequenc distribut salt tast sensit patient cystic fibrosi given normal sibl control patient differ statist combin singl control group analys patient cystic fibrosi differ group normal subject salt sensit howev two children cystic fibrosi tast sensit well observ among normal children age sex differ sensit observ tast sensit children cystic fibrosi correl shwachman kulczycki rate sever diseas seven children determin sweat electrolyt time tast test three fail excret suffici amount measur patient cystic fibrosi group found sensit tast acuiti normal corrobor find wotman associ strongli suggest gener abnorm tast system routin symptomat cystic fibrosi henkin powel hypothes extrem acut tast relat elev concentr electrolyt sweat seem unlik sinc patient given sweat test present studi high level sodium chlorid characterist cystic fibrosi yet tast sensit normal rang wotman associ suggest perhap sever diseas account appear hypersensit chemorecept system clinic rate sever diseas correl tast sensit
263	plasma membran compon skin fibroblast normal individu patient cystic fibrosi plasma membran isol without proteolyt modif fibroblast line deriv patient cf heterozyg parent normal children cell grown presenc 3h 14c label lleucin glucosamin lfucos membran mix suitabl combin allow comparison made differ cell type differ plasma membran composit reveal diverg 3h 14cprofil could detect gel electrophoresi ident protein glycoprotein compon present approxim similar amount group cell
264	compar patholog marin invertebr studi human diseas studi infect gramneg bacteria limulu led discoveri extrem sensit amebocyt gramneg endotoxin led develop method measur small amount endotoxin biolog fluid human blood yet origin observ cantacuzen larg common edibl spider crab follow remark sensit marin arthropod blood endotoxin would recogn much earlier origin work metchnikoff sea star larva stimul develop major theori phagocytosi adult anim genu reexamin half centuri later presenc power substanc select inhibit growth lymphocyt follow primari immun remain unknown though mucu secret fundament characterist invertebr phyla vertebr littl known regulatori mechan secretori process studi respons special invertebr secretori cell infect led new mean studi macromolecular control mucu secret man three stori emphas continu need studi diseas biolog phenomenon
265	colon enterobacteriacea respiratori tract children cystic fibrosi pancrea antibodi respons 72 patient fibrosi 49 harbor enterobacteriacea respiratori tract includ escherichia coli klebsiella enterobact colon two four genera document 29 subject staphylococcu aureu recov 44 49 patient distribut serogroup e coli similar seen patient urinari tract infect antibodi respons antigen patient enterobacteriacea document 29 49 children encount often patient sever diseas colon enterobacteriacea absenc pseudomona aeruginosa seen frequent children mild form ill
266	growth intellig school perform children cystic fibrosi episod malnutrit infanc studi compar two group children cystic fibrosi one group cf children sever malnutrit first year life wherea second group cf children malnourish catchup growth experienc control malnourish group impress gener complet term height weight age find consist report regard catchup growth follow malnutrit associ celiac diseas anorexia nervosa renal acidosi cush syndrom hypothyroid though malnourish group tend lower iq school perform score differ statist signific except backward digit span differ may indic organ impair due malnutrit sever factor data fail demonstr perman devast effect earli malnutrit rapid growth phase subsequ growth iq school perform children cystic fibrosi studi age 7 10 year
267	absorpt digoxin children cystic fibrosi absorpt digoxin cystic fibrosi evalu 16 subject assess relationship dosag express mugkgday serum digoxin concentr result indic relationship exist mainten dosag serum level patient patient without cystic fibrosi thu evid impair absorpt found
268	signific absent va deferen hernia repair infant children absent va deferen may associ unilater renal agenesi undiagnos cystic fibrosi patient evalu sweat chlorid intraven pyelogram find absent va deferen explor undescend testi provid absolut evid absenc testi sinc structur independ embryolog origin
269	size distribut lymphocyt juvenil rheumatoid arthriti diamet circul peripher lymphocyt measur 28 children juvenil rheumatoid arthriti compar lymphocyt measur 68 normal children 19 children asthma 12 children cystic fibrosi averag diamet lymphocyt normal children found 112 micron contrast averag diamet lymphocyt juvenil rheumatoid arthriti 127 micron p less 00001 lymphocyt diamet 13 15 micron children juvenil rheumatoid arthriti normal children
270	cystic fibrosi chines girl four year old chines girl parent emigr singapor south china found suffer bronchiectasi result repeat chest infect failur thrive investig confirm bronchiectasi cours attempt elucid cours sweat cl sweat na found rais patient occasion pass soft bulki stool vitamin absorpt test abnorm pathogenesi problem diagnosi genet briefli review first prove case cystic fibrosi occur child pure chines stock first describ southeast asia cystic fibrosi occur noncaucasian review
271	letter detect cystic fibrosi heterozygot past year develop new assay cystic fibrosi utilis uss chamber techniqu measur electr properti rat jejunum presenc sera test potenti differ pd resist r measur sensit electromet 5minut interv 60 minut abl detect 90 heterozygot possibl detect remain 10 present feel achiev use concentr specimen
272	letter essenti fatti acid cystic fibrosi measur fattyacid profil cf erythrocyt membran view fact variat membran activ observ system result show lower content linol 182 arachidon 204 cf erythrocyt membran total essentialfattyacid content significantli lower either control group signific differ concentr major fatti acid palmit stearat oleat could observ strike alter concentr minor fattyacid compon membran would thu appear overal fattyacid pattern cf erythrocyt membran alter diminut fatti acid dietari origin fact consider overlap cf control data make rather unlik fattyacid profil close reflect biochem lesion diseas essentialfattyacid level cf sampl compar schwachman clinic score patient surprisingli poor correl r 049 statist signific correl nutrit part clinic score equal low diminish essentialfattyacid content often observ mani acut ill addit possibl exist cf patient may particularli suscept essentialfattyacid deplet due pancreat dysfunct research fattyacid transport metabol cf clearli need establish role essenti fatti acid diseas
273	letter complement cystic fibrosi lieberman report consider overlap quantit c3 level cf subject test control group control group howev compos subject bronchiectasi chronic bronchiti cf rule use proper control group lieberman either place parallel diseas control group would provid meaning interpret concern role complement cystic fibrosi agre tendenc c3 higher cf femal cf male although lieberman quick dispel notion c3a implic aetiolog cf overlook one facet initi studi still make hypothesi feasibl rais c3 level cf oblig heterozygot hann et al report serumc5 rais cf patient parent initi data c5 level radial immunodiffus haemolyt studi confirm find support hypothesi cf either complementcaus complementmedi disord c3alik molecul c3a bradykinin either alon complex igg give rise physiolog patholog state cf
274	letter screen cystic fibrosi read interest dr rain paper would like stress hells kollberg use singl radial immunodiffus method radioimmunoassay prosser et al demonstr quit clearli similar result obtain cysticfibrosi cf screen teststrip elabor method albumin detect meconium use radial immunodiffus well teststrip kollberg group notic decreas albumin content cf meconium store room temperatur mail sever day diminish albumin concentr might brought remain proteolyt activ prosser et al found chang albumin content refriger storag approxim 10 cf case rais albumin content meconium problem yet solv
275	letter frequenc cysticfibrosi gene mr stuart dr burdon specul possibl high frequenc cysticfibrosi gene among caucasian may due heterozygot advantag biolog fit normal homozygot suggest might due increas resist typhu endem europ basi wellknown immunolog crossreact caus organ rickettsia prowazeki certain strain speci proteu vulgari agglutin sera cysticfibrosi patient heterozygot howev evid agglutin immunolog reaction appear microscop associ disorganis inhibit bacteri flagella lead clump organ probabl analog effect cilia rabbit trachea oyster mussel gill cilia factor although associ igg known igg may well c3a compon complement observ salivari sweat gland secret sodium flux suggest phenomena membran rather immunolog effect although possibl proteu flagella antigen could also bind site cilia factor seem improb altern hypothesi heterozygot cysticfibrosi gene increas resist tuberculosi would meet requir common diseas recent endem europ least well typhu suggest indirect evid famili studi demonstr significantli lower incid tuberculosi among parent cysticfibrosi patient among parent control
276	letter fattyacid oxid cystic fibrosi natur metabol defect cystic fibrosi cf unknown therefor undertook studi fattyacid oxid betaoxid patient cf signific differ result obtain control either affect individu heterozyg carrier valu affect individu lay within normal rang unless special reason defect express leukocyt result indic metabol pathway involv fattyacid oxid betaoxid intact cf therefor seem unlik report defici certain essenti fatti acid cf result defect fattyacid metabol
277	letter c3 cystic fibrosi believ serumlevel individu complement compon children cannot meaning interpret unless compar normal valu obtain agematch control studi 163 healthi infant children found statist signific correl c3 level age sex race also found wide rang valu within given agegroup contrast previou report find rais c3 level major cf patient valu compar project group mean valu appropri age find signific elev mean c3 level cf patient agegroup test
278	letter heterozygot advantag cystic fibrosi recent studi attempt assess person characterist mother father children cystic fibrosi 150 parent interview cours interview taylor manifest anxieti scale fould person inventori 16 pf test form use appar parent repres wide rang person type differ way gener popul
279	letter essentialfattyacid metabol cystic fibrosi 6 patient proven cystic fibrosi wide varieti schwachman clinic score studi control 10 healthi children undergo minor elect surgic procedur result show children cystic fibrosi decreas proport essenti fatti acid 203 omega9 found case result suggest intrins defect desatur system cystic fibrosi pattern essentialfattyacid defici entir similar found dietari defici essenti fatti acid signific find occur 203 omega9 appar healthi children particularli young probabl dietrel emphasis young child larg requir essenti fatti acid membran synthesi need adequ polyunsatur fatti acid childhood cannot overst whether normal membran synthesi lower serumlipid give possibl protect cardiovascular diseas
280	letter essenti fatti acid cystic fibrosi three literatur report linol acid la level cystic fibrosi cf compar control alway significantli lower arachidon acid aa similarli percentag lower also la aa thu overwhelm evid block absent desaturas caus efa defici must elsewher found 25 total fatti acid serum red cell c203omega9 cf patient shown acid stage perman featur fatti acid profil report c203omega9 would probabl act inhibitor prostaglandin format aa interest conjectur whether could account symptom cf c203omega9 would also incorpor pi could alter membran properti
281	letter essentialfattyacid metabol cystic fibrosi investig effect intestin malabsorpt plasmalipid compar fattyacid composit serumlecithin 23 patient malabsorpt varieti differ caus found similar chang irrespect underli caus malabsorpt except classic efa defici found patient whose malabsorpt due massiv smallbowel resect caus malabsorpt gave rise chang ident found worker cf thu reason postul addit metabol abnorm specif cf rel normal amount arachidon acid report efa defici patient may entir due arachidon acid
282	letter cystic fibrosi detect heterozygot samuel elliott describ new techniqu detect cystic fibrosi cf heterozygot cf test techniqu detail smaller number patient although number sampl test studi small result suggest techniqu like success detect heterozygot cf
283	letter defect essentialfattyacid metabol cystic fibrosi mr river mr hassam propos subnorm level linol acid 182 found plasmaphospholipid patient cystic fibrosi due malabsorpt substanti hypothesi deduc remark remiss observ cysticfibrosi patient given intraven intralipid due 182 content 20 triglycerid compon fat emuls 204 content 12 phospholipid compon 6 state explan seem unlik view rel small proport 204 intralipid phospholipid especi sinc intraven administr intralipid phospholipid healthi subject decreas 182 204 content plasmaphospholipid comparison effect complet intralipid versu intralipid phospholipid level 204 plasmaphospholipid patient cystic fibrosi would soon determin whether lack abil desatur 182 204
284	pancreat supplement prematur babi letter time use screen test cystic fibrosi base level stool trypsin chymotrypsin fourth day life one interest observ number prematur babi littl pancreat trypsin chymotrypsin time exampl babi test st helen matern hospit june 1974 april 1975 84 classifi prematur birthrecord book sampl receiv 65 babi 65 babi 26 40 stooltrypsin level 100 microg per g compar 25 babi test period may expect lowerbirthweight babi tend lower stoolenzym concentr feel data indic least prematur babi would benefit pancreaticenzym supplement predigest food first day birth
285	defect essentialfattyacid metabol cystic fibrosi cystic fibrosi cf characteris low serum level essenti fatti acid efa howev fattyacid pattern total resembl dietari efa defici differ suggest reduct desatur ef known whether defect primari lesion cf result tissu damag diseas propos cf patient might increas linoleicacid requir possibl specif requir desatur product
286	letter cystic fibrosi detect heterozygot develop new techniqu detect cystic fibrosi cf heterozygot cf assay done laboratori aggregomet measur platelet aggreg quantit result obtain compar transmitt record adp ad plateletrich plasma prp cf patient known heterozygot ratio 4 9 time higher healthi subject test prp 40 healthi peopl 25 patient cf 40 known heterozygot could detect cf patient 95 known heterozygot ct 1 burdick hum here 27 366 977 2 hamdi monogr paediatr 10 84 979 3 mancuso g riv ital pediatr 8 665 982 4 davi pb j med sci 288 104 984
287	skin wrinkl cystic fibrosi notic case cystic fibrosi palmar skin finger plantar skin toe wrinkl quickli immers water almost without except children cystic fibrosi notic wrinkl finger within 2 min immers handhot water wherea normal children show minim wrinkl 10 min wrinkl due excess salt skin increas waterbind capac keratin test would thu appear provid simpl cheap screen method cystic fibrosi one may absolut reliabl
288	advers effect iodid thyroid function administr pharmacolog quantiti iodin iodid treatment pulmonari diseas organ iodin present medic xray contrast dye ingest iodinerich natur food may result goiter hypothyroid hyperthyroid especi patient underli thyroid diseas medic contain iodid may induc hypothroid euthyroid patient hashimoto thyroid 131i surgic treat grave diseas follow hemithyroidectomi nodul may induc hyperthyroid patient endem iodin defici goiter autonom nodul nontox nodular goiter patient recent treat antithyroid drug grave diseas rare hypothyroid hyperthyroid may develop patient complet normal thyroid function administr iodid etiolog iodideinduc goiter hypothyroid patient cystic fibrosi remain obscur iodideinduc myxedema may also occur patient receiv drug alter thyroid function lithium phenazon sulfisoxazol final iodid role treatment hyperthyroid use probabl restrict thyroid storm preoper prepar hyperthyroid patient follow 131i treatment
289	challeng cystic fibrosi cystic fibrosi cf gener disord exocrin gland inherit recess genet trait diseas fulli describ specif entiti 1939 patholog dilat duct fibrot chang pancrea copiou secretori intralumin obstruct bronchial tree symptom predomin involv gastrointestin tract frequent bulki malform malodor stool respiratori system cough wheez sign chronic respiratori obstruct certain instanc one two system manifest symptom sign increas concentr sodium chlorid sweat discov 1953 elev salt concentr sweat proven reliabl diagnost tool confirm presenc diseas diseas present mani differ form degre sever differ age cf present treatment cystic fibrosi essenti symptomat sinc studi famili child cystic fibrosi shown incid diseas one fourth sibl classif diseas autosom recess genet disord suggest concept abnorm gene relat alter singl enzym appli diagnosi cystic fibrosi childhood overwhelm even patient famili
290	recurr diarrhoea children diarrhoea defin passag loos stool increas bowel frequenc accept norm individu result excess loss water electrolyt faec may may associ steatorrhea fatti stool histori play vital part diagnosi gastrointestin diseas children time spent often reward batteri specialis investig one must clear parent mean diarrhoea terminolog among doctor nurs parent often confus deal children one must alway adopt comprehens approach consid whole child famili common caus mechan consequ discuss common caus diarrhoea cystic fibrosi gluteninduc enteropathi coeliac diseas giardia lamblia sugar intoler gastrointestin allergi irrit bowel syndrom
291	nurs care studi sallya child cystic fibrosi fibrocyst diseas common diseas childhood pancrea abnorm 90 case fibrosi atrophi exocrin parenchym tissu islet cell tissu rare involv mucou gland throughout bodi grossli distend secret abnorm viscid mucu sweat gland appear normal secret sweat abnorm high concentr electrolyt characterist featur diseas widespread chronic bronchiol due staphylococcu aureu grow best saltrich medium
292	patholog infertil seri infertil patient approxim 40 60 percent discern caus infertil wonder work condit tend seiz upon demonstr tissu abnorm relat infertil use fallibl diagnost tool may lead misdiagnosi inappropri treatment studi accuraci dye inject demonstr tubal patenc roentgenogram larg error introduc method emphas 30 40 percent tube found block use singl dye examin use criterion fill spill periton caviti appar obstruct uterotub junction subsequ found patent similar data offer other lesion less obviou demonstr causal relationship infertil pelvic adhes endometriosi difficult judg etiolog relat assess discuss male femal infertil
293	gastrointestin manifest cystic fibrosi histor view cystic fibrosi cf consid diseas pancrea result maldigest loss fat nitrogen stool number earli synonym includ congenit steatorrhea pancreat infantil pancreat fibrosi concern pediatrician late 1930 earli 1940 distinguish nonfat celiac diseas fatal cystic fibrosi 1954 shwachman present clinic laboratori featur distinguish two entiti today one justifi make diagnosi celiac diseas without confirmatori small intestin biopsi coupl normal sweat test number gastrointestin complic cystic fibrosi examin meconium ileu intestin obstruct pancreat insuffici lactas defici intestin impact intussuscept rectal prolaps growth retard excess appetit cirrhosi portal hypertens gallbladd problem diabet articl close record indic sweat test
294	new assay cystic fibrosi factor effect sera patient cystic fibrosi vitro electr properti rat jejunum vitro electr properti rat jejunum util assay factor factor serum patient cystic fibrosi cf sera patient cf found decreas short circuit current scc scc respons glucos increas electr resist effect present 24 patient cf 10 14 parent cf patient absent serum 21 control subject quantit techniqu provid altern ciliostat assay detect cf factor factor
295	inhibit ouabainsensit atpas saliva patient cystic fibrosi pancrea studi made effect saliva children cystic fibrosi pancrea cfp variou compon atp hydrolyz enzym system ouabainsensit atpas activ erythrocyt membran prepar intact erythrocyt preincub cfp saliva 35 4 nmol pimg fri wt membran suspensionhr compar 48 7 nmol pimg dri wt membran suspensionhr erythrocyt preincub control saliva calciumactiv compon atpas decreas 202 30 nmol pimg dri wt membran suspensionhr erythrocyt preincub control saliva 151 17 nmol pimg dri wt membran suspensionhr incub carri cfp saliva second seri experi ultrafilt saliva ad directli atpas assay saliva children cfp brought mean decreas ouabainsensit atpas 16 compar control saliva
296	studi cystic fibrosi use isoelectr focus assay detect cystic fibrosi homozygot heterozygot carrier serum develop standard biophys assay rapid detect individu homozyg heterozyg cystic fibrosi cf assay employ isoelectr focus thin layer polyacrylamid gel analyz microlit quantiti whole serum presenc cf factor protein delet group protein call protein b c fig 1 ph 510 gradient use fig 2 sampl screen use serum volum contain 300 g immunoglobulin g igg individu homozyg heterozyg cf distinguish normal unaffect individu basi presenc cf factor protein band tabl 1 heterozyg carrier cf distinguish cf homozygot 75 percent time basi delet either band b c tabl 2 basi screen 65 patient cystic fibrosi 61 heterozyg carrier cf 105 normal control subject conclud obviou correl exist either sex age sever diseas individu cf patient absolut presenc absenc cf factor addit correl exist sex age presenc cf factor delet protein b c individu heterozyg carrier cf normal control subject analysi serum sampl 68 patient varieti diseas mani clinic symptom resembl seen patient cystic fibrosi tabl 3 indic cf factor protein describ studi appear diagnost cf genotyp possibl except patient certain type leukemia
297	defici arginin esteras cystic fibrosi pancrea demonstr proteolyt natur activ proteolyt activ defin hydrolysi peptid bond involv carboxyl group larginin plasma patient cystic fibrosi heterozygot control subject assay use fluorometr method protamin substrat fluorescamin reagent mean total proteolyt activ plasma patient cystic fibrosi approxim onehalf mean total activ control subject heterozygot mean proteolyt activ inhibit soybean trypsin inhibitor plasma patient cystic fibrosi approxim onethird control subject heterozygot relationship arginin esteras activ proteolyt activ investig ph optimum action revers irrevers inhibitor similar activ suggest arginin esteras activ proteolyt activ repres similar catalyt entiti find consist hypothesi basic defect cystic fibrosi may resid defici proteolyt enzym result accumul variou cation macromolecular factor describ investig serum patient cystic fibrosi demonstr defici proteolyt activ assay hydrolysi protamin cation polypeptid could explain presenc ciliotox cation protein polypeptid factor serum patient cystic fibrosi may unknown manner relat clinic manifest diseas
298	demonstr human leukocyt degranul induc sera homozygot heterozygot cystic fibrosi abil epsilonamino caproic acid eacatr normal serum cystic fibrosi cfaffect carrier sera promot releas lysosom enzym sensit human polymorphonuclear leukocyt pmn assess measur beta glucuronidas myeloperoxidas activ exposur cell variou test sera studi initi extend analog preciliari dyskinesia factor precdf separ cellfre media cultur deriv cf homozyg heterozyg individu c3a anaphylatoxin extent lysosom degranul human pmn expos fresh untreat sera five control seven cf homozygot eight heterozygot express amount betaglucuronidas releas 784 0934 control sera 1401 179 cfaffect sera 1061 143 heterozyg sera differ cf homozygot control subject signific p less 00001 differ cf affect carrier individu 0001 less p less 0005 control subject carrier 0001 less p less 0005 betaglucuronidas howev differ control subject cf heterozyg individu signific treatment sera 1 eaca gave valu betaglucuronidas myeloperoxidas releas slightli reduc compar obtain fresh untreat sampl eaca appar reduc activ betaglucuronidas releas pmn amicon filtrat studi serum sampl demonstr degranul abil presenc cilicari dyskinesia assess rabbit tracheal bioassay alway associ therefor relationship precdf degranul activ nativ cfaffect carrier sera unclear part limit inher test system employ
299	serum glutathion reductas cystic fibrosi serum glutathion reductas nadphgssg oxidoreductas ec 1642 gr examin cystic fibrosi subject cf oblig cf heterozygot control subject serum protein concentr similar three group regardless unit use express activ milligram protein millilit serum whether sampl dialyz water phosphat buffer mean serum gr cf greater control subject p less equal 0002 seri sever year assay condit differ serum gr control subject carrier detect calcul assay valu combin control cf sera agre expect observ 50 activ 12 sera dilut cf control subject carrier addit fad incub media effect enzym activ three group differ cf control subject persist dialysi membran permit passag molecul approxim 12000 mol wt less find would tend exclud effect extran serum factor explain differ cf control subject percentag initi gr activ four day storag 04 degre significantli greater cf control subject p less 0025 effect heparin serum gr record percentag activ incub heparin vs activ standard assay individu subject effect incub 5 mugml heparin serum gr activ greater control subject carrier p less 00005 cf p less 00005 mean serum gr activ cf carrier unaffect heparin wherea mean activ control subject decreas control percentag initi activ heparin greater mean cf carrier group 3 20 cf 4 20 carrier individu percentag lower control mean cf carrier distribut clearli differ control distribut serum gr determin seven noncf individu chronic obstruct pulmonari diseas copd activ copd differ cf differ control subject none control copd serum gr great cf mean serum gr cf low mean control subject copd conclud serum gr activ greater cf control subject carrier noncf copd subject differ activ attribut extran serum factor activ differ secondari chronic respiratori diseas comparison control subject gr cf serum behav differ storag serum gr cf carrier behav differ control gr presenc heparin
300	brine shrimp diagnos cystic fibrosi nauplii brine shrimp artemia salina depend upon function salt gland maintain osmot pressur within narrow limit number drug interfer function lethal nauplii saliva serum normal person patient cystic fibrosi oblig heterozygot test lethal effect brine shrimp nauplii salt concentr 100 mm 25 differ found among phenotyp lower concentr differ note occasion normal subject individu carri one two gene cystic fibrosi data independ seri experi indic naupliar death result distort ratio nak specif gene product differ note o2 uptak nauplii treat saliva serum obtain normal subject patient cystic fibrosi oblig heterozygot
301	chronic reserpin rat possibl model cystic fibrosi submaxillari gland morpholog ultrastructur rat treat 7 day reserpin develop structur chang submaxillari gland resembl report cystic fibrosi salivari exocrinopathi character increas amount pasreact mucoprotein acinar cell obstruct dilat duct precipit materi stain characterist found acinar element
302	arylsulfatas b defici maroteauxlami syndrom cellular studi carrier identif arylsulfatas b defici demonstr peripher leukocyt cultur skin fibroblast lymphoid line deriv patient ml patient parent demonstr level arylsulfatas b intermedi found patient control subject activ mean plu minu sd leukocyt normal subject patient parent patient 1137 plu minu 362 310 52 nmol 4nitrocatecholmg proteinhr respect skin fibroblast subject activ 1452 plu minu 416 585 70 respect nine lysosom enzym normal skin fibroblast patient arylsulfatas b activ detect lymphoid line establish patient ml arylsulfatas b activ cultur amniot fluid cell 10 normal pregnanc 2032 plu minu 499
303	chronic reserpin rat possibl model cystic fibrosi ii comparison cilioinhibitori effect submaxillari saliva submaxillari saliva reserpinetr rat found alter composit similar report secret patient cystic fibrosi chang includ elev concentr na ca protein carbohydr addit saliva found ciliotox properti similar cf serum similar cilioinhibitori effect salivari composit histolog appear justifi use chronic reserpin rat model cystic fibrosi
304	complex saccharid metabol cystic fibrosi fibroblast sever report secretori abnorm present cultur fibroblast patient cystic fibrosi cf therefor investig aspect complex saccharid synthesi secret cell compar fibroblast deriv heterozyg hz parent normal n children main glycosaminoglycan produc skin fibroblast vitro cultur hyaluron acid heparan sulfat dermatan sulfatelik materi use doublelabel experi d3h 14cglucosamin analyz product ion exchang chromatographi shown five cf two hz four n line polysaccharid secret medium approxim similar proport moreov experi three cf nine hz three n line grown log phase 5 day presenc 35ssulfat 3hglucosamin indic period cf fibroblast secret complex carbohydr rate significantli differ n hz cell neither cell shown abnorm intracellular accumul complex carbohydr latter observ confirm prepar whole cell autoradiograph growth six cf two hz three n line presenc d3hglucosamin subsequ addit unlabel medium
305	polyamin cystic fibrosi polyamin concentr measur blood sampl seri cystic fibrosi cf patient control subject analys made fluorometr method amin react dansyl chlorid separ thin layer chromatographi kieselguhr signific differ polyamin concentr blood sampl cf patient control subject also spermidinespermin ratio similar group polyamin also analyz exocrin fluid although none could detect either cf control sweat saliva signific amount spermin spermidin present sampl bile duoden fluid thu seem like biliari rout signific pathway human excret polyamin observ polyamin excret consider concentr via bile children may interest view report elev urinari polyamin concentr neoplast state sinc measur amount spermin spermidin detect six bile prepar avail studi analysi substanc bile may benefit particular case
306	recurr acut pancreat patient cystic fibrosi normal pancreat enzym ten adolesc young adult cystic fibrosi cf welldocu recurr attack acut pancreat diagnosi cf patient delay pancreat insuffici diagnosi cf document typic pulmonari involv elev sweat sodium chlorid level case posit famili histori six ten patient two patient diagnos acut pancreat diagnosi cf made thu indic acut pancreat may present complaint young adult cf diagnosi acut pancreat base presenc sever abdomin pain usual vomit tender mid epigastrium elev serum urinari amylas serum lipas attack precipit fatti meal alcohol ingest postcholecystectomi tetracyclin administr patient precipit event could elicit intraven secretin pancreozymin stimul test reveal diminish bicarbon secret littl effect secret zymogen enzym mild attack pancreat occur secretinpancreozymin stimul endocrin pancreat function test four patient normal reveal glucos toler test determin serum insulin growth hormon free fatti acid transduoden pancreatogram perform three patient one show normal pancreat duct one show duct obstruct third patient beadi type narrow found selenomethionin se 75 uptak pancrea note head pancrea suggest loss function occur initi greater extent tail bodi pancrea three patient die show characterist lesion cf
307	letter comment outpati intraven therapi recent trend treat pediatr patient chronic diseas ambulatori basi true hemophilia cystic fibrosi despit success keep slightli two third patient hospit think might success futur follow point consid first mani initi select intraven medic due nonrespons oral therapi later consid failur intraven treatment might actual noncompli second point concern lack followup within patient home would seem would ideal place public health nurs check patient condit ensur procedur properli follow actual field condit correct amount medicin util dr david letter regard potenti problem noncompli home followup use outpati intraven antibiot point need type therapi institut center facet well control public health nurs util center supervis assist home manag cystic fibrosi good success
308	studi cor pulmonal cystic fibrosi effect diuresi effect acut diuresi patient cor pulmonal secondari cystic fibrosi studi hemodynam paramet arteri blood ga chang investig major effect note signific reduct system venou pressur pulmonari arteri pulmonari arteri wedg pressur either remain constant declin slightli consist chang note cardiac output arteri blood gase acut diuresi moder degre appear safe effect manner treat system venou congest cor pulmonal situat
309	endogen exogen insulin respons patient cystic fibrosi eight male patient cystic fibrosi normal nutrit normal physic activ rel mild pulmonari diseas evid liver diseas famili histori diabet mellitu underw seri carbohydr toler test comparison group 18 normal male subject match age bodi weight compar normal group patient cystic fibrosi significantli impair glucos toler significantli lower serum immunoreact insulin level oral intraven glucos toler test serum insulin level also significantli lower intraven administr tolbutamid patient cystic fibrosi reduct blood glucos concentr group significantli differ intraven insulin test decreas blood glucos concentr group spite significantli lower serum insulin level patient cystic fibrosi percentag fall plasma free fatti acid least great patient cystic fibrosi normal test procedur signific decreas plasma alphaamino nitrogen intraven administ insulin seen patient cystic fibrosi studi suggest carbohydr intoler cystic fibrosi consequ upon impair insulin respons glucos insulin defici partli compens increas peripher tissu sensit insulin
310	cystic fibrosi detect mean teststrip effect meconium screen albumin indic cystic fibrosi examin bmtest meconium appli 69000 investig 60 posit test cystic fibrosi confirm later increas albumin content observ four case cystic fibrosi
311	studi meconium disaccharidas activ meconium cystic fibrosi patient control meconium ileu repres earliest clinic manifest cystic fibrosi differ found composit amount protein mucoprotein mucopolysaccharid reduc sugar meconium newborn cystic fibrosi might signific rel pathogenesi earli diagnosi diseas studi enzymat activ disaccharidas lactas sucras maltas palatinas meconium infant cystic fibrosi control found increas specif activ enzym meconium infant cystic fibrosi compar specif activ meconium normal infant increas activ express micromol per gram protein per minut lactas 100 time higher sucras 18 time maltas 48 time palatinas 89 time
312	enhanc renal excret dicloxacillin patient cystic fibrosi singl oral dose 625 mgkg dicloxacillin suspens given ten cystic fibrosi cf patient eight normal subject peak serum concentr area concentr versu time curv dicloxacillin variabl averag 2 12 time lower cf patient time occurr peak serum concentr similar group total urinari recoveri dicloxacillin normal increas cf patient suggest intestin absorpt drug unaffect diseas low serum concentr cf patient caus unusu high renal clearanc dicloxacillin averag 282 135 compar 95 28 mlmin173 sq normal subject creatinin clearanc also elev cf patient 55 averag urea clearanc normal serum protein bind dicloxacillin similar group subject rapid excret result low variabl serum concentr antibiot treatment cf patient dicloxacillin may warrant use increas frequent dose monitor serum antibiot level
313	cystic fibrosi comparison two mucolyt drug inhal treatment acetylcystein arginin hydrochlorid clinic bronchoscop spirograph scintigraph chemic analys done 24 children cystic fibrosi assess mucolyt effect acetylcystein inhal versu larginin hydrochlorid aerosol latter drug less activ acetylcystein use treat children cystic fibrosi
314	patholog cystic fibrosi review literatur comparison 146 autopsi case review patholog find cystic fibrosi includ survey morpholog chang origin descript cf numer subsequ report analysi 146 case autopsi john hopkin hospit bill hospit achylia occur 85 90 patient approxim 1 7 patient cf present meconium ileu 1962 describ gallbladd abnorm 24 72 case cf 33 anderson origin descript cf hemosiderosi present nearli everi liver fatti infiltr frequent find respiratori tract invari involv cf heart never consid primari target organ cf bodian describ higher incid nephrocalcinosi cf routin pediatr autopsi 31 compar 11 increas longev patient cf male steril becom recogn complic increas electrolyt concentr sweat diagnost manifest cf although occasion patient escap defect nasal polyp frequent often recurr problem patient cf malabsorpt due pancreat exocrin defici origin describ main manifest cf autopsi diagnosi cf usual base combin lesion rather chang singl organ
315	evalu bronchial drainag patient cystic fibrosi examin studi result six test pulmonari function immedi preced follow bronchial drainag twentysix patient cystic fibrosi highli signific increas averag 567 413 1347 698 percent occur peak expiratori flow rate forc vital capac expiratori reserv volum inspiratori capac respect signific increas peak expiratori flow rate forc vital capac inspiratori capac observ subgroup six patient evid bronchospasm author conclud bronchial drainag produc signific increas routin pulmonari function valu result suggest treatment effect clear larger proxim airway benefit even presenc clinic bronchospasm
316	olfactori tast sensit children cystic fibrosi psychophys experi measur olfactori sensit 1 butanol sodium chlorid tast sensit sodium chlorid normal children children cystic fibrosi sensit children cystic fibrosi fell within normal rang result stand contrast henkin powel found children cystic fibrosi hypersensit olfactori tast stimuli appar hypersensit tast stimuli could result adapt effect rel high level sodium saliva children cystic fibrosi contamin effect saliva remov children cystic fibrosi yield averag tast threshold ident normal children appear simpl explan henkin powel found hypersensit odor present result indic fact children cystic fibrosi display slight hyposensit odor
317	quest basic defect cystic fibrosi search basic defect cystic fibrosi far singularli disappoint doubt diseas recess inherit ie parent carri cystic fibrosi gene without show sign ill health heterozyg transmit offspr child manifest diseas acquir abnorm gene doubl dose homozygot cystic fibrosi common genet determin diseas two type cultur cell fibroblast white cell affect individu heterozyg carrier cystic fibrosi show characterist chang metachromasia seem allow classif patient carrier distribut separ class serum patient cystic fibrosi pancrea disorganis movement cilia isol rabbit tracheal mucosa one earli also constant observ viscos secret mucos gland respiratori tract alimentari apparatu biliari system pancrea strike increas level sodium chlorid lesser extent potassium present sweat practic suffer cystic fibrosi howev frustrat tantalis outcom research basic defect far ultim answer like astonish simplic
318	inhal therapi cystic fibrosi inhal therapi divid two type intermitt aerosol therapi use administ medic brief period mist tent therapi use prolong period treatment present state knowledg basic defect cystic fibrosi make imposs give hard fast guid line use inhal therapi much depend individu experi physician degre pulmonari involv individu patient respons bronchodil assess rel easili assess mucolyt antibiot difficult antibiot use help clear infect patient earli diseas judg clear pathogen cough swab sputum patient chronic cough larg volum purul sputum posit cultur gram neg bacteria cultur never becom neg occasion patient definit clinic benefit claim sever ill patient dramat improv therapi introduc patient convinc benefit treatment cours imposs diseas vari clinic cours prove scientif inhal therapi reason improv
319	physiotherapi adolesc adult cystic fibrosi physiotherapi adolesc adult cystic fibrosi continu along line younger patient certain modif may necessari fit chang need patient transfer care paediatrician thorac physician may help admit hospit reassess admiss opportun taken review daili physiotherapi regimen patient parent postur drainag use aerosol breath exercis longterm followup complic haemoptysi spontan pneumothorax use intermitt posit pressur breath termin care discuss
320	genet incid cystic fibrosi cystic fibrosi genet determin disord evid cystic fibrosi inherit way come sever sourc birth frequenc cystic fibrosi unexpectedli high britain seriou ill easi calcul proport popul carrier birth frequenc diseas explan unlik high birth frequenc cystic fibrosi europ known attempt reduc substanti birth frequenc cystic fibrosi becom possibl practic detect reliabl carrier gene
321	physiotherapi children cystic fibrosi import regular effici postur drainag cannot emphasis strongli parent preschool primari school children young enough physic abl play major role routin physiotherapi treatment parent requir great deal support encourag physiotherapist must readi organis profession physiotherapi crisi time famili well event exacerb
322	medic manag cystic fibrosi manifest cystic fibrosi make complex diseas manag respiratori physician microbiologist gastroenterologist last least psychologist involv 1 10 babi cystic fibrosi born acut intestin obstruct due plug small intestin sticki meconium diagnosi made test excess salt sweat although possibl soon birth easier carri three week age babi sweat freeli great major children treat tend suffer progress frequent chest infect chronic chest infect reason tendenc lung children cystic fibrosi becom colonis harm bacteria known cystic fibrosi children absorb carbohydr normal 50 rang 45 80 protein fat eat major problem activ measur may requir occurr fibrosi liver 5 children children cystic fibrosi brought begin like children
323	cystic fibrosi adolesc adult improv treatment children suffer cystic fibrosi increas averag surviv 17 year age mani patient diseas come care thorac physician nearli everi patient bronchopulmonari diseas major problem pneumothorax encount 15 older patient occur bilater patient develop refractori airway obstruct trial steroid justifi patient cystic fibrosi also requir treatment pancreat insuffici diabet mellitu common cystic fibrosi normal popul analysi sweat essenti diagnosi psycholog stress impos upon patient famili great
324	emot problem cystic fibrosi emot distress associ cystic fibrosi consider moment diagnosi delay parent problem multipli part problem first vagu comprehend mani parent embark long haul care child almost total ignor diseas implic fact diseas inherit outstand import parent basi genet counsel diseas explan recess inherit even genet counsel given effect parent decid children famili plan problem yet solv physiotherapist also necessarili concern emot state behaviour child except latest stage diseas child emot distress directli relat discomfort symptom overprotect parent understand import persuad undesir perhap difficult question protect aris relat child knowledg disord cystic fibrosi miser diseas caus much distress emot otherwis
325	cystic fibrosi cystic fibrosi fibrocyst diseas pancrea common inherit diseas date still fatal outcom divers clinic manifest patholog find ad mysteri natur diseas tantalizingli conflict result biochem physic experiment studi mani laboratori western world one constant clinic observ viscos secret mucos gland respiratori alimentari tract duct biliari system pancrea approxim 10 15 per cent patient cystic fibrosi pancrea earliest manifest meconium ileu occur neonat period remain 85 90 per cent affect infant symptom gener becom evid within cours first year life lung symptom tend domin clinic pictur vast major untreat patient ultim decid outcom lower respiratori tract part involv nasal polyp accumul viscou secret paranas sinus subsequ bacteri infect unusu pancreat defici present vast major patient cystic fibrosi consist gross reduct complet absenc exocrin secret although histolog damag seen neonat period infant suffer meconium ileu gener fullblown pictur extens cirrhosi portal hypertens hepatosplenomegali sever sometim fatal haemorrhag oesophag varic seen older child adolesc screen newborn enabl institut protect measur lung complic aris attempt variou techniqu manag includ diet pancreat enzym replac treatment pulmonari diseas import aspect care patient cystic fibrosi prevent prioriti number one overal manag outlook child born cystic fibrosi depend larg extent upon avoid delay adult life two complic threaten exist cor pulmonal cirrhosi liver
326	screen earli detect diseas great britain account given screen earli detect diseas great britain today organis screen programm provid nation whole popul describ includ programm prenat care screen infant screen schoolchildren screen women carcinoma situ uterin cervix select screen programm tuberculosi variou industri diseas mention experi provis servic nation scale emphasis import evalu futur screen programm implement research studi effect possibl harm side effect cost evid research screen number diseas briefli summar conclud may develop programm earli detect treatment hypertens breast cancer diseas multiphas screen evid far avail insuffici warrant immedi extens research toward servic
327	studi immunoglobulin healthi children variou stage develop chosen ill studi carri view evalu develop immunoglobulin biosynthesi children birth first year life age 15 year well establish normal valu immunoglobulin class healthi children differ age condit investig geograf social econom situat also consider evalu bodi reaction antigen stimul administr gammaglobulin prepar order determin broadli develop humor immun paramet children qualit quantit investig immunoglobulin undertaken also chosen ill chang biosynthesi metabol immunoglobulin may connect pathogenesi ill type treatment cystic fibrosi cf ataxiatelangiectasia syndrom pituitari dwarfism fenyloketonuria pku group children investig systemat repeat evalu dynam chang
328	growth characterist protein content tissuecultur fibroblast cystic fibrosi patient prolifer rate cellular protein content measur cultur fibroblast deriv skin normal volunt cystic fibrosi patient three method measur growth indic condit cf fibroblast divid normal mean doubl time 29 hr logarithm growth phase howev lower cell proteindna ratio observ consist cf cultur differ present contactinhibit confluent fibroblast find appar reduct protein synthesi rapid divis coupl observ other cf fibroblast fail normal induc collagen format suggest possibl disturb biochem regul protein synthesi
329	insulin iontophoresi cystic fibrosi insulin vehicl without insulin administ separ iontophoresi patient cystic fibrosi cf oblig heterozygot healthi control result sweat chlorid concentr treatment prepar compar individu differ two treatment found control sampl decreas sweat chlorid concentr insulin iontophoresi comparison vehicl observ cf p smaller 0005 heterozygot p smaller 001 sampl observ suggest involv insulin cf possibl role insulin sweat gland function
330	decreas inhibit platelet aggreg pge1 children cystic fibrosi parent pge1 inhibit adpinduc platelet aggreg children cystic fibrosi parent much lesser extent normal control suggest may reliabl test heterozygot carrier cystic fibrosi
331	visibl fatti liver fatti infiltr liver identifi roentgenograph sever young children awar possibl sometim allow radiologist contribut understand patient metabol nutrit state child liver shown abnorm radioluc cystic fibrosi consid
332	select bronchial arteriographi patient cystic fibrosi massiv hemoptysi massiv hemoptysi potenti fatal complic long stand cystic fibrosi lobectomi may prevent hemorrhag death hemorrhag sourc identifi involv remain lung tissu mild select bronchial arteriographi perform six patient cystic fibrosi local lobar sourc bleed arteriograph find correl bronchoscop observ bronchial arteriographi may help bronchoscopi cannot done continu hemorrhag sever lung diseas preclud gener anesthesia adequ substitut bronchoscopi patient
333	bronchial labil children suffer diseas bronchi author studi bronchial reactiv children cystic fibrosi deform bronchiti reaction bronchi studi inhalatori exercis provoc inhalatori test monitor mean whole bodi plethysmograph free rang run use exercis test peak expiratori flow rate measur describ techniqu inhalatori test accur safe tire patient distinct differ bronchial reaction two group patient could state bronchial reaction inhalatori exercis test stronger group normal strong asthmat natur bronchial hyperreact patient still unknown inhalatori test seem sensit exercis test detect hyperreact
334	cystic fibrosi south west african afrikan exampl popul drift possibl heterozygot advantag incid genet recess diseas cystic fibrosi mucoviscidosi far excess report recent countri encount south west african afrikan probabl result immigr segment south african afrikan popul rich gene south west africa religi reason reason geograph isol gene persist perhap increas frequenc malaria kill mani earli settler might select spare carrier gene thu enrich occurr popul detail patient particularli regard criteria diagnosi given relev popul birth figur estim incid diseas carrier rate made screen newborn condit compil regist potenti obligatori carrier also discuss
335	electrophoret separ detect variat amylas isoenzym electrophoret techniqu demonstr amylas isoenzym describ separ agaros gel contain linear polyacrylamid polym reduc electroendosmot flow amylas fraction visual incub commerci avail dyestarch polym phadeba amylas test techniqu detect amylas fraction activ 10 ul characterist chang diseas acut chronic pancreat cystic fibrosi pancrea macroamylasemia inherit variant well maxillofaci surgeri mention
336	sourc serum isoamylas normal rang variat age isoamylas variou human tissu homogen bodi fluid separ agaros gel electrophoresi noth suggest signific product amylas liver minut amount amylas belong pancreat group isoamylas might produc gland proxim duodenum specif group isoamylas produc femal genit tract could demonstr serum urin activ amylas serum deriv two group isoenzym one group origin salivari gland pancreat gland contribut two sourc total serum amylas determin earli foetal life adult age low activ salivari isoamylas regularli found serum 14weekold foetus activ increas steadili age reach normal adult level 80 ul age 5 year pancreat group isoamylas serum develop later major children 3 month demonstr pancreat isoamylas activ activ rose slowli reach adult level 80 ul age 10 15 year activ vari sex diurnal variat isoamylas neglig children cystic fibrosi pancrea activ pancreat isoamylas serum low
337	antibacteri precipitin autoantibodi serum patient cystic fibrosi sera 84 patient cystic fibrosi 31 patient respiratori diseas 21 control person investig occurr antibacteri precipitin autoantibodi preciptin studi mean cross immunoelectrophoresi antinuclear factor indirect immunofluoresc techniqu rheumatoid factor latex fixat slide test heterogen antibacteri immun respons found patient cystic fibrosi notabl regard ps aeruginosa none patient control precipitin bacterium occurr precipitin st aureu pneumonia frequent cystic fibrosi patient compar control compar respiratori diseas patient signific differ found regard precipitin h influenza occurr rheumatoid factor antinuclear factor frequent cystic fibrosi patient two group investig pronounc heterogen humor immun respons ps aeruginosa cystic fibrosi patient chronic infect mucoid strain bacterium found correl poor prognosi reason discuss
338	solubl protein bronchopulmonari secret patient cystic fibrosi asthma bronchiti concentr nine plasma protein determin quantit immunoelectrophoresi sputum specimen 29 patient cystic fibrosi cf 24 patient sever asthma chronic bronchiti result suggest popul cf patient could divid two group spite absenc differ clinic statu group averag concentr seven plasma protein sputum group cf patient ident sputum patient bronchiti averag concentr six protein sputum group ii cf patient higher specimen bronchit patient similar correspond concentr sputum patient asthma examin statu asthmaticu averag concentr 14 secretori protein sputum specimen whether produc patient cystic fibrosi asthma bronchiti conclud concentr bronchopulmonari secret protein associ host defenc diminish patient cystic fibrosi failur produc adequ concentr protein antimicrobi activ unlik respons averag suscept chest infect cystic fibrosi suggest exist group cf patient pulmonari allerg reaction gener inflammatori respons sever character statu asthmaticu respons could detriment
339	pulmonari circul cystic fibrosi heart lung 36 patient die cystic fibrosi studi establish relationship right ventricular hypertrophi rvh patholog chang pulmonari circul clinic featur presenc degre rvh measur fulton techniqu weigh ventricl separ subject die age 3 year one six rvh although mean age group significantli differ remaind correl durat cyanosi haemoglobin level rvh although statist signific case without rvh tend club fingernail longer period death electrocardiogram use diagnosi rvh right ventricular hypertrophi common children lung larg volum judg radiograph centil lung length case rvh show reduc background haze arteriogram fewer arteri per unit area lung first time thicken medial muscl layer proport degre rvh demonstr smaller arteri arteri subintim fibrosi common case rvh thicken wall small pulmonari vein implic find discuss
340	comparison peak flow rate spirometr measur cyctic fibrosi patient studi done determin role wright peak flowmet evalu pulmonari function children cystic fibrosi peak expiratori flow rate measur use wright peak flowmet one second forc expiratori volum maxim midexpiratori flow rate maxim voluntari ventil measur spiromet total 55 children 25 cystic fibrosi diseas remaind normal measur repeat administr bronchodil drug cystic fibrosi patient valu four measur decreas significantli cystic fibrosi patient posit signific correl coeffici obtain compar peak flow rate spirometr measur conclud peak expiratori flow rate feasibl use measur pulmonari function cystic fibrosi patient chang observ administr bronchodil drug patient
341	clinicopatholog evalu 37 case cystic fibrosi pancrea infanc necropsi clinic morpholog find 37 case cystic fibrosi pancrea 525 full nonconsecut necropsi present 37 case diagnos postmortem examin autopsi incid 7 none case beyond two year age morpholog find reveal vari sever organ involv case absenc fibrosi pancrea two case histopatholog chang seem confin pancrea studi suggest cystic fibrosi play consider role infant death countri case diagnosi must necessarili base postmortem studi
342	letter congenit absenc vasa although gener true male patient cystic fibrosi infertil due congenit atresia absenc vasal structur find invari taussig et al report 2 wellstudi patient cystic fibrosi normal semen analysi write father children third patient normal semen analysi also known us addit mani instanc presum undocu patern patient cystic fibrosi center estim male fertil 2 3 per cent although low figur warrant semen analysi assum steril view feel diagnosi cystic fibrosi consid vasa absent incorrect exclud diagnosi basi palpabl vasa
343	letter cystic fibrosi absenc va deferen infertil abnorm mesonephr deriv common patient cystic fibrosi uniform find taussig et al report 2 patient cystic fibrosi prove fertil abnorm va could document patholog studi va found present patient die cystic fibrosi mani patient absenc could rule physic examin healthi young children va easili palpabl even degre certainti identif less postpubert male cystic fibrosi diseas protean manifest would mistak rule cystic fibrosi va palpat victim cystic fibrosi label infertil
344	obscur bilater calcifi swell paratesticular tissu case calcifi swell paratesticular tissu discov infant differ age describ exact caus obscur three patholog condit suggest possibl due old reaction meconium periton patent processu vaginali
345	cystic fibrosi complic heart failur surviv studi done 36 children cystic fibrosi heart failur thirti percent surviv first four week median surviv group two three month end first year onset failur 74 percent die 30 month 87 percent die
346	isoenzym alkalin phosphatas serum patient cystic fibrosi 36 children cystic fibrosi cf isoenzym alkalin phosphatas ap determin microelectrophoret polyacrylamid starchgel studi done evalu clinic signific addit data diagnosi liver involv cf result lead follow conclus serum activ total ap compar unsensit mask alter isoenzym pattern contribut ap serum activ 17 children resp 47 bileduct phosphatas increas indic secretostasi marker enzym cholestasi normal part activ bone phosphatas serum show signific correl degre growth retard patient intestin phosphatas present serum one child cirrhosi liver indic liver insuffici determin ap isoenzym serum may provid addit inform organ involv physician handl cf patient
347	mucoviscidosi total amylas activ serum mix saliva homozyg heterozyg subject total amylas activ serum mix saliva studi homozygot heterozygot mucoviscidosi healthi subject mean serum total activ 2690 1137 ul homozygot exceed nearli 50 case valu given literatur observ normal control differ control group signific p less 005 mean serum total amylas activ heterozygot agre mean valu healthi group 2035 795 ul without signific differ total amylas activ saliva homozygot 148700 65700 ul higher heterozygot 118300 74200 ul healthi children 51700 26500 ul differ homozyg healthi group strongli signific p less 001 heterozyg group combin healthi children adult group also signific p less 005 heterozygot salivari amylas activ slightli elev significantli differ control group result chang serum total amylas activ
348	effici two pancreat extract patient cystic fibrosi nitrogen lipid absorpt coeffici studi 62 patient cystic fibrosi age 212 12 year compar result obtain 20 normal children 59 62 patient nitrogen lipid absorpt grossli abnorm agelink differ found efficaci two pancreat enzym prepar found similar prepar produc signific improv absorpt protein lipid
349	bronchial labil cystic fibrosi investig airway respons exercis cystic fibrosi cf due report high incid allergi cf tri demonstr well document postexercis bronchospasm asthma patient cf subject ran treadmil 6 minut speed 3 mile per hour gradient 15 degre 12 control studi mean rise peak expiratori flow rate pefr exercis 47 mean fall pefr recoveri 07 eight atop asthmat studi mean rise pefr 122 mean fall pefr 337 29 patient cf mean rise pefr 203 mean fall pefr 31 patient cf show statist signific postexercis constrict compar control asthmat patient show postexercis fall pefr significantli greater seen control p 0001 cf patient p 0001 patient cf show postexercis bronchospasm differ patient cf posit skin test common allergen pattern bronchial liabil suggest gener desensit therapi institut patient cf mere basi posit skin test without stringent criteria characterist season variat respiratori symptomatolog famili histori atopi posit bronchial inhal provoc test
350	current manag cystic fibrosi although forti year pass sinc discoveri clinic entiti call lack better name cystic fibrosi treatment remain symptomat controversi moreov efficaci therapi difficult evalu sever reason lack suitabl anim model therapeut experiment protean manifest diseas natur variat sever prolong period observ requir chronic frequent lack satisfactori clinic paramet score respons state simplest form treatment cystic fibrosi direct toward longterm control salt loss malabsorpt bronchial obstruct manag sever complic diseas establish posit therapeut environ minim anxieti depress purpos review help pediatr practition gain secur daytoday manag children diseas advoc effect work relationship practition region cystic fibrosi pediatr pulmonari center longterm patient manag problem diagnosi treatment salt loss prevent treatment malabsorpt prevent treatment bronchial obstruct prevent treatment certain complic psychosoci support patient famili discuss
351	prenat detect genet defect intrauterin detect genet disord repres one excit advanc medicin major emphasi chapter detail review newer approach toward antenat detect congenit malform hemoglobinopathi well overview experi problem antenat detect chromosom aberr inborn error metabol approach prenat diagnosi genet disord includ amniocentesi visual fetu fetal blood sampl prenat detect genet disord becom realiti area evolv rapidli major indic intrauterin diagnosi substanti chang within past year prior time matern age previou down syndrom inborn error metabol xlink recess disord primari criteria approxim 85 case use cytogenet analysi within past year number laboratori half referr amniocentesi central nervou system defect certainli develop technic fetal blood sampl distribut frequenc indic may chang substanti probabl next year cytogenet abnorm neural tube defect common indic amniocentesi amniocentesi continu offer mani patient inborn error metabol probabl avail monitor hemoglobinopathi disord fetal blood well accur knowledg health fetu
352	adren cortex cystic fibrosi pancrea morpholog adren cortic zone 25 children cystic fibrosi 24 control patient present technic object measur zone describ hyperplasia zona glomerulosa children cystic fibrosi signific may relat chronic loss salt sweat demand place renal saltconserv mechan
353	bulg fontanel present sign cystic fibrosi vitamin metabol effect cerebrospin fluid pressur 512monthold infant singl problem bulg fontanel diagnosi cystic fibrosi secondari hypovitaminosi made find high sweat chlorid valu low serum caroten level greatli acceler rate weight gain follow addit pancreat enzym supplement confirm presenc malabsorpt infant develop characterist fibrosi pulmonari diseas 20 month age anim studi shown vitamin defici associ increas cerebrospin fluid csf pressur diminish absorpt csf patholog find thicken infiltr mucopolysaccharid dura mater around arachnoid villi
354	intrapleur inject quinacrin pneumothorax child cystic fibrosi pneumothorax occur 2 4 patient cystic fibrosi follow ruptur subpleur bleb pleural space death occur recurr report therapeut procedur includ needl aspir close thoracotomi drainag open thoracotomi pleural scarif intrapleur instil irrit inject pleural space antimalari drug quinacrin hydrochlorid evok inflammatori respons result fibrosi produc tight adher viscer pleural surfac quinacrin therapi pneumothorax frequent use adult pediatr case report
355	clinic observ biliari system cystic fibrosi biliari tree 66 patient cystic fibrosi examin convent roentgenograph method fortyf per cent oral cholecystogram judg abnorm criteria studi consid abnorm visual visual microgallbladd structur abnorm includ margin irregular septat gallbladd cholelithiasi intraven cholangiographi use studi 22 patient visual oral studi anatom abnorm preval six patient group normal appear gallbladd abdomin pain frequent symptom cystic fibrosi associ roentgenograph abnorm correl seen extern biliari tree abnorm multifoc biliari cirrhosi present 40 patient correl seen serum gamma glutamyl transpeptidas level either lesion
356	distribut complement c3 variant individu cystic fibrosi gene frequenc slow fast electrophoret variant complement c3 caucasian individu cystic fibrosi similar valu expect unaffect control therebi rule suspect differenti involv phenotyp diseas one famili cystic fibrosi complement c3 phenotyp segreg independ
357	third compon complement cystic fibrosi studi c3 level phenotyp 64 cystic fibrosi cf patient 92 cf parent 64 normal sibl 126 healthi control signific elev mean c3 level found cf patient parent one genet subgroup siblin ss femal c3 concentr cf patient correl degre clinic impair measur shwachmankulczycki sk score signific differ found preval c3 phenotyp f gene frequenc among group studi
358	amylas polymorph studi sera duoden aspir normal individu cystic fibrosi prior genet studi human pancreat amylas amy2 locu direct princip electrophoret analysi serum urin assumpt fluid receiv neglig contribut salivari ami 1 locu support assumpt observ isozym band lack patient cystic fibrosi postpancreatectomi patient examin sera 97 patient cystic fibrosi find normal level serum amylas electrophoresi threequart cystic fibrosi patient pattern f pattern observ normal sera pattern character absenc pa 1 compar electrophoresi mix experi indic fpattern salivari origin unmask cystic fibrosi absenc pancreat contribut normal serum pattern consid admixtur salivari pancreat amylas assumpt duoden fluid might close reflect pancreat ami 2 locu electrophoret studi perform 148 normal individu 37 individu cystic fibrosi electrophoret phenotyp duoden aspir complex previous report studi urin serum presum higher concentr amylas aspir compar electrophoresi mix experi indic phenotyp observ duoden aspir also reflect admixtur pancreat salivari amylas recognit pancreat salivari admixtur sera fortun alter prior understand genet ami 2 polymorph extens studi led delin ami 2 polymorph essenti base presenc absenc variant band prove outsid zone admixtur
359	transit time analysi forc expiratori vital capac cystic fibrosi transit time analysi forc expiratori vital capac maneuv appli 37 patient cystic fibrosi 8 22 year age analysi divid vital capac segment air assign transit time segment characterist distribut transit time use measur pulmonari function quantiti compar forc vital capac 1sec forc expiratori volum ratio 1sec forc expiratori volum vital capac peak flow forc expiratori flow middl half forc vital capac maxim expiratori flow 25 per cent vital capac specif airway conduct arteri po2 patient standard deviat transit time frequent abnorm mean transit time largest rang valu term standard deviat best singl estim overal lung function correl almost equal larg small airway function coeffici carianc transit time specif detect abnorm small airway sensit detect minim lung diseas standard deviat transit time
360	incid serum antibodi sever aspergillu speci candida albican cystic fibrosi incid serum ige antibodi sever speci aspergillu incid serum precipitin speci candida albican determin 22 children cystic fibrosi 17 children bronchial asthma 18 control subject ige antibodi found 50 per cent patient cystic fibrosi 29 per cent patient bronchial asthma none found control subject precipitin aspergillu speci present 59 per cent patient cystic fibrosi 35 per cent patient bronchial asthma 11 per cent control subject greater differ note total number precipitin band group compar trend sever case cystic fibrosi base shwachmankulczycki score greater incid precipitin lower frequenc ige antibodi aspergillu milder case candida precipitin found frequent patient cystic fibrosi 45 per cent patient bronchial asthma 18 per cent none found control group potenti role fungal hypersensit cystic fibrosi therapeut implic discuss light find
361	cystic fibrosi cystic fibrosi frequent lethal genet syndrom among white children caus much chronic progress pulmonari diseas encount children increas adolesc adult popul patient cystic fibrosi psychosoci employ treatment need review whenev possibl emphas aspect pertin older patient known biochem structur defect account pathophysiolog phenomena cystic fibrosi thu definit diseas rest clinic find cystic fibrosi syndrom yet diseas incid figur cystic fibrosi necessarili minim best diagnost effort current avail fail detect die young age mild symptom sever piec evid indic cystic fibrosi transmit autosom recess trait autosom recess inherit cystic fibrosi suggest discret biochem structur defect date singl lesion prove provid unifi hypothesi pathophysiolog cystic fibrosi exocrin gland dysfunct mucociliari transport immunolog ciliari factor transport mechan discuss manifest cystic fibrosi involv mani organ system pattern present variabl respiratori gastrointestin genitourinari sweat gland manifest discuss least 3 possibl approach screen cystic fibrosi sweat test evalu pancreat function detect product defect gene prenat diagnosi heterozygot test diagnosi adult diagnost problem also examin treatment includ prevent pulmonari therapi gastrointestin therapi pulmonari complic treatment discuss well psychosoci aspect evalu prognosi cystic fibrosi
362	glycoproteindegrad potenti peripher leukocyt cystic fibrosi studi potenti problem discrep cill cultur techniqu avoid isol leukocyt peripher blood patient cystic fibrosi healthi human volunt prepar homogen determin specif activ 5 lysosom enzym involv degrad glycoprotein four lysosom hydrolas involv breakdown carbohydr side chain assay use artifici substrat fifth enzym aspartylglucosamin amido hydrolas cleav linkag side chain peptid backbon assay natur substrat differ enzym activ 2 leukocyt sourc observ enzym activ defici compensatori increas note conclud thick glycoproteinrich exocrin secret cystic fibrosi cannot attribut defect catabol
363	five sevenyear cours pulmonari function cystic fibrosi pulmonari function record 132 patient cystic fibrosi follow 5 7 year review chang forc vital capac 1sec forc expiratori volum mean forc expiratori flow middl half forc vital capac 1sec forc expiratori volum percentag forc vital capac examin consider variat rate chang gener pattern consist theori exponenti declin mean forc expiratori flow middl half forc vital capac show earliest dramat chang pulmonari function 33 patient 25 per cent remain stabl improv throughout followup possibl reflect mild form lung diseas efficaci therapi twenti patient 15 per cent maintain complet normal pulmonari function rate declin pulmonari function valu progress diseas steeper femal patient
364	development factor influenc interact drug author attempt summar current state knowledg regard disposit process infant children variou age tradit process absorpt distribut metabol excret describ newborn infant also infant children age group knowledg effect age effect diseas often uniqu stage postnat develop upon drug action disposit vital necessari prerequisit discuss interact drug abus pediatr popul essenti development statu host taken consider examin interact drug infant children mechan interact similar seen adult patient development statu pediatr patient also play signific role manifest diseas seen sick infant children often profound consequ may play major role modifi drug action interact
365	human respiratori tract secret mucou glycoprotein nonpurul tracheobronchi secret sputum patient bronchiti cystic fibrosi mucou glycoprotein isol agaros gel filtrat nonpurul tracheobronchi secret purul sputum reduc carboxymethyl case purul secret treat deoxyribonucleas solubil purifi glycoprotein fraction diethylaminoethyl cellulos two major ii two minor ia iii blood group activ compon compon ii similar carbohydr amino acid composit typic human blood group substanc two compon differ sever respect compon contain 1426 sulfat inhibit influenza viru hemagglutin compon ii contain 7178 sulfat potent inhibitor viru hemagglutin compon ii also migrat rapidli sodium dodecyl sulfate33 acrylamid gel electrophoresi compon ii purul secret display minor composit differ counterpart nonpurul secret compon ii abund two sputum sampl subject cystic fibrosi purul bronchit secret nonpurul secret
366	quantit submandibular protein resolv normal individu children cystic fibrosi submandibular secret collect children cystic fibrosi cf show increas protein concentr milligramsmillilit increas amylas specif activ unitsmilligram protein rel normal secret differ normal n cf secret follow protein 125 plu minu 051 n 175 plu minu 035 cf p 002 amylas 58 plu minu 18 n 80 plu minu 19 cf p 0001 determin basi elev protein cf saliva sever major protein resolv polyacrylamid disc gel electrophoresi quantit densitometri includ four phosphoprotein pp serum albumin acid phosphatasecontain fraction amylas unidentifi protein refer pi71 togeth protein compris greater 75 total protein secret differ individu protein concentr milligramsmillilit resolv normal cf secret respect follow pp2 002 plu minu 001 003 plu minu 002 ns signific pp3 006 plu minu 004 005 plu minu 003 ns acid phosphatas fraction 006 plu minu 004 012 plu minu 007 p 005 amylas 009 plu minu 004 027 plu minu 016 p 001 pi71 004 plu minu 002 013 plu minu 008 p 002 amylas signific contributor elev protein compris 26 total protein normal secret 38 total protein cf secret thu result support concept gener increas organ compon cf submandibular secret rather increas specif protein name amylas compon pi71 acid phosphatasecontain fraction
367	chlorid lose diarrhoea metabol alkalosi infant cystic fibrosi case hypochloraem metabol alkalosi infant chlorid lose ileostomi drainag cystic fibrosi describ specul intestin loss chlorid play major role develop metabol alkalosi
368	letter life tabl cystic fibrosi read articl dr robinson norman life tabl cystic fibrosi much interest express disappoint find differ life expect children present first year case fact former may littl wors expect sinc infect known present earli first month life diagnosi probabl late nearli case author point necess evalu neonat screen hand logic one expect late diagnosi consist nowaday mild case best therapeut result shwachman report patient 17 year age seem support belief 12 seri diagnos one year age therefor think evalu cours late present case one year age instanc separ sinc larg delay diagnosi may clue mild diseas
369	effect gestat length albumin content meconium screen programm detect cf use meconium albumin techniqu overal falseposit rate found approxim 1 gestat age infant taken account falseposit rate found significantli higher preterm 8 compar term infant 055 due larg sole presenc occult blood possibl explan find discuss attent drawn limit meconium albumin content screen techniqu cf preterm infant
370	cystic fibrosi screen newborn new techniqu measur stool enzym activ dri specimen faec newborn children 45 day age detect 3 case cystic fibrosi first 6000 test known case cystic fibrosi miss addit one case pancreat achylia least 4 month durat detect propos detect cystic fibrosi techniqu suffici practic accept worthwhil newborn screen programm screen test use auckland year set hamilton wellington dunedin new zealand sydney australia
371	screen cystic fibrosi analysi serum protein faec faecal specimen 51 infant free cystic fibrosi cf 9 infant diseas analys albumin alpha1 antitrypsin content faec infant cf mean albumin content less 01 mgg dri weight mean albumin alpha1antitrypsin ratio valu less 01 faec infant cf one except albumin content 20 mgg dri weight ratio valu greater 30 subsequ found duoden aspir child cf whose faec low albumin content ratio valu tryptic activ though much reduc level compar activ aspir healthi infant
372	cystic fibrosi acid mucopolysaccharidosi case cystic fibrosi myocardi fibrosi acid mucopolysaccharid deposit myocardium describ case support theori cystic fibrosi may genet acid mucopolysaccharidosi
373	associ cystic fibrosi allergi immedi skin hypersensit variou inhal allergen present 59 123 children cystic fibrosi cf much higher percentag gener popul consist idea atopi aris result impair handl antigen mucos surfac allerg cf children chest infect wors chest xray appear lower peak expiratori flow rate allerg diseas also frequent cf oblig heterozygot 32 mother 26 father suggest heterozygot may also mucos abnorm result defect antigen handl
374	mucociliari transport trachea patient cystic fibrosi mucociliari tracheal transport rate measur 20 patient cystic fibrosi rate rang 0 128 mmmin patient divid 3 roughli equal group basi transport rate 1 abnorm mucociliari transport detect trachea 2 normal transport rate measur abnorm cessat revers bolu movement observ 3 normal transport rate observ first group rate similar observ popul healthi adult normal rate observ patient product cough mean mucociliari tracheal transport rate increas increas maximum midexpiratori flow patient low shwachman score poor arteri oxygen tension tend fall group 2 3 ciliari dyskinesia assay rabbit trachea serum patient higher transport rate tend initi rapid discharg materi epithelium ciliari dyskinesia
375	serum precipitin respiratori tract pathogen 522 normal children 48 case cystic fibrosi treat cloxacillin well children show steadi increas staphylococc precipitin throughout life lower incid found precipitin h influenza pneumococcu haemolyt streptococcu precipitin proteu pseudomona klibsiella rare mark differ normal children cloxacillintr children cystic fibrosi respect pseudomona h influenza rise 50 cystic fibrosi children third quinquennium howev develop staphylococc precipitin prevent continu antistaphylococc therapi
376	peliosi hepati child peliosi hepati previous report adult occur chronic ill 11yearold boy cystic fibrosi case adult chronic ill longterm anabol steroid therapi right ventricular congest failur may well caus factor case histolog phlebectat parenchym type presum separ found conjointli case compat origin sever right ventricular congest failur rariti peliosi howev indic one yet unknown factor might oper develop
377	cystic fibrosi dilemma metabol pathogenesi genet diseas fundament patholog observ cystic fibrosi cf made three decad ago recent physiolog find direct investig toward plethora humor substanc possibl role disturb secretori process cf applic techniqu molecular biolog tissu cultur begin increas knowledg socal cf factor divers effect epitheli ciliat surfac emphasi current research chemic character cf factor metabol cell cultur patient cf biochem event control process secret current theori metabol pathogenesi cf consid context exist find
378	assess obstruct airway diseas children test best test airway obstruct base forc expir carri 60 children asthma 15 cystic fibrosi determin test test best identifi children airway diseas determin sever diseas document respons therapi maximum expiratori flow measur maximum expiratori flow volum curv maximum midexpiratori flow measur spirogram sensit test detect earli diseas maximum expiratori flow measur maximum expiratori flow volum curv combin measur lung volum gave best overal estim sever peak expiratori flow rate measur peak flow meter simplic measur use test routin use clinic consult room monitor sever respons therapi
379	ventilatori disturb children obstruct lung diseas diseas small airway lead alter slope phase iii singl breath nitrogen washout follow breath 100 oxygen normal children asthma cystic fibrosi studi techniqu measur slope phase iii singl breath washout appear sensit indic abnorm pulmonari function children diseas result obtain mani children cystic fibrosi suggest upper lung region predominantli affect
380	complianc noncompli treatment situat patient current undergo medic treatment home requir complianc fairli rigid disciplin effect found health visitor carri prescrib treatment health visitor role alway attempt influenc patient compli requir treatment occas might accept disregard posit role illustr situat reallif experi two famili discuss
381	prospect prenat diagnosi cystic fibrosi induct biochem abnorm fibroblast patient cystic fibrosi urinari glycoprotein alkalin phosphatas activ assay per cell basi ultra micromethod increas 7fold fibroblast cultur deriv patient cystic fibrosi induct urinari glycoprotein fibroblast normal heterozyg individu significantli induc suggest heterogen among case reflect vari baselin alkalin phosphatas alphaglucosidas level
382	decreas format alpha 2macroglobulinproteas complex plasma patient cystic fibrosi alpha2macroglobulin patient cystic fibrosi shown reduc bind papain trypsin thrombin oblig heterozygot cystic fibrosi reveal intermedi valu control patient sinc papain trypsin plasma endopeptidas becom evid absenc alpha2macroglobulinproteas complex cystic fibrosi due molecular defect within macroglobulin
383	recent advanc cystic fibrosi research cystic fibrosi one time consid lethal condit death occur birth within first year life advent antibiot therapi pancreat enzym replac extens physic therapi gener improv medic treatment mani patient surviv adulthood clinic manifest cf vari patient patient may includ pulmonari diseas malnutrit pancreat insuffici defect ion transport reliabl laboratori method diagnosi cf test elev sweat electrolyt level estim incid cf vari 1 2000 1 3500 among white popul mideuropean heritag diseas rare black popul almost nonexist orient sinc 1967 intens search circul factor factor may directli indirectli respons malfunct manifest diseas sweat factor serum factor metachromasia bioassay variat properti ciliari inhibitor discuss sever group work cf research center attent serum complement system agglutin mucu factor transport studi enzym studi prenat diagnosi also examin
384	distribut spermidin spermin blood cystic fibrosi patient control subject previou studi shown abnorm spermidineto spermin spdspm ratio whole blood cystic fibrosi homoand heterozygot investig spd spm distribut amoung blood compon possibl caus abnorm blood fraction use rabinowitz glass bead techniqu boyum ficollhypaqu method free unconjug polyamin extract perchlor acid quantit amino acid analyz control mean sem concentr nmoles109 cell spd spm respect 102 008 0894 028 erythrocyt 126 31 357 105 lymphocyt 36 16 240 33 granulocyt less 05 less 05 nmolesml plasma convert concentr whole blood found greater 90 spd 70 spm associ erythrocyt higher cellular concentr leukocyt unexpect fact spd spm whole blood primarili associ erythrocyt new find comparison control reveal spdspm ratio whole blood erythrocyt significantli higher group cystic fibrosi patient
385	cellmedi immun patient cystic fibrosi leucocyt 26 patient cystic fibrosi cf 18 healthi control investig migrat inhibit induc varieti antigen patient cf cellmedi immun found human lung pancreat tissu extract well aspergillu fumigatu pseudomona aeruginosa food antigen brain heart kidney patient severest form diseas greatest impair cellmedi immun impair could revers steroid treatment cell mediat cytotox may also concern pathogenesi cf
386	letter heat prostrat children cystic fibrosi wish report three case hyponatraem dehydr children cystic fibrosi admit hospit late june earli juli year three children cystic fibrosi clearli illustr danger present unusu climat condit necess salt supplement environment circumst emphasis concern parent danger administr saltfre glucos solut also born mind past case argu safe electrolyt solut would commerci avail absenc readili avail form electrolyteglucos solut parent need explicit instruct salt supplement administ
387	meconium ileu equival adult cystic fibrosi pancrea report six case eleven episod meconium ileu equival seen six adult cystic fibrosi pancrea three patient initi treat surgic one die two develop seriou postop chest infect six episod success treat medic acetylcystein oral enema nasogastr suction intraven fluid oper avoid possibl mainten treatment acetylcystein may necessari prevent relaps
388	cystic fibrosi physiolog gone wrong cystic fibrosi cf like syphili could accur describ great imit mani organ system involv clear understand diseas mani complic use exercis understand human physiolog cf could call thicksecret diseas exocrin fluid like pancreat juic thick could call multimysteri diseas mani unansw question mani manifest cf understand complic malabsorpt malnutrit physic chemic effect abnorm exocrin secret other includ suscept recurr nasal polyp hypersalin sweat low femal fertil male steril given present knowledg make physiolog sens
389	transform simian viru 40 cell patient mucopolysaccharidosi normal control fibroblast deriv individu mucopolysaccharidosi inborn error metabol found easili transform simian viru 40 cell deriv normal individu increas suscept seem depend upon chang glycoprotein cell surfac repeat observ necessari demonstr differ believ test suitabl routin screen cancer suscept
390	effect cystic fibrosi serum rat parotid gland inject serum human patient cystic fibrosi adult rat caus pronounc structur modif increas mitot rate parotid gland mitot rate increas low level 0021000 acinar cell parotid gland adult rat 651000 acinar cell 2 3 day serum inject light electron microscop level signific acinar cell atrophi degranul observ cellular necrosi increas quantiti lysosomelik dens bodi mast cell macrophag also detect chang suggest tissu respons injuri foreign protein furthermor fact normal sera pronounc kind effect greatli reduc extent strengthen view effect result immunolog respons host organ foreign antigen sinc howev respons rat parotid cystic fibrosi serum consider mark elicit normal serum rat parotid may thu potenti use assay presenc human cystic fibrosi factor
391	siga system hypersensit patient cystic fibrosi number investig use first time examin secretori iga siga system differ bodi fluid patient cystic fibrosi cf free jchain detect sputum specimen examin isol free secretori compon sc cf sputum differ electrophoret mobil sc isol normal human colostrum addit free sc cf saliva form precipitin line partial ident normal human saliva colostrum higher proport cf sera 33 normal sera 10 contain free sc investig suggest may defect synthesi andor assembl siga immunoglobulin confirm may help explain impair type type iii allerg manifest patient cf
392	elev serum igg4 level cystic fibrosi patient quantit measur igg subclass composit sera sixteen patient cystic fibrosi reveal grossli elev level igg4 seven patient possibl signific observ discuss relat recent report high incid immediatetyp hypersensit patient
393	laboratori confirm diagnosi cystic fibrosi recent commerci introduct method detect albumin meconium make screen cystic fibrosi feasibl mani hospit test adopt confirmatori test avail quantit analys sweat sodium flame photometri chlorid silver titrat ionsleect electrod use confirmatori test compar result confirmatori method appli preson cystic fibrosi respiratori disord digest disord control subject
394	use electrolyt measur detect cystic fibrosi six test recommend use diagnosi cystic fibrosi cf compar subject test carri 165 normal person 64 known case cf 67 parent 18 sib test measur sodium fingernail activ sodium saliva chlorid saliva thermal pilocarpineinduc sweat mean ionspecif electrod chlorid pilocarpinesweat standard titrimetr method test rang complex simpl screen method individu clinic procedur none simpler test match standard pilocarpin method diagnost effici whether use singli combin
395	purif properti human acidthermost ribonucleas diagnosi childhood pancreat fibrosi acidthermost ribonucleas isol human pancrea duoden content liver spleen serum urin purifi 15 1000fold ph optima ionic requir specif requir enzym investig isol enzym form two distinct group ribonucleas pancrea duoden content fraction serum urin exhibit ph optimum 85 inhibit an2 cu2 rel rapidli hydrolyz synthet substrat uridin 3 alphanaphthylphosph b ribonucleas liver spleen fraction b serum urin ph optimum 7 less sensit an2 cu2 exhibit neglig activ versu uridin 3alphanaphthylphosph determin serum level pancreatictyp ribonucleas activ use uridin 3alphanaphthylphosph rna substrat appear valid diagnost tool pancreat fibrosi children
396	prolactin growth hormon alphafetoprotein children cystic fibrosi prolactin credit role mainten electrolyt water balanc kidney although effect composit sweat unknown assay prolactin growth hormon alphafetoprotein sera 69 children cystic fibrosi attend hospit sick children sera 12 children without cystic fibrosi use control appear children cystic fibrosi serum level prolactin gh alphafp similar without diseas children significantli higher level alphafp women reproduct age
397	isoelectr focus serum cystic fibrosi failur distinguish homozygot heterozygot sera thinlay isoelectr focus perform sampl sera patient cystic fibrosi sibl oblig heterozygot parent children without cystic fibrosi control protein band isoelectr point ph 548 previous report absent homozygot cystic fibrosi sera found pi 525 present approxim onehalf homozygot heterozygot sera test absent 18 percent control sera presenc band therefor reliabl marker normal gene cannot use identifi heterozyg carrier cystic fibrosi
398	alphafetoproteinlik activ sera patient malign nonmalign diseas healthi individu new method radiocross immunoelectrophoresi demonstr alpha fetoprotein afp sera sensit 1 mug1 method afp alpha mobil found sera healthi individu patient chronic activ hepat cirrhosi primari biliari cirrhosi secondari liver cancer cystic fibrosi sera afp elev measur convent radioimmunoassay method sera contain afp like substanc gamma mobil analyz radiocross immunoelectrophoresi natur gamma substanc still obscur need investig
399	cellular glycosaminoglycan lymphocyt patient cystic fibrosi cellular glycosaminoglycan isol lymphocyt patient cystic fibrosi control isol glycosaminoglycan fraction cellulos acet electrophoresi analyz glucosamin galactosamin content subject hydrolysi bovin testicular hyaluronidas total glycosaminoglycan content per cent glucosamin galactosamin distribut cellular glycosaminoglycan circul lymphocyt cystic fibrosi differ control
400	alter isoenzym pattern liver alphalfucosidas cystic fibrosi isoenzym pattern alphalfucosidas studi isoelectr focus liver seven patient cystic fibrosi normal patholog gm1gangliosidosi type ii sanfilippo diseas control control reproduc pattern consist seven isoenzym alphalfucosidas neutral repres small proport total activ seven cystic fibrosi liver alter alphalfucosidas isoenzym pattern chemic relationship seven isoenzym normal liver alphalfucosidas investig use neuramindas five acid form alpha lfucosidas appear relat neutral form sialic acid residu sinc isoenzym liver alphalfucosidas appear relat sialic acid residu possibl alter alphalfucosidas isoenzym pattern found cystic fibrosi liver may result aberr sialyl
401	cystic fibrosi cell cultur studi adult patient popul skin fibroblast cultur adult popul cystic fibrosi cf patient studi determin possibl genet clinic signific two class describ cultur cf skin fibroblast dane 1973 basi clinic cours 46 adult patient 43 unrel famili studi divid two group 40 typic 6 atyp cultur fibroblast 37 40 patient typic cf class metachromat cystic fibrosi factor activ cffa cultur medium metabol cooper normal fibroblast cultur remain three patient class ii ametachromat cffa cultur medium metabol cooper metachromat cf fibroblast 4year research period one 37 patient class three class ii patient typic cf succumb cultur skin fibroblast two six patient atyp cours cf class four class ii parent three atyp cf class ii patient studi cultur fibroblast one parent famili famili class class ii affect offspr class iii mate may repres genet compound
402	fast isoamylas parotid saliva heterozyg carrier cystic fibrosi increas number fast isoamylas found parotid saliva children cystic fibrosi heterozyg parent clinic healthi fast isoamylas gener least part 6 isoamylas basic pattern deamid asparagin glutamin residu basic pattern present parotid saliva subject test far shift equilibrium amid deamid process discuss term possibl signific pathogenesi cystic fibrosi age
403	hemolyt anemia edema initi sign infant cystic fibrosi consid diagnosi even absenc pulmonari symptom report five infant eventu proven cystic fibrosi pancrea present hemolyt anemia edema sinc sweat test often unreli edemat state possibl cystic fibrosi consid use either protein hydrolys addit pancreat enzym improv nutrit statu edema disappear definit sweat test perform evid vitamin e defici case present possibl caus anemia rais
404	absorpt vitamin patient cystic fibrosi absorpt best emulsifi vitamin alcohol vitamin absorpt test use vitamin palmit alcohol separ oil oilwat emuls done 43 patient cystic fibrosi patient given 7000 unit vitamin per kilogram bodi weight fatti breakfast pancreat enzym given test meal withheld five hour start test blood drawn administr vitamin three five hour administr serum vitamin level estim use carrpric techniqu percentag patient normal vitamin absorpt 85 vitamin alcohol oilwat emuls 61 vitamin alcohol dissolv oil 64 vitamin palmit oilwat emuls 19 vitamin palmit oil number stool per day invers indic retent time intestin absorpt fat solubl vitamin alway abnorm patient four stool day observ cystic fibrosi patient abnorm liver biopsi poor absorpt vitamin statist signific question effect cirrhosi cystic fibrosi vitamin absorpt remain unresolv
405	immunochem quantit 18 protein sera patient cystic fibrosi concentr correl class fibroblast metachromasia clinic radiolog lung symptom sera 32 patient cystic fibrosi classifi accord fibroblast metachromasia three class analys immunochem concentr 18 serum protein addit clinic radiolog statu lung evalu use two score system eleven 16 serum protein differ valu thousanddonor serum pool pronounc differ control sera elev acutephas protein notabl haptoglobin alpha1antichymotrypsin igg iga low serum albumin alpha2hsglycoprotein patient metachromat class iii present pronounc rise acutephas protein furthermor significantli decreas complement c3 igm igg iga normal class iii patient differ control sera possibl reflect inflammatori tissu damag involv immun reaction clinic score posit correl radiolog score score posit correl concentr eight seven respect serum protein neg correl three serum protein base upon correl score concentr serum protein recommend longitudin prospect studi follow individu patient concentr serum haptoglobin albumin iga igg c3 eventu igm alpha1antichymotrypsin present result suggest serum protein yield valuabl inform regard prognosi therapi lung diseas cf
406	hemoglobin aic level insulindepend independ diabet mellitu unusu increas minor hemoglobin compon hb aia b c known elev diabet mellitu found state rel absolut insulinopenia diabet ketoacidosi steroid induc diabet insulindepend diabet cysticfibrosi patient cystic fibrosi occur infant mark suppress insulin secret ketoacidot diabet requir least month high hb ai level 169 26 per cent stabil nonacidot level 128 03 per cent suggest decreas occur new red cell form condit less favor hb ai synthesi abnorm amount os hb hb ai resist remov diabet redcel membran low ionic buffer yield hypoton tri buffer remov result simultan elut peripher integr membran protein suggest hb firmli bound could reduc membran elast cell deform characterist vital normal red cell movement microvasculatur
407	steatorrhea simpl rapid method diagnosi simpl rapid method diagnosi steatorrhea describ method base assess differ specif graviti lipophil properti normal stool steatorrhea use benzenenabr system stool sampl dri pulver investig steatorrhea defin either fat 24hour sampl stool sampl 71 infant children examin among 23 healthi subject 10 upper respiratori tract infect 6 pneumonia 31 children celiac diseas 9 glutenfre diet one child cystic fibrosi procedur describ render singl stool sampl suitabl assess steatorrhea screen test method prove rapid accur diagnosi steatorrhea
408	cystic fibrosi normal volum red cell model experi pathomechan diseas normal valu mean cell volum mcv distribut singl cell volum scv observ erythrocyt patient cystic fibrosi use electron particlevolum analyz sheath flow detector result strong defect red cell salt transport seem improb valinomucin induc shrink increas k permeabl gramicidin induc swell increas na permeabl normal erythrocyt addit cf sweat normal erythrocyt induc volum chang result influenc cf factor passiv ion permeabl conclud
409	alphaamylas activ sweat serum patient cystic fibrosi pancrea hypothesi doggett harrison accord alpha amylas pathogen factor exocrinopathi cystic fibrosi cf investigatedno elev alphaamylas sweat serum cf patient compar control similar age observ conclud cf factor cannot identifi alphaamylas
410	serum alpha1fetoprotein cystic fibrosi 38 children adolesc cystic fibrosi 19 normal children 62 healthi adult serum alpha1fetoprotein concentr measur radioimmunoassay cystic fibrosi patient 975 normal children 95 alpha1fetoprotein valu within normal rang healthi adult 19 ngml critic judgement report find literatur result demonstr investig alpha1fetoprotein serum cannot serv detect homozygot cystic fibrosi gene heterozygot carrier
411	enterokinas trypsin activ pancreat insuffici diseas small intestin interrelationship enterokinas trypsin activ investig 133 infant children varieti gastrointestin pancreat disord fourteen patient diarrhea grade ii mucos injuri reveal signific p less 001 reduct enterokinas trypsin disaccharidas activit compar 59 children normal mucosa nine patient cystic fibrosi pancreat insuffici normal mucos enterokinas activ elev intralumin enterokinas activ low trypsin activ patient hypoproteinemia gastrointestin protein loss associ intestin lymphangiectasia 4 patient intestin lymphoid nodular hyperplasia 3 patient normal insignific decreas enterokinas trypsin activ patient steatorrhea normal sweat test normal intestin mucosa absent trypsin activ two entiti defin one group 3 patient diagnos schwachmandiamond syndrom pancreat insuffici normal mucos intralumin enterokinas activ second group 2 patient absent mucos intralumin enterokinas activ normal lipas amylas activ diagnos congenit enterokinas defici
412	symptomat hepat diseas cystic fibrosi incid cours outcom portal system hunt fifteen 22 693 patient cystic fibrosi seen 18 year period develop clinic hepat diseas 13 patient symptom secondari portal hypertens ten hypersplen 6 varic bleed includ 3 develop condit 5 patient surviv initi episod gastrointestin bleed underw portal system shunt shunt procedur also perform 1 patient hypersplen varic bleed subsequ deterior intellectu function occur either shunt unshunt patient 1 shunt patient show progress hepat diseas surgeri result suggest portal system shunt use treatment bleed esophag varic cystic fibrosi sweat test rule cystic fibrosi includ evalu teenag young adult patient unexplain portal hypertens
413	cholestasi infanc statu report conceptu approach review concern disturb bile flow occur earli life although cholestasi defin physiolog consid morpholog featur morpholog cholestasi presenc bile pigment histopatholog section liver easili recogn bile plug thrombi bile canaliculi physiolog cholestasi reduct bile flow infer find elev serum bile acid infer deriv known posit correl canalicular bile flow bile acid excret found occur speci far examin includ man increas amount bile acid plasma impli reduct hepat transport primari conjug bile acid man therefor decreas associ canalicular bile flow classif cholestat syndrom function abnorm therapi cholestasi syndrom discuss
414	relationship bile acid malabsorpt pancreat insuffici cystic fibrosi bile acid loss mgm2 24h stool 43 cystic fibrosi cf children pancreat insuffici 7511 483 six without clinic evid pancreat diseas 1334 15 9 differ valu 25 control 1098 98 good correl degre bile acid ba fat sequestr concomit chang bile acid fat loss observ one group six patient studi pancreat enzym well second group seven children treat pancreat supplement maintain normal diet follow low fat diet supplement medium chain triglycerid administr na bicarbon led signific decreas fat loss 158 27 lead 103 19 without simultan chang bile acid excret 5331 583 lead 5004 586 qualit bile acid pattern control infant ileal resect patient cf coeliac diseas show percentag primari ba follow close total amount excret except situat antibiot administ exact mechan increas loss ba cf unknown found age group relat presenc degre pancreat insuffici possibl unhydrolys triglycerid may interfer intestin absorpt bile acid need confirm
415	differ frequenc distribut dna dri mass per cell lymphocyt deriv cystic fibrosi patient dna dri mass content lymphocyt normal control heterozygot cystic fibrosi patient studi util biophys instrument lymphocyt cf feulgendna mean valu significantli lower normal control dna valu cf lymphocyt exhibit two subpopul valu mean dri mass total protein valu exhibit greater intercellular variabl among cf cell dri massdna ratio higher cf normal control ratio appear increas concomitantli advanc diseas
416	galactosemia endogen product galactose1phosph cystic fibrosislik appear autopsi infant galactosemia high level galactose1phosph red blood cell blood galactos observ galactosefre diet child thrive develop liver cirrhosi age 5 month die unexpectedli post mortem examin reveal pancrea small intestin chang suggest cystic fibrosi sinc exogen administr galactos diet could exclud endogen product signific amount galactose1phosph consid
417	pseudomona compromis host although incid pseudomona infect low total hospit popul certain condit predispos infect lifethreaten patient cystic fibrosi special group sinc major chronic pulmonari infect pseudomona often mucoid variant rare found patient sever approach tri cf patient none show much promis thu far
418	gi problem children first two articl focus number malabsorpt disord inflammatori bowel diseas caus persist diarrhea diagnosi treatment differ entiti detail
419	lung cystic fibrosi quantit studi includ preval patholog find among differ age group autopsi 82 patient cystic fibrosi review respect patholog chang lung respect preval among differ age group although bronchiti mucopurul plug bronchopneumonia almost univers present among children age epitheli metaplasia bronchiectasi rarer among infant progress preval older age group emphysema absent patient two year age affect 11 per cent patient two six year age 40 per cent patient older six year never sever degre point count method pulmonari hemorrhag although uncommon usual associ promin arteri vessel wall bronchiectat airway quantit assess bronchial gland reveal reid indic significantli higher patient cystic fibrosi compar noncyst fibrosi patient increas indic age patient glandular hypertrophi predomin mucou acini within gland goblet cell hyperplasia bronchial mucosa suggest explan copiou mucou secret patient cystic fibrosi howev possibl ascertain whether find reflect gener exocrin defect patient whether mere respons chronic airway infect even though latter plausibl assumpt
420	biochemistri cystic fibrosi overview pp 15764 cystic fibrosi difficult problem solv one amino acid found elev concentr urin one abnorm sugar polysaccharid found secret bronchial tree caus pulmonari damag uniqu materi inhibit sodium transport yet identifi sweat instead view current state cf research chaotic perhap say posit way divers idea stimul think process sort primari defect wide spectrum pathophysiolog chang recogn recent positivecharg polypeptid associ immunoglobulin g identifi may respons ciliari dyskinesi effect cf serum materi demonstr properti bound immunoglobulin g control sera would interest ident basic protein recent found serum igg fraction cf patient carrier work may identifi polypeptid affect cell membran surfac whether defect peptidas perhap arginin esteras fail break polypeptid unifi hypothesi could emerg tie biochem physiolog find togeth
421	propos model inherit cystic fibrosi pp 291307 geneticist cystic fibrosi perhap frequent encount genet diseas among caucasian european origin present enigmat dilemma variou level problem area complic understand diseas includ method diagnosi ascertain analysi interpret data spite appar clearcut mode inherit autosom recess sever conceptu difficulti exist accept formal transmiss pattern press problem perhap popul genet cf fact lethal gene may maintain elev frequenc restrict given popul group repres seemingli genet paradox aim review problem encount genet studi cf propos theoret model may help elucid topic discuss includ problem diagnosi ascertain data analysi famili studi infer mode inherit popul studi propos model inherit cf main tenet model state cf determin domin allel two autosom loci interact
422	immunolog aspect cystic fibrosi pp 195217 promin role infect cystic fibrosi genet natur cystic fibrosi specif immun defect consider effort expend determin hereditari immun defect cystic fibrosi patient render suscept infect congenit immun defect fact infect nearli alway local lung two organ rather infect multipl site involv multipl organ specif immun mechan b cell system examin nonspecif host defens mechan includ complement system phagocytosi pulmonari clearanc pulmonari barrier system spread infect proteas inhibitor factor xiiidepend system hypersensit state includ allergi atopi allerg aspergillosi immun complex diseas hypersensit pancreat extract presenc absenc specif antigen compon associ hla antigen also discuss
423	psycholog social aspect cystic fibrosi pp 12751 cystic fibrosi diseas enorm sometim overwhelm psycholog social problem encount patient famili present state art pertain psycholog social aspect cystic fibrosi examin attitud toward cystic fibrosi implic genet diagnosi heterozygot screen project futur discuss
424	patholog cystic fibrosi pp 11524 vari morpholog lesion cystic fibrosi result obstruct one type anoth document presum modifi age individu sever condit peculiar tissu lesion plu function chang sweat electrolyt membran transport serum factor affect syncroni cilia repres divers action genet defect intermedi stage yet unknown neither divers abnorm rang sever differ age onset argu convincingli trigger mechan acquir rather inborn defici
425	relev cyclic nucleotid calcium cystic fibrosi pp 24358 gener area research biochem molecular level relat cystic fibrosi suffer lack suitabl anim model although anim model propos yet test attempt circumv problem sever investig turn cell cultur techniqu studi variou aspect cystic fibrosi studi includ use red blood cell lymphocyt skin fibroblast cultur nasal polyp enough posit indic approach indic might fruit consequ final aspect articl consider use cell cultur futur investig possibl metabol lesion cystic fibrosi control cyclic nucleotid level parotid role calcium microfila microtubul secret use cell cultur approach studi biochem defect cystic fibrosi discuss
426	recent observ concern rna methyl polyamin metabol cystic fibrosi pp 22341 determin fibroblast prolifer rate rna methyl pattern laboratori reveal alter cell cystic fibrosi patient blood polyamin locat predominantli erythrocyt low concentr plasma sweat likewis shown low content spermidin spermin whole blood polyamin concentr fluctuat one individu anoth especi variabl femal subject hormon chang menstrual cycl variabl spermidin spermin content blood use express data basi spermidinespermin ratio howev result must analyz accord sex case femal interpret relationship menstrual cycl spermidinespermin ratio significantli elev whole blood extract isol erythrocyt male cf homo heterozygot
427	pulmonari aspect cystic fibrosi pp 324 defect mucociliari transport implic pathogenesi lung diseas cystic fibrosi base sever observ first patient diseas secret mucu normal subject indic gland hypertrophi frequent retain lung second mucu said alter biochem rheolog properti howev although physiochem properti mucu alter lung diseas littl histochem rheolog differ found mucu patient cf hypersecretori condit chronic bronchiti bronchiectasi third factor serum cf patient inhibit normal ciliari activ explain gland ciliat epithelium infect damag human ciliat epithelium cultur could reduc mucociliari transport measur pulmonari function cystic fibrosi physic fit respons exercis cystic fibrosi control breath patient cystic fibrosi region lung function cystic fibrosi therapi cystic fibrosi discuss
428	pulmonari therapi cystic fibrosi pp 2537 report summar select aspect pulmonari therapi cystic fibrosi sinc result chronic bronchopulmonari infect caus death cf patient improv patient surviv pattern may possibl attribut larg part improv antibiot therapi increas therapeut aggress mist tent therapi defin initi 1950 later studi mist tent therapi shown benefici respons mani patient select studi intermitt aerosol therapi continu employ mani physician deliv medic rather bulk liquid bronchial mucosa pulmonari endoscopi lavag expector allerg aspergillosi pneumothorax lobectomi hemoptysi also examin
429	mucou glycoprotein pp 16577 earli investig employ histochem chemic physiochem techniqu attempt identifi differ cystic fibrosi control mucou secret sever mucou glycoprotein abnorm suggest studi retrospect none studi achiev goal describ fundament mucou glycoprotein abnorm peculiar cf improv method devis collect mucou glycoprotein human respiratori tract secret studi chemic physic properti therefor possibl make preliminari comparison human tracheobronchi mucou glycoprotein cf noncf sourc gener properti mucou glycoprotein human tracheobronchi mucou glycoprotein comparison cf noncf tracheobronchi mucou glycoprotein suggest direct futur studi cf mucou secret discuss
430	physiolog pharmacolog secret cystic fibrosi review past develop project futur pp 31136 cystic fibrosi recess inherit metabol diseas character univers dysfunct exocrin gland affect individu dysfunct result abnorm composit andor physiochem behavior variou exocrin gland product although signific advanc made understand exocrin gland physiolog pharmacolog mani question remain unansw signific gap exist knowledg exocrin gland function perhap clarif issu may lead better understand pathogenesi cystic fibrosi develop better form therapi patient purpos articl review past present develop area biomed research point area exocrin gland physiolog pharmacolog knowledg need order clarifi natur diseas like cystic fibrosi composit acinar fluid secretori mechan modif ductal fluid ionic depend energi requir secretori process calcium metabol exocrin gland exocrin gland dysfunct cystic fibrosi discuss
431	water electrolyt exocrin secret pp 17991 recogn level water electrolyt derang mani exocrin secret cystic fibrosi patient sodium chlorid level serou secret cf patient elev contrast proteinrich mucoid isoton secret viz pancrea tracheobronchi mucu gland found sodium concentr near normal even somewhat decreas howev secret significantli reduc water content abnorm hypoton secret appear rise decreas na reabsorpt duct low water content isoton secret cf patient appear result decreas secret water electrolyt earli studi tracheobronchi secret cf patient led investig suggest primari defect may decreas level water monoval ion attempt provid unifi hypothesi suggest increas calcium concentr variou exocrin secret lead hyperperm mucu line thu excess loss water small ion concentr calcium exocrin secret appear follow concentr protein especi mucou glycoprotein suggest calcium may import factor increas viscos insolubl cf mucu organ ion also potenti perturb macromolecular structur addit possibl perturb role polyamin potenti role water electrolyt transport
432	polypeptid mediat cystic fibrosi pp 25971 although complex model involv multipl loci may plausibl high frequenc cystic fibrosi caucasian probabl best explain select advantag heterozygot carrier short analog cystic fibrosi hemoglobin sickl cell anemia may greater taysach diseas term molecular mechan protein polypeptid differ report humor fluid cystic fibrosi patient heterozygot rel connect select bioassay system direct relat model propos intermedi stage physiolog cystic fibrosi build larg bodi eleg experiment work basic tenet cell cystic fibrosi heterozygot normal individu stimulatori loop chronic reserpin treatment exagger normal rat loop similar one exagger genet differ human elev patholog level otherwis normal process
433	gastrointestin nutrit manifest cystic fibrosi pp 83111 purpos paper summar present state knowledg gastrointestin manifest absorpt metabol nutrient patient cystic fibrosi gastrointestin manifest includ pancreat exocrin insuffici pancreat calcif stone diabet liver gall bladder abnorm intestin obstruct complic malabsorpt nutrit aspect cystic fibrosi includ growth retard bodi composit fat nitrogen absorpt amino acid absorpt mediumchain triglycerid absorpt defici fatsolubl vitamin critic question project futur fall three categori intestin absorpt gastrointestin function experiment design
434	factor relat cystic fibrosi pp 27784 varieti bioassay identifi molecul circul cystic fibrosi genotyp synthes vitro cultur cell genotyp function disturb observ assay employ preliminari character factor gener agreement properti includ small molecular weight polypeptid within rang 4000 10000 mw heatlabil protein cation charg protein present saliva serum urin perhap sweat synthes vitro fibroblast shortterm lymphocyt longterm lymphoid line relationship factor factor pathogenesi cystic fibrosi present unknown presenc cystic fibrosi genotyp appear relat basic defect
435	enzym studi pp 28590 report saliva serum patient contain macromolecular factor presum cation inhibit transport electrolyt induc dyskinesi degranul sensit polymorphonuclear leukocyt contain polypeptid moieti differ level trypsinlik activ mix saliva patient cystic fibrosi control confirm number studi carri order determin defici proteolyt activ might account presenc cystic fibrosi serum factor presum observ partial defici arginin esteras activ might well repres total defici one sever arginin esteras assay experiment condit although postul defici arginin esteras activ relat elev level polypeptid protein factor hydrolysi peptid band activ plasma could demonstr probabl due limit method employ defici plasma arginin esteras cystic fibrosi question confirm anoth laboratori
436	cor pulmonal relat cardiovascular effect cystic fibrosi pp 4180 cor pulmonal defin committe world health organ right ventricular hypertrophi secondari diseas lung parenchyma pulmonari vasculatur due abnorm pulmonari function estim 70 children die cystic fibrosi cor pulmonal though children live longer number may higher clinic diagnosi manag prognosi echocardiographi echocardiographi measur left ventricular dysfunct studi 94 ambulatori hospit cystic fibrosi patient discuss studi establish patient cystic fibrosi left ventricular dysfunct hypertrophi occur relat increas sever pulmonari involv
437	interact pseudomona aeruginosa immunoglobulin complement sputum interact pseudomona aeruginosa humor factor sputum patient cystic fibrosi investig use indirect immunofluoresc techniqu fluorescein conjug monoval antiserum specif heavi chain human immunoglobulin iga igg igm complement c3 use strain p aeruginosa recov sputum specimen patient cystic fibrosi found coat antibodi iga igg igm class c3 specif antibodi coat determin fluoresc intens iga follow intens igg igm c3 differ note rough mucoid strain p aeruginosa subcultur p aeruginosa incub sputum eluat similar pattern fluoresc demonstr indic humor factor present sputum coat process take place lower respiratori tract patient singl radial immunodiffus signific quantiti humor factor sputum eluat detect find suggest p aeruginosa opson sputum patient cystic fibrosi
438	chronic ill children psycholog emot deviant popul studi evalu psychosoci function level group chronic ill diabet asthmat cystic fibrot hear impair children across batteri standard person instrument assess perform provid rigor test popular hypothesi chronic ill children especi vulner psychopatholgi contrast sterotyp result across measur demonstr normalci rather devianc children although except note children function strength cope abil notic outweigh weak
439	diseasemed relationship alter tast sensit review evid abnorm tast acuiti elicit sever factor chang patient tast acuiti consider diagnosi nutrit statu treatment receiv receiv offer understand percept food futur studi furnish inform patient abil tast smell may alter thu affect attitud toward food
440	care children condit character high nutrit risk key success prevent nutrit program longterm follow reinforc earli intervent necessari dietitian must evalu effect approach care monitor variou paramet growth length weight head circumfer skinfold measur essenti awar advantag limit complic dietari program describ three exampl complex nutrit problem encount intens care nurseri mani equal challeng frustrat medic surgic disord demand expertis dietitian success manag dietitian futur cannot reli knowledg alon must util consider ingenu creativ manag complic nutrit enigma accept effect maintain
441	antibiot therapi cystic fibrosi increas resist mucoid pseudomona aeruginosa carbenicillin present commun report effect bacteri mucu activ antibodi strain p aeruginosa mucoid variant p aeruginosa obtain nonmucoid strain pao 381 pat 404 select phenotyp resist virul phage e 79 resist carbenicillin nonmucoid parent strain mucoid p aeruginosa strain isol two cf patient resist carbenicillin nonmucoid strain isol sampl sputum experi alreadi describ repeat oxytetracyclin contrast experi carbenicillin mucoid strain found sensit nonmucoid strain prove hypothesi mucoid strain select vivo carbenicillin therapi necessari show level carbenicillin cf secret less minimum inhibitori concentr mucoid strain greater nonmucoid strain investig addit cf isol conjunct rang antibiot use chemotherapi cf patient
442	antibiot manag cystic fibrosi cystic fibrosi common autosom recess disord great britain central europ north america affect 1 2000 live born children antibiot treatment cystic fibrosi differ treatment respiratori infect condit cystic fibrosi patient suffer progress deterior respiratori function often danger complic condit culmin superinfect highli resist organ basic principl antibiot therapi must rigidli appli cystic fibrosi first principl identifi pathogen suscept antibiot second principl ensur chosen antibiot reach site infect third principl antibiot therapi ought complement immunolog defenc patient fourth principl therapi must given without first decid upon criteria accept indic clinic improv
443	differ incorpor thymidin dna normal cystic fibrosi fibroblast vitro although similar fraction cell phase cell cycl normal human skin fibroblast shown incorpor twice 3htdr dna vitro cell obtain individu cystic fibrosi cf oblig heterozygot incorpor intermedi amount dna precursor studi initi determin basi differenti incorpor 3htdr among genotyp analog thymidin budr produc vari effect growth kinet three genotyp growth cell budr result 50 increas popul doubl time three genotyp caus cell morpholog chang spindl shape one cell becam broaden flat numer cytoplasm project extend distanc sever cell diamet activ thymidin kinas particip exogen de novo pathway synthesi tmp found approxim three genotyp data suggest alter transport thymidin cell may account differ tdr incorpor dna may associ chang cystic fibrosi appar membran associ
444	format calcium phosphat saliva dental plaqu xray diffract studi miner phase saliva earli dental plaqu saliva studi came patient cystic fibrosi cf asthma heavi light calculu former oneweek old plaqu studi individu heavi moder light calculu former
445	oral health patient cystic fibrosi sibl cari preval oral hygien index submandibular gland hypertrophi occlus dental hypoplasia stain perman teeth evalu 63 patient cystic fibrosi cf maintain regimen broadspectrum antibiot oral pancreatin find compar near age sibl gland hypertrophi dental stain increas patient cf wherea cari significantli decreas signific differ found
446	experi paediatr gastroenterolog clinic paediatr gastroenterolog clinic hospit start follow children gastroenterolog problem discharg hospit particular monitor clinic dietari progress dietitian see open work hospit may find experi interest glutenfre diet cow milk free diet sugar intoler cystic fibrosi nonspecif case discuss
447	evalu safeti amantadinehc1 role respiratori viral infect children cystic fibrosi amantadinehc1 antivir drug clinic effect strain influenza viru evalu doubleblind trial 153 children cystic fibrosi initi appear influenza aengland42 viru new england area infect variant strain influenza viru reach epidem proport studi effect amantadin studi popul could fulli assess howev potenti symptomat biochem toxic amantadin care monitor pediatr popul serolog screen complement fixat test indic respiratori virus may import pathogen exacerb respiratori diseas patient cystic fibrosi
448	tobramycin treatment infect due pseudomona aeruginosa patient cystic fibrosi effect safeti tobramycin infect due pseudomona aeruginosa patient cystic fibrosi studi 15 patient moderatetosever exacerb chronic pulmonari infect seventeen cours treatment given tobramycin 575 mgkg per day administ intraven three divid dose per day seven 21 day specimen sputum yield moderatetoheavi growth p aeruginosa isol inhibit 4 mug tobramycinml seven case isol inhibit 4 mug gentamicinml mean level tobramycin blood 44 mugml 051 hr 08 mugml 758 hr administr patient receiv antistaphylococc agent therapi patient except two receiv 750 mg carbenicillinkg per day intraven six divid dose 1 g carbenicillin mask inhal three time day clinic radiolog improv note patient white blood cell count elev seven patient return normal level blood gase improv p aeruginosa elimin sputum five case advers side effect note
449	tobramycin therapi infect due pseudomona aeruginosa patient cystic fibrosi effect dosag concentr antibiot sputum establish respiratori infect mucoid pseudomona aeruginosa patient suffer cystic fibrosi treat convent well larger dose tobramycin infect erad four 17 patient treat durat followup studi one patient short appear treatment success patient highest peak concentr tobramycin sputum obtain side effect note even tobramycin given larg dose two week
450	tobramycin ticarcillin therapi exacerb pulmonari diseas patient cystic fibrosi patient cystic fibrosi acut infecti exacerb pulmonari diseas produc pseudomona aeruginosa treat combin tobramycin ticarcillin p aeruginosa recov patient inhibit lower concentr drug gentamicin carbenicillin thirteen cours treatment administ 11 patient mean 144 day favor respons seen 11 12 complet cours treatment improv associ decreas white blood cell count temperatur sediment rate advers reaction uncommon although p aeruginosa erad sputum clinic result suggest combin tobramycin ticarcillin may particularli use treatment acut exacerb pulmonari diseas patient cystic fibrosi p aeruginosa isol
451	composit nasal secret patient cystic fibrosi quantit examin nasal secret patient cystic fibrosi reveal significantli greater normal concentr calcium find keep hypothes import ion pathophysiolog diseas
452	quantit evalu serum pancreat isoamylas cystic fibrosi amylas sera 20 patient cystic fibrosi pancrea cfp 17 pancreat insuffici pi 34 normal control subject separ pancreat salivari compon quantit electrophoret separ achiev polyacrylamid disc gel subsequ section gel column amylas content intern unit per liter iul obtain section insolubl blue starch substrat method mean total serum amylas cfp patient pi significantli lower control group highli signific decreas found pancreat isoamylas consid alon salivari isoamylas level remain essenti three patient cfp without pi demonstr higher normal pancreat amylas valu serum patient may earli stage progress involv pancrea increas releas amylas method electrophoret separ quantit serum amylas sensit effici allow simultan process multipl specimen result obtain agre previous publish ratio serum isoamylas method valuabl studi diseas exocrin pancrea salivari gland
453	inflammatori reaction airway damag cystic fibrosi cystic fibrosi chronic infect inflammatori reaction airway accompani destruct shed airway epithelium leukocyt migrat airway disintegr liber deoxyribonucleoprotein incorpor gel structur bronchial mucu compar statu process cystic fibrosi chronic bronchiti bronchiectasi examin sputum rais lower airway measur also made sputum induc normal subject result indic migrat leukocyt airway shed damag airway epithelium minim normal subject signific patient chronic bronchiti higher bronchiectasi still higher cystic fibrosi larg increas found total content dna solid cystic fibrosi sputum due increas insolubl fraction contain whole leukocyt particul debri remain sputum mucu gel solubil mercaptoethanol despit larg increas total content dna solid content mucu gel compon deoxyribonucleoprotein disintegr leukocyt actual present mucu gel structur cystic fibrosi sputum significantli higher sputum patient chronic bronchiti brochiectasi
454	search linkag cystic fibrosi linkag locu cystic fibrosi genet marker explor 40 famili birmingham 20 manchest strong evid found linkag marker examin evid close linkag abo hla rh
455	small bowel mucos dysfunct patient cystic fibrosi jejun biopsi obtain 37 children cystic fibrosi 16 gluteninduc enteropathi 18 control subject follow studi 1 disaccharidas activ 2 lalalph hydrolas activ 3 intestin uptak three 14clabel amino acid valu significantli reduc three determin patient gluteninduc enteropathi compar control subject lactas lalalph hydrolas activ significantli reduc p less 001 cf patient compar control subject definit hypolactasia also observ 23 children cf uptak lysin normal cf patient wherea phenylalanin cycloleucin reduc compar control subject studi suggest intestin compon malabsorpt patient cf
456	emot adjust adolesc young adult cystic fibrosi twentyseven adolesc young adult cystic fibrosi studi evalu phycholog impact chronic ill first glanc patient appear function adequ daili basi howev four sourc psycholog stress lead emot disturb identifi alter physic appear caus distort bodi imag denial sexual strain interperson relationship result isol mental strain conflict upbring increas awar futur death guidelin physician treat young adult famili includ 1 encourag greater involv patient father 2 assist mother find outsid interest allow independ patient 3 stress commun cystic fibrosi within home 4 emphas outsid activ patient 5 repeat discuss patient concern emphas strength 6 anticip problem specif cystic fibrosi steril male 7 encourag interpati commun
457	easi bruisabl termin coma normal 5monthold infant patient 5monthold white male admit coma via transferr anoth hospit clinic discuss argu child acquir coagulopathi due vitamin k defici secondari fat malabsorpt occur cystic fibrosi left third nerv palsi contralater hemiparesi patient rapid neurolog deterior suggest mass lesion left cerebr hemispher uncal herniat patholog discuss also suggest intracrani hemorrhag massiv left accompani cystic fibrosi sever pancreat lesion bleed disord probabl due vitamin k defici
458	pseudomona carrier rate patient cystic fibrosi member famili major 866 patient cystic fibrosi found carrier pseudomona aeruginosa none howev carri p aeruginosa nare contrast none noncf famili member patient cf carrier p aeruginosa exampl 4 468 cultur skin throat nare famili member posit p aeruginosa isol p aeruginosa cf patient often pyocin type specif pyocin type p aeruginosa predomin patient cf isol p aeruginosa sibl cf may may pyocin type famili proband colon patient cf p aeruginosa threat noncf member famili
459	letter protein level meconium homozygot heterozygot infant cystic fibrosi patient second child marri coupl heterozyg cystic fibrosi meconium protein content higher control symptom cystic fibrosi determin sodium chlorid ion sweat exclud homozygos bromid test led us conclud child heterozygot patient protein content meconium major albumin two threefold control elev protein content howev characterist homozygos result lead us conclud high protein content meconium uncondit indic homozygot state cystic fibrosi would appear heterozygos cystic fibrosi complet without abnorm find perhap explain fals posit result record literatur highprotein content meconium may use identif heterozygot
460	electrolyt valu sweat obtain local whole bodi collect method cystic fibrosi patient composit sweat relationship condit site collect interest environment physiolog dermatolog studi cystic fibrosi studi undertaken compar concentr sodium chlorid whole bodi sweat normal control patient cf patient obtain thermal stimul sampl collect local pilocarpin iontophoresi electrolyt concentr whole bodi sweat sampl correl highli signific fashion sodium chlorid valu found arm patch sweat patient cf howev show significantli higher sodium chlorid concentr arm patch sweat whole bodi sweat increas sodium excret rate
461	cours cystic fibrosi 95 patient cours 95 patient cystic fibrosi present survivor mean followup period 14 year minimum 13 year 45 patient diagnos prior extens irrevers pulmonari involv one die none disabl contrast 50 patient diagnos substanti irrevers pulmonari diseas present 26 die mortal morbid greater femal possibl factor contribut improv prognosi includ earli diagnosi aggress manag comprehens care easi access special care improv antimicrobi therapi
462	cours cystic fibrosi black patient seventeen black patient show typic sweat gland gastrointestin pulmonari manifest cystic fibrosi unusu high incid meconium ileu equival 35 three infant sibl patient studi die cystic fibrosi prior referr famili member center one patient die age four year emot problem interf treatment program statu asthmaticu play major role termin respiratori failur remaind patient substanti less morbid pulmonari diseas compar much larger group white patient one patient age 28 marri employ fulltim sever pulmonari involv assess pulmonari function studi chest roentgenogram 16 surviv patient mean age 13 12 year mean followup period 10 year black patient cystic fibrosi surviv infanc group may rel good prognosi
463	infarct common bile duct infant surfic explor jaundic possibl caus extrahepat biliari atresia infant explor obstruct jaundic die 6 day postop found extens infarct common duct would gone undetect patient surviv without care sampl autopsi incid unsuspect complic unknown surgic infarct may one caus fibrosi secondari atresia extrahepat bile duct
464	occult appendic abscess complic cystic fibrosi three case histori illustr diagnost dilemma encount whenev patient cf receiv antibiot evalu abdomin pain although acut append perfor abscess format common complic cf occur frequent gener appreci larg number abdomin situat cf caus pain confus typic acut append true underli condit mask concurr use antibiot pulmonari infect higher index suspicion need rule acut append patient cystic fibrosi abdomin pain greater awaremess possibl occult appendic abscess may help avoid complic
465	valu screen paediatr popul screen carri test procedur everi individu within popul defin limit geographi administr race sex age risk screen carri test procedur person person alreadi exist medic reason suppos find may posit review condit popul screen may consid exhaust serv show central dilemma field apart congenit disloc hip phenylketonuria possibl homocystinuria none seem show quit strong enough case consid worthwhil screen
466	fertil man cystic fibrosi patient wellcompens lateappear cystic fibrosi manifest moder decreas exercis toler normal semen analysi presum father one child import emphas physician oblig determin fertil male cystic fibrosi patient particularli lateonset symptom provid appropri genet counsel
467	cystic fibrosi black woman articl report case 22yearold unmarri black woman cystic fibrosi one report literatur cystic fibrosi black person 20 year old due part defici pancreat exocrin secret product copiou amount highli viscou mucu gastrointestin gland patient cystic fibrosi prone recurr intestin obstruct intussuscept volvulu well abdomin pain mass shwachman holsclaw firmli state diagnosi cystic fibrosi may made histolog appear appendix
468	mucoid pseudomona aeruginosa sign cystic fibrosi young adult chronic pulmonari diseas two adult patient cystic fibrosi late onset symptom princip involv lung absenc typic featur cystic fibrosi confus diagnosi recoveri mucoid pseudomona aeruginosa sputum cultur help establish diagnosi patient mucoid isol rare obtain subject cystic fibrosi recent find identifi mucoid isol predominantli singl strain p aeruginosa document widespread carriag unit state patient cystic fibrosi point interest epidemiolog relationship bacterium diseas
469	ph sweat patient cystic fibrosi ph sweat patient cystic fibrosi control measur function sweatrat use fluorescenceph indic umbelliferon popul sweat acid low sweatrat alkalin high one result favour abnorm ductal hsecret pathomechan cystic fibrosi
470	cystic fibrosi effect serum factor mucu secret effect serum children cystic fibrosi normal children mucussecret ciliat epithelium investig vitro use explant tissu rabbit lung optic scan electron microscopi sequenc structur chang observ incub cystic fibrosi serum sequenc occur normal serum earliest chang involv swell goblet cell subsequ discharg mucu onto epitheli surfac follow disrupt normal rapid synchron ciliari activ mucu gradual extend surfac entangl cilia final shed ciliat cell occur epithelium find suggest factor cystic fibrosi serum caus discharg mucu lead disturb normal ciliari activ rabbit lung postul chang result dysfunct mucociliari clearanc mechan dysfunct may contributori factor pathogenesi lung diseas
471	letter screen cystic fibrosi screen cystic fibrosi cf newborn vogu sinc introduct rapid simpl test base presenc albumin meconium cf babi falseposit test observ prematur specimen contamin blood reduc number fals posit addit studi meconium includ detect lactas lactas activ detect meconium babi cf meconium healthi babi test 200 normal meconium neg albumin test note 3 posit test lactas 3 patient cf falseposit lactas test could distinguish addit distil water meconium instead lactos simpl test may provid addit altern method detect cf screen programm test use addit albumin test number falseposit albumin test reduc
472	letter falseneg meconium test cystic fibrosi two review question valu meconium test routin screen cystic fibrosi high proport falseposit perhap importantli falseneg result wish report find falseneg result evalu variou method meconium screen includ boehring mannheim test strip semiquantit test protein electroimmunoassay albumin estim albuminalpha1antirypsin ratio figur small draw conclus appar relationship falseneg result famili histori diseas feel result illustr littl relianc put neg meconium test say meconium test valueless studi least 40 infant cystic fibrosi posit meconiumtest result meconium ileu thu possibl cystic fibrosi infant recognis within day birth usual well definit clinic sign diseas manifest
473	calcium flux cystic fibrosi letter effort determin whether increas permeabl calcium ion could explain cystic fibrosisserum ciliari dyskensia factor respons tracheal test system select increas membran permeabl tracheal epithelium calcium ion ad calcium ionophor a23187 tracheal cultur medium studi determin calcium ionophor a23187 cultur medium produc chang mucociliari function tracheal test system indistinguish promot cf sera investig extend includ ultrastructur alter induc epithelium rabbit tracheal bioassay system point import role calcium cofactor product cdf respons gener cf sera cf serum substanc seem act cellularmembran level promot membraneperm chang least respect calcium rabbit tracheal test system mechan would necessarili result net physiolog imbal calcium rabbit tracheal system local chang calcium concentr would subsequ alter secret microtubular function sinc cf serum like sweat saliva patient promot ionic flux perhap common factor bodyfluid relat basic defect cf tempt specul factor produc membraneassoci phenomenon may gener repres invivo cf disord may reflect natur cellular glandular abnorm diseas
474	letter cystic fibrosi heterozygos pathogenesi allergi articl dr warner colleagu may great signific understand aetiolog pathogenesi cystic fibrosi cf accord observ allerg symptom posit skin test common cf homozygot healthi control apart fact 59 cf homozygot gave posit skin test one 40 differ class bencard antigen main one aspergillu fumigatu least 85 cf heterozygot strong posit histori allergi mother matern progenitor follow sibl account studi requir establish relationship gene respons allerg manifest popul cf phenotyp
475	finger club quantit survey analysi shadowgraph fingerclub measur magnifi silhouett right index finger shadowgram 125 subject compris children young adult profil hyponychi angl found good discrimin club independ age sex normal profil angl 1683 degre 36 mean normal hyponychi angl 1801 degre 42 patient cystic fibrosi cyanot congenit heartdiseas found grossli elev valu angl asthmat found moder degre club significantli elev valu angl shadowgram prove conveni object method record degre progress fingerclub clinic practic
476	letter infect dose salmonella outbreak salmonellosi patient consum pancreatin uk prompt studi hospit includ determin infect dose children cystic fibrosi known contract schwarzengrund enter contamin porcin powder pancreatin found infect especi preval young cysticfibrosi patient receiv broadspectrum antibiot treatment chest infect pancreatin ad meal immedi consumpt suscept infect depend mani factor variabl necessari take account thing age condit patient discuss actual number organ caus infect
477	cystic fibrosi heterozygos pathogenesi allergi 47 cystic fibrosi cf heterozygot posit prick skin test 1 9 antigen 53 histori allerg diseas occur significantli often control group sinc 1 20 popul cf carrier would contribut allergi commun
478	current biochem approach cystic fibrosi research clinic abnorm cystic fibrosi categor three head pulmonari diseas digest disord ion transport abnorm research direct cystic fibrosi evolv observ characterist malfunct inher diseas includ defect mucociliari function mucou secret membran transport glycoprotein biosynthesi draw known base inherit diseas one could predict cystic fibrosi result abnorm function protein sickl cell anemia enzym defici phenylketonuria defici normal inhibitor hereditari angioedema
479	rna methyl polyamin metabol cystic fibrosi autosom recess inherit disord cystic fibrosi clinic identifi patient pathognomon find increas electrolyt content exocrin secret sweat two observ merit mention first demonstr mago exist factor cf sweat interf reabsorpt sodium rat parotid secondli exist cf serum compon interf ciliari rhythm organ cultur system investig cystic fibrosi orient toward establish possibl pedigre caus unit observ secondli develop possibl method heterozygot detect cystic fibrosi rna rel undermethyl comparison contrast cultur addit cf heterozygot fibroblast cultur also appear undermethyl interpret data impli primari defect rna methylas cystic fibrosi rather suggest defect elsewher biochem sequenc involv methionin
480	recent advanc research cystic fibrosi advanc made two area cystic fibrosi research univers missouri school medicin first investig improv understand normal mechan underlin product exocrin secret second involv recent observ relat import effort develop method heterozygot detect author conclud effort made shift emphasi research qualit bioassay reliabl detect system
481	adenosin 35cyclic amp fibroblast patient cystic fibrosi relationship secret known involv cyclic amp control secret exocrin mammalian cell studi cyclic amp metabol cultur cystic fibrosi cell hope demonstr abnorm detail comparison 5 cf 5 control strain show cf cell synthes 3 time intracellular cyclic amp control paper present data addit 10 cf 10 control strain measur intracellular cyclic amp provid clearcut differ cf control strain previous observ cf strain synthes cyclic amp control differ larg earlier studi consider overlap two group clear two studi yield dispar result
482	mucin cystic fibrosi sputum biochem studi bronchial mucin sputum patient cystic fibrosi undertaken order determin chemic featur compar bronchial mucin secret physiolog patholog condit mucin studi present work obtain insolubl fibrillar part sputum bronchial mucin main glycoprotein fibrillar mucu data suggest high proport acid mucin within bronchial secret cf patient predomin acid mucin may specif featur cf sinc sputum 2 patient diseas similar mucin distribut far cf concern present imposs state whether bronchial mucin repres normal mucin child structur abnorm molecul
483	tracheobronchi mucu secret vivo vitro epitheli tissu cystic fibrosi control subject paper review effort compar mucou glycoprotein tracheobronchi tract cystic fibrosi patient control subject use secret sever sourc includ sputum bronchial wash obtain aid fiberopt bronchoscop tracheobronchi aspir endotrach tracheostomi tube final secret discharg human tracheobronchi epitheli explant solubil fraction secret properti major mucou glycoprotein compon composit major compon noninfect bronchit cf lung organ cultur human tracheobronchi epithelium discuss
484	bronchial mucu secret cystic fibrosi mucu primari aetiolog factor develop pulmonari diseas cystic fibrosi biochem studi bronchial secret yet confirm qualit differ composit natur glycoprotein major compon secret lack clear evid basic abnorm natur mucu attent direct possibl defect control mucu secret encompass alter normal regul autonom nervou system stimul either cellular intracellular control level recent year attent focus presenc ciliotox factor serum children cystic fibrosi possibl role pathophysiolog cystic fibrosi control mucu secret submucos gland goblet cell experiment model lung diseas cystic fibrosi role serum factor mucu secret mucu blanket chronic lung diseas discuss
485	pathophysiolog mucu secret cystic fibrosi abnorm mucu secret either biochem physic long claim primari caus pulmonari complic obstruct infect patient suffer cystic fibrosi cf review draw larg measur experi prof l reid research team last 15 year studi mucussecret structur secret normal diseas lung variou angl develop structur ultrastructur histochemistri organ cultur biochem analysi rheolog character
486	mucou glycoprotein widespread accept mucou glycoprotein product correl pathogenesi cystic fibrosi yet rel littl known chemistri control synthesi secret heteromacromolecul present describ briefli chemistri biosynthesi glycoprotein gener focus mucou glycoprotein chemistri glycoprotein carbohydr amino acid linkag carbohydr structur analysi biosynthesi regul discuss
487	impair mucociliari transport cystic fibrosi past year studi variou laboratori suggest presenc factor cystic fibrosi serum caus widespread vitro abnorm compon lung defenc mechan particularli respect macrophag dysfunct quantit qualit alter mucu ciliari motil possibl vivo role ciliari dysfunct pathogenesi diseas particular clinic interest sinc vitro ciliari dyskinesia factor previous demonstr pulmonari complic hallmark cf yet clearanc clinic stabl cf subject rel well maintain suggest us mucociliari transport abnorm might present intermitt order explor design nasal mucociliari clearanc studi determin whether cf serum might exhibit mct inhibit vivo studi conclud substanc cf serum capac slow mct whether effect cilia via overproduct normal abnorm mucu known
488	mucociliari clearanc cystic fibrosi fulli understand factor control mucociliari clearanc throughout human lung interrelationship clearanc diseas necessari measur mucociliari clearanc rate airway level within lung past year technic mean sought wherebi rate mucu clearanc within individu airway measur laboratori develop rel noninvas techniqu measur mucociliari tracheal transport rate measur mttr 20 patient cystic fibrosi mttr correl well degre pulmonari diseas patient measur mttr would suggest derang mucociliari clearanc mechan necessari condit patient cf also interest evalu effect therapi use treatment cf
489	research cystic fibrosi first three part review describ major direct cystic fibrosi research last nine year report cystic fibrosi nativ african negro gener accept cystic fibrosi follow simpl autosom recess transmiss difficult howev explain mainten lethal gene high frequenc noth known chromosom local trait present simpl reliabl method heterozygot detect secret patient cystic fibrosi often copiou exhibit peculiar rheolog properti sever group emphas decreas water content cystic fibrosi secret pathogenesi diseas consist abnorm glycoprotein glycosaminoglycan explain mucu secret precipit obstruct organ passag
490	research cystic fibrosi second three part tissuecultur studi involv metachromasia glycosaminoglycan rna methyl cell membran ciliatox activ medium describ although fulfil hope quick rout discoveri basic defect diseas rais first find studi fibroblast cystic fibrosi given import inform evid present indic lysosom probabl intracellular organel normal morpholog function cystic fibrosi sever humor abnorm found cystic fibrosi influenc ciliari activ experiment model affect membran transport abnorm polyamin distribut number abnorm humor factor found cystic fibrosi limit interpret seriou assay use delin abnorm often univers reproduc inher variabl other technic forbid therefor unifi definit socal cystic fibrosi factor possibl present
491	research cystic fibrosi third three part recent autonom nervou system studi cystic fibrosi outlin miscellan observ regard salivari tear gland calcium kallikreinkinin system proteas inhibitor alphafetoprotein endocrin gland discuss 90 per cent patient cystic fibrosi die progress pulmonari involv complic infect staphylococcu aureu pseudomona aeruginosa question immunolog deficit frequent rais extens investig shown immun system cystic fibrosi intact studi regard pulmonari ciliari clearanc bacteriolog also outlin despit extens investig basic defect cystic fibrosi still unknown explan two defect homozygot lead clinic manifest sweat electrolyt defect abnorm physiochem behavior mucou secret former satisfactorili explain sodiumreabsorptioninhibitori factor present sweat saliva patient mucoussecret abnorm effect increas calcium concentr decreas solubl glycoprotein suggest mechan might respons precipit obstruct organ passag give rise symptom cystic fibrosi although excel diagnost test homozygot sweat test one cannot reli present biolog assay determin heterozygos antenat diagnosi
492	hyperuricosuria due highdos pancreat extract therapi cystic fibrosi dysuria uric acid crystalluria hyperuricosuria develop child cystic fibrosi normal serum uric acid hyperuricosuria patient two children directli relat ingest larg amount pancreat extract three children reduc pancreat extract dosag 85 percent lower purin intak 307 225 148 mg respect urinari uric acid excret decreas 245 239 158 mg overmed result parent decis increas enzym dosag cystic fibrosi clinic 15 32 patient screen random take higher prescrib dose pancreat enzym 14 15 children hyperuricosur basi inform suggest minim effect dose pancreat extract determin adher child cystic fibrosi avoid potenti renal injuri hyperuricosuria
493	kappachain defici immunoglobulin disord sinc kappachain defici unusu condit studi clinic laboratori find patient defici patient cystic fibrosi concurr malabsorpt diabet mellitu iga defici serum level igm igg 085 722 mg per millilit respect kappa type igm igg present serum extern secret gamma mu lambda chain probabl polyclon charact antibodi kappa chain detect either patient mother plasma cell contain kappatyp immunoglobulin absent jejunum sampl bone marrow kappachainbear b lymphocyt could detect blood bone marrow serum one patient sister contain trace amount kappatyp immunoglobulin patient display complet absenc kappa type immunoglobulin probabl owe genet defect
494	current concept genet cystic fibrosi cystic fibrosi attract attent biomed investig preval chronic diseas inherit caucasian children carrier gene lead cystic fibrosi occur quit frequent caucasian popul major aim research cystic fibrosi develop test offer reliabl detect heterozygot fetu cystic fibrosi consider number patient diseas diagnos death therapi patient cystic fibrosi still symptomat includ appropri diet diet pancreat enzym vitamin supplement treatment chronic obstruct pulmonari involv chronic infect antibiot physic therapi inhal therapi psychoemot support vocat rehabilit
495	lung defens mechan first two part one import function lung asid role ga exchang metabol provis essenti biolog barrier man environ fundament import way airway lung parenchyma prevent entri neutral remov injuri agent task perform effici lung normal steril first bronchial divis termin lung unit inhal particl may deposit respiratori tract result impact sediment brownian motion turbul diffus minim degre electrostat forc particl deposit posterior two third nasal caviti nasopharynx larynx termin bronchiol land airway line mucuscov ciliat epithelium remov mean mucociliari transport mechan structur mucociliari transport system physic aspect mucu nonspecif solubl factor airway secret cilia mucociliari transport discuss
496	cystic fibrosi gone day thought prognosi hopeless least three quarter children live past age 19 especi diseas diagnos birth diagnosi treatment cystic fibrosi explain
497	cystic fibrosi new zealand incid mortal data incid mortal cystic fibrosi new zealand year 19651971 review data obtain hospit admiss death record 171 case european parentag except one partmaori child minimum incid cystic fibrosi european popul one 3185 live birth compar popul similar background somewhat lower deriv becroft 1968 data show period survey approxim 30 percent cystic fibrosi sufferer die less 12 month age
498	salivari secret health diseas potenti use analysi salivari secret diagnosi prognosi begin explor depth preliminari work alreadi undertaken indic modern method appli secret may provid inform differ obtain bodi fluid saliva collect point manufactur therefor unaffect collect storag bodi product protein synthesi within gland known water electrolyt exchang mechan salivari composit affect autonom hormon stimuli specif influenc factor better understood studi fluid provid import clue understand diseas evalu therapi place bodi possibl directli util noninvas techniqu examin product larg number import biolog process obviou care handl collect analyt techniqu essenti secret util futur investig clinic situat take full advantag strong base knowledg physiolog gland develop field depend care clinic investig design make full use current knowledg
499	alter golgi complex glycoprotein biosynthesi normal diseas tissu golgi complex import role regul normal develop cell contribut anabol function includ assembl secret macromolecul catabol function synthesi lysosom central role golgi complex biosynthesi glycoprotein demonstr purpos review focu attent structur function correl golgi complex liver relat involv diseas hepat parenchym cell use wide model studi biosynthet absorpt secretori function epitheli cell type studi group five broad head structur organ develop differenti ultrastructur chang patholog condit alter glycoprotein biosynthesi alter glycosyltransferas
500	impair natur defens ii endogen caus diseas malign malnutrit organ transplant articl provid evid opportunist infect expect chronic debilit immunosuppress person onset infecti diseas patient sudden insidi prodrom sign anorexia malais fever vomit nonspecif symptom children may manifest primari ill treatment insult natur defens barrier may caus seriou infect compromis host infect wound insect bite easili control local measur healthi person may becom focu septicemia child leukemia despit diagnosi appropri treatment specif infect immunosuppress person still subject overwhelm infect resist opportunist organ natur defens mechan restor awar vulner compromis host key effect diagnosi manag variou complic infecti diseas
501	constip children although constip well defin brought attent physician rais certain question newborn obstip due hirschsprung diseas meconium ileu intermitt volvulu obstip child mass cecum due cystic fibrosi ie meconium ileu equival formula mix correctli patient spinal defect child medic child constip psychogen reason us deal children consid entiti patient miss sever diseas grave prevent consequ
502	echocardiograph assess cor pulmonal cystic fibrosi earli clinic recognit assess cor pulmonal frequent difficult evalu use echocardiograph measur right ventricular dimens septal motion assess cor pulmonal studi 94 patient cystic fibrosi vari sever signific relationship increas right ventricular dimens index rvdi 1 decreas clinic score vital capac forc expiratori volum one second fev1 maxim midexpiratori flow rate mmfr 2 increas residu volum thorac ga volum correl right ventricular dimens index pao2 find support electrocardiogram patholog evid right ventricular involv abnorm septal motion observ frequent patient sever obstruct airway diseas measur decreas vital capac fev1 mmfr data show echocardiograph evid mild right ventricular enlarg andor hypertrophi much earlier cours cystic fibrosi previous suspect echocardiogram use tool evalu cor pulmonal patient cystic fibrosi
503	colloid crystal format parotid saliva cystic fibrosi patient noncyst fibrosi subject ii electron microscopi electrophoresi centrifug pellet turbid parotid saliva cystic fibrosi cf patient noncf subject obtain saliva kept 2 degre 10 min electron microscop appear amorph round particl thought colloid aggreg organ materi drop turbid saliva sampl incub 2 hr 2 degre 37 degre addit contain discret electrondens crystal well defin angular morpholog usual cubic retangular approxim hexagon inhibitor urea guanidin hydrochlorid edta result crystal observ select area electron diffract individu crystal show predominantli hexagon rectangular pattern could index come hydroxyapitit transit hexagon rectangular pattern back hexagon pattern could obtain individu crystal tilt electron microscop squar diffract pattern may octacalcium brushit polyacrylamid gel disc electrophoresi parotid saliva indic sparingli solubl protein 2 degre 37 degre pellet compris prolinerich protein calciumprecipit trichloroacet acid tcaprecipit phosphoprotein fluoresc amido schwarz coomassi brilliant blue g250
504	absenc alpha twomacroglobulinproteas complex cystic fibrosi present studi use immunolog methodolog confirm previou observ laboratori absenc proteas compon arginin esteras activ plasma patient cystic fibrosi studi pool plasma control individu activ partial purifi adsorpt column soybean trypsin inhibitor conjug sepharos 4b follow elut benzamidin fraction purifi isoelectrofocus polyacrylamid gel protein around pi rang 55 elut util prepar antiserum immunoelectrophoresi activ plasma sampl control subject patient cystic fibrosi perform util antiserum control four precipitin arc residu esteras activ observ wherea three seen plasma patient cystic fibrosi doubl gel diffus experi use specif antisera rule presenc trypsin chymotrypsin plasminogen prothrombin c1 esteras alpha onetrypsin inhibitor interalphatrypsin inhibitor concentr benzamidin eluat antisera alpha two macroglobulin gave immunoprecipit readili stain proteolyt activ immunoelectrophoresi alpha two macroglobulin precipitin band correspond band absent plasma patient cystic fibrosi contrast alpha two macroglobulin level similar plasma control subject patient cystic fibrosi use antiserum protein fractith proteolyt activ could demonstr control plasma one specif enzymeact rocket absent plasma patient cystic fibrosi doubl blind studi 15 control sampl 15 sampl patient cystic fibrosi specif rocket shown present 13 control sampl absent 14 cystic fibrosi sampl alpha twomacroglobulin determin immunolog procedur trypsin bind trypsin protein esteras concentr ratio immunolog assay biolog activ assay 90 normal plasma sampl 65 cystic fibrosi sampl
505	pancrea cystic fibrosi chemic composit compar morpholog section pancrea 16 individu die cystic fibrosi cf classifi morphometr criteria four categori increas order pancreat involv concentr acini islet main duct lobular duct connect tissu fat compar control level result show least involv pancreas neonat die 5 month age acini reduc 33 control level follow increas islet 410 lobular duct 250 main duct 1700 control increas sever pancreat diseas acini reduc 5 lobular duct 37 control level respect main duct increas 19fold fatti infiltr account 25 fresh weight pancrea 9 16 specimen compar biochem studi 35 fibrocyst pancreas quantit relat sever pancreat involv follow water volatil matter normal account 80 weight fresh pancrea reduc less 30 affect organ concentr zinc diminish near normal mean level 193 mugzng dri pancrea 10 amount sever involv pancrea elev concentr calcium amount 10 time control level found obstruct ductal structur calcium deplet pancreat section adjac obstruct follow biochem indic significantli differ mean level 35 fibrocyst pancreas compar 17 control p less equal 0001 fat water zinc calcium copper magnesium potassium sodium p less equal 001
506	effect spermidin spermin prolifer vitro fibroblast normal cystic fibrosi patient effect spermidin spermin vari concentr upon replic abil human fibroblast cell cultur studi averag concentr spermidin caus 50 inhibit prolifert id50 3 day growth three normal cell strain three strain deriv patient cystic fibrosi cf 44 x 106 12 62 x 106 21 respect valu spermin 20 x 106 05 normal 22 x 106 01 fibroblast cystic fibrosi patient signific differ replic abil normal cf cell strain seen wide rang polyamin concentr employ period 3 day
507	elev plasma level carcinoembryon antigen cystic fibrosi elev level plasma cea found patient cystic fibrosi elev well correl shwachman score patient parallel chang level plasma cea clinic condit four patient also observ followup studi close clinic examin indic elev plasma cea cystic fibrosi patient may deriv sputum produc abnorm amount hypothesi support high content chromatograph profil cea activ sputum patient cystic fibrosi
508	letter serum glutathion reductas cystic fibrosi obtain addit data support specif report serum glutathion reductas gr chang cystic fibrosi cf previou seri mean gr cf 20 greater control p 0005 differ found cf control either lactat dehydrogenas ldh glutamicpyruv transaminas gpt appear underli process process leakag serum cellular damag reflect rais ldh gpt might lead rais gr demonstr posit correl control absenc posit correl enzym gr cf sampl well normal valu ldh gpt cf suggest rais serum gr cf attribut tissu leakag damag cell secondari diseas
509	parotid gland function children cystic fibrosi child control subject parotid saliva collect 22 children cystic fibrosi cf 21 control children stimul 01 ml 5 citric acid tongu everi 15 sec period 10 min sampl collect 2min interv stimul saliva show lag period low amylas releas activ period higher amylas releas major differ cf child control parotid saliva elev calcium concentr cf subject flow rate amylas although higher cf group rais statist signific level higher mean valu sodium inorgan phosphat cf children statist signific minim potassium valu almost ident cf control saliva activ parotid saliva sampl control cf subject posit correl flow rate calcium flow rate sodium anylas calcium sodium calcium neg correl sodium potassium parotid function test valu diagnost test cystic fibrosi even calcium valu show much overlap control saliva diagnost worth
510	colloid crystal format parotid saliva cystic fibrosi patient noncyst fibrosi subject physicochemistri two type turbid found parotid saliva cystic fibrosi cf patient noncf subject cool saliva rapidli form revers colddepend turbid appear increas amount decreas temperatur increas protein concentr 37 degre slowli form stabl turbid appear increas amount parotid saliva sampl contain increas amount calcium 2 degre centrifug pellet consist predominantli protein wherea 37 degre pellet contain calcium inorgan phosphat protein cold depend turbid 2 degre inhibit edta 37 degre turbid dramat inhibit urea guanidin hydrochlorid reduc 2 degre turbid lesser extent inhibit 37 degre turbid tendenc toward higher level protein amylas calcium cf compar child control parotid saliva 4 6 caus greater incid degre turbid format saliva cf patient paper natur turbid investig rel occurr group subject
511	absenc serum factor patient cystic fibrosi serum factor demonstr normal individu 1 enhanc incorpor l3hfucos cultur human skin fibroblast 2 nondialyz 3 heat labil 50 degre 4 present noneuglobulin fraction 5 appear defici serum patient cystic fibrosi specif activ l3hfucos incorpor skin fibroblast normal individu presenc serum 12 control subject 3337 168 cpmmg protein contrast 2294 172 activ obtain either presenc serum 10 agematch patient cystic fibrosi absenc serum differ signific p less 0001 comparison signific differ detect amount l3hfucos incorpor skin fibroblast deriv normal individu patient cystic fibrosi plasma membran cultur skin fibroblast deriv patient cystic fibrosi appear grossli unalt protein lfucos label pattern
512	simpl techniqu detect cystic fibrosi heterozygot homozygot examin serum protein 18 cf subject 14 control individu unabl detect consist differ stain serum protein pattern cf control subject pattern show greater resolut protein previous publish contrast consist differ cf control subject addit modifi publish method procedur would enhanc likelihood electrophoret detect abnorm protein report properti portion sampl analyz publish procedur also analyz modif none modifi procedur show consist differ serum protein cf control subject explan readili appar differ result thoma et al result one hand previous report result attempt rigor reproduc isoelectr focus techniqu given literatur howev isoelectr focus polyacrylamid gel affect small technic differ thu factor essenti reproduc techniqu may evid publish procedur
513	studi cystic fibrosi use isoelectr focus ii demonstr defici proteolyt cleavag alpha2macroglobulin cystic fibrosi plasma protein isoelectr point pi 548 found defici plasma cystic fibrosi cf homozygot oblig heterozygot carrier cf compar normal control plasma purif protein pi 548 normal plasma perform use ammonium sulfat precipit deae cellulos cmcellulos chromatographi sephadex g200 gel filtrat starch block electrophoresi sepharos 4b gel filtrat purifi protein migrat singl band polyacrylamid gel electrophoresi display singl arc immunoelectrophoresi polyval antiserum whole human serum result variou techniqu use character indic protein fragment alpha2macroglobulin alpha2m deriv alpha2m proteolyt cleavag intact alpha2m subunit quantit alpha2m level plasma indic signific differ level alpha2m cf homozygot oblig heterozygot carrier normal control plasma sampl quantit arginin esteras activ plasma treat cloroform ellag acid indic total arginin esteras activ fraction arginin esteras activ inhibit soybean trypsin inhibitor sbti decreas cf homozygot oblig heterozygot plasma sampl rel normal control valu result studi indic plasma sampl cf homozygot oblig heterozygot carrier cf show defici proteolyt cleavag alpha2m compar normal control plasma suggest structur abnorm alpha2m defici plasma proteolyt activ may respons defici proteolysi
514	high speed cinemicrograph studi rabbit tracheal ciliat epithelia cytolyt effect cystic fibrosi serum tracheal epitheli cell high speed cinemicrograph made ciliari activ rabbit tracheal cilia aid nomarski optic detail natur ciliari beat pattern determin slow motion analysi high speed cinemicrograph 13 document form ciliari beat pattern physiolog state tracheal epithelia util basic refer control investig physiolog effect cystic fibrosi serum ciliat epithelia cystic fibrosi tracheal mucu stagnat phenomenon care analys high speed cinemicrograph reveal cystic fibrosi serum effect rhythm beat pattern rabbit tracheal cilia howev shown control procedur cystic fibrosi serum cytolyt effect tracheal epitheli cell also cell junction ciliari dyskinesi describ previou report 69 actual secondari effect cytolysi cell destruct
515	determin character ciliari atpas presenc serum cystic fibrosi patient purpos investig twofold 1 identifi character enzymat atp hydrolysi system epitheli cilia 2 develop quantit biochem test ciliotox cystic fibrosi cf factor base inhibit atp util ciliari prepar rational select system cf factor analysi relat tight essenti mechanochem coupl function cilia use rabbit tracheal epithelium sourc high molecular weight greater 200000 atpas identifi partial purifi extens character properti protein similar observ previou studi other flagellar ciliari dynein motilityassoci atpas isol microorgan analysi ph profil reveal broad rang high enzymat activ 65 9 studi potenti cation activ show enzym activ equal either ca2 mg2 equimolar concentr activ occur presenc zn2 na h na plu k effect mg2 ca2 inhibit na k na plu k enzym hydrolyz mg2 contain solut utp ctp adp 5154 rate atp dephosphoryl wherea mgdeoxyatp hydrolyz 79 effect atp use newli devis analyt techniqu gamma32patp substrat atp hydrolysi variou ciliari prepar rabbit trachea oyster gill includ motil suspens monitor presenc sera cf homo heterozygot reproduc rate atp dephosphoryl averag 27 nmolminmg protein demonstr homogen ciliat epithelium none test system evalu howev capabl demonstr cfrelat differ atpas activ atp util although attemp unsuccess thu far approach describ report provid exampl object quantit biochem assess ciliari function
516	effect calcium intestin mucin implic cystic fibrosi major featur diseas cystic fibrosi excess concentr mucu within duct gland mucousproduc organ mucou secret also show elev calcium concentr use purifi rat intestin goblet cell mucin model mucin investig effect millimolar addit 125 mm cacl2 physic properti mucin isoton incub media preserv order mimic vivo condit cacl2 815mm caus 1533 decreas viscos chang electrophoret mobil acrylamid gel 2030 decreas solubl mucin solubl chang revers addit edta 20 mm incub insolubl also produc incub mucin mixtur solubl intestin content nacl wash find strongli suggest mucin becam smaller dens calcium ad process probabl achiev loss intramolecular water
517	detect cystic fibrosi protein electrofocus detect cystic fibrosi protein cfp use method involv rather exact requir collect serum sampl subsequ analysi electrofocus minor variat method describ sampl collect storag may caus degrad loss cfp could lead erron result sinc mani cf sampl would appear cfp neg make imposs observ consist differ group cf sampl normal control sampl electrofocus result present thoma et al figur 1 letter smith et al obviou neither group reproduc protein handl pattern present either previou report ph gradient locat sampl pad rel anod protein band pattern total differ question valid techniqu use claim reproduc method detect cfp suppos improv design enhanc detect cfp
518	cystic fibrosi enzymat detect ciliostat factor ciliostat cystic fibrosi cf factor investig order develop enzymat assay detect saliva factor associ alphaamylas remov addit factor dialysi affect alphaamylas catalyt activ cf control normal saliva crude prepar dialyz factor cf saliva ciliostat alphaamylas catalyz starch hydrolysi cf control saliva found insensit hydroxyalkylamin inhibitor method could use detect differ cf control amylas sinc anoth carbohydras mammalian debranch enzym much sensit inhibit effect isol crude factor enzym determin mean valu percentag inhibit debranch enzym activ fraction obtain saliva cf patient oblig heterozygot control subject 32 27 sampl 13 21 sampl 6 11 sampl respect fifteen cf valu exceed maximum 13 inhibit observ control inde five sampl almost complet inhibit debranch enzym inhibitori action provid basi enzymat assay detect ciliostat cf factor
519	chronic reserpin rat possibl anim model cystic fibrosi iv protein composit pulmonari lavag fluid lung lavag sampl obtain patient cystic fibrosi cf significantli higher level total protein per ml lavag fluid 049 vs 030 mgml signific increas absolut rel amount low molecular weight glycoprotein 15000 mol wt note lavag specimen cf patient reserpinetr rat also show signific increas total protein recov lung lavag fluid 233 increas absolut rel amount low molecular weight glycoprotein 15000 mol wt thu reserpin induc chang secret lung rat similar observ sampl obtain lung cf patient
520	fatti acid prostaglandin cystic fibrosi paper elliott campbel et al suggest new approach toward etiolog pathophysiolog therapi patient cystic fibrosi elliott origin report effect intraven fatti acid therapi cf patient present report fare remark well particularli regard weight gain paper campbel et al suggest oxygen simpli diffus across membran instead transport influenc fatti acid composit membran elliott suggest disarrang fatti acid metabol may relat alter prostaglandin product attract studi prove whether fatti acid andor prostaglandin alter secondari intestin fat malabsorpt relat primari metabol defect cf
521	abnorm fatti acid composit impair oxygen suppli cystic fibrosi patient impair oxygen suppli deterior health cystic fibrosi patient correl abnorm chang fatti acid composit blood lipid proport oleat increas linol decreas erythrocyt membran interfer format intracellular oxyhemoglobin increas arteri oxygen pressur decreas physicalchem basi chang seem oleic linol acid differ abil undergo revers oxygen respons chang oxygen pressur oxygen complex linol acid dissoci rel high pressur wherea oleic dissoci low pressur accordingli excess substitut oleic linol acid membran lipid would expect decreas intracellular oxygen pressur level hemoglobin oxygen oxygenrequir process would impair
522	therapeut trial fatti acid supplement cystic fibrosi seven children cystic fibrosi cf treat least one year intraven administ soya oil emuls improv least one biochem abnorm charact diseas appear children clinic cours remain benign cours remark better children cf treat without intralipid auckland period though placebo effect cannot discount postul intraven supplement essenti fatti acid cf may turn partial correct error metabol prostaglandin present diseas
523	coexist cystic fibrosi celiac diseas two patient cystic fibrosi cf subsequ develop celiac diseas cd describ sinc organ cultur intestin mucosa use establish vitro model studi cd util opportun determin whether duoden mucosa obtain two patient immedi famili differ organ cultur behavior mucosa obtain patient cd alon addit specif hla type associ cd use hla type determin whether two patient cfcd differ genet patient cd alon one patient hla8 common type associ cd hla12 mani nonhla8 celiac patient respons organ cultur mucosa two patient respons organ cultur mucosa patient cd alon data suggest cd occur patient cf differ cd occur alon
524	letter question regard arginin hydrochlorid inhal regard recent studi dietzsch et al use arginin hydrochlorid inhal cystic fibrosi patient wish point investig act irrespons expos patient appreci period seven week prepar known irrit would suggest deleteri effect seen dietzsch et al due inattent experiment detail lack commun investig dietzsch et al give impress articl arginin solut detriment lung wish point larginin hydrochlorid buffer sodium solut irrit airway cystic fibrosi patient howev comparison studi done larginin buffer free base fate children cystic fibrosi depend qualiti inhal treatment mean replac good mucolyt drug better one step step approach ideal mucolyt solut think uneth use less effect drug solut control group eg salin distil water state arginin solut irrit arginin treatment danger nacetylcystein solut success use treatment patient buffer sodium hydroxid ph 70 quantiti sodium administ inhal amount 004 mval sodium injuri pharmacolog effect exclud drug well toler deleteri effect
525	paradox effect adrenerg methylxanthin drug cystic fibrosi studi examin effect aerosol isoproterenol oral theophyllin pulmonari function cystic fibrosi cf determin often drug benefici whether correl respons isoproterenol respons oral theophyllin obtain baselin pulmonari function test isoproterenol aerosol 12 patient cf put doubleblind trial highdosag theophyllin 10 mgkg three time per day placebo four week switch altern regimen next four week patient weekli evalu pulmonari function plasma theophyllin determin gastrointestin side effect common theophyllin respons aerosol bronchodil inconsist week week aerosol bronchodil five 12 patient averag increas 10 fef45 55 fef7080 take oral theophyllin five patient 10 decreas fef 4555 six patient decreas fef7080 conclud concord respons isoproterenol theophyllin adrenerg methylxanthin drug must use caution patient cf
526	letter intralipid cystic fibrosi stimul professor r b elliott aucklandaustralia administ intralipid regularli small number babi last two year volum use 10 ml 10 solut per kilogram bodi weight volum administ everi three week infus take approxim three hour four entrant trial well clinic ct 1 hubbard vs lancet 2 1302 977 2 lloydstil jd pediatr 64 50 979 3 rogier v pediatr re 14 1088 980 4 hubbard vs j clin nutr 33 2281 980 5 mischler eh pediatr re 20 36 986
527	metabol cirrhos infanc earli childhood cirrhosi liver infanc earli childhood common phenomenon howev attend morbid frequent mortal repres signific diagnost therapeut problem age group review present briefli metabol cirrhos infanc discuss current propos pathogenet mechan outlin diagnost techniqu may aid pathologist approach problem metabol cirrhosi young hereditari tyrosinemia galactosemia hereditari fructos intoler alpha1antitrypsin defici glycogenesi type iv amylopectinosi fibrocyst diseas pancrea niemannpick diseas gaucher diseas mucopolysaccharidosi hurlerhunt syndrom wolman diseas hemochromatosi wilson diseas cystinosi cerebrohepatoren syndrom zellweg indian childhood cirrhosi infantil polycyst diseas liver kidney congenit hepat fibrosi iatrogen metabol cirrhos idiopath congenit cirrhosi discuss
528	bronchial drainag aerosol medic cystic fibrosi examin studi immedi effect bronchial drainag preced inhal aerosol solut mucolyt agent bronchodil combin upon four measur pulmonari function 20 patient cystic fibrosi three separ occas pulmonari function test preced follow treatment consist one three aerosol solut follow bronchial drainag order solut use random subject receiv one treatment solut greatest overal improv function seen bronchodil bronchial drainag combin bronchodilatormucolyt agent bronchial drainag next effect techniqu mucolyt agent use alon bronchial drainag decreas function comparison pulmonari function score indic signific differ among three treatment
529	differenti caus wheez infant cannot emphas strongli infant wheez asthma lifethreaten consequ failur detect clinic entiti present wheez clinician thoroughli investig infant wheez case illustr caus wheez addit caus wheez approach diagnosi discuss
530	abnorm level 35cyclic amp isoproterenolstimul fibroblast patient cystic fibrosi determin abnorm exocrin secret characterist cystic fibrosi could investig vitro studi synthesi 35cyclic amp isoproterenol stimul skin fibroblast deriv patient cystic fibrosi normal individu comparison normal cystic fibrosi cell show latter 2 5fold greater level intracellular cyclic amp stimul isoproterenol differ strain observ everi stage cultur cycl specif stimul betaadrenerg agonist could account differ dose time respons curv leakag cyclic amp medium increas sensit catecholamin may reflect intrins genet properti cystic fibrosi cell may feasibl use system studi biochem basi genet defect cystic fibrosi
531	relationship hepat pancreat diseas volumin literatur dealt varieti patholog entiti may effect liver pancrea much includ poorli vagu document observ facet subject experiment studi despit result difficulti unravel report infer relationship two organ avail inform analyz accord follow arbitrari categor 1 involv liver pancreat diseas 2 involv pancrea hepat diseas 3 involv organ system diseas
532	cystic fibrosi adolesc adult fortyf patient 25 male 20 femal 12 year age cystic fibrosi studi clinic radiolog physiolog mean age first visit 17 year follow mean period 4 year attend least everi six month first symptom develop age five 42 45 patient respiratori thirtytwo 45 patient sever lung diseas group iii start studi seven patient die studi cough sputum almost univers 23 haemoptys eight pneumothorac staphylococcu pyogen haemophilu influenza pseudomona aeruginosa common pathogen isol sputum increas preval latter confirm acquisit mucoid strain pseudomona signifi poor prognosi establish infect never erad fortythre patient evid pancreat insuffici one patient symptom mild five patient abandon dietari restrict pancreatin without ill effect seven patient symptom partial bowel obstruct meconium ileu equival one requir surgic relief liver enlarg seven patient spleen felt three three patient diabet mellitu influenc cystic fibrosi growth develop reportedth growth spurt late major growth failur confin sever lung infect malabsorpt circumst remain unexplain mean weight low relat height puberti delay sex
533	cystic fibrosi new challeng patientcar team date case cystic fibrosi treat pediatr hospit chang advanc treatment patient consid termin ill live adulthood stress result chronic ill consid herein standpoint social casework plan crucial role patientcar team new problem regard person develop patient present particular emphasi role cf patient parent role respiratori therapist care patient uniqu due extens patient contact verbal physic primari threat pulmonari diseas pose patient cf therapist abil cope problem aid famili patient becom crucial child rehabilit requir fulfil role educ development natur pursu model futur patient care
534	nasal polyposi sinus cystic fibrosi cystic fibrosi appear milder form partial express diseas occurr nasal polyposi sinus patient abnorm chest xray may clue diagnosi
535	carcinoembryon antigen cystic fibrosi protein blood cystic fibrosi homozygot heterozygot carrier carcinoembryon antigen cea activ measur radioimmunoassay blood cystic fibrosi cf homozygot heterozygot carrier cf normal healthi control patient control carcinoma involv gastrointestin organ sampl also screen electrofocus cystic fibrosi protein cfp metabol marker previous shown associ cf gene significantli increas level cea activ found cfpposit group howev one except patient control mark increas cea activ cfp neg immunodiffus perchlor acid extract cealik materi heterozygot carrier blood indic cealik materi elev homozygot heterozygot cf show partial ident two separ cea prepar obtain colon carcinoma ident either b oh blood group substanc glycoprotein materi howev react three differ anticea antisera find abnorm increas glycoprotein cystic fibrosi taken togeth previou report demonstr abnorm carbohydr portion glycoprotein found variou exocrin secret cf suggest primari defect diseas manifest partli defect glycoprotein metabol defect may result abnorm one glycosyltransferas possibl caus primari defect polyamin metabol
536	serolog type diplococcu pneumonia isol respiratori tract children cystic fibrosi children diseas distribut serolog type pneumonia investig 40 strain isol 26 children cystic fibrosi 57 strain isol 39 children diseas strain isol sputum tracheal secret strain cystic fibrosi patient belong 14 differ serolog type preval 19f 19a 3 strain group children belong 20 differ serolog type preval 23f 19f 11a differ two group patient preval type small conclud special serolog type pneumonia associ cystic fibrosi
537	haemophilu lower respiratori tract patient cystic fibrosi fiftysix nonhaemolyt haemophilu strain isol current bacteriolog examin materi lower respiratori tract 39 patient cystic fibrosi 6 month period except six strain belong haemophilu parainfluenza strain identifi haemophilu influenza biotyp h influenza predomin taxon 38 especi relat patient recurr prolong colon two strain capsul unexpectedli high percentag strain produc lysin decarboxylas signific properti pathogenesi respiratori tract colon discuss
538	treatment pseudomona infect cystic fibrosi use tobramycin decid treat seventeen cystic fibrosi patient care known activ infect mucoid strain pseudomona use larg intraven dose tobramycin object observ made result satisfactori chang white blood cell count erythrocyt sediment rate seem often conflict clinic impress improv howev closer agreement subject judgement weight gain respiratori function chang erad pseudomona sputum achiev four case although durat followup one short
539	preval divorc among parent children cystic fibrosi chronic diseas data preval divorc separ among parent children cystic fibrosi chronic diseas indic marit breakdown preval among coupl gener popul coupl attend genet counsel clinic children spina bifida leukemia divorc rate lower unit state nation averag parent children cystic fibrosi divorc rate nation averag high recurr risk cystic fibrosi may deter mani parent reproduct specul inabl plan children may factor respons higher preval among parent compar children chronic diseas
540	roentgenograph recognit bronchocel bronchocel often characterist plain film tomograph bronchograph appear may trap air roentgenograph recognit bronchocel allow distinguish neoplasm sometim help avoid unnecessari surgeri
541	manifest cystic fibrosi adult letter cystic fibrosi cf recess autosom genet diseas exocrin gland secret highli viscou mucu variabl genet penetr organ spare result broad spectrum clinic present diagnosi cf usual establish presenc chronic obstruct lung diseas andor gastrointestin dysfunct togeth elev level sweat electrolyt chlorid 60 meqlit markedli diminish duoden pancreat enzym concentr patholog chang tissu famili histori may occasion help metabol basi cf unknown classic stereotyp cf patient infant chronic cough diarrhea growth failur improv medic care enabl mani patient reach adulthood increas diagnost suspicion result identif diseas adult base upon analysi 11000 case cf report year 1974 119 cystic fibrosi center nation cystic fibrosi foundat estim probabl individu cf surviv age 20 approxim 39 although adult current care pediatrician develop medic psychiatr surgic obstetr complic may necessit involv profession joint studi cystic fibrosi adult conduct duke medic center nih shown major affect adult includ diagnos earli life marri work full parttim mani manifest symptom rel late life sinc studi retrospect report frequenc clinic find tend underestim instanc actual incid popul studi report incid cf unit state conserv estim 12000 live birth adult club infertil symptom evalu cf true incid would certainli higher
542	detect cystic fibrosi heterozygot use zeta potenti reduct method parotid saliva sampl cystic fibrosi homozygot heterozygot normal individu test zeta potenti techniqu secret factor doubleblind experi overlap zeta potenti reduct control group cystic fibrosi test group indic zeta potenti test may detect uniqu compon saliva cystic fibrosi genotyp
543	lfucos metabol cystic fibrosi fibroblast capac skin fibroblast cystic fibrosi cf noncf individu incorpor exogen lfucos variou metabol pool compar incorpor intracellular acidsolubl pool extracellular glycopeptid measur duallabel co chromatograph techniqu wherea total macromolecular incorpor measur singlelabel procedur although cf normal fibroblast incorpor exogen fucos intracellular acid solubl high molecular weight compound similar manner cf cell appear character increas incorpor label low molecular weight extracellular glycopeptid
544	polyamin metabol cystic fibrosi increas blood level spermidin increas spermidinespermin ratio document 31 patient cystic fibrosi cf 29 percent cf patient overlap control group abnorm urinari free polyamin metabol deriv relat electrolyt transport serum ciliostat factor autonom nervou system elabor upon
545	effect polyamin cystic fibrosi serum glucos transport effect plasma serum homozygot heterozygot cystic fibrosi cf gene activ uptak 3014cmethyl dglucos 3014cmdg rat jejun epithelium studi furthermor role polyamin spermidin product metabol degrad glucos transport investig relationship pathogenesi membran dysfunct cystic fibrosi postul glucos transport evert rat jejun ring use studi result express 3014cmdg concentr ratio intracellular icf extracellular fluid space ecf jejun ring end 60 min incub period mean ratio obtain incub rat jejun ring medium consist krebsring bicarbon buffer label sugar consid 100 uptak plasma serum without spermidin mix medium volum ratio 13 decreas activ uptak 3014cmdg observ express percent inhibit percent inhibit 3014cmdg uptak obtain rat jejun ring incub normal plasma compar obtain plasma cystic fibrosi genotyp found 1 plasma 25 homozyg children greater inhibitori effect glucos uptak plasma 26 normal children 2 plasma 9 heterozyg women greater inhibitori effect 6 normal women 3 inhibitori effect plasma 3 homozyg children influenc dialysi 4 inhibitori effect pair plasma serum sampl 9 homozygot compar 5 spermidin ad incub electrolyt solut affect glucos transport 6 addit spermidin reaction mixtur contain normal plasma potenti inhibitori effect 7 mix incub fresh bovin serum reaction mixtur contain plasma homozygot decreas inhibitori effect predomin inhibitori effect plasma serum homozygot heterozygot cf gene appear relat nondialyz molecul seem reflect presenc high plasma glucos level cystic fibrosi result competit inhibit sugar seem result sodium electrolyt differ similar inhibitori effect acquir normal plasma addit spermidin hand plasma cf homozygot lose inhibitori effect incub fresh bovin serum find may indic product metabol degrad spermidin respons inhibitori effect glucos transport suggest possibl role abnorm polyamin metabol pathogenesi cystic fibrosi
546	effect cystic fibrosi serum ciliari inhibitor oyster gill ultrastructur analysi scan transmiss electron microscopi ultrastructur analysi includ scan transmiss electron microscop studi sem tem carri oyster gill tissu exposur either serum fraction individu homozyg heterozyg cystic fibrosi cf compar serum fraction normal individu sea water 4 experi examin topolog sem cf sera either heterozyg homozyg stimul product mucu found close associ cilia associ excess mucu cell surfac could respons part wellknown inhibit ciliari activ factor cf serum 3 addit sem experi involv shorter treatment time littl differ could observ homozyg cf heterozyg cf normal serumfractiontr oyster tissu parallel experi ultrathin section gill tissu examin mean tem sampl respons determin tem display sever characterist featur includ enlarg partial exud goblet cell alter mucu structur along twist mat cilia overal swell gill filament also observ respons tissu tem analysi detect alter fine structur appar gill tissu treat sera heterozyg normal individu
547	electrophoret studi cystic fibrosi ciliari inhibitor interact immunoglobulin g cystic fibrosi ciliari inhibitor cfci partial purifi serum plasma cystic fibrosi cf homozygot heterozygot media cultur fibroblast deriv cystic fibrosi genotyp character comparison fraction contain cfci carri polyacrylamid gel electrophoresi gel electrophoresi confirm previou molecular weight estim 4500 11000 cfci provid estim number protein present fraction low molecular weight protein serum media combin igg prepar specif bind igg media fraction contain cfci could demonstr techniqu employ decreas bind low molecular weight serum fraction contain cfci nativ igg molecul cystic fibrosi patient compar igg normal individu howev igg cf individu demonstr increas bind cfci contain low molecular weight serum fraction gel filtrat presenc guanidinium chlorid suggest 1 low concentr cfci present media fraction 2 nativ cf igg cannot bind low molecular weight cfci fraction degre nativ igg normal cf igg dissoci noncoval bound compon
548	express cystic fibrosi genotyp cultur somat cell observ characterist cell cystic fibrosi cf genotyp cultur review although numer divers abnorm describ none specif cf gene relev abnorm clinic syndrom known cf discuss emphas valu thu far cell cultur research learn cf gene influenc cellular function
549	electron microscopi microchem analysi cystic fibrosi diploid fibroblast vitro fibroblast deriv cystic fibrosi homozygot heterozygot compar normal fibroblast topolog ultrastructur microchem topolog examin mean scan electron microscopi sem reveal signific differ 3 genotyp survey cell gener flatten andor fusiform structur less devoid surfac detail howev divid cell popul survey found less spheric configur involv highli complic surfac surfac manifest includ bleb ridg microvilli repres sampl cell stage growth lag phase exponenti phase plateau phase survey studi ultrastructur fibroblast 3 genotyp found similar cytolog detail highli infold nuclei distinct organel compon surfac detail also seen sem studi observ numer bundl microfila note within cytoplasm metachromat granul observ cell 3 genotyp microchem analysi mean energi dispers xray analysi demonstr slight recogniz differ element composit 3 genotyp notabl interest peak intens calcium sulfur cf homozyg cell present higher valu element compar valu observ cf heterozyg normal cell popul although consist differ could observ cf genotyp compar noncf cell attempt made quantit concentr element within cell
550	cultur cell cystic fibrosi research review cystic fibrosi cf common inherit disord character product exocrin secret elev ion content abnorm viscou mucu last year cell obtain peripher blood cultur tissu cystic fibrosi patient use increasingli studi diseas investig follow properti cystic fibrosi cell review morpholog ultrastructur growth kinet cellular metachromasia product ciliari inhibitor cellular composit plasma membran composit transport inorgan ion small organ molecul lysosom enzym content rna methyl studi effect cultur cell erythrocyt membran factor cf cell cultur medium biolog fluid cf patient discuss
551	somat cell genet studi cystic fibrosi express gene code cystic fibrosi ciliari inhibitor examin somat cell hybrid clonal line hybrid produc fusion cultur skin fibroblast cystic fibrosi patient mous rag lm tk cell line ciliari inhibitor detect oyster ciliari assay sever primari hybrid clone detect other indic segreg associ nuclear gene
552	introduct current investig theori genet defect cystic fibrosi recent research cystic fibrosi suggest least two theori regard genet defect underli preval diseas mutant gene cystic fibrosi genotyp respons synthesi alter protein interfer membran transport mucociliari activ mutant gene cystic fibrosi genotyp respons enzym defici lead presenc undegrad metabolit interfer membran transport circul factor cystic fibrosi effect membran transport mucociliari system discuss search enzymat defici investig alter metabol pathway comparison somat cell cystic fibrosi normal genotyp also outlin
553	larval brine shrimp nauplii potenti use model studi cystic fibrosi one consist characterist cystic fibrosi abnorm handl electrolyt exocrin gland present studi examin possibl diminish respiratori energi format primari biochem error respons abnorm use oxygen consumpt intact larval brine shrimp quantit differ observ reaction mix mouth saliva cf heterozygot cf homozygot addit inform demonstr correl biochem abnorm diseas sever observ differ observ inhibit saliva cf homozygot oblig heterozygot may occur result 1 interfer electron transfer organ fuel molecul molecular oxygen 2 interfer mechan respons gener biochem reduc power necessari multipl biosynthet reaction
554	natur defect cystic fibrosi sera lymphocyt cultur media deriv cystic fibrosi cf affect carrier subject contain ciliari dyskinesia factor cdf detect rabbit tracheal bioassay addit also find cdf fibroblast media donor amniot fluid cell media deriv cf carrier affect fetus latter instanc media inact bioassay becam activ mix purifi igg instanc cdf activ elimin addit antiigg separ low molecular weight fraction 1000 10000 mw cf sera cultur media inact bioassay igg ad presumpt indirect evid indic fraction behav similarli complement deriv anaphylatoxin c3a addit found activ sera cf patient lesser extent carrier induc degranul cytochalasinb treat human polymorphonuclear leukocyt sinc activ appear differ molecular speci contain cdf postul primari defect cf defici enzym whose substrat includ famili membraneact molecul
555	purif character serum protein use detect cystic fibrosi genotyp isoelectr focus sera cystic fibrosi cf homozygot oblig heterozygot contain cf factor gamma cf factor found isoelectr focus thinlay polyacrylamid gel normal control sera addit sera oblig heterozygot lack anoth protein bland b c commonli found sera normal cystic fibrosi individu standard biophys assay describ employ isoelectr focus detect cf homozygot heterozygot base analysi whole serum presenc gamma cf factor band b c result analyz sera select cf patient isoelectr focus indic gener correl amount gamma cf factor clinic sever diseas partial purif character gamma cf factor protein band b c accomplish use deaecellulos chromatographi sephadex g 200 gel filtrat sequenti molecular filtrat seri amicon diaflo ultrafiltr membran affin chromatographi cellulos acet electrophoresi gamma cf factor cation protein pi 846005 gamma electrophoret mobil molecular weight 3500 10000 appar exist cf serum 2 form free solut complex igg band b c cation protein pi valu 785 810 gamma electrophoret mobil molecular weight approxim 100000150000
556	immunochem studi plasma cultur fibroblast media fraction contain cystic fibrosi ciliari inhibitor cystic fibrosi ciliari inhibitor cfci fraction plasma cystic fibrosi cf homozygot media cultur fibroblast deriv cf homozygot plasma fibroblast media normal control fraction ident manner fraction plasma fibroblast cultur media demonstr ciliari inhibitori activ contain sever protein molecular weight rang approxim 500011000 protein partial character immunochem analysi antisera 33 human serum protein immunolog determin albumin c3 c3a c4 c5 alpha1lipoprotein beta lipoprotein beta2microglobulin immunoglobulin light chain detect hemagglutin fraction cf plasma inhibit ciliari activ analog fraction normal sera none protein detect media cultur fibroblast either genotyp sinc protein protein fragment identifi cf normal plasma fraction detect cf fibroblast media appear none protein identifi cfci identif protein permit purif cfci immunochem method
557	surfac enzym cultur fibroblast cystic fibrosi patient membran function examin cultur cell cystic fibrosi patient assay sever enzym intact skin fibroblast attach cultur dish techniqu requir cell minim disrupt cellular organ comparison enzym activ intact broken cell show 12 total glucose6phosph dehydrogenas cytoplasm enzym measur use intact cell adenosin monophosphatas measur use intact cell alkalin paranitrophenylphosphatas activ divid cell surfac interior substrat competit experi indic substrat specif adenosin monophosphatas paranitrophenylphosphatas activ differ adenosin monophosphatas activ 2 control 2 cystic fibrosi strain fluctuat similarli cell cultur cycl appar km valu rel adenosin monophosph similar strain chromatograph fraction serum cystic fibrosi patient inhibitori oyster ciliari activ effect adenosin monophosphatas activ normal fibroblast furthermor fraction media cystic fibrosi homozygot heterozygot fibroblast cultur inhibitori adenosin monophosphatas activ intact normal fibroblast part icul fraction prepar light previou studi show factor cystic fibrosi serum cultur medium disrupt specif membran activ propos cystic fibrosi factor interact plasma membran interf conspicu protein function sensit chang membran environ
558	review growth characterist cystic fibrosi normal human diploid fibroblast vitro growth kinet human diploid skin fibroblast deriv cystic fibrosi cf homozygot cf heterozygot normal individu determin popul doubl time increas time cultur differ observ 3 genotyp test cell cycl time remain constant 10th subcultur growth fraction fraction cell cell cycl decreas cultur time howev chang growth fraction popul doubl time appear relat cellular senesc vitro rather cystic fibrosi
559	aspect serum sputum antibodi chronic airway obstruct immunoglobulin level precipit antibodi rang microbi antigen measur simultan collect serum sputum sampl patient chronic bronchiti 11 cystic fibrosi 9 bronchiectasi 9 asthma 4 sputum prepar dialysi highspe centrifug method result show possibl detect precipit antibodi sputum rate increas method use discrep note detect rate sputum serum combin lack correl sputum serum immunoglobulin lack relationship bronchial inflamm sputum immunoglobulin lack igm sputum suggest antibodi immunoglobulin local produc sputum iga 7s patient chronic bronchiti significantli lower p less 005 found patient cystic fibrosi bronchiectasi signific differ p less 0 05 also note serum igg level patient chronic bronchiti bronchiectasi cystic fibrosi serum igm level patient chronic bronchiti significantli lower p less 005 compar serum level patient cystic fibrosi presenc precipit antibodi sputum rais possibl type iii reaction may import pathogenesi condit
560	dead space ventil normal children children obstruct airway dieas anatom dead space measur 72 normal children age 5 16 year use singl breath method linear increas measur height weight endinspiratori lung volum physiolog dead space measur 52 normal children use bohr equat substitut rebreath pco2 alveolar pco2 parallel increas measur height weight endinspiratori lung volum differ two dead space measur constitut alveolar dead space constant whole age rang 45 22 ml ratio physiolog dead space tidal volum 336 46 unalt age chang lung volum effect airway obstruct dead space volum studi 36 children asthma 28 cystic fibrosi physiolog dead space increas increas airway obstruct anatom dead space remain constant spite mark increas lung volum associ airway obstruct
561	hypertroph osteoarthropathi adult cystic fibrosi three adult patient cystic fibrosi present arthralgia investig usual caus arthriti prove neg radiograph long bone reveal periost new bone fromat characterist hypertroph osteoarthropathi symptomat improv occur analges antiinflammatori therapi patient cystic fibrosi bone joint pain diagnosi hypertroph osteoarthropathi consid long bone radiograph obtain
562	differenti diagnosi bronchial asthma children bronchial asthma children uncommon tropic condit simul diseas tropic discuss view arriv diagnosi without sophist investig
563	vitamin e review make deliber attempt put inform vitamin e requir absorpt metabol function anim man better perspect larg clinic trial vitamin e given pharmacolog level presum medic indic well trial vitamin e bona fide defici diseas man extens review nutrit aspect discuss includ dietari intak biolog activ evalu nutrit statu relationship dietari polyunsatur fatti acid metabol concern includ absorpt transport deposit cellular function clinic aspect includ defici state approach therapi possibl pharmacolog effect
564	crohn diseas caus arthriti oxal stone fistula cystic fibrosi patient cystic fibrosi growth failur occur malabsorpt moder sever pulmonari diseas occasion growth lag seen patient disproportion sever primari diseas profound growth failur major characterist crohn diseas children report document first associ two diseas patient unit state show crohn diseas alter gastrointestin manifest cystic fibrosi adolesc patient cystic fibrosi anemia fistula arthriti calcium oxal stone proven crohn diseas microscop evalu surgic resect termin ileum colon
565	cystic fibrosi hla associ hereditari diseas twelv homozygot patient thirtytwo heterozygot gene carrier famili cystic fibrosi hlatyp diagnost criteria sweat electrolyt concentr pancreat enzym level duoden juic stool szczepanski bromid test group homozygot latter case heterozygot comparison 130 healthi blood donor type 29 hla antigen b18 prove frequent group patient gene carrier 50 31 respect 14 normal popul associ seem stronger homozygot heterozygot p less 002 respect
566	distribut serum amylas isoenzym cystic fibrosi homozygot heterozygot simpl method elabor routin separ quantit determin amylas isoenzym ratio ps quotient activ valu obtain densitometr evalu pancreat salivari isoenzym use character distribut healthi adult children valu ps 1 80 case mean 187 023 90 heterozygot cf genecarri ps 1 mean 068 013 addit higher total amylas activ mv homozygot patient ps less 01 even 0001 phenomenon explain compensatori enhanc salivari activ method suitabl diagnost test exocrin function pancrea evalu serum amylas isoenzym ps valu allow differenti heterozygot cf genecarri homozygot healthi individu
567	insulin glucagon respons arginin infus cystic fibrosi glucagon insulin respons intraven arginin studi 17 children cystic fibrosi 9 control children found overal secret insulin diminish howev four cf children normal output glucagon respons parallel insulin glucagon output vari cf childrenseven normal four excess high six low output three four children extrem high output sever diseas third centil weight chart four fast hypoglycaemia also low glucos insulin respons confirm diminish insulin secret cystic fibrosi diminish glucagon secret note insulin secret preserv high level glucagon seen insulin defici subject may deriv extrapancreat sourc may associ stress reaction patient also sever pulmonari involv data would consist diminish glucagon insulin secret pancrea diseas progress excess secret extra pancreat glucagon result
568	cystic fibrosisa psycholog studi 52 children famili primari goal investig disclos special characterist among children cystic fibrosi famili focu import consequ ill main issu 1 explor qualiti magnitud psycholog problem cf impos child parent 2 investig cf child experi react ill 3 assess cf child differ emot intellectu visualmotor function peer 4 see parent adapt child condit cope problem 5 assess need help given
569	assess cor pulmonal cystic fibrosi echocardiographi thirtyon patient cystic fibrosi vari sever examin echocardiographi right ventricular dimens rvd upper normal limit 14 patient right ventricular dimens index rvd index higher upper normal limit 11 patient furthermor signific relationship increas rvd index 1 decreas forc vital capac fvc actual test result averag 6 month valu 2 decreas peakexpiratori flow rate pefr actual test result averag 6 month valu observ suggest persist heart involv five patient either heart failur andor electrocardiograph evid right ventricular abnorm patient increas rvd index one patient highest rvd index die 8 week examin present studi shown use echocardiograph measur right ventricular dimens septal motion assess cor pulmonal develop electrocardiograph abnorm right heart failur
570	immun complex cystic fibrosi eleven patient cystic fibrosi cf chronic infect mucoid p aeruginosa ten patient without p aeruginosa infect examin occurr circul immun complex immun complex deposit dermoepiderm junction skin precipitin p aeruginosa aureu h influenza pneumonia antigen serum concentr haptoglobin orosomucoid immunoglobulin c1q c3 c4 total haemolyt complement antinuclear rheumatoid factor activ well white blood cell count erythrocyt sediment rate determin also result indic 6 patient chronic p aeruginosa infect group exhibit spectrum serum precipitin p aeruginosa antigen also immun complex serum one patient suffer select iga defici group without p aeruginosa infect posit solubl immun complex granular deposit igm found skin 10 chronic p aeruginosa infect patient 7 patient without p aeruginosa infect pactient group dermo epiderm deposit c1q c3 fibrinogen well eight patient chronic infect group five group without p aeruginosa infect organ nonspecif antinuclear factor haptoglobin level appear elev chronic infect patient p less 005 none paramet show signific differ two group
571	pseudomona aeruginosa infect cystic fibrosi bactericid effect serum normal individu patient cystic fibrosi p aeruginosa strain patient cystic fibrosi diseas p aeruginosa strain origin respiratori tract patient cystic fibrosi cf patient diseas noncf analys regard sensit bactericid activ human serum p aeruginosa strain isol cf patient sensit strain noncf patient bactericid activ normal human serum bactericid activ heatlabil regard sensit normal human serum mucoid nonmucoid variant found differ strain origin chronic infect cf patient mani precipitin bacteria differ respect serum sensit strain origin intermitt colon cf patient without p aeruginosa precipitin compar normal sera cf sera show similar higher bactericid activ panel p aeruginosa strain respect differ cf sera precipitin cf sera without precipitin p aeurginosa found sera three cf patient chronic infect p aeruginosa mani precipitin bacteria show select inabl bactericid activ patient p aeruginosa isol possibl reflect presenc bactericid block antibodi
572	pseudomona aeruginosa infect cystic fibrosi diagnost prognost signific pseudomona aeruginosa precipitin determin mean cross immunoelectrophoresi survey purpos first part present work review literatur concern lower respiratori tract infect antimicrobi resist mechan cystic fibrosi patient second part work deal import therapeut problem cystic fibrosi today viz pseudomona aeruginosa lung infect survey made investig present author colleagu immun respons pseudomona aeruginosa infect literatur concern subject furthermor possibl mechan tissu damag respiratori tract cystic fibrosi patient infect discuss
573	pseudomona aeruginosa infect cystic fibrosi rel preval antibodi serum cathod anod migrat p aeruginosa antigen determin immunoelectrophoret method sera 119 patient cystic fibrosi examin precipit antibodi anod migrat p aeruginosa antigen mean cross immunoelectrophoresi presenc precipitin cathod migrat p aeruginosa antigen investig mean classic immunoelectrophoresi thirtysix per cent sera contain precipitin anod cathod antigen 20 contain precipitin anod antigen none contain precipitin cathod antigen 44 demonstr p aeurginosa precipitin amount extra inform obtain combin result classic immunoelectrophoresi result cross immunoelectrophoresi small
574	treatment mucu hypersecret human diseas treatment mucu hypersecret human diseas first direct prevent hypersecret mucu even absenc pu sputum sign infect associ significantli poor lung function infect probabl import stimulu cystic fibrosi certain antiinflammatori agent known caus retent mucu within secretori cell although rate synthesi rais may offer new way control hand cell becom larger may undesir would prefer see studi effect drug cellular stage synthesi discharg rather concentr mucolyt agent
575	physic properti bronchial secret weissenberg rheogoniomet design estim viscos singl appli shear vari shear associ detail variat viscos may studi level viscos depend macroscop appear sampl diseas may associ particular signific relat cystic fibrosi cystic fibrosi sputum viscos abnorm high higher macroscop similar sputum chronic bronchiti asthma whatev featur differenti cystic fibrosi diseas viscos sputum
576	gallbladd diseas cystic fibrosi 84 consecut patient cystic fibrosi oral cholecystographi abnorm 39 464 incid abnorm cholecystogram increas patient age 26 patient nonvisu gallbladd follow doubledosag oral cholecystographi evalu intraven cholangiographi 19 703 abnorm ten patient found calculi incid 119 awar high incid cholecystograph abnorm calculi help evalu patient cystic fibrosi particularli sinc symptom abdomin pain frequent patient may lead radiograph investig
577	evalu sensori integr develop young children cystic fibrosi studi shown children chronic ill prone develop secondari handicap area educ achiev behavior psycholog maladjust normal children besid physic symptom child chronic ill must endur prolong hospit psycholog stress decreas activ often deni opportun skill practic peer group activ factor result overal decreas sensori stimul could impair perceptualmotor function well child abil success adapt diseas therefor purpos research obtain gener idea perceptualmotor sensori integr develop children cf determin fact need sensori integr treatment care children
578	pediatr gastroenterolog 1169123175 review part hollow viscera pancrea cumul surviv cystic fibrosi cf three success 5year period 1952 1967 35 64 77 respect oper mortal meconium ileu reduc 25 70 nacetylcystein effect cleans bowel tenaci meconium plug directli inject laparotomi howev mucomist enema alon gener suffic select case treat success hyperosmolar gastrograffin enema sever screen test base increas albumin concentr present meconium avail cf boehringermannheim test strip favor yield fals posit 69000 test meconium howev 4 60 neonat subsequ prove cf fals neg test pathognomon elev sodium chlorid concentr sweat collect pilocarpin iontophoresi remain definit diagnost test bile acid malabsorpt occur cf celiac diseas author postul presenc maldigest materi absenc pancreat enzym interfer bile acid absorpt defect disappear pancreat extract substitut mediumchain triglycerid dietari longchain fatti acid reduc steatorrhea cf howev posit effect mct weight gain transitori growth retard correl better degre pulmonari diseas pancreat insuffici
579	echocardiographi cystic fibrosi echocardiogram obtain 25 patient cystic fibrosi cf 20 control evalu techniqu mean assess right ventricular chang patient cf right ventricular anterior wall thick per squar meter bodi surfac rvawsq right ventricular intern dimens per squar meter bodi surfac rvidsq compar techniqu detect cor pulmonal signific correl exist rvawsq rvidsq forc vital capac forc expiratori volum one second midmaxim expiratori flow rate clinic score sever diseas roentgenograph score pulmonari involv rvawsq slightli sensit rvidsq rvawsq thick echocardiogram vivo compar well actual measur autopsi five patient correl found echocardiographi electrocardiogram vectorcardiogram thorac index cardiothorac ratio
580	system amyloidosi cystic fibrosi report two sibl cystic fibrosi system amyloidosi major clinic problem case recurr respiratori infect pulmonari fibrosi bronchiectasi prior death age 20 22 year find postmortem examin disclos diffus amyloidosi addit amyloid infiltr develop patient enlarg thyroid gland one requir thyroidectomi autopsi review 17 addit case cystic fibrosi fail disclos instanc system amyloidosi
581	effect earli diagnosi treatment cystic fibrosi sevenyear studi 16 sibl pair data 16 sibl pair cystic fibrosi analyz test hypothesi earli treatment condit improv prognosi younger sibl condit diagnos 1 year age usual onset pulmonari diseas older sibl condit diagnos 1 year age onset pulmonari diseas although sibl pair receiv similar treatment comparison 7 year age show younger sibl significantli better chest roentgenogram score total clinic score residu lung volum ratio residu volum total lung volum younger sibl also requir fewer hospit admiss control lung diseas result suggest gener earli initi therapi benefici patient cystic fibrosi
582	test strip meconium screen cystic fibrosi boehringermannheim corpor bmc strip test extrem reliabl indic albumin content 20 mggm dri meconium infant born one year 14 milwauke area hospit test 16224 newborn two diagnos correctli suffer cystic fibrosi two miss falseposit test obtain 09 infant prematur melena gastroschisi intrauterin infect strip test present best avail perfect screen method cystic fibrosi
583	hepat steatosi children childhood hepat steatosi commonli gener benign reaction occur mani pathophysiolog state steatosi result follow mechan impair tgc clearanc increas hepat lipogenesi decreas fa oxid increas lipolysi cystic fibrosi syndrom produc pancreat insuffici pancreat result variabl degre steatosi probabl depend nutrit hormon state patient patient cystic fibrosi impair glucagon insulin releas alter fat metabol treatment hepat steatosi aim primari caus
584	isoamylas abnorm cystic fibrosi letter articl town et al provid confirm initi studi refer isoamylas pattern serum duoden fluid urin patient cystic fibrosi cf howev impress given town et al articl data first demonstr isoamylas abnorm cystic fibrosi wish point previou work publish 2 year earlier referenc town et al demonstr cf patient decreas amount pancreat isoamylas serum urin duoden aspir cf patient contain salivari pancreat amylas conclud elud town et al salivari amylas duoden fluid probabl secondari intub procedur
585	ricket adult cystic fibrosi myopathi pancreat insuffici proxim renal tubular dysfunct ricket report 19 year old white man cystic fibrosi pancreat hepat involv advanc evid secondari hyperparathyroid proxim renal tubular acidosi aminoaciduria phosphaturia hypophosphatemia treatment oral pancreat parenter vitamin supplement led full recoveri rachit syndrom proxim renal tubular dysfunct
586	lipid composit airway secret patient asthma patient cystic fibrosi lipid particul materi obtain pulmonari lavag patient asthma cystic fibrosi isol character case lipid constitut 30 40 per cent dri insolubl materi phosphatidylcholin predomin lipid signific amount phosphatidylethanolamin phosphatidyglycerol present hexosyl ceramid spingomyelin phosphatidylinositol phosphatidylserin lysobisphosphatid acid present minor lipid compon appreci quantiti neutral lipid also found signific amount lysophosphatid free fatti acid present lavag sediment patient asthma patient cystic fibrosi phosphatidylcholin lysophosphatidycholin sphingomyelin phosphatidylglycerol asthmat lavag cystic lavag highli satur contain mostli palmit acid
587	clinic aspect mucociliari transport long believ mucociliari apparatu airway serv remov inhal particul matter tracheobronchi mucosa therebi contribut pulmonari host defens review deal mainli factor affect mucociliari transport may clinic import inform avail present strongli suggest mucociliari transport least central airway impair patient cystic fibrosi howev still unclear whether disord nonspecif featur chronic inflammatori airway diseas repres essenti factor pathogenesi pulmonari abnorm
588	ventilatori muscl endur train normal subject patient cystic fibrosi ventilatori muscl becom fatigu contribut respiratori failur patient chronic obstruct lung diseas may benefit improv ventilatori muscl endur improv resist fatigu ventilatori muscl endur measur 30 normal subject 55 patient cystic fibrosi find highest level normocapn hyperpnea could sustain 15 min subject cystic fibrosi 36 per cent higher ventilatori muscl endur normal subject reflect chronic train stress breath increas respiratori load four normal subject 4 subject cystic fibrosi particip specif ventilatori muscl endur train program consist 25 min per day maxim normocapn hyperpnea 5 day per week 4 week cystic fibrosi patient train improv ventilatori muscl endur 516 per cent wherea normal subject train show 221 per cent increas ventilatori muscl endur seven subject cystic fibrosi particip 4week physic activ train program consist least 15 hour per day intens swim cano summer camp increas ventilatori muscl endur 567 per cent pulmonari function chang ventilatori muscl endur readili improv cystic fibrosi equal well specif ventilatori muscl endur exercis
589	chronic bronchiti cystic fibrosi two chronic obstruct lung diseas adult editori patient cystic fibrosi surviv longer number adult chronic obstruct lung diseas increas rapidli chronic bronchiti cystic fibrosi similar number respect treatment cystic fibrosi chronic bronchiti similar chronic bronchiti cystic fibrosi also differ mani respect pathogenesi chronic bronchiti clearli relat exogon factor smoke air pollut cystic fibrosi genet determin clinic differ also exist major differ treatment cystic fibrosi chronic bronchiti current vogu special problem adulthood appropri mani adult patient cystic fibrosi care internist previous focus attent chronic bronchiti emphysema increas commun internist pediatrician issu cystic fibrosi badli need today ct 1 howi ad scott med j 24 193 979 2 santagnes pad j med 66 121 979 3 henri rl aust paediatr j 18 43 982 4 gotz atemweg lungenkrankh 10 594 984 5 kauffmann f bull eur physiopath resp 20 163 984 6 davi pb chest 85 802 984 7 gotz med klin 80 657 985
590	abnorm respons cultur lymphocyt phytohemagglutinin autolog serum cystic fibrosi lymphocyt adult homozyg heterozyg cystic fibrosi show biochem abnorm cultur 48 hour presenc phytohemagglutinin autolog serum contrast 45 per cent increas total protein betaglucuronidas concentr seen healthi control subject measur per 1010 cell concentr decreas 1 per cent adult heterozyg cystic fibrosi 18 per cent adult homozyg cystic fibrosi abnorm respons lymphocyt person cystic fibrosi due serum factor intrins abnorm lymphocyt abnorm respons hytohemagglutinin occur 14 per cent 44 healthi control subject 100 per cent 14 adult homozyg cystic fibrosi 85 per cent 26 adult presum heterozyg cystic fibrosi result phenomenon lymphocyt betaglucuronidas concentr significantli lower normal patient cystic fibrosi cell cultur phytohemagglutinin autolog serum demonstr phenomenon homozygot presum heterozygot parent suggest relationship genet defect cystic fibrosi
591	granulocyt nadh oxidas cystic fibrosi nitro blue tetrazolium dye test evalu use detect superimpos bacteri infect 50 children cystic fibrosi correl percentag posit neutrophil superimpos infect clinic statu bacteri organ could determin cystic fibrosi granulocyt gener greater nadh oxidas activ control
592	method analys fertil heterozygot autosom recess disord special refer cystic fibrosi taysach diseas phenylketonuria increas fertil heterozygot respect decreas foetal loss among offspr heterozygot propos sever author possibl explan high gene frequenc cf tsd pku certain popul studi compar reproduct outcom heterozygot reproduct perform gener popul special control group done sever occas studi howev known heavili bias one side fact ascertain heterozygot affect offspinrg tend underestim rel frequenc smaller famili side inadequaci censu data comparison bias inher select control famili care analysi bias involv provid suggest proper correct method develop offer better approach studi heterozygot fertil autosom recess condit lack test direct heterozygot detect
593	cystic fibrosi diagnos age 13 twentyf teenag adult patient includ three asymptomat men cystic fibrosi diagnos age 13 25 patient elev sweat chlorid either sibl cystic fibrosi typic pulmonari infect digest symptom caus exocrin pancreat defici fourteen longstand pulmonari digest symptom contrast four eight patient whose symptom began age 13 present biliari cirrhosi three male patient asymptomat diagnosi opacif paranas sinus found patient examin radiolog diagnosi pulmonaryfunct test show obstruct chang 19 patient sputum cultur show pseudomona aeruginosa 15 patient delay menarch five seven femal patient infertil asymptomat male patient two found aspermia could led earlier diagnosi teenag young adult longstand pulmonari digest symptom unexplain cirrhosi aspermia sibl cystic fibrosi sweattest pilocarpin iontophoresi
594	limit diagnost valu sweat test sweat test even carri experienc technician sometim lack reproduc owe presum physiolog variat patient diet temperatur factor present unrecogn patient particularli prone exhibit variabl singl sweat test almost valueless aldosteron statu believ respons reciproc relationship sweat sodium potassium concentr test done 8 patient show high sweat potassium associ correspondingli lower sodiuma circumst must born mind interpret patient sweat sodium 30 patient present varieti symptom compat diagnosi cystic fibrosi sweat sodium rang 50 75 meq1 5075 mmol1 4 prove cystic fibrosi sever year observ 13 later diagnos asthma problem grey area uncertainti aggrav heterozyg state also associ sweat sodium rang repeat sweat test indic sweat sodium lie within grey area diagnost import accord test diminish sodium valu approach area diagnosi cystic fibrosi must remain doubt unless strong support clinic evid
595	serotonin metabol cystic fibrosi averag blood serotonin level 67 children cystic fibrosi found twice agematch normal children correspond increas urinari excret 5 hydroxyindoleacet acid 5hiaa children cystic fibrosi well abl metabol serotonin taken mouth signific correl found blood serotonin level platelet count height weight skinfold thick pulmonari function test 5 44 patient rais serum ige level mean blood serotonin higher normal ige level explan emerg compar find rais blood serotonin normal platelet count normal urinari 5hiaa report sever mental retard studi phenomenon warrant rais blood serotonin level suffici characterist cystic fibrosi explor use diagnosi b may help explain pathogenesi cystic fibrosi c metabol function serotonin
596	serum complement depress viral lower respiratori tract ill cystic fibrosi cystic fibrosi cf patient viral lower respiratori tract ill lri depress level third fourth compon complement return normal recoveri clinic evid immun complex diseas cf patient lri viru isol cf patient stabl statu non cf patient lri complement depress postul antigenantibodi complex activ complement may occur cf patient viral lri
597	cystic fibrosi myocardi fibrosi letter interest case report mukherji et al suggest cystic fibrosi might acid mucopolysaccharidosi seen similar child age 5 year admit hospit pneumonia spite convent treatment cloxacillin colistin collaps die 48 hour admiss heart enlarg myocardium show grossli abnorm appear variat thick extens area firm pale tissu histolog heart muscl show dramat chang sever replac fibrosi distribut patchili myocardium similar mixtur neutral acid mucopolysaccharid shown pancrea salivari gland number report myocardi fibrosi complic cystic fibrosi case report mukherji et al case first mucopolysaccharid deposit found myocardium mixtur neutral acid mucopolysaccharid case support hypothesi cystic fibrosi simpli genet acid mucopolysaccharidosi
598	test meal assess intralumin phase absorpt childhood test meal assess intralumin phase absorpt childhood valid 132 test meal administ 110 patient age 2 week 18 year mean age 43 year 10 children suspect malabsorpt proven normal extens investig constitut control group activ pancreat enzym total individu bile salt concentr present control subject pancreat enzym level group compar seen children pancreat insuffici cystic fibrosi test meal design administ children suspect gluten cow milk disaccharid intoler control data provid basi interpret inform obtain applic test meal clinic investig children suspect malabsorpt
599	heterozygot advantag genic disord manifest offend allel loci fibrocyst diseas loss two abnorm allel affect birth sinc homozygot rare reproduc loss compens could 50000 allel surviv convey effect gamet normal allel partner becom establish british isl half million got world currenc first migrat settlement involv proport defect allel loci conserv varieti increas secondli could gener tendenc due advantag health vital could manifest diseas resist cold resist number physic psycholog mechan thirdli may compens death infant may lead replac result replac sib surviv would 23 chanc carrier fourthli diseas may maintain mutat four possibl three unrealist substanti select advantag heterozygot last hundr year must postul
600	porcin pancreatin sourc salmonella infect children cystic fibrosi contamin powder prepar pancreatin salmonella schwarzengrund eimsbuettel result infect least 31 one group paediatr patient cystic fibrosi pancreatin contain small number salmonella infect dose least one child less 44 organ stringent bacteriolog standard need pharmaceut food use paediatr patient
601	salivari amylas parent children cystic fibrosi mix submaxillarysublingu saliva oblig heterozygot cystic fibrosi show significantli elev concentr amylas high low saliv rate compar normal sixti per cent known carrier valu outsid rang appar normal control
602	effect chronic ill children 03 year famili taken exampl chronic ill infanc four differ type disabl emot depriv infant subnorm develop children suffer mucodiscoidosi children neoplast diseas
603	membran fluiditi normal cystic fibrosi fibroblast observ distinct differ polar fluoresc temperatur depend emiss intens highli fluoescent phospholipid deriv 1acyl2n4nitrobenzo2oxa13diazoleaminocaproyl phosphatidylcholin nbdpc incorpor plasma membran normal cystic fibrosi fibroblast fluoresc polar measur indic fluorochrom much higher degre rotat mobil cystic fibrosi fibroblast compar normal cell temperatur depend transit emiss intens nbdpc incorpor normal fibroblast indic 177 212 degre c abnorm cell membran appar undergo transit 87 135 degre c differ might due chang plasma membran composit andor organ case cystic fibrosi cell
604	cystic fibrosi leakag lysosom enzym alkalin phosphatas extracellular space nine lysom enzym alkalin phosphatas assay two differ ultramicro techniqu intra extracellular space fibroblast cultur deriv skin cystic fibrosi patient cystic fibrosi carrier normal control respect evid obtain multipl leakag lysom enzym alkalin phosphatas medium fibroblast cultur cystic fibrosi patient carrier situat compar certain extent observ icelldiseas mucolipidosi ii multipl leakag result decreas intracellular activ sever lysosom enzym cultur cystic fibrosi patient carrier due coordin regulationof synthesi leaki enzym overshoot intracellular alkalin phosphatas activ cultur cystic fibrosi patient also explain retard catabol certain molecul tammhorsfal glycoprotein cystic fibrosi cell specul basic defect cystic fibrosi lead abnorm recognit site lysosom enzym alkalin phosphatas consequ leakag enzym extracellular space present find allow one develop method pre postnat diagnosi cystic fibrosi cell cultur detect cystic fibrosi carrier peripher blood
605	abnorm distribut alphalfucosidas cystic fibrosi increas activ skin fibroblast alphalfucosidas activ elev skin fibroblast cystic fibrosi patient compar control activ nine acid hydrolas includ neuraminidas similar cystic fibrosi control fibroblast relationship result recent find decreas activ alphalfucosidas serum cystic fibrosi patient discuss propos abnorm distribut alphalfucosidas involv pathogenesi diseas
606	membran function cystic fibrosi putrescin transport normal cystic fibrosi fibroblast putrescin transport examin normal cystic fibrosi fibroblast differ observ accumul pattern kinet uptak efflux cf normal cell grow growtharrest cf normal fibroblast exogen suppli putrescin remain unchang least 60 min differ observ respons cf normal cell environment media chang
607	membran function cystic fibrosi ii methionin transport normal cystic fibrosi fibroblast initi rate kinet methionin transport time cours accumul methionin efflux accumul methionin studi three normal four cf human diploid fibroblast strain rang appar km 127321 micromet cf strain 183392 micromet normal strain rang appar vmax 669922 nmole mg1 min1 cf strain 559787 nmole mg1 min1 normal strain pattern accumul efflux quit similar strain studi except wi38 show somewhat higher efflux lower accumul other signific differ kinet paramet methionin transport cf normal skin fibroblast methionin transport serv marker cystic fibrosi cultur fibroblast
608	bronchial asthma due allergi pancreat extract hazard treatment cystic fibrosi mother two children suffer cystic fibrosi develop mark allerg symptom affect eye nose bronchi sever bronchial asthma ensu caus allergi prove powder releas open capsul pancreat extract provid children mealtim risk pancreat extract handl possibl also patient suffer cystic fibrosi emphas
609	cystic fibrosi camp couchich four summer camp lake couchich children cf start 1973 initi certain chang necessari make camp suitabl cf camper activ normal avail camper camp couchich continu usual cf camper month august staff member spend great deal time teach camper need pancreat enzym cystic child requir two three physiotherapi treatment everi day inhal prescrib bronchodil antibiot
610	valid therapeut bronchoscop bronchial wash cystic fibrosi valid rigidtub bronchoscopi smallvolum 5ml increment exceed 300 ml bronchial wash therapeut adjunct perform six patient cystic fibrosi use serial test pulmonari function yardstick assess efficaci two patient undergo procedur serv control subject patient character vari sever pulmonari involv larg central airway sever obstruct older patient trap ga lung hypoxemia larg alveolararteri oxygen pressur differ paao2 due inhomogen alveolar ventil result indic ten day two week bronchoscop bronchial wash may instanc improv maxim expiratori flowvolum curv specif airway conduct decreas paao2 toward normal distribut alveolar ga pa ao2 toward normal distribut alveolar ga becam homogen conclud bronchoscop bronchial wash may effect manag patient cystic fibrosi augment inadequ cleans function conduct airway
611	comparison three techniqu lung lavag patient cystic fibrosi one hundr fiftythre lung lavag procedur perform 81 cystic fibrosi patient year 1963 1976 local analgesia use 24 lavag done via rigid bronchoscop group 73 lavag direct fiberopt bronchoscop abnorm cardiac rate rhythm observ lavag direct fiberopt bronchoscop fiftysix lavag perform gener anesthesia 20 cardiac abnorm note among group subject improv note 96 56 patient lavag gener anesthesia object improv appar 45 24 patient lavag rigid bronchoscop 64 36 patient lavag fiberopt bronchoscopi conclud patient cystic fibrosi vari stage disabl safeti good improv bronchial washout fiberopt bronchoscop either two techniqu
612	passiv cutan anaphylaxi pca specif ige cystic fibrosi heterozygot serum 75 patient cystic fibrosi cf posit prick test skin least one antigen togeth elev concentr total serum ige also gave strong immedi pca reaction baboon skin aspergillu fumigatu bovin serum albumin egg albumin cf patient 37 also elev serum specif ige fumigatu wherea 810 either rais specif ige pca reaction dermatophagoid pteronyssinu abolit pca activ incub cf sera sputum 56 degre c suggest reagin antibodi ige rather igg4 pca reaction number allergen could detect cf sputum saliva sever cf heterozygot strongli posit histori allergi signific number heterozygot elev serum total ige well posit pca timothi grass pollen pteronyssinu similar patient asthma hay fever three cf patient die gave strong prick test reaction sever allergen sera also rais serum ige posit pca least three differ allergen suggest immedi hypersensit signific patient cf
613	variabl skin test hypersensit reaction cystic fibrosi asthma cystic fibrosi cf children greater variabl skin prick test respons compar asthmat children test perform two occas suggest differ caus allergi two group perhap asthmat transient period suscept sensit infanc cf children persist vulner amongst asthmat children clinic improv associ loss skin prick test reaction clinic deterior increas number posit reaction thu continu allerg reaction may maintain mucos defect result persist suscept allergen sensit control reaction may reestablish normal mucos defenc mechan
614	studi salivari glycoprotein cystic fibrosi patient control fucos incorpor protein pattern incorpor fucos glycoprotein acceptor prepar saliva cystic fibrosi cf patient compar incorpor acceptor control cf acceptor glycoprotein incorpor significantli fucos presenc either patient control plasma fucosyl transferas activ patient plasma significantli differ control fucosidas activ similar also group protein band acceptor glycoprotein patient saliva differ control number electrophoret mobil basi studi fucos incorpor propos glycoprotein salivari secret eapati qualit differ normal
615	quantit assay enzym activ singl cell earli prenat diagnosi genet disord combin use special cell cultur techniqu biochem ultramicromethod permit one handl small amount materi reduc cost chemic accur assess gene dosag effect express enzym activ per cell instead per total cell protein alkalin phosphatas induct test develop allow one screen small number fibroblast lysosom storag diseas cystic fibrosi chromosom disord success attempt made autom microtechniqu combin alkalin phosphatas induct ultramicro automat eventu permit one screen pregnanc major possibl fetal genet defect autom ultramicro enzym assay contribut gener develop clinic chemistri
616	differenti serum amylas determin use inhibitor design routin procedur describ new method measur pancreat salivarytyp amylas serum requir electrophoresi chromatographi inhibitor protein wheat 100fold greater specif human salivari human pancreat amylas use analyz mixtur two enzym concentr pancreat salivari amyalas determin 141 normal sera 72 men 69 women statist signific differ found serum pancreat amylas mean women higher valu shown women sexrel differ found salivari compon serum amylas method increas serum amylas activ pancreat shown attribut pancreat compon mump increas attribut salivari compon pancreat insuffici serum pancreat amylas activ significantli lower control method simpl rapid result agre well author use chromatograph electrophoret method
617	cystic fibrosi effect medium cultur cystic fibrosi fibroblast atpas activ cultur medium fibroblast cystic fibrosi patient control examin abil inhibit calcium plu magnesiumactiv atpas sodium plu potassiumactiv atpas atpas system use solubilis prepar dogfish membran associ prepar human erythrocy contrari report medium cystic fibrosi fibroblast inhibit atpas activ
618	sweat test cystic fibrosi error associ insitu sweat test use chlorid ion select electrod insitu sweat test prone error variou sourc paper examin error due evapor absorpt water skin pressur electrod skin evapor caus seriou error accuraci precis measur small chloridesweat sampl skin significantli wors measur bulk solut
619	sweat test cystic fibrosi characterist combin chlorid ionselect electrod fill solut leakag reproduc stabil interfer temperatur effect studi relat use orion 961701 combin chlorid ionselect electrod sweat test cystic fibrosi stabil reproduc good certain antisept system especi hibitain chlorhexidin glucon interfer electrod therefor need absent sweat test temperatur condit calibr sweat test need control view extent respons variat even modest temperatur differ sensorskin interfac electrod stem
620	plasma arginin esteras activ cystic fibrosi pancrea use micromethod determin plasma arginin esteras activ investig valu soybean trypsin inhibitor stiinhibit arginin esteras activ patient cystic fibrosi oblig heterozygot age match control individu mean stiinhibit activ lowest cystic fibrosi patient mean normal control highest mean stiinhibit activ heterozygot midway valu patient normal individu defici arginin esteras activ statist signific cystic fibrosi patient heterozygot
621	abnorm breakdown alpha2macroglobulintrypsin complex cystic fibrosi complex trypsin purifi alpha2macroglobulin normal patient cystic fibrosi studi form complex fail reveal proteolyt activ toward high molecular weight substrat wherea esterolyt activ toward low molecular weight substrat retain esterolyt activ resist inhibit high molecular weight inhibitor iincub 38 degre c complex normal alpha2macroglobulin slowli inhibit high molecular weight inhibitor regain activ high molecular weight substrat phenomenon obtain alpha2 macroglobulin cystic fibrosi examin data suggest gradual convers normal alpha2macroglobulintrypsin complex alpha2macroglobulin fragmenttrypsin complex defici patient cystic fibrosi
622	intract diarrhoea infanc intract diarrhoea syndrom infanc continu major diagnost therapeut challeng paediatrician paediatr gastroenterologist care organ stage approach diagnosi provid best method identifi infant specif aetiolog exist specif therapi often avail regardless aetiolog howev earli use appropri nutrit support reduc morbid mortal infant prevent develop mani secondari consequ malnutrit physician must compuls pay attent detail daili manag provid organ approach diagnosi treatment order improv outcom infant intract diarrhoea
623	bile acid metabol infant children appar bile acid metabol young child must evalu within context matur organ accordingli inform present physician investig abl integr new data concern mechan bile salt action pose new question concern previous exist hypothes hepat intestin function children
624	pancreasdevelop adapt malfunct infanc childhood pancreat develop begin fourth week gestat annular pancrea ventral pancrea fail migrat right duodenum duplic pancreat duct rare entiti probabl aris accident misplac mucos cell duodenum stomach develop pancreat pouch congenit pancreat cyst may singl multipl unilocular multilocular associ polycyst diseas kidney liver spleen ectop pancrea occur rotat ventral pancrea fusion dorsal pancrea tumour pancrea report children less 15 year age evalu patient via differ pancreat function test signific result interpret light clinic manifest test exocrin pancreat function childhood includ stool examin triolein test blood examin analysi duoden content secretinpancreozymin test pancreat scan selenomethionin transduoden pancreatogram abdomin ultrasound arteriographi upper gastrointestin xray preval disord pancrea infanc childhood exocrin pancreat insuffici well 96 per cent infant children pancreat insuffici cystic fibrosi shwachman syndrom second common caus pancreat insuffici associ neutropenia metaphys dystosi sever stunt growth eczema suscept infect patient cystic fibrosi partial pancreat insuffici sometim show dissoci differ enzym activ although pancreat compar rare infanc childhood suspect often overlook
625	acidsolubl glycoprotein amniot fluid cystic fibrosi foetu suggest intrauterin detect cystic fibrosi may base investig amniot fluid known protein content meconium homozygot newborn infant significantli increas wherea heterozygot infant moder increas result intrauterin intestin activ bowel content may excret amniot fluid thu detect deviat protein content amniot fluid may expect decid determin total protein content amount acidsolubl glycoprotein 86 amniot fluid sampl polographi measur hexos content homozyg case slight increas observ total protein content wherea heterozyg case chang observ
626	serum pancreat isoamylas diagnosi cystic fibrosi heterozygot nonvalu test group 102 oblig heterozygot cystic fibrosi gene examin genet type pancreat isoamylas well enzym activ pancreat isoamylas salivari isoamylas total amylas serum analysi perform use electrophoret separ detect variou type isoamylas rel activ determin mean densitometri activ salivari isoamylas total amylas serum show signific differ cystic fibrosi heterozygot control group frequenc variant gene pancreat isoamylas also control mean valu pancreat isoamylas slightli higher cystic fibrosi heterozygot control group 005 greater p greater 002
627	cystic fibrosi studi oyster ciliari assay bioassay use ciliari system detect factor factor cystic fibrosi cf sera tissu cultur medium deriv cf cell typic shortcom assay measur biolog activ studi mean overcom weak oyster gill cilia assay establish presenc cystic fibrosi mucociliari inhibitor cfmi experiment fraction may determin accept data assay authent cf normal noncf fraction give defin reaction measur reaction sampl least three time examin experiment sampl protein concentr greater minimum establish studi rel concentr cfmi present first step purif serum medium calcul term unit inhibit gener unit inhibit present serum medium fraction heterozygot close onehalf fraction homozyg sourc analog fraction concentr normal noncf sourc never inhibit mucociliari activ even test nearli 100 time cf concentr ciliari assay util oyster gill essenti monitor fraction procedur aim purifi cfmi shown capabl reliabl enough
628	cystic fibrosi evid genet compound famili studi cell cultur although major patient cystic fibrosi cf show typic clinic cours minor clinic phenotyp time initi diagnosi atyp mild cours skin fibroblast cultur establish 49 member famili one atyp cf adult patient previous identifi dane et al 1976 cf class ii ametachromat metabol cooper cf class fibroblast offspr class metachromat metabol cooper normal fibroblastsclass ii mate cultur phenotyp class trace matern side class ii patern side consecut gener cultur phenotyp class segreg famili studi ad experiment evid support hypothesi atyp mild clinic featur cours adult cf patient due two differ cf gene combin produc genet compound express mild form cf
629	depress erythropoiesi physic growth hair growth chloramphenicol threeyearold child cystic fibrosi patient cystic fibrosi cf pancrea optic neuriti peripher neuriti report follow treatment chloramphenicol toxic sequel appear relat dosag durat therapi patient diseas treat chloramphenicol risk devast bone marrow toxic estim rang 140000 1100000 found two report patient cf hematolog complic treatment chloramphenicol report 3yearold girl select depress erythroid bone marrow anorexia weight loss temporari hair loss retard growth prolong administr chloramphenicol
630	meconium ileu equival infant aggrav soy bean formula meconium ileu neonat present symptom 10 20 per cent instanc cystic fibrosi pancrea similar intestin obstruct occur later postneonat period rare occurr call meconium ileu equival jensen 40 case affect syndrom report medic literatur 13 infant report 7weekold patient die 3 day surgeri small bowel obstruct clinic suspicion cystic fibrosi confirm autopsi
631	minocyclin antibiot regimen cystic fibrosi patient weight gain clinic improv minocyclin hydrochlorid given 100 patient cystic fibrosi pancrea period 3 month broad spectrum antibiot drug rotat last 2 year increas weight gain clinic improv seen treatment minocyclin patient sever diseas gain weight mild moder diseas male gain femal minocyclin hydrochlorid drug use patient lost weight health declin
632	dysfunct aspect support group number voluntari organ exist support patient rel suffer specif medic condit usual assum membership provid posit emot social support membership may provid dysfunct respons smallscal studi parent fibrocyst children provid evid dysfunct aspect membership one specif organ research effect formal inform refer group activ type support accept patient famili suggest
633	environment factor diseas pancrea five major diseas pancrea togeth make signific contribut morbid mortal among peopl unit state diseas diabet cystic fibrosi acut chronic pancreat carcinoma exocrin pancrea four diseas model laboratori anim acut chronic administr chemic poison carcinogen human pancreat diseas attribut effect chemic agent includ alcohol drug includ mani case chronic pancreat case acut pancreat caus known mani case human pancreat includ interstiti acut chronic clinic form epidemiolog studi suggest increas incid carcinoma exocrin pancrea unit state may reflect chemic carcinogenesi basi experiment observ know pancreat islet cell damag directli toxic chemic islet cell tumor chemic induc thu adequ background data conclud sever pancreat diseas obscur etiolog may due part hitherto unidentifi toxic effect chemic agent encount person gener environ
634	reassess diagnost valu vectorcardiogram cystic fibrosi correl clinic score pulmonari function test echocardiogram 21 children cystic fibrosi vectorcardiogram vcg correl variou indic sever diseas best correl found 1 azimuth angl spatial qr loop area repres rightward posterior shift main electr forc pulmonari function test pft fev1 predict r 0671 p less 0005 vc predict r 0607 p less 0005 2 right ventricular anterior wall index measur echocardiograph r 0472 p less 005 vcg paramet correl significantli pft echocardiogram show major influenc pulmonari chang vcg patient sever subgroup differ clinic score vcg analyz compar normal limit age sexmatch control small seri vcg specif sensit method predict degre sever diseas echocardiographi vectorcardiographi consid two complementari techniqu evalu cystic fibrosi
635	fast isoamylas parotid saliva children cystic fibrosi heterozyg carrier electrophoresi parotid saliva alway exhibit basic pattern 6 isoamylas addit faster migrat isoamylas occur vari number fast isoamylas gener least part deamid compar juvenil adult control significantli greater number fast isoamylas found parotid saliva children cystic fibrosi healthi heterozyg parent shift equilibrium amid deamid discuss term possibl connect metabol defect respons cystic fibrosi
636	decreas ouabain bind cystic fibrosi fibroblast potassiumfre medium previous demonstr cystic fibrosi cf cell show increas surviv compar normal cell expos ouabain medium lack potassium report show cf cell bind significantli less ouabain normal cell potassiumdefici medium use agematch normal cf skin fibroblast strain show 1 ouabain concentr 20x109 bind normal cf cell linear time 1 h reach equilibrium 4 h 2 ouabain concentr 2 20x109 initi rate bind cf cell approx 70 normal cell 3 equilibriumbind condit scatchard analysi reveal three differ cf strain 12 16 44 fewer ouabainbind site match normal control addit studi potassiumfre medium inhibit 86rb flux kplu analogu cell ouabain show differ cf normal cell also previous shown low glucos potassiumdefici medium cf cell surviv ouabain exposur better normal cell report equilibriumbind studi 3houabain clearli show cf cell bind less ouabain condit normal cell result indic ouabain resist cf cell sole function differ ouabain bind furthermor differenti ouabain kill may due ion transport differ rather yet unknown mechan cf cell thu appear unlik previous character ouabainresist mutant
637	reduc microbi transform bile acid cystic fibrosi microbi transform bile acid incub stool homogen children cystic fibrosi decreas
638	minim bile acid malabsorpt normal bile acid breath test cystic fibrosi acquir pancreat insuffici studi undertaken report mark increas fecal bile acid excret children cystic fibrosi attempt confirm find perform 114ccholylglycin breath test measur fecal bile acid fat excret patient cystic fibrosi acquir pancreat insuffici studi done patient take pancreat enzym cotazym also without medic 14co2 excret breath normal patient acquir pancreat insuffici even lower cystic fibrosi without cotazym therapi fecal bile acid excret slightli elev group without cotazym becam normal cotazym patient acquir pancreat insuffici steatorrhea present patient group improv cotazym therapi bile acid malabsorpt cystic fibrosi acquir pancreat insuffici minim probabl clinic import
639	minim bile acid malabsorpt letter roller kern report bile acid malabsorpt patient cystic fibrosi cf acquir pancreat insuffici minim find varianc studi deserv comment absenc fecal bile acid valu control author cannot state level cf twice normal valu especi sinc paper cite normal bile acid excret refer measur obtain differ techniqu also question valid breath test index bile acid malabsorpt cf recent report show 8 older cf mean age 121 year magnitud bile acid loss stool compar younger age group mean age 39 year correl age degre bile acid loss hand must take issu roller kern suggest bile acid malabsorpt cf probabl clinic import find bear relev intestin manifest cf increas incid cholelithiasi perhap also earli deposit within intrahepat duct eosinophil mucu concret propos caus biliari cirrhosi diseas
640	meconium ileu equival complic cystic fibrosi postneonat children young adult report 12 case twelv patient meconium ileu equival complic cystic fibrosi postneonat period seen mayo clinic year 1950 1975 child young adult known suspect cystic fibrosi triad recurr colicki abdomin pain mass right lower quadrant mechan intestin obstruct provid clue diagnosi meconium ileu equival clinic suspicion meconium ileu equival may confirm meglumin diatrizo gastrografin enema uncompl case also serv treatment
641	bile salt kinet cystic fibrosi influenc pancreat enzym replac bile acid kinet investig stabl isotop dilut techniqu 6 children age 3 12 month 4 12 year previous untreat cystic fibrosi patient clinic laboratori evid malabsorpt normal intestin mucos function judg glucos absorpt intestin histolog disaccharidas level normal function gallbladd children maintain constant diet throughout studi period fat intak averag 42 g per kg per day administr pancreat enzym replac fat excret equal 50 plu minu 4 mean plu minu se intak reduc 20 plu minu 10 intak therapi total bile acid pool size nearli doubl enzym replac 379 plu minu 32 micromol per kg 620 plu minu 36 micromol per kg secondari bile acid compris 57 total pool therapi 40 therapi total bile acid synthesi chang littl therapi equal 139 plu minu 17 micromol per kg per day total 602 plu minu 109 mg per day without enzym replac 125 plu minu 19 micromol per kg per day total 470 plu minu 86 milligram per day enzym replac confirm fecal excret bile acid 545 plu minu 166 milligram bile acid per day excret without enzym compar 513 plu minu 146 milligram per day enzym therapi fraction turnov rate bile acid pool reduc 0602 plu minu 005 per day 0233 plu minu 03 per day cholic acidand 0696 plu minu 009 per day 039 plu minu 004 per day chenodeoxychol acid data indic primari secondari bile acid conserv within enterohepat circul enzym therapi mechan regul hepat bile acid synthesi intact cystic fibrosi howev demonstr larg amount bile acid continu excret therapi suggest interrupt enterohepat circul continu defici intralumin phase may persist enzym therapi diseas
642	classif time diagnosi subsequ surviv children cystic fibrosi surviv rate 204 patient suffer cystic fibrosi observ januari 1956 june 1976 record patient divid five group accord symptom present time diagnosi surviv rate record separ group surviv less good group patient present initi pulmonari symptom compar group present gastrointestin symptom group present meconium ileu surviv poor initi later cours diseas becam similar observ group differ surviv differ categori occur first two year diagnosi studi show clinic ground sever form diseas character earli manifest pulmonari symptom poor surviv distinguish protract form better surviv great interindividu variabl larg number patient evalu order achiev statist signific result studi attempt compar differ therapeut approach number cannot reach may necessari compar patient belong symptomat categori
643	influenc lyophil total pancrea plasma lipid fat absorpt cystic fibrosi 31 children cystic fibrosi cf subdivid three group age studi treatment lyophil pancrea compar 27 control cf character lower phospholipid cholesterol polyunsatur fatti acid plasma concentr reduc coeffici fat absorpt treatment tend toward normal valu age polyunsatur fatti acid increas normal cf signific correl exist fat absorpt coeffici polyunsatur fatti acid percentag neutral lipid cf children suggest use latter percentag index stage malabsorpt
644	chronic lung diseas children sinc tuberculosi still signific threat famili physician need familiar method diagnosi treatment among entiti discuss atyp mycobacteriosi sarcoidosi cystic fibrosi
645	inbreed recess diseas consanguin parent born franc individu recess diseas studi frequenc first cousin marriag less 02 gener french popul among parent affect individu follow frequenc first cousin mate observ cystic fibrosi 14 cystinosi 71 nephronophtisi 56 spinal muscular atrophi 45 albin 50 achromatopsia 125 albin spinal muscular atrophi heterogen condit increas frequenc first cousin marriag rel gener popul much greater expect cystinosi rare diseas cystic fibrosi frequent recess disord franc inbreed cystinosi cystic fibrosi also studi comput distanc parent birth place distanc smaller cystinosi cystic fibrosi
646	frequenc gene cystic fibrosi view replac recognit effect reproduct homozygot appar frequenc recess autosom allel cystic fibrosi cf high satisfactorili explain mutat equilibrium howev higher reproduct fit heterozygot express greater 0 higher gamet viabil cf allel express greater 05 provid reason explan present frequenc furthermor birth replac famili cf children rpe account estim histor valu today howev probabl approach zero result discontinu rpe futur look impercept slow decreas incid cf reproduct cf femal caus increas incid slightli slow rate decreas
647	util electron microscopi prenat diagnosi genet diseas use electron microscopi method diagnosi diseas cultur skin fibroblast cultur amniot fluid fibroblast present demonstr taysach diseas fabri diseas metachromat leukodystrophi distinct abnorm cultur skin fibroblast cultur amniot fluid fibroblast shown control cultur condit made possibl distinguish normal cell line certain cell line carri known genet diseas
648	carotid bodi hypertrophi patient cystic fibrosi cyanot congenit heart diseas carotid bodi 71 patient rang age 28 week gestat 30 year obtain autopsi patient divid two group base presenc absenc chronic hypoxemia high correl weight individu carotid bodi case among 12 patient chronic hypoxemia eight patient carotid bodi heavier predict statist analysi eight patient six cystic fibrosi two cyanot heart diseas morphometr cell popul analys carotid bodi eight patient control popul indic enlarg carotid bodi normal abnorm growth result proportion increas lobul parenchyma stroma also increas width length lobul without increas diamet cell cord chang size proport chief cell growth develop carotid bodi studi control group 59 patient without chronic hypoxemia sex relat differ carotid bodi weight combin weight carotid bodi correl strongli bodi weight although correl age bodi length regress equat reflect data relat bodi weight bw combin weight carotid bodi mg 029 bw kg 30 leukem infiltr present two patient acut lymphocyt leukemia diffus lymphocyt infiltr nodul format present one patient mental retard metaplast cartilag present carotid bodi one patient
649	cellular immun bacteria impair vitro lymphocyt respons pseudomona aeruginosa cystic fibrosi patient lymphocyt respons mitogen phytohemagglutinin concanavalin streptococcu pyogen staphylococcu aureu haemophilu influenza pseudomona aeruginosa evalu patient cystic fibrosi normal individu lymphocyt prolifer vitro stimul gentamicinkil whole bacteria prolif respons measur 3hthymidin incorpor vitro lymphocyt respons antibiotickil bacteri reach maximum thymidin incorpor 5 day cultur follow unimod doserespons curv bacteria studi signific specif incapac respond p aeruginosa detect cystic fibrosi patient advanc clinic diseas
650	enzym phospholipid metabol airway secret patient asthma cystic fibrosi alveolar proteinosi phospholipas a2 lysolecithinas lysolecithinlysolecithin acyltransferas present airway secret patient asthma cystic fibrosi cf alveolar proteinosi assay enzym condit extract human polymorphonuclear leukocyt alveolar macrophag pig tracheal mucosa indic extracellular airway enzym probabl deriv cell type although three enzym present secret patient three diseas larg amount palmitoyl lysolecithin free fatti acid dipalmitoyl lecithin found patient alveolar proteinosi asthma amount free fatti acid secret suffici inhibit lysolecithinas lysolecithinlysolecithin acyltransferas phospholipas a2 find suggest larg amount dipalmitoyl lecithin free fatti acid lysolecithin found secret result extracellular remodel enzym phospholipas a2 present larg amount possibl delipid purifi homogen stabl enzym appar molecular weight 75000 estim sdsmercaptoethanol gel electrophoresi
651	defici kappa lambdatyp immunoglobulin wide recogn immunoglobulin carrier antibodi activ play import role defens individu infect known case kappa lambda light chain type immunoglobulin defici heterogen regard clinic immunolog find also number similar may suggest common underli factor accur investig addit patient avail provid insight basi kappa lambda type immunoglobulin defici
652	cystic fibrosi netherland netherland retrospect studi preval cystic fibrosi cf birth perform mean inquiri set among 815 medic specialist paediatrician lung specialist pathologist analysi hospit admiss data death certif data nation cf foundat studi confin year birth 19611965 total 1239566 live birth 342 infant children found cf 13600 list studi frequenc cf caucasian popul present appendix season trend express cf gene birth either without meconium ileu note
653	hypersensit pancreat extract parent patient cystic fibrosi immedi hypersensit reaction occur individu expos powder pancreat extract 36 patient cystic fibrosi 51 patent patient wwer studi evid sensit sensit extract evid histori skin test infrequ children cystic fibrosi howev skin test immedi hypersensit either crude pancreat extract inactiv trypsin correl well patent histori clinic symptom ige mediat reaction sensit individu demonstr antigen induc histamin releas leukocyt passiv transfer studi immedi respons inhal challeng
654	dental aspect patient cystic fibrosi preliminari clinic studi oral condit 42 patient treat cystic fibrosi evalu patient group age aspect compar small control group sibl patient group lower incid plaqu less gingiv diseas control group everi person amount plaqu gingiv diseas calculu format minim reason find minim plaqu patient group could relat sever factor includ lifelong use variou antibiot agent chew digest enzym supplement effect medic manag tooth hard effect stain teeth possibl tetracyclin deposit plaqu microorgan appear therapi cystic fibrosi benefici periodont health patient much studi need understand interrelationship alter oral environ salivari chang cystic fibrosi alter microbi flora antibiot enzym even alter tooth surfac possibl tetracyclin deposit patient found one oral habit tooth mobil associ tension habit patient club finger indic pulmonari compromis possibl sever diseas process appear either stain teeth sever gingiv associ relationship tetracyclin tooth stain could pinpoint
655	comparison measur forc expir theoret relationship among number paramet deriv ideal time vital capac tvc maxim expiratori flow volum mefv curv determin minim set independ paramet normal pediatr subject cystic fibrosi studi verifi relationship experiment averag flow middl half fef2575 forc vital capac fvc flow variou exhal percentag fvc fef50 fef75 well moment tvc mefv curv comput tvc moment mean transit time mtt index dispers id also calcul minimum inform need detect pulmonari mechan chang associ obstruct lung diseas requir least two reproduc measur one relat mean slope eg fef2575fvc mtt shape eg id effortindepend portion mefv curv
656	comparison purifi alpha2macroglobulin prepar normal control patient cystic fibrosi kinet structur properti complex bovin trypsin alpha2macroglobulin purifi plasma obtain three healthi control three patient cystic fibrosi normal patient prepar indistinguish antigen uv absorpt spectra competit inhibit prepar hydrolysi benzoyllarginin ethyl ester bovin trypsin observ ki valu normal alpha2macroglobulin 53 x 108 compar 18 x 107 cystic fibrosi patient prepar km valu alpha2macroglobulintrypsin complex 63 x 104 normal protein 15 x 104 alpha2macroglobulin cystic fibrosi patient gel chromatographi normal alpha2macroglobulin preincub molar ratio bovin trypsin reveal format alpha2macroglobulin fragment fragment obtain prepar cystic fibrosi patient normal cystic fibrosi alpha2macroglobulin shown gel chromatographi sodium dodecyl sulfat tetram noncoval bound reduct alkyl monom found singl polypeptid chain fragment obtain preincub normal alpha2macroglobulin trypsin approxim half molecular weight intact monom cystic fibrosi alpha2macroglobulin preincub trypsin sodium dodecyl sulfat singl major compon ident intact monom format alpha2macroglobulin fragment
657	occurr effect human vitamin e defici studi patient cystic fibrosi role vitamin e human nutrit studi investig patient cystic fibrosi cf associ pancreat insuffici vitamin e statu assess measur plasma concentr princip circul isom alphatocopherol result determin 52 cf patient pancreatogen steatorrhea reveal defici vitamin extent decreas plasma tocopherol vari markedli correl indic intestin malabsorpt serum caroten concentr percentag dietari fat absorb supplement 510 time recommend daili allow vitamin e watermisc form increas plasma alphatocopherol concentr normal 19 cf patient evalu studi effect vitamin e defici focus possibl hematolog alter improv techniqu develop measur erythrocyt hemolysi vitro presenc hydrogen peroxid erythrocyt suspens control subject demonstr resist hemolysi 3h incub sampl tocopheroldefici cf patient show abnorm oxid suscept evidenc greater 5 hemoglobin releas degre peroxideinduc hemolysi relat plasma alphatocopherol concentrationin invers sigmoid manner possibl vivo hemolysi assess measur surviv 51crlabel erythrocyt 19 vitamin defici patient moder statist signific decreas mean 51cr erythrocyt halflif valu found group measur erythrocyt surviv supplement 6 patient vitamin e demonstr shorten erythrocyt lifespan could correct normal treatment hematolog indic defici subject howev normal chang upon supplement vitamin e conclud cf invari associ vitamin e defici provid patient question pancreat achylia take supplementari dose tocopherol concomit hematolog effect consist mild hemolysi anemia occur may revers vitamin e therapi patient cf given daili dose watermisc form vitamin e correct defici
658	bronchiectasi mucoviscidosi sweat chlorid 25 healthi adult test iontophoresi method control mean valu 274 plu minu 154 meql thirtysix adult patient bronchiectasi prove bronchographi investig mucoviscidosi patient sweat chlorid 60 meql consid diagnost mucoviscidosi five 139 per cent 36 adult bronchiectasi patient mucoviscidosi mean valu sweat chlorid 31 adult bronchiectasi patient 329 plu minu 117 meql mean valu sweat chlorid 36 adult bronchiectasi patient includ 5 mucoviscidosi patient 423 plu minu 268 meql 36 patient 18 cylindr type 18 saccular type bronchiectasi three 166 per cent 18 cylindr type bronchiectasi patient 2 111 per cent 18 saccular type bronchiectasi patient mucoviscidosi five 139 per cent patient emphysema 6 166 per cent patient emphysema cor pulmonal one patient group mucoviscidosi ecg show ppulmonal 3 83 per cent patient one mucoviscidosi one mucoviscidosi patient coagulas posit staph aureu sputum
659	safeti antigen inactiv influenza viru vaccin children trial monoval bival anew jersey76 hswn1 avictoria75 viru vaccin washington dc safeti antigen monoval bival anew jerseynj76 hssn1 avictoria75 inactiv influenza viru vaccin studi 125 children age three 18 year recruit famili knew studi team profession involv andor close continu care like volunt studi unfamiliar team institut antibodi respons system reaction occur often administr inactiv wholeviru vaccin splitviru vaccin signific titer greater equal 140 hemagglutinationinhibit antibodi anj76 viru occur 95 normal children three 18 year age receiv two dose vaccin whole split howev insuffici number children achiev reason antibodi titer greater equal 140 one dose vaccin ct 1 vasilyeva ri zh mikrobio epidemio immunobi 1982 96 982
660	clinic trial bival anew jersey76avictoria75 influenza vaccin highrisk children variou dose two wholeviru one splitproduct bival influenza anew jersey76avictoria75 vaccin administ 253 children age six 18 year statist signific differ either reactiv humor antibodi respons among 167 children seven chronic diseas categori 86 healthi children wholeviru vaccin associ unaccept high rate reaction given suffici antigen initi dose rel nonreact use booster immun splitproduct vaccin reactiv placebo vaccin prepar induc adequ seroconvers rate protect titer antibodi avictoria viru one dose anew jersey viru two dose
661	pharmacokinet methicillin patient cystic fibrosi disposit methicillin normal subject subject cystic fibrosi cf studi administr singl intraven dose 15 mgkg area serum concentr vs time curv cf patient averag 75 found normal subject low concentr serum caus rapid urinari excret antibiot rate renal clearanc averag 425 mlmin per 173 m2 patient cf 362 mlmin per 173 m2 normal subject differ found volum distribut metabol clearanc rate methicillin rate creatinin clearanc two group subject data support previou find dicloxacillin show patient cf exhibit unusu rapid activ tubular secret certain penicillin may necessit use larger dose drug treatment infect
662	normal plasma arginin esteras hageman factor factor xii prekallikreinkininogen system cystic fibrosi previou investig suggest biolog activ plasma prekallikrein defect cystic fibrosi contrast differ demonstr normal cystic fibrosi plasma esterolyt activ synthet substrat ptoluen sulfonylarginin methyl ester tame evolv normal cystic fibrosi plasma treat chloroform ellag acid measur gener plasma kallikrein addit plasma prekallikrein fletcher factor high molecular weight kininogen fitzgerald factor substrat plasma kallikrein normal thu concept cystic fibrosi associ abnorm plasma kallikreinkinin system could support
663	nasal aspect cystic fibrosi children despit extraordinari preval upper respiratori allergi infect children nasal polyposi extrem rare condit seven case cystic fibrosi present order demonstr nasal aspect diseas one nasal polyposi literatur review particular refer clinic radiolog histopatholog featur conserv treatment stress
664	nasal polyp cystic fibrosi ii polyp patient cystic fibrosi pancrea densiti shape architectur mucou gland studi wholemount method compar 102 noncysticfibrosi polyp differ densiti polyp less 05 glandmm2 shape architectur well histolog appear polyp also alik group polyp could distinguish pathogenesi nasal polyp cystic fibrosi discuss appar noncysticfibrosi polyp
665	syndrom inappropri antidiuret hormon secret caus hyponatremia cystic fibrosi syndrom inappropri secret antidiuret hormon observ two patient cystic fibrosi acut exacerb chronic pulmonari diseas diagnos accept clinic laboratori criteria confirm one case valu immunoreact vasopressin inappropri high plasma osmol sever hyponatremia correct fluid restrict alon combin intraven treatment diuret hyperton salin solut addit simultan therapi pulmonari diseas siadh thu must ad salt loss caus hyponatremia cf may common realiz patient cf sever pulmonari diseas
666	cystic fibrosisrel inhibit mucociliari clearanc vivo man studi perform demonstr possibl cystic fibrosi relat inhibit mucociliari clearanc man topic applic normal serum cf serum inhibit vivo nasal mcc induct local inflamm topic antiig reduc nasal mcc cf subject increas mcc normal individu furthermor nasal mcc inhibit normal patient cf serum normal serum appli antiigetr nasal mucosa observ consist hypothesi cf serum inhibit mcc vivo inflam mucosa
667	pharmacokinet amikacin children pharmacokinet variabl amikacin measur 20 children adolesc four 16 year age mean plasma clearanc amikacin 120 mlminute173 m2 major rout elimin renal 82 simultan measur inulin clearanc show major 64 drug filter kidney excret urin mean volum distribut amikacin 32 bodi weight halflif final pseudoequilibrium phase averag 16 hour signific accumul drug seen four dose given intraven 420 mgm2 everi 8 hour plasma concentr inject fourth dose averag 24 plu minu 11 microgramml mean plasma concentr 60 75 minut inject drug 287 microgml littl interpati variat sd 35 microgml dose express term milligram per kilogram found children often need 50 100 drug compar adult achiev equival plasma concentr larger requir primarili due higher clearanc amikacin proport bodi weight dosag base surfac area howev result uniform requir predict plasma concentr patient studi
668	mother daughter cystic fibrosi improv therapi recognit patient mild diseas increas number children cystic fibrosi reach reproduct year although virtual male cystic fibrosi steril unknown percentag femal cystic fibrosi fertil know one case mother cystic fibrosi produc child diseas purpos commun report birth child cystic fibrosi whose mother also diseas
669	therapeut approach pancreat extractinduc hyperuricosuria cystic fibrosi relationship dosag pancreat extract excret uric acid investig 29 patient cystic fibrosi exocrin pancreat insuffici urinari excret uric acid normal patient receiv small dose pancreat extract abnorm high receiv larg amount latter group normouricosuria achiev reduc dose pancreat extract normal stool pattern adequ weight gain preserv diet modif well accept patient elimin potenti renal consequ hyperuricosuria seem appropri control need increas amount pancreat enzym limit dietari intak fat maintain posit calor nitrogen balanc high intak protein carbohydr supplement mediumchain triglycerid
670	altern complement pathway activ cystic fibrosi letter possibl rais complement play role pathogenesi cystic fibrosi cf impair would consist thesi altern pathway activ vivo therefor deplet purpos work explor function altern pathway cystic fibrosi examin data use student test analysi varianc show signific differ mean hemolyt activ sera cf patient compar control group data present support work polley bearn demonstr abnorm cf patient use convers c3 inulin assay reason discrep clear result preclud vivo activ altern pathway sinc compensatori increas synthesi compon could offset compon consumpt sinc net result complet normal level activ howev seem like signific consumpt occur
671	prolong obstruct jaundic giant cell hepat infant cystic fibrosi letter histolog evid liver involv consist focal biliari cirrhosi andor intrahepat mucu frequent autopsi find infant cystic fibrosi cf wish report infant cf liver biopsi show featur typic neonat giant cell hepat patient none patholog featur usual describ cf present either biopsi rather chang describ neonat hepat knowledg report associ cf like giant cell hepat coincident find unrel cf emphas howev one cannot assum uniform etiolog instanc obstruct jaundic seen infant cf
672	putrescin uptak cystic fibrosi fibroblast letter laboratori report abnorm polyamin level extract whole blood individu cystic fibrosi cf sinc abnorm putrescin uptak cf fibroblast would impli direct relationship genet lesion initi studi confirm possibl extend observ signific increas vmax cf fibroblast compar valu obtain control cell conclud growth assay condit attempt duplic describ origin investig consist signific increas vmax putrescin uptak cf fibroblast
673	cystic fibrosi black children feel cystic fibrosi black popul occur frequent 117000 report kulcycki schauf experi black patient indic cours prognosi differ white popul cystic fibrosi
674	pancreat extract manag cystic fibrosi univers kansa group establish pancreat extract dose current use manag patient cystic fibrosi caus hyperuricosuria may occasion symptomat correctli worri longterm ill effect therapi treat cf patient uricosuria result primarili increas dietari purin load though abnorm transport physiolog cf may contribut even though final evid risk hand prudenc would suggest hold purin load cf patient minimum need ensur digest suffici foodstuff without necessarili permit normal diet san steatorrhea altern purifi enzym prepar free remain sweetbread could elimin excess nucleic acid intak administ dosag permit luxuri redund safeti
675	inappropri secret adh caus hyponatremia cystic fibrosi letter read syndrom inappropri antidiuret hormon adh secret siadh caus hyponatremia cystic fibrosi cf puzzl certain unusu phenomena two case present agre would import recogn occurr adh mediat hyponatremia cf would though appreci author comment weight loss fluid electrolyt balanc earli patientss cours also help would inform furosemid dosag drug acetaminophen may given understand pathophysiolog two complex patient think hypovolemia either case patient 1 given one dose 600 mg acetaminophen fourth day hospit recoveri patient 2 receiv one dose acetaminophen 650 mg 2 twentyfirst day admiss recoveri patient receiv antibiot patient 2 receiv digitali well reason product adh remain obscur case siadh although mention discuss transient natur siadh patient cystic fibrosi would argu product hormon lung
676	pancreat alpha beta cell function cystic fibrosi insulin glucagon secret studi oral glucos toler test arginin infus 13 patient cystic fibrosi two group patient identifi group n6 whose ogtt entir normal group ii n7 abnorm glucos ogtt group basal glucagon concentr normal supress appropri p less 005 glucos insulin respons attenu peak respons delay arginin stimul insulin secret impair group howev glucagon secret diminish group ii thu insulinopenia found group hyperglucagonemia found contributori factor hyperglycemia group ii
677	treatment pulmonari infect patient cystic fibrosi compar studi ticarcillin gentamicin effect ticarcillin pseudomona aeruginosa acut exacerb pulmonari infect patient cystic fibrosi evalu seventyon percent patient treat ticarcillin alon respond favor respons rate similar patient treat combin ticarcillin plu gentamicin gentamicin alon sever underli diseas import determin respons treatment ticarcillin resist organ recov treatment 50 patient receiv drug recoveri prevent inclus gentamicin therapeut regimen interfer clinic improv ticarcillinresist strain persist followup two six month complet therapi one ten patient seriou toxic ticarcillin note studi period
678	fals neg meconium test result screen cystic fibrosi valu boehringermannheim bm meconium test routin screen cystic fibrosi question recent high proport fals neg result report present observ valid bm meconium test find show bm meconium test may contribut fals neg result even exocrin pancreat function newborn infant cf abnorm observ support doubt express recent regard valid bm meconium test screen neonat cystic fibrosi
679	manag major hemoptysi patient cystic fibrosi although bronchoscopi remain best definit method local site hemorrhag patient massiv hemopytsi angiographi remain import adjunct local combin embol bleed bronchial arteri effect method therapi manag massiv hemoptysi patient cystic fibrosi
680	new method investig region lung function children local lung diseas lung function studi use 13nitrogen use determin region total lung function 16 children suspect local lung diseas amen surgeri method simpl requir activ cooper part child give radiat dosag onethird bronchogram studi provid inform sever local diseas addit inform remain lung area
681	manag portal hypertens cystic fibrosi found proper select preoper prepar major portosystem shunt done consider safeti major cystic fibrosi patient thu provid signific palliat improv qualiti life
682	rehabilit research disabl new horizon paper present overview research disabl integr rehabilit research mainstream scientif activ research disabl appli scienc use gener tool scientif method solv specif problem research disabl embrac wide varieti physic intellectu emot condit psycholog aspect physic disabl especi stress adapt lost function exampl research given spinal cord injuri endstag renal diseas facial disfigur cancer larynx
683	glycosyl vsv glycoprotein similar cystic fibrosi heterozyg carrier normal human fibroblast singl envelop glycoprotein vesicular stomat viru use specif probe glycosyltransferas activ fibroblast two cystic fibrosi patient oblig heterozyg carrier normal individu gel filtrat pronasedigest glycopeptid purifi virion infect cellassoci vsv glycoprotein label with3h glucosamin reveal signific differ glycosyl pattern differ cell cultur 4 cell line appar abl synthes mannos glucosamin contain core structur branch chain termin sialic acid characterist asparaginelink carbohydr side chain cellular glycoprotein analysi tryptic glycopeptid anionexchang chromotographi indic 2 major site viru polypeptid recogn glycosyl 4 vsvinfect cell cultur studi suggest basic biochem defect cystic fibrosi absenc defici enzym respons biosynthesi complex carbohydr side chain
684	manag pneumothorax children chronic pulmonari diseas cystic fibrosi common form chronic pulmonari diseas pediatr age group children surviv longer improv therapi incid pneumothorax increas patient 10 year age incid pneumothorax 125 percent review record 22 patient 44 episod pneumothorax complic cystic fibrosi addit experi includ one child histiocytosi pneumothorax seriou complic one pneumothorax occur teenag girl apic bullou diseas child present even minim pneumothorax complic cystic fibrosi consider risk develop increas lung collaps even pneumothorax resolv high risk recurr children treat chest tube 50 percent recurr consequ recommend chest tube episod pneumothorax child cystic fibrosi instal scleros agent lung expand three patient treat recurr children persist air leak confin bed retain secret pursu rapid downhil cours aggress approach children consist thoracotomi sutur air leak pteural symphysi pulmonari lavag feasibl mortal rate low pneumothorax child evid cystic fibrosi rare event persist air leak indic thoracotomi sutur air leak lung biopsi histiocytosi x one rare caus complic children
685	cystic fibrosi iraqi children cystic fibrosi cf firmli establish singl diseas anderson 1938 although previous case report appear european literatur subsequ cf describ mani part world first report cystic fibrosi arabiraqi children seventeen case cystic fibrosi diagnos medic citi teach colleg hospit univers baghdad 1970 1976 studi sexratio 21 compar roughli equal ratio usual quot possibl explan discrep prefer given boy iraqi famili medic attent like sought behalf
686	cystic fibrosi expand challeng intern medicin number adult cystic fibrosi cf receiv care us cystic fibrosi center increas averag rate 200 patient year model base continu rate increas predict almost 4000 adult receiv care center end 1985 four model develop base continu steadi state two variat 50 reduct mortal univers newborn screen model show boundari equilibrium popul 24000 64000 patient 7000 18000 adult
687	serotyp pseudomona aeruginosa patient cystic fibrosi pancrea serotyp 30 mucoid strain isol cystic fibrosi patient carri slide agglutin test live heatkil cell tube agglutin test heatkil cell comparison result obtain 2 method reveal tube agglutin heatkil cell superior method half strain found homma serotyp 15 group new schema 2 slide agglutin live cell give clear result strain show occasion posit neg agglutin serotyp serum chang serotyp group new schema 2 found strain although number small
688	reninlik angiotensinogenas activ sweat patient cystic fibrosi control use bioassay method rat blood pressur techniqu well radioimmunoassay reninlik activ rla measur eccrin sweat patient cystic fibrosi pancrea cf control sweatform induc pilocarpineiontophoresi local inject carbamylcholin doryl rlavalu measur 460 ngmlh measur increas sweat flowrat tendenc lower rlavalu detect signific differ observ cf control observ rla sweat 30 time higher plasma conclud rla probabl releas plasma sweat gland store synthes
689	bioavail food iron59f vitamin b1260co protein bound selenomethionine75s pancreat exocrin insuffici due cystic fibrosi absorpt biosynthet 59felabel hemiglobin pork hog liver 60 covitamin b12 75seselenomethionin label pork measur children cystic fibrosi whole bodi count absorb radionuclid within 4pi geometri larg volum radioact detector liquid organ scintil
690	absorpt inorgan iron 59fe2 relat iron store pancreat exocrin insuffici due cystic fibrosi absorpt 59fe diagnost 056 mg 59fe2 dose measur 4pigeometri whole bodi count relat amount stainabl diffus cytoplasmat non heme storag iron bone marrow macrophag children cystic fibrosi storag iron within normal rang 2 children cystic fibrosi absorb 1038 xasd2193 oral 59fe2 dose ident 59feabsorpt normal children normal iron store 9452387 deplet iron store caus increas 59feabsorpt 4395 xa sd6219 children cystic fibrosi 45100 xa sd7318 control children interrupt continu pancreatin mainten therapi simultan administr 115 g pancreatin influenc 59fe2 absorpt cystic fibrosi evid pancreat factor requir inhibit inorgan food iron absorpt human be iron absorpt control also cystic fibrosi chiefli amount avail storag iron therefor justifi apprehend develop hemosiderosi children cystic fibrosi suffici treat pancreatin
691	glycoprotein synthesi transport secret epitheli cell human rectal mucosa normal cystic fibrosi synthesi transport secret glycoprotein human rectal epithelium normal volunt patient cystic fibrosi diseasefre sibl studi autoradiographi rectal biopsi pulselabel 3hglucosamin maintain organ cultur variou interv 24 hour human rectal goblet columnar cell transport 3h glucosaminelabel secretori product substanti slower rate compar colon cell smaller mammal within one biopsi sampl movement label mucu goblet cell vari wide among cell even individu cell label mucou granul often move concert toward apic cell surfac averag transport time cell six cystic fibrosi patient six sibl control differ significantli four adult control carbohydr composit glycoprotein secret rectal epitheli cell investig compar autoradiograph 3hglucosaminelabel biopsi label 3hfucos 3hnacetylmannosamin 35 sulfat pattern incorpor four precrusor normal goblet columnar cell suggest cell type may alter quantiti composit newli synthes glycoprotein migrat matur senesc incorpor pattern cystic fibrosi biopsi indistinguish sibl adult control techniqu use abnorm epitheli glycoprotein product detect cystic fibrosi rectal mucosa
692	fattyacid composit lecithin fraction mucu cystic fibrosi letter studi seven patient cf ten normal children confirm low level efa plasma redcel membran cf group would like report preliminari result fattyacid pattern lecithin fraction bronchial mucu group patient control content palmit acid lower oleic acid higher cf patient normal children abnorm fattyacid composit lecithin mucu could import find relat respiratori symptom cf experiment work support hypothesi
693	falseposit meconium screen letter bm meconium test use screen test cystic fibrosi howev falseposit result two babi caus use rectal glycerin suppositori babi present sign suggest intestin obstruct possibl due meconium ileu glycerin suppositori insert speed passag meconium bm test could done help confirm diagnosi test posit babi subsequ shown cystic fibrosi found glycerin suppositori produc typic blue colour test strip
694	heterozygot disadvantag cystic fibrosi letter found cystic fibrosi cf common south west africa occur almost exclus white afrikan probabl result inbreed drift northern cape coloni religi geograph separ howev found cf descend angola boer small proport 6 7 white popul belong small branch dutch reform church absenc cf may stem limit number 7000 suggest may least partial genet basi homozygot cf subject saltlos crise fatal hot weather heterozygot often increas concentr sodium chlorin ion sweat influenc environment temperatur drought may explain cf occur among black temper zone unit state africa less frequent hot southern region europ colder northern area neg select type may oper hot arid environ possibl environ offer advantag cf heterozygot cannot exclud
695	high breastmilk sodium cystic fibrosi letter increas sodium concentr sweat characterist cystic fibrosi howev read noth sodium content breast milk condit patient sweattestprov cystic fibrosi mild pulmonari diseas first babi normal deliveri term sampl breast milk obtain sixth seventh day post partum mother breast feed two sodium concentr 132 280 mmoll concentr much higher milk sampl test hospit larg survey higher seen literatur milk high sodium content would unsaf babi suggest mother cystic fibrosi breast feed sodium mild measur first breast like mani exocrin gland seem affect secretori abnorm cystic fibrosi ct 1 dann lg lancet 2 405 978 2 berlin cm obstet gynecol 58 17 981 3 welch mj pediatr 67 664 981 4 walpol ir j pediatr 98 333 981 5 mckiernan j pediatr re 16 60 982 6 gruskin pediatr clin north 29 907 982 7 alpert se j pediatr 102 77 983 8 seal tw ann clin lab sci 15 152 985 9 stead rj arch di child 62 433 987
696	abnorm fattyacid composit plasmalipid cystic fibrosi primari secondari defect percentag fattyacid composit variou plasmalipid fraction cysticfibrosi patient without pancreat insuffici oblig heterozygot normal subject determin cysticfibrosi patient pancreat insuffici significantli abnorm fattyacid composit gener observ correl vitamin defici age sex sever diseas thu alter fattyacid composit differ plasmalipid fraction appear secondari consequ pancreat insuffici commonli associ cystic fibrosi direct metabol defect relat cysticfibrosi gene
697	cysticfibrosi heterozygos childhood bronchial asthma letter found szczepanski bromid test simplifi aid ionsensit electrod suitabl detect cf heterozygos case examin sweat 74 randomli select children respiratori asthma past 2 year sodium chlorid concentr bromid index determin sodium chlorid concentr sweat asthma children slightli significantli higher p 005 control differ bromid index even signific p 001 suggest cf gene carrier unusu preval among children bronchial asthma one possibl enhanc ion loss variou diseas allerg patholog mechan secondari natur howev seem unlik sinc materi high sweatelectrolyt concentr observ proport control children whose ill similar sever asthmat children normal sweat valu obtain even child condit seriou
698	cysticfibrosi screen newborn new method test stool sampl newborn babi cystic fibrosi cf colourless substrat benzoylargininep nitroanilid bapna releas yellow pnitroanilin hydrolys trypsin sampl infant cf lack trypsin give neglig colour 2 infant cf detect among 2500 consecut newborn babi test incid fals posit result 12 first specimen 005 second specimen refin reduc posit rate 01 first specimen 2000 sampl test sampl 5 older patient untreat cf yield evid falseneg result
699	thymidinerequir haemophilu influenza staphylococcu aureu letter past year isol thi staphylococcu aureu sputum four children cystic fibrosi receiv cotrimoxazol late isol thi strain haemophilu influenza patient cystic fibrosi also receiv cotrimoxazol view exact growth requir h influenza feel thi strain might easili overlook assum die fail grow sensitivitytest media
700	malabsorpt laboratori diagnosi malabsorpt syndrom children difficult obviou reason involv collect specimen earli diagnosi cystic fibrosi extrem urgent sinc diseas treatabl standard test sweat test 99 percent patient diseas elev sodium chlorid sweat three test use assess pancreat function first measur stool trypsin chymotrypsin second stimul hormon standard secretin cck test third procedur test carbohydr toler increasingli import test sinc evergrow number patient late childhood earli adulthood cystic fibrosi found diabet mellitu commonest import hereditari diseas affect pancreat function cystic fibrosi commonest form pancreat insuffici childhood mucoviscidosi cystic fibrosi pancrea incid diseas approxim one per 1000 live birth occur race defect transmit autosom recess classic featur frequent bowel movement characterist appear steatorrh stool failur grow develop normal
701	multilobular biliari cirrhosi liver associ cystic fibrosi mucoviscidosi case includ autopsi find report multilobular biliari cirrhosi strictli nodular liver develop 20 yearold male cystic fibrosi mucoviscidosi pathogenesi biliari cirrhosi cystic fibrosi briefli discuss
702	cystic fibrosi screen sweat analysi critic review techniqu current employ method assay electrolyt sweat relev diagnosi cystic fibrosi critic evalu particular refer measur electr conduct attent drawn factor respons potenti larg error basi experiment support laboratori practic recommend made reduct error clinic accept level data concern sodium potassium content electr conduct osmol undilut sweat collect compar feasibl compar advantag measur sweat osmol vapour pressur osmomet discuss
703	cystic fibrosi new outlook 70 patient 25 year age present group 70 patient 25 year age januari 1 1975 diagnos cystic fibrosi cf variou age birth 28 year patient diagnos late life spite classic symptom characterist histori diseas patient cf present broad spectrum symptom vari consider sever older age group repres approxim 10 current roster patient cf diseas longer confin earli life continu seen increas frequenc older patient experi diseas indic number affect individu attain adulthood find use place societi qualiti life provid adult illustr intellectu socioeconom achiev marit life aim recogn diseas earli life possibl provid comprehens medic program includ aspect health care
704	pathophysiolog diseas involv intestin brushbord protein intestin brush border complex organel contain hydrolyt enzym receptor protein involv transport contractil protein articl review molecular organ brushbord protein within whole membran discuss synthesi turnov knowledg provid framework understand mechan certain diseas associ chang brushbord protein
705	abnorm biliari lipid composit cystic fibrosi effect pancreat enzym increas incid gallston cystic fibrosi compar biliari lipid composit 26 patient cystic fibrosi seven children cholelithiasi cysticfibrosi 13 control eighteen cystic fibrosi group cholecystogram one gallston 14 patient cystic fibrosi stop take pancreat enzym one week molar percentag lipid composit account cholesterol mean se 163 29 satur index 20 03 compar valu cholelithiasi group higher p less 001 control 12 patient cystic fibrosi take pancreat enzym molar percentag cholesterol 86 17 satur index 10 01 differ control cystic fibrosi preponder cholic chenodeoxychol acid 17 02 19 03 therapi compar cholelithiasi 07 01 control 08 00 group glycinetaurin ratio conjug bile acid lower enzymetr patient cystic fibrosi 37 06 patient treatment 64 10 higher p less 001 control 18 02 bile lithogen untreat cystic fibrosi respond pancreat enzym
706	ciliari dyskinesia factor cystic fibrosi asthma use modifi rabbit tracheal bioassay confirm serum individu bronchial asthma serum homozygot heterozygot cf caus ciliari dyskinesia wherea normal healthi control sera evalu specif ciliari dyskinesia activ cda detect bioassay serum eight patient bronchial asthma found eight asthmat sera caus ciliari dyskinesia reaction howev sera asthmat gener caus subsequ ciliostasi cessat ciliari beat concurr evalu sera cda bioassay cystic fibrosi protein cfp electrofocus show cdaposit sera except seven eight asthmat sera also posit cfp specif marker cf gene two find indic activ detect patient asthma respiratori diseas could substanc differ cfspecif cdf test hypothesi set purifi cda asthmat cf homozygot ohcf sera repres result clearli indic asthmat cda found deaeii sephadex g200 fraction ii wherea cda found cf ohcf sera elut deaei sephadex g200 fraction iii iv weak cda conclud cda asthma cf distinct substanc find may facilit purif feel cfspecif cdf cf ohcf serum purif prerequisit elucid exact natur substanc role pathophysiolog cf
707	intussuscept patient cystic fibrosi 16yearold boy cystic fibrosi intermitt episod abdomin pain probabl due recurr intussuscept type bowel obstruct probabl frequent patient fibrocyst diseas thick vascid inspiss fece appear caus intussuscept prevent inspiss may reduc incid obstruct treatment problem noncyst patient
708	degener fasciculu gracili cystic fibrosi spinal cord 19 percent patient die cystic fibrosi 5 year age show posterior column degener risk appear increas advanc age none patient find pernici anemia spinocerebellar degener lesion undetect clinic possibl nutrit toxic hereditari factor may play role produc lesion
709	cystic fibrosi nurs indispens member team health profession provid comprehens treatment need patient complex emot physic demand diseas cystic fibrosi comprehens medic manag health care team compos physician nurs social worker physic therapist nutritionist psychologist essenti patient cf form obstruct pulmonari diseas
710	nitrogen balanc trial cystic fibrosi patient preliminari nitrogen balanc trial carri six patient known pancreat insuffici investig utilis protein gener diet protein gener diet plu exogen pancreat extract predigest protein compris 85 dietari nitrogen intak absenc pancreat supplement case addit pancreat supplement gener diet improv protein digest utilis substitut 85 dietari protein enzym casein hydrolys result improv nitrogen balanc digest five patient urinari nitrogen level casein hydrolys diet tend lower account find acidhydrolys protein urinari nitrogen higher compar excret partial casein hydrolys provid smaller posit nitrogen balanc preliminari find indic patient pancreat insuffici partial hydrolys greater potenti nitrogen retent administr exogen pancreat extract intact protein suggest daili supplement predigest protein might advantag ch children ensur minimum protein requir met
711	region pediatr pulmonari center ohio acut chronic respiratori disord play larg role practition daili care infant children adolesc assist sophist problem diseas ohio committe pulmonari standard establish pediatr pulmonari care center distribut state ohio referr center may request practic physician illustr valid concept articl review care given patient cystic fibrosi cf improv prognosi diseas entiti advantag expertis central care
712	nasal polypectomi sinu surgeri cystic fibrosisa 10 year review patient cystic fibrosi like develop nasal polyp pansinus present concern result variou surgic procedur use treat nasal polyposi cystic fibrosi present recurr nasal polyposi still major problem follow surgeri literatur deal specif comparison differ surgic procedur aim control nasal obstruct surgic manag sinu diseas cystic fibrosi patient perhap lack reflect unsatisfactori result would report sinc high recurr rate expect also prolong surviv children mean reach adolesc adulthood increas risk nasal obstruct nasal polyposi
713	otorhinolaryngolog complic cystic fibrosi inasmuch cystic fibrosi gener exocrinopathi affect mucou gland bodi complic diseas involv ear nose throat obvious protean present includ discuss chronic ear infect rel diagnosi cystic fibrosi discuss nasal polyp treatment salivari gland involv cystic fibrosi result sialographi effect respiratori therapi upon upper respiratori tract problem gener anesthesia patient undergo surgic procedur also discuss ct 1 myer cm pediatr 72 766 983 2 todd nw int j pediatr otorhinolaryngo 10 27 985 3 david tj j roy soc med 79 23 986
714	critic evalu bronchial hygien pediatr pulmonari diseas variabl inher analyz effect modal use achiev bronchial hygien numer treatment may given varieti set includ intensivecar unit pediatr ward respiratiori therapi depart physic therapi depart chroniccar hospit special educ center patient home treatment administ varieti medic profession alli health personnel lay volunt motiv care provid well patient may vari greatli also effort need studi patient compar stage growth develop progress particular diseas rather perpetu unquest use variou treatment seri car construct control studi done collabor fashion need perform time recommend outlin deal variou segment bronchial hygien may serv use guidelin
715	cystic fibrosi involv home treatment program children adolesc young adult cystic fibrosi one frequent seriou chronic diseas childhood adolesc common genet diseas among caucasian children medic research home treatment program greatli improv outlook children nurs profess play signific role progress home hospit school commun goal teach treatment may help maintain health children long possibl face help famili lead normal life possibl
716	relationship chest radiograph score respiratori function test children cystic fibrosi chest radiograph score respiratori function 80 set result 50 patient cystic fibrosi analyz chest radiograph score assess independ use method chrispin norman respiratori function test found correl well chest radiograph score best correl forc expiratori volum 075 sec forc vital capac ratio fev 075 fvc r 0674 n 80 p less 0001
717	enhanc udpgalactoseglycoprotein galactosyl transferas activ cultiv skin fibroblast patient cystic fibrosi possibl relationship pathogenesi diseas homogen cultiv skin fibroblast deriv patient cystic fibrosi higher level udpgalactoseovalbumin galactosyl transferas activ compar fibroblast deriv control subject activ control subject 182 043 nmol galactos transferredhrmg protein wherea activ fibroblast patient 295 077 differ signific p less 001 activ fibroblast oblig heterozygot 215 060 differ activ fibroblast heterozygot patient signific p less 005 activ control fibroblast could enhanc basic polypeptid like polylysin polyarginin histon protamin neutral acid polypeptid fibroblast patient releas significantli higher amount solubl form enzym activ cultur medium control fibroblast
718	studi cystic fibrosi use isoelectr focus iii correl cystic fibrosi protein ciliari dyskinesia activ serum shown modifi rabbit tracheal bioassay develop modifi rabbit tracheal bioassay use investig possibl correl cystic fibrosi protein cfp ciliari dyskinesia factor cdf human serum bioassay requir high standard tissu select epitheli tissu must free underli connect tissu serum sampl collect process care warm 37 degre assay cdf could reliabl detect 31 31 sera cystic fibrosi cf homozygot oblig heterozygot 35 min less without prior fraction concentr sera wherea 13 14 normal control sera nonreact cdfposit serum react three consecut phase 1 initi increas ciliari beat frequenc 2 ciliari dyskinesia 3 tissu destruct extrus singl ciliat cell mucu debri result confirm associ cdf cystic fibrosi bioassay specif cf howev whole sera bioassay sinc serum sever patient bronchial asthma also caus ciliari dyskinesia howev find need preclud use rabbit tracheal ciliat epitheli tissu assay follow purif cdf isoelectr focus show presenc absenc cfp correspond dyskinesia activ sera test except activ sampl seven asthma patient neg cfp result indic cfp cdf may ident close relat marker cf gene suggest activ detect rabbit tracheal bioassay sera patient asthma diseas probabl caus substanc differ cf specif cdf
719	addit note use analyt isoelectr focus detect cystic fibrosi protein serum letter previou commun written respons letter smith et al suggest sever possibl reason inabl thoma et al investig detect cystic fibrosi protein cfp use electrofocus techniqu thoma cowork commun us purpos determin possibl reason inabl detect cfp electrofocus key point made convers reiter firm attempt allevi futur problem inexperienc investig attempt use analyt electrofocus detect cfp commun thoma cowork learn despit suggest analyz sampl screen either use equip awdeh et al employ standard procedur unknown whether exercis requir serum sampl collect process storag feel reason suffici explain report failur thoma et al reproduc result detect consist cfp sera individu cf gene
720	electrophoret analysi serum protein cystic fibrosi letter attempt reproduc isoelectr focus thin layer polyacrylamid gel iefag method specifi wilson et al laboratori sinc resolut obtain procedur appear inadequ identifi singl protein band relev region incorpor sever methodolog improv isoelectr focus techniqu improv significantli enhanc resolut thu enabl us demonstr greater degre heterogen serum gammaglobulin visibl paper wilson et al despit signific increas number band resolv method differ among cf heterozygot control sera ph 84 85 region could detect addit twostep iefagdisc electrophoresi techniqu altland et al test laboratori also modifi analyt procedur enabl fraction sever small protein portion igg fraction despit improv resolut reveal heterogen uniqu protein observ consist cf heterozygot area
721	biolog activ cystic fibrosi serum effect cystic fibrosi sera calcium ionophor 23187 rabbit tracheal explant ionophor a23187induc increas membran permeabl calcium ion cultur medium produc rabbit tracheal mucociliari respons indistinguish caus cystic fibrosi cf sera three differ occas specif chelat calcium ion egta basal medium eagl bme media addit nativ cf sera abolish mucociliari disturb case increas membran permeabl calcium may import product mucociliari respons cf serum factor tracheal assay system
722	chronic reserpin rat possibl model cystic fibrosi vi synergist effect isoproterenol ca protein submaxillari gland elev calcium protein concentr consist abnorm submaxillari saliva patient cystic fibrosi cf experiment anim model develop chronic administr either isoproterenol ipr reserpin possibl effect two drug may addit investig assess combin effect glandular salivari c protein rat submaxillari gland individu effect also assess relat dose use result indic 1 treatment 7 day 005 050 50 mgkg daili dose reserpin caus respect 45 95 120 increas glandular ca 93 165 374 increas glandular protein 2 treatment 7 day 50 mgkg daili dose isoproterenol caus 138 increas gland ca 1238 increas gland protein treatment 50 mgrat daili dose drug caus increas 166 103 gland ca protein 3 experi involv combin two drug isoproterenol administ 50 mgkg daili dose day 17 reserpin 05 mgkg daili dose day 410 treatment schedul procedur result 217 increas gland ca 257 increas gland protein b mark accumul granular basophil materi acinar cell develop intraduct precipit c secret turbid saliva high ca protein concentr secretori dose isoproterenol type stimul also reduc gland ca 50 protein 20 content produc vacuol acinar cell secret saliva elev ca protein respons pilocarpin elev concentr howev onefifth obtain isoproterenol stimul e secret smaller volum saliva type stimul find indic ipr reserpin doserel signific effect submaxillari gland ca protein individu effect synergist implic synerg physiolog state submaxillari gland secretori abnorm cystic fibrosi discuss
723	ornithin decarboxylas sadenosyl methionin decarboxylas skin fibroblast normal cystic fibrosi patient key enzym synthesi natur occur polyamin ornithin decarboxylas odc sadenosyl methionin sam decarboxylas investig cell growth age fibroblast cultur normal patient patient cystic fibrosi linear correl increas sadenosyl methionin activ putrescin concentr appar cell line putrescin concentr 08 mm optim enhanc sam decarboxylas activ passag number cell line correl invers maxim putrescinestimul sam decarboxylas activ earlier passag number highest specif activ fig 1 signific differ basal putrescinestimul sam decarboxylas activ note normal fibroblast cultur cell patient cystic fibrosi fig 2 sam decarboxylas activ increas cell line approach confluenc activ lowest exponenti growth fig 3 odc activ increas earli exponenti growth fell cell reach confluenc fig 4 differ odc activ putrescin inhibit normal cystic fibrosi cell cultur equival point exponenti growth note
724	improv method detect cystic fibrosi protein serum use lkb multiphor electrofocus apparatu develop improv method detect cystic fibrosi protein cfp method employ lkb multiphor electrofocu whole serum instead apparatu use previou studi two basic modif necessari 1 ph 25100 gradient instead ph 510 gradient 2 constant power focus serum protein instead constant voltag first modif ensur adequ dissolut cfpigg complex precursor complex may liber cfp second modif ensur linear gradient ph 38 ph 92 excel resolut ph 89 region separ cfp within 2 hr without overh gel electrofocus lkb multiphor permit detect cfp mani 24 serum sampl per gel result obtain analysi 31 cystic fibrosi 28 oblig heterozygot carrier 28 normal control sera indic cfp reproduc accur detect sera use lkb multiphor
725	pulmonari clearanc staphylococcu aureu mutant mice hereditari alter resembl cystic fibrosi pulmonari clearanc staphylococcu aureu examin two inbr strain mice hereditari alter resembl cystic fibrosi cf mice mice abnorm electrolyt metabol dbajcri mice spontan pneumon c57bl6jbg mice without cflike alter balbc method use produc pulmonari infect essenti laurenzi associ adapt need mutant mice anim mention expos fine divid aerosol suspens coagulaseposit strain aureu phosphat buffer immedi exposur half anim kill remain half kill 4 hr later experiment unit mice kill immedi exposur similar possibl mice kill 4 hr later respect genotyp age sex sibl unclear bacteria ubr 4 hr 020 mice without cflike alter balbc c57bl6jbg bgbg genotyp 028 c57bl6jbg genotyp 050 dba2jcri genotyp 056 cricri mice number viabl staphylococci found immedi aerosol exposur co c57bl6jbg strain significantli lower co balbc p 005 dba2jcri strain p 001 latter two differ sex differ respect ubr co data dba2jcri strain mice cri mutat first appear decreas capac clearanc aureu lung togeth cflike alter cri mutat name failur reabsorpt na parotid duct high level na fur cf abnorm serum factor activ serum cricri mice suggest cribriform degener mous mutant may provid potenti anim model studi cf find mous mutat electrolyt alter cflike abnorm serum activ simialr activ found cf children inbr strain mice decreas bacteri clearanc lung make mice use cf studi
726	electrophoret analysi serum protein cystic fibrosi studi util isoelectr focus electrophoresi attempt detect cystic fibrosi cf serum factor consider indirect evid method isoelectr focus polyacrylamid gel iefag specifi wilson et al 53 reproduc laboratori enabl detect cf factor protein report focu near ph 8485 consequ employ modifi iefag techniqu enabl us demonstr significantli enhanc resolut strike heterogen serum gammglobulin despit signific increas number band resolv method neither differ ph 8485 differ throughout alkalin ph rang could detect consist cf heterozyg sera twostep iefagdisc electrophoresi techniqu outlin altland et al 2 reproduc laboratori indic least one small cation protein could fraction serum sampl improv method disc electrophoresi result observ numer band sampl differ among sampl protein band uniqu cf genotyp observ approach employ differ electrophoresi techniqu vari condit sampl analysi increas likelihood detect protein protein specif cf genotyp despit mani variat approach consist uniqu protein observ cf heterozyg sera cf serum factor cannot readili demonstr electrophoret techniqu describ valu biophys assay nonbiolog techniqu report literatur suspect promis applic techniqu diagnost test cf gene care evalu
727	arginin esteras lysosom hydrolas liver cystic fibrosi subject total activ isoelectr focus pattern arginin esteras cathepsin b1 sever lysosom hydrolas normal liver two patient cystic fibrosi abnorm observ valu ph optimum km vmax arginin esteras cathepsin b1 liver cystic fibrosi patient compar valu liver control subject soybean trypsin inhibitor concentr 100 microgramml effect liver arginin esteras cathepsin b1
728	separ serum ciliari dyskinesia substanc cystic fibrosi subject purifi serum immunoglobulin g igg deriv eight cystic fibrosi cf five carrier subject shown respons mucociliari disturb note rabbit tracheal bioassay small molecular substanc less 10000 greater 1000 dalton amicon filtrat found associ gammaglobulin fraction isol sera cystic patient parent separ pm10 ultrafiltr small substanc unabl promot ciliari dyskinesia respons eight eight cf five five cf carrier individu unless pool purifi human igg ad addit iggrich fraction retain pm10 ultrafiltr still abl promot ciliari dyskinesia respons bioassay event note earlier work whole serum size small serum substanc associ igg close correspond describ oyster test system well produc cultur cell deriv homozygot heteroxygot genet disord persist abil promot mucociliari disturb iggrich retent pm10 fraction may indic ineffect molecular separ amicon ultransfiltr apparatu may repres anoth cfrelat iggassoci substanc influenc ultrafiltr specul genet disturb cf explain presenc molecul affin igg turn give rise variou physiolog facet disord molecul present cf defici enzym normal control level inactiv
729	studi cystic fibrosi use isoelectr focus iv distinct ciliari dyskinesia activ cystic fibrosi asthmat sera associ cystic fibrosi protein activ cystic fibrosi serum cystic fibrosi protein cfp ciliari dyskinesia activ cda sera cf homozygot heterozygot carrier individu bronchial asthma partial purifi concurr cda sera patient cystic fibrosi cf bronchial asthma shown differ substanc ion exchang gel permeat chromatograph procedur sephadex g200 chromatographi indic cfcda elut protein fraction molecular weight mw 68000150000 asthma cda found protein fraction mv greater 150000 two activ could also separ deaecellulos chromatographi prior acidif whole normal cf homozygot oblig heterozygot asthmat sera ph 37 use edta follow fraction sephadex g200 remov cda fraction highermolecular weight shift activ protein fraction mw 110013700 procedur afford 200fold purif cda sera patient asthma cf edta treatment howev also gener cda previous nonreact normal sera subsequ fraction variou activ g200 fraction biogel p10 allow separ three separ activ biogel fraction iiiv v fraction shown repres activ sera patient asthma determin c3a mw 9000 fraction also found normal cf carrier sera therefor specif cda fraction iiiv thought repres cfspecif cda mw 5000 sinc could demonstr either normal asthmat sera found sera oblig heterozygot fraction iiiiv also react antisera human c3a fraction v gener serum type upon acidif serum edta thought nonspecif cda biogel p10 filtrat sephadex g200 fraction provid 823fold 650 fold purif asthmat cf cda respect concurr analysi column fraction cda bioassay cfp electrofocus show cfp fraction contain cfcda combin analys employ acid disc gel electrophoresi isoelectr focus edta treatment activ cfimmunoglobulin ig g sephadex g200 column fraction follow biogel p10 chromatographi provid evid cfp associ cfcda unknown yet whether cfp respons cfcda activ
730	electron microscop cytochem studi concanavalin bind site mobil normal cystic fibrosi fibroblast vitro concanavalin con bind site visual ultrastructur cultur fibroblast cystic fibrosi patient obligatori heterozygot normal individu peroxidas label techniqu con bind site local continu layer extern side plasma membran fix fibroblast three genotyp live cell con induc later vertic movement bind site express cap format intern plasma membran fibroblast three genotyp respond similarli con treatment fail show signific detect differ
731	blood volum chang patient cystic fibrosi simultan red blood cell rbc plasma volum determin obtain 16 patient cystic fibrosi cf moder sever pulmonari involv hypervolemia increas rbc plasma volum observ chang blood volum mark valu index weight less signific index height decreas system arteri oxygen satur associ progress increas rbc mass hematocrit valu hemoglobin level decreas mean corpuscular hemoglobin concentr rbc total blood volum highest patient cor pulmonal congest heart failur howev compensatori polycythem respons patient cf inadequ compar respons hypoxemia patient cyanot congenit heart diseas insuffici oxygencarri capac may compromis tissu oxygen deliveri necessit treatment
732	roentgenograph visibl fatti liver cystic fibrosi initi roentgenogram 178 consecut newli diagnos patient cystic fibrosi seen past five year review determin presenc fatti liver seven case visibl fatti liver identifi incid visibl fatti liver initi roentgenogram newli diagnos case cystic fibrosi 4 caus fatti infiltr liver cystic fibrosi clear howev basi like nutrit defici protein
733	amikacin therapi exacerb pseudomona aeruginosa infect patient cystic fibrosi amikacin new semisynthet aminoglycosid antibiot activ pseudomona aeruginosa use treat 22 acut exacerb chronic pulmonari infect 18 patient cystic fibrosi patient rang 5 32 year age mucoid p aeruginosa isol sputum amikacin dose usual 75 mgkg everi eight hour increas 10 mgkg andor carbenicillin ad select case depend clinic cours although p aeruginosa elimin patient sputum except two case good clinic respons 19 22 cours signific improv chest xray film spirometri arteri oxygen tension document 11 17 cours one instanc serum creatinin level elev could attribut antibiot two patient show minim 15 db unilater highfrequ hear loss serial audiogram activ mani gentamicinresist strain high blood level among attract properti amikacin amikacin clinic effect treat pseudomonasassoci pulmonari infect complic cystic fibrosi
734	effect graviti tracheal mucu transport rate normal subject patient cystic fibrosi noninvas radionuclid imag techniqu measur rate mucu clearanc trachea rt use studi gravit effect mucu clearanc 13 patient cystic fibrosi cf averag age 17 year 7 normal nonsmok adult averag age 26 year normal subject recov acut upper respiratori tract infect urti upright posit nine cf patient subject urti demonstr abnorm tracheal mucu clearanc approach normal place 25 degre headdown posit normal subject two cf patient show signific differ rt measur two posit result studi indic forc graviti major influenc tracheal mucu clearanc cf urti subject conclus support use postur drainag effect form therapi patient cystic fibrosi
735	mucos enterokinas activ pancreat insuffici celiac diseas jejun biopsi specimen obtain children cystic fibrosi cf celiac diseas cd congenit exocrin pancreat hypoplasia ceph control subject section examin histolog homogen use measur enterokinas sucras activ work undertaken enterokinas consid brush border enzym releas intestin lumen influenc pancreat enzym also recent shown small bowel mucos dysfunct patient cf expect sucras activ reduc p 05 children cd compar three group hand enterokinas activ children pancreat insuffici cf ceph higher p 05 control subject present studi shown patient cf ceph mucos enterokinas activ increas compar control subject seem pancreat enzym play larg role turnov enzym brush border membran observ increas mucos enterokinas activ probabl explain reduc degrad patient exocrin pancreat insuffici
736	cystic fibrosi present anemia hypoproteinemia ident twin cystic fibrosi pancrea recess inherit disord gener consid result chronic pulmonari digest symptom therefor may readili appreci diseas also present anemia edema hypoproteinemia especi infant take breast milk soybas formula follow exampl involv monozygot twin given cow milk formula sinc birth serv illustr associ
737	hemoglobinoxygen equilibrium cystic fibrosi studi 35 patient cystic fibrosi demonstr increas sever pulmonari involv associ mild definit increas erythrocyt 23diphosphoglycer 23 dpg decreas hemoglobin affin oxygen predomin regul 23dpg blood ph cardiac output system oxygen transport signific relationship observ erythrocyt 23dpg content arteri oxygen tension hypophosphatemia may prevent greater increas erythrocyt 23dpg content inadequ increas 23dpg consequ insuffici chang hemoglobinoxygen affin coupl insuffici compensatori erythrocyt respons may advers affect tissu oxygen patient sever cystic fibrosi
738	dietari essenti fatti acid cystic fibrosi analys serum lipid children cystic fibrosi cf indic defici essenti fatti acid efa view report intraven administr soybean oil emuls normal sweat sodium valu cf children studi effect oral administ essenti fatti acid corn oil one year improv note patient one consist factor predomin howev arachidon acid found trace amount absent sera children cf clinic trial increas significantli sera oral administr efa one year find includ signific decreas sweat sodium t3 patient
739	orchiti cystic fibrosi letter wish report case j j 1712yearold white boy known cystic fibrosi sinc earli infanc develop acut left orchiti epididym may 1975 review past literatur current read unabl find report case acut orchiti andor epididym patient cystic fibrosi offer case report invit comment
740	children cystic fibrosi psycholog test find patient sibl parent psycholog evalu 43 famili child cystic fibrosi report person test parent show 32 father 22 mother obtain score rang suggest emot disturb familyconcept sort assess famili interact indic primari effect child cystic fibrosi term decreas famili satisfact famili adjust result support previou estim increas incid emot disturb children cystic fibrosi evid neg psycholog impact chronic ill sibl develop also lack futur research would benefit focu strength resili children cystic fibrosi famili
741	pulmonari diseas children respiratori infect infant children caus much illhealth also appreci mortal found time schoolchildren infant especi larg famili live poor circumst respiratori infect whole respiratori tract involv descript purpos use divid infect upper respiratorytract infect infect predominantli larynx lower respiratorytract infect predomin infect larynx acut upper respiratorytract infect usual viral polyviru infect coryza commonest acut lower respiratorytract infect discuss two group infant two year age children two includ cystic fibrosi
742	anorexia nervosaa difficult diagnosi boy illustr three case three patient describ seen recent royal hospit sick children edinburgh present diagnost problem three case present difficult establish true diagnosi first case symptom compat diagnost criteria beumont colleagu directli result slowgrow cerebr neoplasm elus diagnos second patient boy cystic fibrosi show symptom strongli suggest anorexia nervosa respond dietari measur without pancreat enzym replac unabl demonstr organ diseas third case henc presumpt diagnosi anorexia nervosa made remain said condit extrem rare boy anorexia weight loss warrant extrem thorough investig
743	manifest cystic fibrosi diagnosi cystic fibrosi usual establish presenc chronic obstruct lung diseas andor gastrointestin compromis togeth elev sweat electrolyt patholog chang tissu highli variabl genet penetr diseas character vari degre involv differ exocrin system
744	cystic fibrosi cystic fibrosi regard diseas infant yet improv manag high percentag patient surviv young adulthood addit mild case may detect long infanc older patient often minim symptom major social activ product
745	increas dexamethason resist cystic fibrosi fibroblast demonstr previous fibroblast cystic fibrosi cf patient significantli resist toxic effect ouabain normal human fibroblast ouabain gener assum act primarili level cell membran caus kill cell inhibit ion transport therefor examin abil normal cf cell surviv exposur ethacryn acid anoth inhibitor ion transport surviv colchicin aminopterin resist associ membran alter cell effect dexamethason sterol nucleu similar ouabain thought differ site cellular action also test exposur cell ethacryn acid colchicin aminopterin reveal differ surviv normal cf fibroblast howev cf cell surviv exposur dexamethason significantli better normal cell result suggest normal cf cell differ term gener resist ion transport inhibitor drug must pass membran activ instead result rais possibl cf cell enhanc resist drug sterol nucleu found ouabain dexamethason
746	increas resist cystic fibrosi fibroblast ouabain toxic diploid skin fibroblast deriv sever unrel patient cystic fibrosi cf test resist cytotox effect ouabain comparison cell normal individu cell cf normal individu plate low densiti expos ouabain differ concentr 24 hr dose respons curv show cf cell surviv significantli better normal cell ouabain concentr 01 nm 1 micronm potassiumdefici medium medium contain usual amount potassium 625 mm surviv cf cell expos ouabain decreas normal cell glucos concentr potassiumdefici medium decreas 10 usual amount resist cf cell ouabain disappear surviv ident normal cell find may use understand biochem basi cg clinic manifest
747	nutrit immun cystic fibrosi much attent focus antibiot therapi cystic fibrosi therebi overshadow measur led improv prognosi may well true doubt regular intens physiotherapi perform daili patient rel play major part improv airway obstruct skil nutrit manag includ adequ pancreat replac therapi highenergi highprotein diet also benefici effect respiratori defect infect cf patient may requir high dose antibiot might benefit simpl nutrit alter new suggest nutrit factor import influenc resist infect cf patient measur differ aspect immun respons patient malnutrit simplest direct therapi chosen
748	caus delay respiratori distress infanc mani caus respiratori distress stare one week birth infant transient minor respiratori problem immedi birth may divid two broad group primari pulmonari patholog extrapulmonari patholog secondari effect lung expans former categori includ wilsonmik syndrom chylothorax congenit pulmonari lymphangiectasia congenit lobar emphysema cystic fibrosi hystiocytosi x acut infect second group includ congenit heart diseas foregut duplic tracheooesophag fistula diaphragmat hernia asphyxi thorac dysplasia
749	antibodi respons enterobacteri lipoprotein patient vari infect due enterobacteriacea present studi initi determin antibodi respons lipoprotein patient variou enterobacteri infect investig also consid import patient infect respond differ anoth antigen common enterobacteriacea common enterobacteri antigen includ 33 patient cystic fibrosi complic enterobacteri respiratori tract infect lipoprotein lp antibodi level healthi subject patient vari enterobacteri infect determin none healthi children one healthi adult antibodi lp contrast 18 children periton complic append 24 patient enterobacteri infect respiratori tract complic cystic fibrosi 42 adult subject bacteremia complic malign lp antibodi serum reason strike differ immun respons common antigen remain elucid
750	unusu radiograph manifest cystic fibrosi author report 2 radiograph find previous describ patient cystic fibrosi 1 linear form pneumatosi coli 2 larg pancreat concret resembl pancreat calcificaiton hereditari pancreat patient pancreat calcif also labil diabet episod ketoacidosi unusu complic cystic fibrosi
751	histolog nasal polyp differ etiolog aim present studi elucid correl etiolog histolog nasal polyp special regard cystic fibrosi cf nasal polyp 15 children cf control group noncf polyp 15 adult patient examin light microscopi histolog evalu carri blind basi order avoid bia among paramet use tissu eosinophilia prove valuabl factor differenti cf noncf polyp eosinophil found cfpolyp polyp gland gener patholog characterist abnorm grandular morpholog appar common cf polyp conclud histolog examin nasal polyp import correct classif patient diagnosi cf cannot made base microscopi polyp studi includ blind histolog examin nasal polyp tissu might contribut differenti diagnos nasal polyposi
752	lateonset intestin obstruct cystic fibrosismeconium ileu equival
753	collect sweat patient cystic fibrosi letter dr soldin describ method collect sweat diagnosi cystic fibrosi involv place patient electr blanket wrap warmli 2 5 hour profus sweat occur 30 minut one import omiss titl abstract mention safeti children cystic fibrosi may develop heat prostrat expos high temperatur may caus massiv sodium chlorid loss via sweat could occur method describ apparatu describ gibson cook classic pilocarpin iontophoresi method collect sweat neither overli sophist expens remain method choic although attent detail import
754	role screen prevent inherit diseas south africa possibl screen presenc carrier state number inherit diseas screen alert one need antenat diagnosi feasibl ensur earli treatment given affect infant assist carrier reach decis children facil certain type screen alreadi exist centr south africa new techniqu introduc futur
755	manag meconium ileu resect endtoend anastomosi six patient meconium ileu bowel resect endto end anastomosi perform present meconium ileu may simpl complic simpl form may treat gastrografin enema surgeri indic conserv treatment fail patient complic obstruct provid bowel disobstruct care resect endtoend anastomosi prefer confirm diagnosi care histolog examin resect bowel urg
756	cystic fibrosi cystic fibrosi cf seriou genet disord occur mainli among white start earli childhood even birth name shorten old term cystic fibrosi fibrocyst diseas pancrea come histor appear postmortem first describ landstein 1905 1938 dorothe anderson fanconi realis diseas separ entiti simpli manifest ill anoth name mucoviscidosi give clue one import featur diseas mucu form thicker stickier viscid normal tend clog bronchi duct particularli pancreat duct chronic bronchiti recurr sever infect malabsorpt main symptom diseas import abnorm increas amount sodium chlorid salt sweat fact use diagnosi first realis heat wave new york 1953 notic children heat prostrat suffer cf littl known caus abnorm sweat mucu generalis cell abnorm enzymat seem possibl doubt condit genet transmit evid favour recess mode inherit
757	human amylas isoenzym purpos investig elucid variat isoenzym human amylas health diseas well physicochem differ individu isoamylas cystic fibrosi determin serum isoamylas valu although absenc pancreat serum isoamylas normal find first year life demonstr pancreat serum isoamylas earli life argu diagnosi one year age test posit diagnost valu
758	pseudomona aeruginosa infect cystic fibrosi diagnost prognost signific pseudomona aeruginosa precipitin determin mean cross immunoelectrophoresi total 133 patient cystic fibrosi follow 5 year monthli examin includ bacteriolog examin sputum sera patient examin mean cross immunoelectrophoresi occur number precipit antibodi specificit pseudomona aeruginosa poor prognosi cystic fibrosi associ chronic colon 9 month 5 year respiratori tract mucoid pseudomona aeruginosa onset chronic colon puberti among patient chronic pseudomona aeruginosa colon poor prognosi associ high number precipitin antigen bacteria 61 number pseudomona aeruginosa precipitin increas averag five per year chronic colon patient rapidli increas number precipitin associ poor prognosi patient degre impair ventilatori function chang chest radiograph could contract chronic pseudomona aeruginosa colon poor ventilatori function sever chang chest radiograph associ high number pseudomona aeruginosa precipitin poor prognosi although mani group pseudomona aeruginosa found chronic colon group patient 53 patient harbour strain belong group 3 39 highest number precipitin found serum patient
759	particip hageman factor depend pathway human diseas state abnorm hageman factor depend pathway describ wide varieti human diseas state congenit defici factor xii hageman trait prekallikrein fletcher trait high molecular weight kininogen william fitzgerald flaujeac trait although result profound vitro chang caus vivo difficulti contrast defici c1 esteras inhibitor hereditari angioedema result signific morbid mortal acquir diseas may exhibit decreas synthesi three protein cirrhosi dengu fever vivo activ factor xii initi pathway occur septic shock dissemin local intravascular coagul typhoid fever polycythemia vera hyperbetalipoproteinemia coronari arteri diseas nephrot syndrom transfus reaction hemodialysi extracorpor bypass activ intrins system tissu mediat contribut vasomotor phenomena carcinoid syndrom postgastrectomi dump role factor xii prekallikrein kininogen suggest gouti arthriti allerg disord cystic fibrosi evid yet convinc disord
760	hla frequenc patient cystic fibrosi thirtythre patient cystic fibrosi hla type rel risk valu phenotyp frequenc calcul statist signific differ hla antigen distribut found among patient cystic fibrosi
761	cystic fibrosi infant present metabol alkalosi recent opportun studi fourmonthold boy failur thrive hypochlorem metabol alkalosi high serum aldosteron valu found cystic fibrosi children cystic fibrosi moder elev plasma renin secondarili elev serum aldosteron valu due chronic sodium chlorid loss sweat patient high serum aldosteron valu associ slightli elev serum cortisol valu high serum aldosteron valu increas despit correct condit stimul aldosteron secret suggest longstand salt deplet caus abnorm reninaldosteron system
762	reactiv neuroaxon dystrophi children clinic patholog correl aim present studi determin frequenc etiolo factor neuroaxon dystrophi nd brainstem spinal cord children variou nonneurolog diseas materi use studi consist 266 consecut autopsi 19741976 addit 13 case previou year far common caus nd children chemotherapeut drug particularli vincristin use treatment malign tumor approxim 90 children develop nd chang rang mild sever approxim twothird children cystic fibrosi congest heart failur chronic renal failur develop nd chang mostli mild onethird patient congenit biliari atresia malnutrit develop nd chang alway mild frequenc sever nd increas patient prolong clinic cours nd seen patient die acut case trauma acut infect intox acut renal failur prematur type nd may consid reactiv wide varieti injuri factor drug toxic malnutrit chronic hypoxia chronic renal failur either alon combin contrast previou report low incid nd children sharp increas recent year due advent chemotherapi
763	rel underweight cystic fibrosi prognost valu basi observ 117 children cystic fibrosi seen januari 1956 june 1976 demonstr rel underweight weight loss correct height pronounc children predominantli pulmonari sypmtom degre underweight close correl invers surviv prognost valu recommend clinic paramet includ checkup period carri children suffer cystic fibrosi
764	hypergammaglobulinem purpura cystic fibrosi four patient present age 14 20 year cystic fibrosi recurr purpura leg polyclon increas ig intermedi complex demonstr ultracentrifug 4 patient differ patient cystic fibrosi rapid deterior clinic condit establish perman pulmonari infect also prone haemophilu influenza infect clinic laboratori find compat diagnosi waldenstrom hypergammaglobulinem purpura heterogen syndrom discuss
765	electrolyt nail analys xray microanalysi electron microscopi consider new method diagnosi cystic fibrosi patient cystic fibrosi cf increas concentr sodium nail hitherto neutron activ analysi consid diagnosi cystic fibrosi analysi electrolyt nail thoroughli test methodolog clinic howev intrins advantag xray microanalysi result obtain studi suggest method test may use diagnost acid cystic fibrosi comparison neutron activ analysi xray microanalysi advantag simultan give concentr sever element may access hospit electron microscop fit necessari equip nail cfpatient shown increas concentr na k cl make diagnosi cystic fibrosi reliabl possibl use sulphur refer element may elimin weigh procedur necessari neutron activ analysi
766	reliabl diagnosi major type cystic fibrosi fibroblast cultur doubl blind studi doubl blind studi carri demonstr common type cystic fibrosi cf reliabl diagnos skinderiv fibroblast cultur alkalin phosphatas aip activ measur 6 normal control 12 cfheterozygot 6 cfhomozygot stimul tammhorsfal glycoprotein thp isoproterenol theophylin thpinduct test mean aipact thpinduct 88 127 346 three differ genotyp respect overlap valu cfhomozygot one hand valu cfheterozygot normal control hand 24 specimen correctli diagnos present doubl blind studi indic high degre reliabl thp induct test detect predomin type cystic fibrosi fibroblast cultur normal control cf heterozygot could discrimin individu basi group cfheterozygot display higher aipvalu
767	increas intracrani pressur cystic fibrosi three cystic fibrosi infant sever respiratori distress increas intracrani pressur bulg fontanel clear parri passu improv chest condit propos intracrani hypertens result rais venou pressur secondari intrathorac obstruct venou return consequ bronchial obstruct diseas
768	cystic fibrosi pancrea human fetu postmortem examin 26 week old postmenstru human fetu deliv cesarean section reveal meconium ileu mani swollen mucussecret cell gastrointestin mucosa pancrea show extens fibrosi acinar destruct dilat duct contain eosinophil cast mucou gland lung also reveal mucou cell swollen distend secretori product patient believ cystic fibrosi pancrea suggest patholog manifest diseas may begin earli fetal life
769	sulphat bloodgroup substanc pancrea factor cystic fibrosi present studi show pancrea two monkey speci contain sulphat bloodgroup substanc strongli anion molecul known bind calcium solut form gel presenc cation suggest mechan may involv cystic fibrosi
770	immun complex sputum patient cystic fibrosi suffer chronic pseudomona aeruginosa lung infect 12 cystic fibrosi cf patient chronic infect mucoid p aeruginosa present multipl precipitin serum bacterium 12 patient without p aeruginosa infect examin occurr solubl immun complex sputum sol phase complement consumpt assay solid phase rheumatoid factor bind assay correl result obtain two assay signific r 0625 p less 001 patient chronic infect p aeruginosa show significantli p less 001 higher frequenc immun complex activ sputum sol phase compar patient without p aeruginosa lung infect find point possibl chronic lung infect mucoid p aeruginosa cf may immun complex diseas
771	pancreat function diseas infanc childhood normal develop pancrea great import neonat infant review evalu develop exocrin pancreat function hormon control function interrelationship pancreat enzym pancreat adapt food function chang occur differ diseas process pancrea affect infant also discuss sinc treatment pancreat exocrin insuffici oral administ pancreat enzym children often difficult expect practic approach enzym treatment discuss morpholog develop congenit malform pancrea tumor pancrea normal function exocrin pancrea develop exocrin pancreat function development aspect amylas activ starch digest dietari adapt exocrin pancrea pancreat function test pancreat insuffici cystic fibrosi shwachman syndrom isol pancreat enzym defici treatment exocrin pancreat insuffici pancreat childhood treatment acut pancreat discuss
772	total bodi opacif total bodi opacif phenomenon wherebi introduct iodin contrast materi blood stream render structur differenti radiopaqu accord blood suppli term impli physiolog whole bodi opacifi proport iodin plasma extravascular extracellular fluid time radiograph densiti inher tissu inject ad opac iodin circul transud tissu even water densiti minor intrins differ xray absorpt may also minor differ blood flow transud extracellular fluid combin minor differ often make invis visibl
773	exocrin disord asthmat demonstr high sweat chlorid level chronic patient rel 87 patient svere chronic asthma sweat chlorid cl level determin increas concentr found 12 137 76 rel patient increas sweat cl level also found author give data clinic allergi studi conclud 137 patient investig clinic characterist asthma allergi function exocrin disord exocrinopathi may import factor pathophysiolog certain type asthma
774	zinc statu vitamin transport cystic fibrosi zinc statu retinol transport system examin 18 retinol supplement cystic fibrosi cf patient 40 agematch control plasma vitamin significantli lower cf group compar control correl posit plasma retinolbind protein rbp cf control group plasma zinc cf group significantli lower control wherea hair zinc plasma zinc posit correl plasma rbp vitamin albumin cf group control plasma concentr vitamin rbp albumin zinc decreas age cf group control data support previou suggest low plasma vitamin level cf due defect retinol transport system zinc statu cf group whole judg lownorm howev subgroup cf patient margin defici categori subgroup also lower level plasma vitamin rbp data suggest zinc may contribut factor low plasma vitamin arbp level cf patient margin defici zinc statu
775	modifi ionselect electrod method measur chlorid sweat modifi method analysi sweat chlorid concentr ionselect electrod present origin method sweat chlorid analysi propos orion research corpor cambridg massachusett 02139 inadequ produc errat mislead result modifi method compar refer quantit method gibson cook modifi method individu electrod pad cut place electrod rather use pad suppli compani pilocarpin nitrat 2000 mgl use place pilocarpin hcl 640 mgl sodium bicarbon weak electrolyt use instead k2so4 10minut period sweat accumul employ rather zerotim collect origin orion method modif studi reproduc individu reproduc right left arm individu compar extens quantit method gibson cook normal individu patient cystic fibrosi excel agreement modifi method quantit refer method appear slight bia toward higher concentr chlorid right arm compar left arm differ medic signific
776	cystic fibrosi present meconium plug syndrom meconium plug syndrom mp common caus low intestin obstruct newborn infant usual benign associ intestin dysfunct describ case three infant intestin obstruct consist mp cystic fibrosi cf later document suggest associ mp cf condit infant mp evalu possibl hirschsprung diseas cf
777	edema present symptom cystic fibrosi difficulti diagnosi hypoproteinemia edema may develop infant cystic fibrosi whatev diet although prior ingest soy bean formula appear predispos factor neg sweat chlorid test may present cf child hypoproteinem phase ill diagnosi cannot exclud neg test adequ secret sweat obtain edema hypoproteinemia resolv
778	meconium plug syndrom cystic fibrosi exocrin pancreat defici letter observ sever meconium plug syndrom mp newborn infant found neonat period extens exocrin pancreat defici cystic fibrosi exclud sever sweat chlorid test observ mp patient exocrin pancreat defici suggest mp observ cf patient report rosenstein probabl caus pancreat defici frequent occurr meconium ileu mi cf rariti mp cf curiou sinc may differ manifest patholog process conceiv mp may occur total absenc pancreat enzym patient patient cf low level enzym cf may limit express meconium ileu wish suggest evalu exocrin pancreat function patient even cf exclud sweat test conflict albeit fragmentari data suggest exocrin pancreat defici may sole caus meconium obstruct cf sever investig suggest mi may result abnorm protein mucoprotein secret intestin goblet cell lack pancreat enzym alon observ suggest exocrin pancreat defici may play major role instanc meconium obstruct import note may littl correl histolog appear pancrea exocrin function
779	meconium ileu equival case meconium ileu equival 30year old man present patholog therapi condit discuss
780	compar studi ticarcillin plu tobramycin versu carbenicillin plu gentamicin treatment seriou infect due gramneg bacilli combin ticarcillin plu tobramycin tt carbenicillin plu gentamicin cg use treat 82 patient sever system gramneg infect prospect random studi pseudomona aeruginosa primari pathogen 7 93 per cent patient patient treat tt respond frequent 92 per cent 37 40 patient treat cg 71 per cent 30 42 p less 005 differ primarili due greater respons tt patient pulmonari infect 93 per cent versu 68 per cent infect due pseudomona 92 per cent versu 70 per cent sever underli diseas also import determin respons except greater incid hepatotox cg 23 per cent versu 3 per cent p less 002 differ toxic colon drugresist microorgan superinfect two treatment group combin tt appear superior cg treatment pulmonari infect due pseudomona aeruginosa
781	fetal cystic fibrosi present dystocia due midgut volvulu lethal perfor fetal neonat volvulu rare event usual associ anatom defect massiv abdomin distens secondari ruptur unruptur volvulu never report caus obstruct labor present report document case secondari chemic periton result ruptur midgut volvulu case demonstr unusu present presum cystic fibrosi meconium ileu volvulu led ischem infarct perfor small bowel case likewis emphas need consid presenc fetal anomali omphalocel gastroschisi usual maneuv fail reliev shoulder dystocia
782	effect sputum patient cystic fibrosi activ vitro 5 antimicrobi drug pseudomona aeruginosa vitro test 12 strain pseudomona aeruginosa sputum patient cystic fibrosi sharpli increas minim bactericid concentr polymyxin b neomycin sputum lesser effect test gentamicin tobramycin essenti none test carbenicillin
783	relationship among digit club diseas sever serum prostaglandin f2alpha e concentr cystic fibrosi patient nine patient cystic fibrosi without digit club group match prospect sex approxim age 9 cystic fibrosi patient digit club group b 9 normal person control subject patient group b significantli p less 005 lower clinic score forc vital capac group indic sever pulmonari diseas former howev spiromet test pulmonari function reveal differ group b degre digit club signific p less 005 linear relationship forc vital capac r 073 clinic score r 0853 group b plasma concentr prostaglandin f2alpha e significantli increas p less 005 group x se 048 003 087 010 ng per ml respect group b x se 068 004 181 016 ng per ml respect compar control group x se 014 001 039 002 ng per ml respect group b significantli larger concentr group howev plasma concentr prostaglandin 15keto13 14 dihydro metabolit differ group b significantli smaller control group studi suggest degre digit club cystic fibrosi relat sever pulmonari involv prostaglandin system may play import role diseas
784	treatment prognosi massiv hemoptysi cystic fibrosi massiv hemoptysi volum expector blood 300 ml 24 hour occur 38 5 per cent 728 patient cystic fibrosi twentytwo patient midst rel longlast flareup pulmonari infect consist precipit event 7 patient admit initi episod treat parenter antimicrobi drug postur drainag resum rapidli possibl cessat acut bleed vitamin k administ patient volum expector blood larg 2500 ml initi episod blood pressur chang occur 4 patient five patient receiv blood transfus bleed stop without surgic intervent patient usual within 4 day 38 patient total 85 episod bleed surgic treatment undertaken center one patient underw lobectomoy anoth hospit continu bleed postop ten patient die mean surviv hemoptysi 25 year rang 3 month 6 year surviv rate compar anoth group patient equal sever lung diseas never bled profus 28 patient remain aliv 7 month 20 year initi episod dat suggest massiv hemoptysi complic cystic fibrosi may omin event believ past tendenc patient stop bleed without aggress surgic intervent futur studi new therapeut measur massiv hemoptysi must appropri untreat control patient receiv medic manag
785	chemic marker mucou serum glycoprotein relat viscos mucoid purul sputum variou hypersecretori diseas mucu serum alway present sputum concentr marker measur mucoid purul sputum patient chronic bronchiti asthma cystic fibrosi bronchiectasi differ concentr mucou serum glycoprotein greater among differ macroscop type sputum among diseas macroscop type comparison diseas show sputum patient asthma widest variat concentr marker mucou glycoprotein dri macromolecular weight astham group analyz becam appar patient extrins asthma without chronic bronchiti repres homogen group wherea intrins asthma without chronic bronchiti respons wide variat concentr marker mucou serum glycoprotein sputum sampl correl appar viscos sputum establish rel contribut glycoprotein viscos sputum mucoid sputum mucou glycoprotein import determin viscos wherea infect sputum mucou serum compon contribut viscos
786	treatment prognosi lobar segment atelectasi cystic fibrosi lobar atelectasi occur 30 41 per cent segment atelectasi occur 6 08 per cent 728 patient cystic fibrosi right lung involv 11 patient less 5 year age 18 26 episod 19 older patient five younger patient die within 5 year initi episod bronchoscopi without local lavag perform addit intensifi medic therapi appear improv outcom futur studi therapeut measur includ bronchoscopi treatment atelectasi complic cystic fibrosi must includ appropri control patient receiv medic therapi
787	season variat birth offspr coupl heterozyg cystic fibrosi test whether month birth patient cystic fibrosi cf season distribut report dutch survey publish australian data examin differ monthli variat found birth cf patient unaffect sib two group combin analys period regress use success higher fourier term signific fit observ frequenc obtain bimod curv possess singl cf gene seem therefor suffici express cyclic variat substanti agreement dutch seri maximum frequenc found occur march april septemb suggest one parent may subject variabl fertil mediat temperaturedepend mechan relev period fertil pattern preserv cf gene popul select heterozygot advantag discuss
788	cystic fibrosi adult letter adult male recent discov cystic fibrosi uniqu clinic present mention review articl patient recurr episod heat exhaust hyponatremia extraordinari sourc na loss sweat case repres import new present cystic fibrosi internist view diseas one seen chronic ill children
789	onehour bloodxylos cystic fibrosi onehour bloodxylos concentr oral xylos load measur children cystic fibrosi cf healthi control mean 1hour bloodxylos valu significantli increas group cf find confirm earlier observ roll et al 1973 signific present understood suggest small intestin function investig cf
790	cimetidin cystic fibrosi letter pilot studi examin effect cimetidin steatorrhea children pancreat insuffici due cf receiv pancreat supplement administr cimetidin pancreat supplement reduc faecal fat excret 4 5 children 3 case 50 case 4 steatorrhea increas cimetidin without symptom explan none children side effect drug studi need determin indic cimetidin dietari manag cf
791	limit sweat test letter agreement schwarz et al state sweat test limit diagnosi cystic fibrosi cf diagnosi justifi basi abnorm sweat test unless support evid diseas experi much greater problem sweat test accuraci occur hospit test carri much smaller number patient laboratori much lesser degre experi author signific number patient refer region children hospit abnorm sweat electrolyt measur elsewher unequivoc normal measur repeat laboratori carri larg number test need go extent serial collect sweat give spironolacton author obtain test within grey area repeat occas care seek evid diseas particularli evid pancreat diseas advoc gener use spironolacton merit drug experi certain patient mere support suspicion temporari hyperaldosteron condit might led erron conclus absenc k cl determin
792	immunolog studi cystic fibrosi evid present support concept much allergi cystic fibrosi cf ige mediat total ige level higher allerg nonallerg cf patient level also higher patient greatest number chest infect preced 12 month ige antibodi level dermatophagoid pteronyssinu timothi grass pollen aspergillu fumigatu higher posit result skin test allergen serum igg igm iga level allerg nonallerg cf patient differ overal mean valu igg igm higher report healthi british children highest level tend present patient greatest number recent major chest infect differ signific igg 16 patient iga level 2 sd report mean agematch control 11 nonallerg iga level also higher patient recent experienc major chest infect 45 patient tissu type hla b antigen signific clinic associ singl antigen observ antigen phenotyp a1 b8 common patient multipl allerg symptom singl allergi mere posit result skin test nonsignific increas w19 patient frequent infect a2 patient present meconium ileu also note data present permit choic made altern concept allergi primari abnorm cf allergi aris secondari infect
793	effect artifici diet growth patient cystic fibrosi effect artifici diet growth examin control trial 43 patient cystic fibrosi 28 patient receiv diet 12 month comparison made growth dietari treatment growth chang also assess 15 patient receiv convent diet artifici dietari treatment led improv height weight subscapular skinfold thick disproportion advanc bone age group whole 10 36 patient clinic signific improv height weight ie 05 standard deviat score greatest improv young mildli affect patient propos futur use unpleas expens diet restrict select case rather given routin treatment
794	serial lung function studi cystic fibrosi first 5 year life lung mechan studi 8 infant cystic fibrosi 6 month life radiosotop lung function measur 5 5 year age children initi asymptomat normal lung mechan infanc 2 restudi later abnorm radioisotop lung function symptomat children show abnorm infanc mark chang later conclud lung cystic fibrosi probabl normal initi damag occur later even absenc symptom
795	paba screen test exocrin pancreat function infant children paminobenzo acid paba split specif pancreat chymotrypsin synthet tripeptid nbenzoylltyrosylpaba urinari excret absorb paba serv index exocrin pancreat function peptid 0015 gkg administ oral 20 control age 5 month 16 year 6 patient exocrin pancreat insuffici caus cystic fibrosi cf 9 newborn infant control mean 6hour paba recoveri 585 112 sd recoveri patient cf lower p less 0001 overlap newborn infant mean 6hour paba recoveri 234 177 sd overlap 3 instanc result cf patient simpl noninvas test thu appear promis merit investig younger infant especi newborn
796	reduct bile acid loss cystic fibrosi dietari mean normal diet increas faecal bile acid excret found 14 16 children cystic fibrosi steatorrhoea excret normal 2 children without steatorrhoea 16 children steatorrhoea took 3 regimen diet therapi normal diet pancreat enzym supplement diet reduc longchain triglycerid ad mediumchain triglycerid diet ad pancreat enzym supplement three regimen steatorrhoea faecal bile acid loss significantli less treatment lowest excret occur diet reduc longchain triglycerid ad mediumchain triglycerid pancreat enzym supplement although reduct steatorrhoea nearli alway accompani decreas bile acid excret initi bile acid loss variabl could predict given degre steatorrhoea suggest least one factor possibl liver diseas bile acid pool size influenc bile acid loss faec
797	sweat test cystic fibrosi diagnost screen combin chlorid ionselect electrod screen sweat chlorid newborn infant orion skin chlorid measur system incorpor procedur innov describ result indic diagnost screen cystic fibrosi readili undertaken test chlorid ionselect electrod best left least second day life later insuffici sweat young babi measur 2 babi cystic fibrosi also discuss
798	sweat test cystic fibrosi letter bray et al conclud mass screen newborn babi chlorid ionselect electrod feasibl method diagnosi cystic fibrosi also suggest procedur might use conjunct meconium analysi reduc incid fals posit result 1972 report detail child prove cystic fibrosi rais sweat sodium normal sweat chlorid level obtain treatment cloxacillin attent drawn implic find regard screen procedur suggest made least children cystic fibrosi cloxacillin radic might replac chlorid ion sweat mass screen cystic fibrosi undertaken use method base estim sweat chlorid level therefor prudent inquir whether infant receiv medic sourc interpret result caution instanc falseneg sweat chlorid read evid yet 1205 test neg cystic fibrosi sweat chlorid statist chanc case small sever case suggest need systemat investig effect medic sweat ion level gener well cystic fibrosi case
799	cystic fibrosi atopi airway labil survey cystic fibrosi cf avon area 48 children cf 40 famili togeth 71 parent studi spirometri exercis test pinch test control group 42 young adult similarli test control data children taken previous publish work preval atopi posit prick test children cf 48 sensit grass pollen hous dust mite common children 29 normal popul 34 hypersensit aspergillu fumigatu found 35 children cf associ sever lung diseas parent normal pattern preval atopi exercis induc airway obstruct present 22 children cf associ sever lung diseas render interpret difficult parent normal respons exercis hypersensit fumigatu exerciseinduc airway labil featur acquir characterist noth present studi support hypothesi possess cf gene predispos atopi
800	activ serum inhibitori proteas bronchial secret children variou chronic nonspecif respiratori diseas group 223 children variou chronic nonspecif respiratori diseas level serum inhibitori proteolyt enzym bronchial secret measur activ inhibitori proteolyt enzym analyz accord natur bronchial lesion observ bronchoscopi charact cellular composit bronchial secret statist signific increas mean inhibitori valu comparison valu control group found children recurr bronchiti a1 cystic fibrosi a1at a1x chronic bronchiti a1x bronchiectas a1x children obstruct bronchiti 2m
801	structur function small airway health diseas last two decad great stride made understand function aspect airflow peripheri lung seem small airway import site obstruct varieti chronic respiratori disord associ airflow obstruct review deal anatom function aspect small airway normal diseas lung particular basi obstruct narrow depend intrins airway lesion review varieti patholog chang small airway observ diseas outlin along physiolog test current use detect dysfunct stage long produc symptom alter standard test lung function
802	spectrum cystic fibrosi children adult cystic fibrosi autosom recess disord remain common lethal genet diseas caucasian peopl diagnosi cf usual made base upon clinic present chronic respiratori andor gastrointestin symptom posit sweat electrolyt test often famili histori disord manifest chronic cough recurr pneumonia bronchiectasi club pneumothorax hemoptysi malabsorpt secondari pancreat insuffici well associ cystic fibrosi diagnosi usual delay howev often appreci physician cf may associ broad spectrum less common manifest well extrem variabl sever ill lack familiar manifest may delay diagnosi adolesc adulthood first seem mild clinic express disord patient genet variabl second subtl manifest cf wide appreci physician practic
803	control trial use intraven infus soya oil emuls treatment children cystic fibrosi five children cystic fibrosi given repeat intraven infus soya oil emuls intralipid 12 18 month effect growth health sweat chlorid pancreat enzym activ compar control group benefici effect demonstr recommend form therapi place routin treatment children cystic fibrosi possibl treatment may modifi degre weight loss note 12 month age lack benefici effect problem involv longterm intralipid infus preclud use form therapi routin treatment children cystic fibrosi
804	manag cystic fibrosi editori controversi still surround appropri method manag children cystic fibrosi reason much uncertainti manag cystic fibrosi mani therapeut approach propos without properli conduct control trial current approach therapi least 80 children cystic fibrosi expect reach adult life minim lung damag howev dramat improv surviv indic cystic fibrosi easi condit manag longer requir specialis care
805	fals neg sweat test appar adequ sweat collect sweat test collect two occas normal children children cystic fibrosi analys accord weight sweat collect five case collect 5099 mg sweat gave fals neg result although 50100 mg sweat consid adequ author result support studi confirm view least 100 mg sweat must collect give reliabl result
806	cystic fibrosi review clinic patient respons 72 patient intens antimicrobi prophylact programm present review treatment first commenc 1968 evalu last 4 month 1975 assess confirm favour clinic impress
807	influenc cystic fibrosi serum calcium secret rabbit tracheal mucociliari apparatu cystic fibrosi serum isol compon igg fraction calcium ionophor a23187 produc quantit greater increas mucu glycoprotein secret rabbit tracheal epithelium control serum isol compon igg fraction valu determin dri weight secret per gram tissu subsequ sialic acid content secret demonstr increas mucu product repres measur differ function cultur mucociliari apparatu due influenc cystic fibrosi serum
808	antiplasmin alpha2macroglobulin activ plasma cystic fibrosi patient studi plasimalpha2macroglobulin interact use plasma cystic fibrosi patient system alpha2macroglobulin cystic fibrosi plasma differ control abil bind inhibit plasmin
809	cystic fibrosi serum promot 45ca uptak normal human leukocyt twofold increas 45ca label observ normal human leukocyt incub presenc serum obtain patient cystic fibrosi degre 45ca label leukocyt isol patient cystic fibrosi also significantli greater observ leukocyt isol normal individu
810	serum ribonucleas level patient cystic fibrosi cystic fibrosi autosom recess diseas usual fatal third decad character chronic obstruct lung diseas elev sweat electrolyt concentr pancreat insuffici present investig carri determin ptype serum rnase activ reduc cf patient 3 24 year age differ serum rnase activ found among group 17 normal 21 cf patient 5 cf heterozygot appear observ decreas rnase activ serum young children pancreat insuffici cannot extend older children least without withhold pancreat supplement
811	studi meconium cystic fibrosi activ alphadmannosidas betaglucuronidas betadfucosidas acid alkalin phosphatas specif activ alphadmannosidas betaglucuronidas betadfucosidas acid alkalin phosphatas studi meconium infant cystic fibrosi cf control subject studi reveal signific variat specif activ enzym except acid phosphatas variat uniform activ alphadmannosidas betaglucuronidas alkalin phosphatas markedli decreas p less 0001 p less 0002 p less 0001 respect activ betadfucosidas significantli increas p less 0001 meconium infant cf suggest decreas activ alphadmannosidas beta glucuronidas might contribut accumul abnorm substanc cf meconium highli increas activ betad fucosidas rais possibl addit altern method screen newborn cf use meconium test materi
812	wolffian duct anomali editori fact serum factor cystic fibrosi patient inhibit ciliari movement cell isol trachea observ ciliari movement associ pinocytot activ led ohno et al suggest defect respons aplasia hypoplasia wolffian duct structur male cystic fibrosi ohno hypothesi lack definit proof hypoplasia aplasia va male cystic fibrosi extrem common produc steril affect male
813	pulmonari infect rheumatoid arthriti five eleven patient bronchiectasi andor cystic fibrosi develop polyarthr posit test rheumatoid factor possibl mechan complic discuss
814	meconium ileu equival adult case report case describ meconium ileu equival present small bowel obstruct adult patient cystic fibrosi import conserv manag acetylcystein intraven fluid emphas
815	meconium health diseas meconium defin first stool pass newborn infant first stool pass within 24 hour birth 90 newborn paper review current knowledg sourc meconium composit health diseas state precis origin compon meconium defin qualit quantit pattern individu constitu meconium health consid water inorgan element enzym plasma protein glycoprotein lipid haemoglobin metabolit steroid bile acid sterol meconium infant cystic fibrosi extens studi diseas paper concentr entiti composit meconium cystic fibrosi screen test cystic fibrosi diagnosi cystic fibrosi meconium ileu discuss
816	zinc defici syndrom british youth cystic fibrosi syndrom dwarfism retard sexual develop among iranian egyptian teenag boy shown due zinc defici british patient cystic fibrosi nephrot syndrom show growth retard hypogonad associ low plasma zinc concentr combin cystic fibrosi nephrot syndrom appear fortuit undoubtedli advers effect zinc homoeostasi cumul nevertheless zinc defici consid somat sexual growth failur occur patient cystic fibrosi
817	diseas respiratori system bronchiectasi cystic fibrosi bronchiectasi characteris dilat bronchi dilat may generalis confin singl segment lobe lung may tubular fusiform spindl shape saccular cystic aetiolog symptom diagnosi treatment complic prevent bronchiectasi consid cystic fibrosi affect mani exocrin gland throughout bodi present diagnosi treatment complic treatment manag associ social problem death due cystic fibrosi discuss
818	bronchiectasi cystic fibrosi letter otherwis excel articl bronchiectasi cystic fibrosi dr margaret hodson serious mar failur emphasis advic manag drug dosag direct throughout adult adolesc child firstli tetracyclin prescrib young children obviou reason secondli dosag antibiot recommend high infant small children final paragraph give pessimist impress undoubtedli distress condit stress earli mortal past mani older patient today without note effect earli diagnosi perhap result neonat screen togeth effect treatment may futur qualiti life length life
819	fight life patient cystic fibrosi discuss experi diseas
820	dexamethasoneresist cystic fibrosi fibroblast show crossresist sex steroid diploid skin fibroblast deriv individu autosom recess diseas cystic fibrosi cf shown previous significantli resist cytotox dexamethason glucocorticoid hormon normal human fibroblast cystic fibrosi fibroblast also shown resist normal human fibroblast cytotox effect sex hormon 17 betaestradiol dihydrotestosteron progesteron sinc cell believ contain differ receptor steroid hormon probabl resist cf cell hormon result receptor defici shown fact cf cell found exhibit receptor activ normal cell 3hdexamethason furthermor neither normal human cf fibroblast could demonstr contain detect receptor activ 3h17 betaestradiol addit studi fibroblast kill hormon led interest observ normal human diploid fibroblast regardless sex tissu donor sensit kill sex hormon find suggest cytotox effect steroid hormon may observ independ specif hormon receptor studi report thu suggest resist cf cell differ steroid hormon probabl result defect pathway cellular steroid hormon metabol involv receptor
821	repair dna singl strand break human cell genet disord aim work make preliminari examin hereditari diseas relat precoci age order determin whether defect involv result impair dna repair capac test impair dna singl strand capac cell patient differ diseas follow rate dna xirradi sediment alkalin sucros gradient found cell observ lesh nyhan cystic fibrosi trisomi 15 et 21 retinoblastoma abl repair singl strand break dna extent initi rate
822	pulmonari function morbid 40 adult patient cystic fibrosi pulmonari function cardiopulmonari complic studi group 40 patient cystic fibrosi reach age 25 year mean valu vital capac vc function residu capac residu volum rv ratio rv total lung capac rvtlc conduct ratio forc expiratori volum one second vc abnorm variabl pattern progress patient patient men differ women significantli larger tlc inspiratori capac women result preserv vc may advantag surviv patient observ pseudomona aeruginosa encount increas frequenc age massiv hemoptysi result earli death occurr rightsid heart failur secondari cor pulmonal without respiratori failur poor prognost sign
823	role fiberopt bronchoscop lung lavag patient cystic fibrosi studi compar use fiberopt bronchoscop lavag techniqu gener anesthesia techniqu use rigid bronchoscop seventyseven procedur perform 39 patient cystic fibrosi vital capac improv 46 75 valid measur arteri blood ga level show improv 14 33 valu obtain prospect studi need incorpor valu pre postop mmev rvtlc flow volum curv arteri blood ga valu evalu complic eas oper may greater valu
824	bronchoscopi lavag manag pulmonari complic cystic fibrosi articl present experi bronchoscopi therapeut diagnost tool manag patient cystic fibrosi result therapeut bronchoscopi bronchial irrig cystic fibrosi patient quit impress level blood ga procedur gener shown improv vital capac fef1 gener shown small consist improv dramat effect patient assess oper patient state breath less labor less rapid much deeper bronchoscopi offer effect therapeut tool manag pulmonari complic cystic fibrosi unfortun benefit shortliv repeat bronchoscop procedur often necessari must accept point time cardiopulmonari state patient cystic fibrosi may progress beyond salvag limit convict earlier bronchoscopi thorough bronchial irrig may prevent critic pulmonari event follow inevit progress deterior pulmonari statu patient cystic fibrosi ct 1 emsland hp internist 21 11 980 2 rothmann bf ann otol rhinol laryngol 91 641 982 3 fitzpatrick sb j di child 137 595 983 4 moazam f j pediatr surg 20 398 985 5 sherman jm pediatr pulmonol 2 244 986
825	cystic fibrosi famili challeng learn famili cope cystic fibrosi interview 18 famili gave us vivid descript daytoday process live devast diseas famili diseas describ prediagnosi diagnosi home manag treatment famili commun cf reaction sibl relationship peer hospit sourc support discuss
826	measur chlorid sweat chlorideselect electrod describ improv method sweat test chlorideselect electrod sweat product stimul pilocarpin give result compar tediou procedur gibson cook cystic fibrosi never diagnos sole result kind sweat test diagnosi must consist result physic examin histori studi includ repeat two sweat test anoth time clinic examin repeat sweat test physician confirm rule diagnosi
827	carboxypeptidas activ cultur skin fibroblast relationship cystic fibrosi properti carboxypeptidas cultur skin fibroblast control cystic fibrosi patient studi use alphan carbobenzoxylglutamylltyrosin substrat carboxypeptidas inhibit thiomers cyanid iodoacet n ethylmaleimid similar manner control cystic fibrosi fibroblast trypsin dithiothreitol treatment activ enzym 110phenanthrolin inhibit presenc dithiothreitol zn2 co2 revers inhibit trypsin treatment carboxypeptidas produc form enzym higher km valu control cystic fibrosi fibroblast dithiothreitol treatment control fibroblast result form similar properti trypsin activ form cystic fibrosi fibroblast yield variant form even higher km vmax valu sinc properti similar seem like differ reflect bind molecul enzym rather defect enzym
828	urinari cyclic nucleotid adult male cystic fibrosi patient urinari adenosin 35 cyclic monophosph guanosin 35 cyclicmonophosph excret significantli elev adult male cystic fibrosi patient compar normal men valu express way consid smaller size cystic fibrosi subject age cystic fibrosi patient excret 322 116 nmol adenosin 35 cyclicmonophosphateg creatinin per 24 h vs 197 043 normal men p less 002 cystic fibrosi patient excret 050 016 nmol guanosin 3k cyclicmonophosphateg creatinin per 24 h vs 030 007 normal men p less 005 subject adult complet linear growth sexual develop thu elimin possibl effect slower matur cystic fibrosi patient subject male thu avoid fluctuat urinari cyclic nucleotid menstrual cycl problem complic interpret previou studi
829	autom immunoprecipit meconium albumin cystic fibrosi screen newborn cystic fibrosi frequent substanti lethal inherit diseas unit state newborn screen cystic fibrosi suggest earli diagnosi permit genet counsel parent improv treatment prognosi cystic fibrosi patient fact cystic fibrosi newborn abnorm high meconium albumin seem offer best screen approach equivoc fals posit result meconium albumin test strip develop nephelometr autom immunoprecipit method quantit specif analysi meconium albumin total 3895 meconium far examin eleven albumin elev undetermin origin detect nine associ prematur far detect true posit known fals neg normal rang meconium albumin agreement previous publish rang determin use manual immunochem method method rapid econom question sensit specif predict valu detect method discuss
830	doubl time alphaaminoisobutyr transport calcium exchang cultur fibroblast cystic fibrosi control subject popul doubl time kinet transport alpha aminoisobutyr aib calcium ca exchang studi skin fibroblast monolay obtain 5 subject cystic fibrosi cf 5 age sexmatch control popul doubl time estim cell count protein dna differ two group km vmax maxim uptak time half maxim uptak aib differ two group intracellular ca pool size base exchang 45ca unlabel ca significantli greater monolay cf subject
831	serum alphafetoprotein cystic fibrosi pancrea serum alphafetoprotein concentr measur three differ type radioimmunoassay 30 patient cystic fibrosi pancrea 55 control highest valu obtain cystic patient 102 ngml control 108 ngml within publish normal limit previous report larg increas serum afp patient cystic fibrosi heterozygot carrier confirm
832	activ serum alphaamylas cystic fibrosi new method use differenti inhibitor measur pancreat salivari type alphaamylas ec 3211 appli serum sampl 46 cystic fibrosi cf patient age rang 4 14 year 50 control age group level pancreat type amylas lower cf patient median 265 iu1 control median 815 p less 0001 result salivarytyp enzym howev support previous report find higher usual level cf patient discrep probabl due differ analyt method felt procedur valu investig patient cystic fibrosi pancreat disord
833	lysosom hydrolas cystic fibrosi liver specif activ sever lysosom hydrolas normal cystic fibrosi cf liver investig neuraminidas activ respect two natur substrat fetuin bovin submaxillari mucin normal cf liver signific differ found cf normal liver 4 methylumbelliferylalphadmannosidas specif activ determin three differ ph valu 43 565 65 correspond lysosom golgi cytosol compon enzym respect specif activ pnitrophenylbetad mannosidas 4methylumbelliferylbetanacetylglucosaminidas also similar cf normal liver
834	cystic fibrosi liver sialyltransferas activ sialytransferas regard glycoprotein substrat asialofetuin asialoovin submaxillari mucin determin normal patholog control cystic fibrosi liver homogen cystic fibrosi patholog liver 40 averag normal specif activ sialytransferas sever properti cystic fibrosi sialytransferas investig compar normal liver enzym alhadeff et al 1977 ph optima curv similar cystic fibrosi sialyltransferas appear thermolabil normal liver enzym isoelectr focus studi reveal three basic form sialyltransferas found normal liver defici absent cystic fibrosi liver data suggest alter glycoproteinsialyltransferas may present cystic fibrosi liver probabl secondari effect due gener liver patholog
835	cluster cystic fibrosi case limit area brittani franc cystic fibrosi northern sector french depart finister 11787 live birth within sector concentr diseas found small area minim frequenc area 1946 1972 calcul 1 per 377 live birth gene frequenc 00515 genealog analysi go back begin 18th centuri show relationship 8 10 famili patient belong origin deleteri gene may explain least five primari ancestr coupl live 18th centuri random drift probabl explan concentr cystic fibrosi region
836	glycoprotein cystic fibrosi review articl review major research last 20 year abnorm glycoprotein abnorm glycoprotein metabol cystic fibrosi purpos focu attent area consid author great import elucid primari biochem defect cf major studi glycoprotein cf done crude mixtur glycoprotein tissu tissu fluid secret excret studi compar properti composit purifi glycoprotein cf patient control compar studi enzym involv degrad biosynthesi carbohydr portion glycoprotein cf patient normal control discuss sever studi suggest abnorm cf alphalfucosidas cf lfucos metabol sever studi indirectli suggest abnorm glycoprotein metabol may involv pathogenesi cystic fibrosi fruit area futur investig comparison properti composit specif glycoprotein purifi homogen cf control tissu particularli regard carbohydr composit comparison activ properti enzym involv degrad biosynthesi glycoprotein cf control tissu studi effect increas electrolyt concentr physicalchem properti glycoprotein
837	purif character alter cystic fibrosi liver alphalfucosidas alphalfucosidas ec32451 two cystic fibrosi liver purifi character purif accomplish affin chromatograph procedur previous use normal liver alphalfucosidas character two cystic fibrosi alpha lfucosidas indic similar normal liver alphalfucosidas regard ph optima profil micha constant km subunit structur antigen howev ga liquid chromatograph analysi reveal alter carbohydr composit cystic fibrosi alphalfucosidas three major sugar found normal purifi liver alphalfucosidas mannos nacetylglucosamin sialic acid reduc cystic fibrosi alphalfucosidas averag 51 44 32 respect normal amount
838	cystic fibrosi cell cultur class danish popul cystic fibrosi cf cultur phenotyp dermal fibroblast metachromasia metabol cooper group 131 danish cf patient famili studi determin distribut two cf cultur class prognost signific 626 82 class 313 41 class ii 611 8 propos genet compound occurr class ii twice found group patient new york 13 minnesota 18 prognosi class ii cf patient consid poorer 1 initi diagnosi made earlier class ii class compound 63 class ii diagnos first year life compar 35 class 13 compound 2 5 class ii patient surviv age 15 year deceas end studi 1976 wherea 24 class 63 compound 15 year end studi research ad evid genet heterogen within clinic syndrom cystic fibrosi
839	spine deform cystic fibrosi patient cystic fibrosi increas risk develop kyphosi scoliosi risk kyphosi scoliosi increas age sever kyphosi appear greater older age group patient retard bone age may like signific spinal deform presenc spine deform correl sever pulmonari involv height weight serum protein albumin patient cystic fibrosi
840	precipitin hypersensit reaction cystic fibrosi larg number wide varieti precipitin detect sputum cystic fibrosi patient suggest precipitin may nonprotect even harm patient sputum precipitin direct princip food fungi bacteria human bodi tissu hand precipitin staphylococcu alphahemolysin main type immunoprecipitin detect cf serum found 60 serum specimen examin seem like precipitin patient cf may involv format immun complex conjunct complement may respons respiratori gastrointestin lesion common patient cf immun complex may result excess food bacteri antigen escap across gut lung result abnorm siga system 80 sputum specimen test gave posit precipitin agar gel human semin fluid colostrum suggest antibodi form cf patient could direct host tissu may account autoimmunetyp reaction cf crossreact hightit antibodi staphylococcu basement membran lung pancrea complement activ may occur cf requir studi high number bcell detect antibodi coat complement activ sheep erythrocyt eac rosett may partli respons synthesi varieti antibodi detect cf patient
841	intestin mucin health diseas intestin mucin complex glycoprotein secret goblet cell form gellik cover mucos surfac assum provid lubric protect underli epithelium potenti injuri chemic enzym bacteria dietari constitu recent advanc understand mucin structur secret function properti review paper implic diseas cystic fibrosi peptic ulcer malign inflammatori bowel diseas briefli discuss
842	reaction 4methylumbelliferylguanidinobenzo proteas plasma patient cystic fibrosi proteas activ assay use 4 methylumbelliferylguanidinobenzo activ site titrant certain proteas significantli defici plasma patient cystic fibrosi defici demonstr chloroformellag acid activ plasma proteas hydrolyz ester arginin unactiv plasma proteas neglig activ toward ester defici also demonstr separ proteas isoelectr focus polyacrylamid gel chromatographi agaros columsn sinc proteas defici demonstr unactiv plasma defici cystic fibrosi probabl due reduc number proteas molecul rather decreas catalyt effici
843	occurr secondari cystathioninuria children inherit metabol disord liver diseas neoplasm cystic fibrosi celiac diseas secondari cystathioninuria found two 46 children suffer tumor leukemia liver diseas inherit metabol disord cystic fibrosi celiac diseas two patient one congenit biliari atresia cytomegaloviru infect seven children moder elev excret cystathionin suggest secondari cystathioninuria uncommon diseas investig
844	ultramicroelectrophoresi protein sweat patient cystic fibrosi pancrea control 46 sweatsampl 32 children cystic fibrosi pancrea cf 35 sampl 23 controlchildren collect glass microcapillari protein determin ultramicroelectrophoresi result 1 protein detect 48 sampl cf control 2 ph 23 cfsweat show least one band controlsweat 3 ph 89 cfsweat occasion show one band controlgroup 4 ph 23 protein found electrophoresi start point use cfsweat wherea ph 89 opposit found 5 ph 23 protein found fewer sampl ph 89 cffactor postul repres basic polyelectrolyt induc follow pathogen mechan aggreg protein give rise high viscos secret saliva b bind cellmembran glandular epithelium thu induc disturb activ naclreabsorpt eg reduct lumin passiv nainflux
845	complement cystic fibrosi complement compon c3 c4 c3a estim 30 patient cystic fibrosi age 1 21 year mf 1614 compar result 40 healthi agematch subject influenc clinic score sputum microbiolog patient sex also investig contrast previou commun paper show compar control group signific decreas c3 p less 0001 c4 p less 002 observ wherea c3a level alter increas complement shwachmanscor 70 influenc complement level exacerb diseas chang level influenc patient sex could shown pseudomona aer sputum clearli associ complement defect 1418 alternativepathway involv complement activ could demonstr 32 result make complement activ due pulmonari infect like defect observ probabl repres secondari chang
846	progress screen inborn error metabol inborn error matabol seri individu rare biochem anomali caus seriou clinic manifest great interest biochemist geneticist well paediatrician internist often present special diagnost therapeut problem studi inborn error metabol also implic field epidemiolog social medicin number known inborn error metabol increas rapidli recent year other yet unidentifi presum await recognit condit treat realis earli diagnosi essenti order achiev good result stimul interest possibl examin either whole popul select predispos group individu biochem differ characteris particular inherit metabol diseas articl review recent develop particular refer indic screen programm progress identif previous unknown inborn error metabol otherwis homogen popul group inborn error metabol due singl gene mutat recognit asymptomat individu heterozyg abnorm gene caus diseas may import clinic identif consid one aspect metabol screen inborn error metabol
847	rectal mucosa cystic fibrosi morpholog featur short term organ cultur histolog chang observ larg intestin mucosa cystic fibrosi cf patient includ crypt enlarg well intracellular extracellular accumul mucu consid use diagnost sign diseas extent chang howev evalu quantit studi quantit stereolog method appli biopsi rectal mucosa 5 cf patient 5 sibl control 2 normal adult measur goblet cell number crypt lumin volum volum intracellular mucu found cf crypt lumina variabl dilat averag rel volum intracellular mucu number goblet cell cf mucosa compar sibl adult control cf biopsi howev surfac columnar absorpt cell consist contain put lipid droplet rapidli accumul addit larg lipid droplet short term organ cultur lipid droplet observ cell type control biopsi short term organ cultur
848	simpl method estim heparin bind capac human serum method estim heparin bind capac human serum describ human serum dilut low ionic strength heparincontain buffer ph 55 proteinheparin electrostat complex form solut subsequ format insolubl aggreg collect centrifug quantit determin rel amount weight protein heparin insolubl heparinprotein aggreg permit estim combin ratio serum protein bind heparin precipit solut weight combin ratio protein heparin quantit measur total affin heparin protein serum bind heparin ph 557 form insolubl complex unusu high affin heparin abnorm serum protein increas amount normal occur high heparinaffin serum protein would alter averag protein heparin combin ratio increas heparin bind capac human serum convers would true serum protein low affin heparin lower heparinbind capac human serum describ method use evalu heparinbind capac serum protein normal individu person cystic fibrosi
849	studi lymphocyt betaglucuronidas abnorm cystic fibrosi possibl relat carboxypeptidas blike activ presenc serum cystic fibrosi cf homozygot heterozygot factor inhibit respons lymphocyt lysosom betaglucuronidas activ vitro phytohaemagglutinin pha stimul confirm studi lymphocyt beta glucuronidas activ pha stimul repres way confirm cf diagnosi screen cf heterozygot technic complex howev method cannot use mass screen use confirm diagnosi suspect case relationship serum factor inhibit effect pha betaglucuronidas ciliari dyskinesia factor carboxypeptidas b like activ discuss
850	liver involv cystic fibrosi report 9 case 9 204 unselect cystic fibrosi cf patient seen depart pediatr univers bern switzerland last 20 year clinic overt liver diseas 7 patient liver cirrhosi demonstr 34 focal biliari cirrhosi pertin find 3 case wherea anoth 3 show unspecif nodular cirrhosi one infant present prolong obstruct jaundic due partial extrahepat atresia delay pass meconium two patient steatosi review literatur deal clinic laboratori find cf patient liver diseas given
851	incid cystic fibrosi caucasian popul estim newborn frequenc cystic fibrosi differ caucasian group rang 4 time 40 time less common gener accept figur 12000 current meconium screen trial may effect popul incid equal greater 12000 may use popul incid low 17000 maximum improv method true incid variabl incid proven caucasian popul screen trail negro orient indian popul requir
852	case abnorm duodenum intermitt epigastr pain partial reliev food reason examin upper gastrointestin tract 30yearold man second portion duodenum strikingli abnorm patient histori daili multipl loos stool sinc birth age 12 diagnosi small bowel malabsorpt due fibrocyst diseas pancrea establish view histori duoden chang consid manifest fibrocyst diseas pancrea present time caus duoden abnorm unknown
853	reliabl detect cystic fibrosi skinderiv fibroblast cultur specif induct alkalin phosphatas tammhorsfal glycoprotein isoproterenol theophyllin skinderiv fibroblast cultur patient cystic fibrosi permit one reliabl discrimin cystic fibrosi patient one hand heterozygot normal found fibroblastlik intermediari type amniot fluidderiv cell behav essenti like skinderiv fibroblast find impli differ amniot fluid cell type reliabl separ prenat diagnosi cystic fibrosi becom feasabl near futur
854	c3 polymorph danish cystic fibrosi popul possibl associ antibodi respons c3 type human serum report materi 113 danish cystic fibrosi patient age 030 year frequenc c3f gene 02832 significantli higher p less 00005 frequenc found control group 224 healthi babi c3f 01585 also differ significantli p less 001 c3f gene frequenc 01780 found 177 blood donor age 2024 year signific associ c3 phenotyp seriou infect cystic fibrosi chronic mucoid p aeruginosa infect antibodi respons bacteria found
855	mucou glycoprotein cystic fibrosi pp 10821 cystic fibrosi common lethal genet trait caucasian caus much chronic progress lung diseas children young adult also respons intestin obstruct birth meconium ileu pancreat insuffici maldigest failur grow obstruct liver diseas age group furthermor obliter va deferen caus aspermia infertil male cf individu cf secret sweat contain excess amount chlorid sodium diagnost criteria includ detect elev chlorid level sweat individu typic pulmonari gastrointestin genit manifest diseas sever well document alter mucou secret individu cystic fibrosi alon combin may interfer mucou clearanc lung passageway organ seem clear addit studi defin basic aspect normal mucou biochemistri physiolog pharmacolog must preced parallel studi cf mucou secret data pertin cf pathophysiolog gener particular need includ understand chemic determin physic rheolog properti secret elucid mechan control sulfat glycoprotein biosynthesi
856	lipid composit sputum patient asthma patient cystic fibrosi lipid sputum patient asthma cystic fibrosi isol character case lipid constitut approxim 30 dri materi phosphatidlycholin abund lipid signific amount phosphatidylethanolamin phosphatidylglycerol present hexosyl ceramid sphingomyelin phosphatidylinositol lysophosphatidylcholin lysophosphatidylethanolamin present minor lipid compon apperci quantiti neutral lipid present triglycerid cholesterol main constitu phosphatidylcholin sphingomyelin phosphatidylgycerol highli satur larg amount phosphatidylcholin contain mostli palmit acid particularli asthmat sputum suggest htat highli satur larg amount phosphatidylcholin contain mostli palmit acid particularli asthmat sputum suggest highli satur phospholipid synthes upper airway reason benefici surfaceact properti alveoli
857	screen newborn cystic fibrosi assess valu detect albumin meconium screen procedur cystic fibrosi cf 68000 meconium sampl examin bm meconium test singl radial immunodiffus benzidin reaction specif sensit combin test 9967 7857 respect preval cf birth confirm 13600 countri low preval result rel high number fals posit therefor posit test result low predict valu 339 seriou drawback method experi opinion 37 local paediatrician screen programm evalu simpl questionnair gold decis rule appli least rel cost misclassif justifi massscreen programm 3 time higher actual rel cost suggest aggreg opinion paediatrician region result support view method use screen may disadvantag screen
858	effect supplement vitamin e vitamin serum level cystic fibrosi effect ingest vitamin e vitamin serum level vitamin urinari creatin creatinin ratio 18 children cystic fibrosi diseas pancrea cf studi daili ingest two month special prepar capsul contain 5000 iu vitamin palmit 100 mg alphatocopherol acet aqueou dispers form signific increas vitamin well vitamin e level serum taken 3 12 hr postprandi creatin creatinin ratio singl void urin decreas
859	cystic fibrosisan eleven year survey purpos commun review experi children cystic fibrosi seen januari 1964 januari 1975 analys factor contribut improv prognosi occur period number new patient increas six 1964 12 1974 sex equal affect respiratori infect failur thrive diarrhoea predomin present featur order thu one present featur indic cystic fibrosi least consid exclud patient assess monthli clinic attend formal physiotherapi carri parent instruct techniqu percuss drainag fortytwo sixtyfour patient still aliv thirtythre fall excel categori seven good one fair poor period review obviou improv fall morbid mortal increas proport patient excel group attribut fact earlier diagnosi regular care followup supervis therapeut programm includ parent educ particip would seem therefor earli diagnosi activ treatment prolong life give better health
860	cystic fibrosi israel clinic genet aspect total 140 case cystic fibrosi 110 famili identifi israel year 194675 reason suspect inadequ ascertain cystic fibrosi frequent among ashkenaz arab popul incid approxim caucasian european ancestri 11800 14000 live birth half frequent sephardim rare iraqi yemenit jew perhap absent iranian jew clinic pictur cystic fibrosi israel ethnic group found elsewher world depthinterview 50 famili conduct assess understand genet diseas attitud toward famili plan
861	cystic fibrosisproblem prospect editori cystic fibrosi autosom recess trait common hereditari lethal condit among caucasian approxim preval 1 per 2500 birth carrier frequenc 125 popul origin west europ markedli elev frequenc cf consider proport human race present genet enigma sever solut propos genet heterogen heterozygot advantag reduc penetr genet drift linkag epistasi discuss basic defect cf fundament biochem physiolog ramif unknown
862	review cystic fibrosi cystic fibrosi inherit diseas affect mainli caucasian exocrin gland obstruct caus multipl manifest lethal aspect pulmonari involv earli diagnosi treatment influenc prognosi sweat test diagnost tool must done center perform frequent qualiti control avail specif therapi vari center center agre consist comprehens approach manag one must acut awar psychosoci aspect care children cystic fibrosi
863	cephalometr studi patient cystic fibrosi children cystic fibrosi skelet matur epiphys anomali similar children nutrit problem howev patient found normal somat develop treatment begun earli group children cystic fibrosi undergo medic treatment cephalometr measur compar favor establish normal standard
864	mucoid pseudomona aeruginosa cystic fibrosi resist mucoid carbenicillin flucloxacillin tobramycin isol mucoid variant vitro mucoid strain pseudomona aeruginosa isol sputa patient cystic fibrosi vitro select phage resist carbenicillin flucloxacillin tobramycin sensit tetracyclin relat nonmucoid strain observ led develop techniqu isol mucoid variant vitro base enhanc resist carbenicillin mucoid variant isol variou strain ps aeruginosa exopolysaccharid found similar obtain mucoid ps aeruginosa isol patient cystic fibrosi
865	continu distribut specif ventil recov inert ga washout describ new techniqu recov continu distribut ventil v function tidal ventilationvolum ratio vv0 nitrogen washout analysi yield continu distribut v function vv0 repres fraction ventil 50 compart plu dead space procedur verifi recov known distribut data nois ad use apparatu control subject tidal volum frc mix expir n2 data gave follow result distribut young normal subject narrow unimod mean ln standard deviat 056 plu minu 013 b subject age 40 broader ln sd 086 plu minu 019 poorli ventil unit c patient pulmonari diseas descript show enlarg dead space patient cystic fibrosi show multimod distribut bulk ventil go overventil unit e patient obstruct lung diseas fell sever class three illustr result suggest approach well suit clinic investig
866	empti pattern lung studi multiplebreath n2 washout chang nitrogen concentr seen singlebreath nitrogen washout reflect chang rel flow v unit differ ventilationvolum ratio vv0 multiplebreath washout provid suffici data v unit vari vv0 plot function volum expir flow dead space may also determin young normal empti pattern narrow unimod throughout alveolar plateau littl flow dead space end breath older normal show flow dead space particularli toward end breath show high vv0 mode earli breath patient obstruct lung diseas high flow dead space present throughout breath well ventil mode end breath seen obstruct subject patient cystic fibrosi show poorli ventil mode appear end breath well high dead space
867	isol staphylococcu aureu sputum cystic fibrosi success isol staphylococcu aureu differ method sputum process investig 60 specimen collect 14 patient cystic fibrosi sevenmonth period fifti specimen 83 11 patient yield staph aureu one method direct plate purul portion sputum media design gener use respiratori infect gave unsatisfactori result 35 yield staph aureu increas isol obtain preliminari liquefact sputum best result given addit medium select staphylococci mannitol salt agar bbl initi sonic sputum 83 yield seven 11 strain staph aureu thymidinedepend otherwis atyp laboratori characterist isol patient receiv cotrimoxazol
868	cystic fibrosi make correct earli diagnosi cystic fibrosi detect increas frequenc older children adolesc even young adult qualiti life longev patient cystic fibrosi favor earlier diagnosi made therapeut regimen begun report present review five case chich diagnosi cystic fibrosi made age six year emphasi place variabl present sign symptom problem aris confirm suspect diagnosi cystic fibrosi
869	challeng cystic fibrosi cystic fibrosi autosom recess genet disord exocrin gland frequenc approxim 11500 live birth diseas present challeng physician health care team pediatr pulmonari center univers florida gainesvil coordin cystic fibrosi center clinic throughout state help physician patient recogn manag chronic diseas
870	antibodi proteas exotoxin pseudomona aeruginosa patient cystic fibrosi demonstr radioimmunoassay sera 33 patient cystic fibrosi two pediatr patient treat chronic pulmonari infect relat cystic fibrosi six sera serum pool uninfect individu test microtit radioimmunoassay reactiv exotoxin two proteas pseudomona aeruginosa exotoxin purifi lowproteas strain p aeruginosa shown adenosin diphosphateribos transferas activ mous lethal proteas purifi isol p aeruginosa patient cystic fibrosi proteolyt activ elastin collagen assay employ dimethyl protein substrat antibodi respons patient detect use 125ilabel antibodi human immunoglobulin correl clinic evalu express composit score base pulmonari find case histori growth nutrit chest x ray valu radioimmunoassay patient sera compar control serum pool express ratio count per minut cpm patient serum cpm control pool invers correl found ratio pseudomona exoproduct clinic score highest ratio occur patient show lowest clinic score result confirm proteas exotoxin p aeruginosa produc cystic fibrosi pulmonari infect due p aeruginosa suggest may serv signific virul factor chronic infecti state
871	studi basic defect cystic fibrosi kinin hypothesi hypothesi cystic fibrosi genet determin specif defici activ either glandular kallikrein activ enzym defect primari defect diseas immedi consequ either defect absenc kallidin result failur reabsorpt fact may mutat affect distinct enzym could account genet heterogen cystic fibrosi consequ defect kallikrein system would accumul precursor relat low molecular weight kininogen propos compound ciliarydyskinesia factor
872	separ ciliari dyskinesia substanc found serum secret cystic fibrosi leukocyt lymphoid cell line use protein asepharos cl4b cellfre cultur medium phastimul pbl cultur longterm lymphoid cell line cf homozygot oblig heterozygot well serum individu produc three distinct chang ciliari beat rabbit tracheal ciliat epithelium 1 increas beat frequenc 2 cd 3 ciliostasi abil produc 1 2 seem characterist leukocyt cultur cf genotyp 46 49 cf cultur produc effect compar none 16 cultur normal control 1 10 noncf patient control bronchial asthma cta specif cf pbl cultur sinc 13 normal control 60 noncf patient control cultur produc ciliostasi similar find obtain serum individu cultur medium longterm lymphoid cell line test use protein staphylococcu aureu coval coupl sepharos cl4b reagent separ cda present serum cultur medium pbl lymphoid cultur protein specif adsorb igg bind mild condit physiolog ph cda noncoval bound igg physiolog ph copurifi igg iggcda complex readili desorb protein asepharos cl4b ph 30 condit cda dissoci igg retain activ separ chromatographi biogel p10 sephadex g200 three distinct activ remov serum pbl cultur show cda cta two obtain sampl show cda one cda believ specif cf cfcda separ cf serum pbl lymphoid cell cultur medium cfcda complex noncoval igg subclass igg3 molecular weight 4000 6000 stabl acid ph found biolog fluid homozygot heterozygot cf shown c3a anaphylatoxin requir igg activ posit charg ph valu acid 80
873	mucocel paranas sinus cystic fibrosi two children 9 year age mucocel cystic fibrosi report mucocel agegroup rare probabl pathognomon cystic fibrosi
874	screen cystic fibrosi cystic fibrosi great unknown lot inform diseas common denomin noth pull piec togeth repres diagnost therapeut challeng progress made perhap someday abl understand complex entiti
875	acid mucin human intestin goblet cell acid mucin goblet cell duodenum jejunum ileum neonat infant cystic fibrosi cf without cf measur scan microdensitometri alcian blue stain accord protocol mccarthi reid 1963 characteris four group acid mucin cf infant 6 mth age control increas along gut duodenum ileum weakli acid strongli acid sulphomucin ileum increas total mucin 6 mth previous cf patient differ could account increas sialidaseresist mucin increas sulphomucin mark tip base villi cf neonat signific differ quantiti acid mucin question whether mucin cf chemic abnorm mere accumul abnorm extent probabl best investig analysi sialidaseresist mucin sulphomucin ileum strongli acid sulphomucin duodenum jejunum cf infant 6 mth age
876	onehour blood xylos test reliabl index small bowel function retrospect analysi oral dxylos toler test 435 pediatr patient perform signific differ found 126 normal subject 47 untreat children celiac diseas one hour load onehour valu found reliabl fecal fat analysi screen children celiac diseas sex age weight bodi surfac influenc result onehour valu control subject fortyeight children cystic fibrosi onehour xylos level within normal rang mean 90 120 180 minut load exceed significantli p less 001 control nonceliac group 63 children abnorm low xylos level almost found clinic condit compat upper small bowel mucos impair studi show singl estim xylos blood one hour load reliabl index small bowel mucos function good screen test celiac diseas small bowel disord produc malabsorpt children
877	iatrogen hyperuricemia children cystic fibrosi report frequent presenc hyperuricemia group children cystic fibrosi known consum larg dosag pancreat extract part therapi hyperuricemia common older patient treat longer period time clarif role renal function factor product hyperuricemia await care studi relationship purin load urat excret variou age patient
878	incid cystic fibrosi black childrenrevisit letter februari 1977 issu journal dr heffer comment public concern occurr cystic fibrosi cf black children feel cf occur frequent report tenyear search washington dc area show minimum incid cystic fibrosi among black newborn infant one per 17000 sinc 1972 identifi addit four black patient cystic fibrosi black children consist previous report incid one 17000 therefor disagre heffer common diseas among black
879	diagnosi exocrin pancreat insuffici cystic fibrosi synthet peptid nbenzoylltyrosylpaminobenzo acid synthet peptid nbenzoylltyrosylpaminobenzo acid specif cleav chymotrypsin bzti paba liber paba absorb excret urin accordingli paba recoveri reflect intralumin chymotrypsin activ index exocrin pancreat function test evalu 24 patient cystic fibrosi determin role diagnosi exocrin pancreat insuffici cumul percent paba recoveri six hour significantli lower cf patient compar control group overlap note two group good correl paba recoveri fecal chymotrypsin activ coeffici fat absorpt find indic paba recoveri significantli reduc patient cf steatorrhea may prove practic reliabl test pancreat insuffici
880	intrapancreat compress common bile duct cystic fibrosi report infant cystic fibrosi present birth meconium ileu develop prolong cholestat jaundic compress common bile duct pancreat duct advanc pancreat fibrosi extrahepat biliari obstruct natur previous describ cystic fibrosi
881	disaccharidas activ small intestin mucosa patient cystic fibrosi disaccharidas activ small intestin biopsi relat morpholog mucosa age 63 patient cystic fibrosi 177 healthi control subject caucasian origin patient cf healthi control subject 5 year age normal intestin mucosa low lactas activ found patient cf 5 year age one group high one group low lactas activ occur healthi caucasian control subject age find support view patient cf lactas defici relat diseas entiti patient without cf degre mucos atrophi decreas disaccharidas activ follow pattern indic enzym activ affect extent damag mucosa patient cf pancreat insuffici disaccharidas activ significantli p less 0001 higher compar control subject age ethnic group although increas uniform patient cystic fibrosi
882	abil bacteria activ termin complement compon serum patient cystic fibrosi termin complement compon c3 c9 contribut host defens infect studi perform determin defect activ c3 c9 bacteria contribut pathogenesi recurr pulmonari infect cystic fibrosi bacteria incub serum patient cystic fibrosi 30 minut consumpt avail c3 sera control patient two patient chronic sever bronchiectasi base result present studi unlik defect activ c3 c9 contribut pathogenesi increas suscept pulmonari infect patient
883	bronchial hyperreact cystic fibrosi asthma studi 113 patient cf compar respons inhal methacholin 50 asthmat children 26 normal children posit respons mch occur 51 patient cf 98 asthma signific correl posit respons mch cf poor pulmonari function relationship allerg rhiniti posit allergen skin test posit mch respons doserespons curv time cours mch challeng differ cf asthma bronchial hyperreact thu common cf differ asthma
884	lymphocyt respons pseudomona aeruginosa cystic fibrosi relationship statu pulmonari diseas sibl pair lymphocyt prolif respons pseudomona aeruginosa staphylococcu aureu evalu six sibl pair cystic fibrosi pair one sibl advanc clinic diseas wherea sibl good clinic condit three latter group clinic appar pseudomona bronchiti case averag respons pseudomona isol sibl pair lower sibl advanc clinic diseas differ observ respons staphylococcu normal plasma plasma patient cf good clinic condit restor respons patient advanc clinic diseas howev plasma patient low respons pseudomona inhibit respons respond sibl progress specif lymphocyt unrespons pseudomona may play import role increas destruct chronic pulmonari pseudomona infect cystic fibrosi
885	iodideinduc hypothyroid without goiter infant cystic fibrosi suggest patient cystic fibrosi may intrins abnorm thyroid function may enhanc administr iodid wish report infant cf hyperthyroid develop absenc goiter follow shortterm iodid therapi
886	open thoracotomi pleural abras treatment spontan pneumothorax cystic fibrosi variou treatment spontan pneumothorax cystic fibrosi examin 15yr period open thoracotomi pleural abras compar observ tube thoracostomi tube thoracostomi instil quinacrin open thoracotomi pleural abras perform 31 time 20 patient discuss center around select patient preoper prepar oper techniqu postop care follow includ analysi pulmonari function studi experi open thoracotomi pleural abras safe effect method util manag pneumothorax patient cystic fibrosi
887	cystic fibrosi black infant present meconium ileu volvulu case report meconium ileu complic intestin volvulu infarct black infant
888	neonat meconium obstruct ileum without mucoviscidosi two newborn intestin obstruct termin ileum without mucoviscidosi cure gastrografin enema case prematur infant show autopsi larg intestin contain normal meconium ileum plug tenaci meconium contain pasposit alcian blueneg mucu 3 case similar case meconium diseas report rickham meconium plug small intestin report emeri primari caus diseas lie larg amount pasposit mucu secret goblet cell ileal mucosa hypertrophi lymph nodul ileal submucosa
889	assist ventil cystic fibrosi letter colleagu review diagnosi manag prognosi 17 case infant cystic fibrosi sever respiratori distress admit children hospit medic center boston 1968 1972 60 mortal overal six 17 infant treat assist ventil one surviv subsequ experi assist ventil shown improv surviv infant
890	parent understand genet risk data genet counsel letter rel littl publish parent abil grasp import empir risk data mendeliantyp probabl basic problem mani reason consum know recurr risk variou genet diseas cystic fibrosi often problem health care effect mean commun health care inform use even known problem commun probabl work would like make suggest tri help provid probabl data alway record probabl valu discuss genet counsel session deal famili physician inform becom part medic histori futur refer provid document probabl alway includ interpret probabl diagram chart simpl mean use avail pamphlet brochur provid variou organ foundat depart health
891	pseudomona colon cystic fibrosi studi 160 patient investig role pseudomona aeruginosa colon respiratori tract cystic fibrosi cf patient relat effect colon progress bronchial airway patholog condit patient clinic progress identifi predispos factor persist p aeruginosa colon bronchial tree damag half 160 cf patient studi persist p aeruginosa respiratori tract colon half none pseudomona aeruginosa seem exclus propens respiratori tract may appear age treatment antibiot includ aminoglycosid fail erad p aeruginosa continu use antibiot seem contribut persist p aeruginosa appear mucoid strain p aeruginosa
892	intermediaterang sweat chlorid concentr pseudomona bronchiti cystic fibrosi variant preserv exocrin pancreat function studi clinic laboratori characterist seven patient sweat chlorid concentr consist 40 60 meqlit chronic pseudomona bronchiti lack digest symptom laboratori find indic preserv exocrin pancreat function patient includ two five children one famili two four anoth third famili one five sibl intermedi sweat chlorid concentr anoth typic fibrosi valu 105 meqlit one patient die respiratori failur result autopsi show bronchiolectasi typic cystic fibrosi minim pancreat chang data suggest genet basi variant cystic fibrosi patient may homozyg portion close link multigen cystic fibrosi locu may modifi gene amelior pancreat sweat lesion
893	assist ventil patient cystic fibrosi fortysix patient cystic fibrosi cf 1 month 32 year age 51 episod assist ventil thirtyf 69 die 1 395 day mechan ventil six other 12 die hospit 1 42 day assist ventil therapi discontinu three patient surviv longer one year discharg result much poorer report patient chronic obstruct pulmonari diseas caus probabl differ natur histori respons therapi cf patient cf whose condit progress deterior despit optim therapi longer respond antibiot physic therapi good candid mechan ventil occasion patient good baselin statu acut respiratori failur develop consid assist ventil
894	variabl cystic fibrosi letter us care patient cystic fibrosi cf well awar vari degre clinic involv long known wherea patient pulmonari involv one degre anoth approxim 15 20 patient pancreat involv 80 85 patient pancreat involv degre involv vari greatli accept concept clinic heterogen pulmonari gastrointestin system reason doubt exist clinic variabl major organ system affect diseas sweat gland
895	cystic fibrosi problem encount sweat test sweat test practic reliabl laboratori test confirm diagnosi cystic fibrosi among 234 patient refer john hopkin hospit sweat test 62 previou test 29 test report neg 33 test report posit result quantit pilocarpin iontophoresi sweat test center led chang diagnosi 27 435 62 patient error fals posit
896	ige antibodi product exoenzym common antigen oep pseudomona aeruginosa mice ige antibodi product exoenzym common antigen oep p aeruginosa studi mice inject antigen incorpor waterinoilinwat wow emuls aloh3 gel oep proteas toxoid pt elicit ige antibodi respons elastas toxoid et capac oep produc ige antibodi reduc remark proteas treatment suggest capac lie protein portion oep wow emuls less effect aloh3 gel adjuvant elicit ige antibodi respons emuls enhanc igm andor igg antibodi respons pt maintain constant level long period find may suggest ige antibodi respons compon p aeruginosa could induc man high serum level ige observ case cystic fibrosi caus p aeruginosa infect although ige antibodi activ yet determin
897	effect sera cystic fibrosi homozygot heterozygot glucos metabol vero cell effect intracellular product carbon dioxid glucos sera cystic fibrosi cf homozygot heterozygot determin establish cell line vero cell doubleblind assay co2 product reduc cell incub ammoniumsulphateprecipit fraction sera cf homozygot heterozygot similar fraction sera healthi donor
898	abnorm level prostaglandin fatti acid cystic fibrosi letter like dr chase dr dupont found essenti fattyacid defici usual subclin cystic fibrosi patient howev feel data prostaglandin synthesi may interpret patient defici linol acid oleic acid use altern substrat instead dihomogammalinol acid altern 203 fatti acid produc found increas amount substanc plasma patient cystic fibrosi agre author conclus level linol acid specif relat pg product children cystic fibrosi remain shown whether children cystic fibrosi primari abnorm fattyacid metabol whether observ disturb prostaglandin metabol secondari malabsorpt dietari essenti fatti acid either case certain clinic featur diseas may well explain prostaglandin disturb
899	child realli cystic fibrosi diagnosi cystic fibrosi incorrectli made fals posit sweat test 14 children 13 children test hospit seem like sweat test done often children normal sweatelectrolyt valu test repeat region paediatr centr approxim 250 sweat test done year 5 case detail test pancreat function normal none children typic chest diseas 2 gastrointestin symptom absenc typic clinic featur diseas diagnosi cystic fibrosi made extrem caution meticul test sweat electrolyt pancreat function
900	exocrinegland function basic biochem defect cystic fibrosi biochem link propos secret reabsorpt exocrin gland form factor kinin e initi ion reabsorpt activ factor involv arginin esteras cystic fibrosi may defect prevent format kinin e cystic fibrosi stimul exocrin gland produc abnorm reabsorpt ion lead physiolog abnorm clinic manifest diseas
901	bacteri content ionic composit sputum cystic fibrosi letter burn may propos follow pattern bacteriolog cystic fibrosi 1 staphylococcu aureu initi bacteri pathogen damag caus render lung suscept infect speci 2 control aureu antibiot allow influx haemophilu influenza 3 pseudomona aeruginosa introduc continu chemotherapi encourag establish 4 p aeruginosa supplant aureu h influenza becom sole pathogen examin idea quantit cultur sputum 20 patient seen cystic fibrosi treatment research center univers oregon health scienc center 1965 1977 result accord origin hypothesi burn may 13 20 patient sputum bacteri flora chang hypothesi burn may predict preliminari data suggest one primari sputum abnorm cystic fibrosi may increas ca make sputum suscept colonis aureu infect ca concentr reduc lung becom suscept colonis microorgan includ h influenza p aeruginosa escherichia coli
902	thymidinerequir staphylococcu aureu letter confirm thymidinerequir thi staphylococcu aureu strain common patient cystic fibrosi 7 month isol staph aureu 11 14 patient cf despit longterm cotrimoxazol staph aureu tend persist sputum even though isol requir thymidin first trimethoprimsensit vitro staph aureu less commonli isol less signific chest condit cotrimoxazol given factor may explain thi staphylococci recognis frequent cf diseas
903	abnorm level prostaglandin fatti acid blood children cystic fibrosi 12 children cystic fibrosi cf lower level essenti fatti acid linol acid plasma red blood cell control children product prostaglandin f2alpha pgf2alpha higher control 10 month oral linoleicacid supplement 6 children cf linoleicacid level plasma red cell platelet higher pgf2alpha product lower 6 children cf receiv placebo lipid prostaglandin f2alpha associ bronchoconstrict increas product children cf might causal relat chronic pulmonari diseas
904	lectin cystic fibrosi letter dr freed dr buckley shown lectin concanavalin con caus sever rhiniti sinus increas mucu secret inhal man smallintestin colic foulsmel flatu mucusco stool ingest somewhat surpris author suggest suitabl inhal ingest lectin may use treat patient cystic fibrosi sinc symptom produc ingest lectin resembl associ diseas attract recommend would patient cystic fibrosi avoid substanc contain lectin con avoid stimul addit mucu releas underli pathogenet defect cystic fibrosi may inappropri excess stimuli lectinlik substanc observ suggest increas protein content lymphocyt stimul plasma factor present patient cystic fibrosi carrier cystic fibrosi gene observ plu freed buckley might suggest cystic fibrosi diseas involv plasma factor lectin con alik activ stimul secret mucu increas enzym content circul cultur lymphocyt professor lieberman confus caus effect excess mucu product cystic fibrosi suggest secret difficult remov mucos surfac goblet cell mucu gland becom clog hyperviscid mucu remov stimul mucu product depriv patient mucotract valu dietari lectin would therapeut mischief equival prescrib coughsuppres product cough
905	sweat test cystic fibrosi letter dr smalley colleagu rightli stress commonest reason abnorm high sweatelectrolyt level apart cystic fibrosi faulti techniqu caus falseposit result potenti import list rare disord usual cite atop dermat dr ampola investig ten children eczema tuft new england medic center boston found higher sodium andor chlorid level sweat obtain affect skin sweat normal skin individu four atop children level within diagnost rang cystic fibrosi obtain 60 mmoll
906	fattyacid composit serumlecithin cysticfibrosi patient without steatorrhoea letter investig fattyacid composit serumlecithin four group cf patient defin pancreat function evalu 72h quantit stool fat determin coeffici fat absorpt cf patient without pancreat insuffici pancreat extract significantli higher percentag linol acid patient group alter fattyacid composit serumlipid fraction seem secondari consequ pancreat insuffici commonli associ cf diseas direct metabol defect suggest
907	improv safeti sweattest equip patient cystic fibrosi higher concentr sodium chlorid sweat normal observ led introduct iontophoresi techniqu stimul sweat gland pilocarpin occasion electr burn result defect equip incorrect badli appli test procedur new design equip present elimin possibl burn test
908	cystic fibrosi screen newborn editori mani attempt made establish suitabl screen test cystic fibrosi newborn recent new method describ crossley associ base measur pancreat trypsin sampl faec collect filter paper 4th 5th day life falseneg rate new test yet determin older children cf pancreat achylia gave abnorm result test disadvantag test meconium albumin test 10 children cf said pancreat achylia whilst method need extens evalu appear technic satisfactori other far describ
909	cystic fibrosi fast move haemoglobin letter measur fast move compon haemoglobin fmh nine children cystic fibrosi without clinic evid diabet mellitu nine patient cystic fibrosi mean fmh 93 differ significantli 97 control mean fmh 76 correl fmh age fmh durat diseas result rais question extent fmh reflect hyperglycaemia insulinopenia
910	malabsorpt malabsorpt infanc childhood roughli defin condit inadequ growth spite seemingli adequ nutrit accompani excess excret food compon stool acquir lactas defici introduct sugar diet coeliac diseas cystic fibrosi discuss
911	recent advanc screen inborn error metabol screen test diagnost procedur appli without specif clinic indic point view individu patient concern nonselect whole popul screen inborn error metabol select screen inborn error metabol screen nonamino organ aciduria select screen inborn error metabol genet indic discuss main point emerg futur review need develop multidiseas screen programm detect rare diseas postnat prenat carrier screen consid develop collect us urgent need develop screen thallasaemia sickl cell diseas cystic fibrosi congenit hypothyroid
912	cystic fibrosi adult letter long consid childhood diseas cystic fibrosi recogn increas frequenc adult case report diagnosi made adult initi diagnosi cystic fibrosi patient 30 year age rare report patient diagnosi cystic fibrosi first made 48 year age serv emphas point physician consid cystic fibrosi differenti diagnosi adult unexplain chronic obstruct lung diseas
913	risk factor develop cholelithiasi man second two part demograph characterist person high risk pigment gallston differ cholesterol stone like develop condit associ pigment gallston includ hemolyt anemia alcohol cirrhosi infect bile condit associ cholesterol gallston includ obes diet bloodcholesterollow drug disord gastrointestin tract femal sex hormon genet ethnic influenc problem area case find common disord pregnanc discuss along clinic implic diagnosi prevent therapi
914	trypsinbind igg cystic fibrosi observ cystic fibrosi patient lack alpha2 macroglobulinproteas complex bind trypsin proteas alpha2 macroglobulin lower plasma cf patient normal control therefor decid studi interact trypsin plasma protein cf patient report trypsinbind igg tbigg present 80 cf patient 30 mother 97 normal control rel cf patient experiment evid support antibodi natur tbigg presum produc porcin trypsin ingest cf patient pancreat extract substitut enzym therapi
915	cystic fibrosi challeng research manag cystic fibrosi common seriou diseas present challeng manag paediatrician nurs dietitian physiotherapist member care team outstand research challeng discov basic defect treatabl find method identifi carrier affect infant utero task work cystic fibrosi research trust rais money research support advis patient much appreci
916	cystic fibrosi nurseteach carer mother child author explain import nurs care direct member famili involv care cystic fibrosi child particular mother
917	cystic fibrosi 7 rule physiotherapi author explain treatment although timeconsum must carri everi day
918	cystic fibrosis1 clinic aspect cystic fibrosi fatal inherit diseas involv mani differ organ one time affect children die within year birth modern manag led mark improv prognosi cours increas number affect older children young adult cystic fibrosi therefor longer diseas encount paediatr unit increas surviv teen twenti affect patient appear adult unit aetiolog patholog clinic pictur diagnosi treatment prognosi discuss
919	cystic fibrosis2 genet social aspect inherit cystic fibrosi impact patient commun examin inherit genet counsel antenat diagnosi screen cystic fibrosi psychosoci aspect employ prospect cystic fibrosi research trust discuss
920	pathophysiolog failur thrive gastrointestin disord gi approach child ftt syndrom detail histori physic examin give us clue often probabl diagnosi sever laboratori test help establish fact malabsorpt among complet blood count smear quantit stool fat excret serum protein chemistri screen panel prothrombin time oral toler absorptioni glucos iron vitamin xylos special procedur may use nail diagnosi radiolog biopsi duoden intub etc never employ routin screen test howev outlin comprehens success therapi attend physician find help consid particular pathophysiolog mechan specif diseas exact diagnosi make therapi ration effect
921	recognit manag patient cystic fibrosi cystic fibrosi common lethal genet diseas childhood broad rang clinic express involv practic everi specialti medicin patholog cystic fibrosi clinic featur diagnosi treatment discuss pediatrician want attempt provid exclus care cf patient patient requir mani support special center chest surgeon pediatr surgeon otolaryngologist cardiologist gastroenterologist fact field medicin medic specialti may need variou clinic problem associ diseas
922	use new antibiot agent chronic pulmonari diseas modern advanc develop antimicrobi agent chemotherapi made avail potent aminoglycosid antibiot effect one come effect p aeruginosa great contribut patient cystic fibrosi chronic disord develop carbenicillin augment effect aminoglycosid antibiot ticarcillin similar carbenicillin play similar role antibiot therapi cephalosporin serv altern agent princip antistaphylococc activ urgent need potent antibiot agent p aeruginosa given oral rout tmpsmx combin potent chemotherapeut agent administ oral rout effect treatment p carinii pneumonia common owe extend surviv patient leukemia malign allograft prone develop infect immunosuppress therapi
923	meconium screen cystic fibrosi hand bmctest meconium signific step toward goal develop ideal newborn screen test cf easili perform highli specif reason high sensit andgiven limit identifi patient cf intrauterin pancreat insufficiencyi best method screen newborn cf devis date mani technic problem remain solv test endors without reserv test current constitut identifi potenti subject test might cf made mandatori howev better avail screen method cf prais benefit concept indic valuabl new direct massscreen possibl perhap futur modif made sensit enough warrant univers usag
924	right paratrach stripe children width right paratrach stripe rp establish normal adult normal children thymu great vessel rel larger children adult could obscur widen rp found obscur occur therefor rp less often measur children adult widen thymu great vessel howev occur width rp normal children 05 30 mm slightli less adult studi normal children subsequ experi pediatr patient conclud child rp 4 mm wider reliabl evid diseas affect trachea mediastinum pleura
925	childhood sarcoidosi fatal cor pulmonal 14 yearold white girl develop fatal cor pulmonal sever pulmonari sarcoidosi previou clinic diagnosi cystic fibrosi chest radiograph demonstr mark pulmonari fibrosi without chang sever bronchiectasi would anticip cystic fibrosi
926	cystic fibrosi protein diagnost marker individu harbor defect gene letter almost 5 year sinc public origin report describ cystic fibrosi factor design cystic fibrosi protein cfp detect serum homozygot heterozygot cystic fibrosi analyz use isoelectr focus thin layer polyacrylamid gel recent report scholey et al confirm cfp present major cf sera detect method discuss whether cfp use diagnost marker cystic fibrosi would like examin close requir method seem critic detect cfp scholey et al would like point scholey cowork adher close guidelin attempt detect cfp exact natur cfp ciliari dyskinesia factor partial known aspect metabol yet understood therefor may time comprehend incomplet concord found cfp pathogenesi cf
927	cystic fibrosi isol physic properti salivari cystic fibrosi factor ciliostat factor isol cystic fibrosi cf saliva dialyz purifi alphaamylas prepar glycogencomplex method method isol cf factor improv previous employ heparin procedur activ isol factor proport concentr use oyster gill ciliostat assay inhibit mammalian glycogen debranch enzym ciliostat action factor revers heparin certain condit type inhibit debranch enzym isol cf factor indic chemic structur similar observ hydroxyalkylamin polyamin metabolit physic properti isol factor indic low molecular weight labil function ph temperatur neutral ph condit maintain direct effect length time stabl
928	reaction 4methylumbelliferylguanidinobenzo cultiv human skin fibroblast deriv patient cystic fibrosi proteas activ cultiv human skin fibroblast quantit use 4methylumbelliferylguanidinobenzo mugb activ site titrant trypsinlik proteas 7 reaction proteas mugb complet 1 hr inhibit benzamidin pnitrophenylpguanidinobenzo p hydroxymercuribenzo extent reaction proport protein concentr independ mugb concentr activ present particul fraction cell mean titr valu nanomol 4methylumbelliferon releas per mg protein proteas fibroblast eight control n 8 oblig heterozygot h 14 patient cystic fibrosi cf n 127 011 h 082 012 cf 066 010 differ titr valu ncf nh signific p less 0001 hcf p less 001 mean titr valu obtain cultiv control amniot fluid cell 129 017 data indic reduct mugb reactiv proteas skin fibroblast deriv patient cf compar either control oblig heterozygot data consist earlier suggest 11 15 decreas proteolyt level tissu fluid patient cf may gener phenomenon
929	cystic fibrosi prognosi fiveyear surviv statist discrimin analysi appli 41 concomit variabl obtain first year studi 226 patient cystic fibrosi discrimin function base six variabl develop use predict index index estim probabl 5year surviv individu patient also use classifi patient one two group 1 live 5 year 2 die within 5 year specul classif rule cystic fibrosi present correctli assign 90 5year survivor 84 expir classif scheme use clinic research purpos
930	spermin spermidin modul cell surfac enzym adenyl cyclas adenyl cyclas activ measur membran prepar cultur fibroblast control patient cystic fibrosi enzym activ increas transit exponenti growth confluenc occur sodium fluoridestimul activ markedli display relationship basal cyclas activ vitro addit spermin 1 x 106 2 x 103 membran prepar caus inhibit basal sodium fluorid stimul enzym activ 50 inhibit basal activ occur 106 spermin spermidin 104 caus 1525 inhibit adenyl cyclas activ increas fibroblast adenyl cyclas activ transit exponenti growth compar cell obtain cystic fibrosi patient control subject basal sodiumfluorid stimul adenyl cyclas activ well inhibit enzym activ spermidin spermin undistinguish differ cell genotyp potenti modul cellular prolif activ polyamin interact adenyl cyclas system postul
931	detect cystic fibrosi protein electrofocus letter wilson et al report biophys assay cystic fibrosi employ isoelectr focus serum protein work appear establish presenc definit marker cf serum form protein band present normal serum tri repeat work found background color fresh electropherogram made rather difficult detect unequivoc presenc absenc band appropri ph region cf vs control serum howev gel photograph use kodak panatom x film wratten 25 red filter color respons contrast film elimin interfer great extent much easier detect put band agre partial observ wilson fudenberg would like stress techniqu diagnost test
932	chronic reserpin rat possibl model cystic fibrosi vii alter secretori respons cholecystokinin secretin pancrea vivo chronic reserpin rat propos anim model cystic fibrosi basi morpholog secretori alter submaxillari gland abnorm pulmonari secret investig volum composit pancreat juic reserpin treat rat 05 mgkgday compar untreat control stimul purifi cholecystokinin 01 microgramkg bodi weight crude purifi prepar secretin 6 microns100 g bodi weight infus iv 30min period result demonstr treat anim secret significantli lower volum pancreat juic stimul secretagogu flow rate also significantli reduc stimul cholecystokinin crude secretin protein amylas output respons cholecystokinin smaller control anim unrestritc feed greater 24hr fast total bicarbon output also reduc stimul either crude purifi secretin normal excret pattern bicarbon chlorid either absent revers secretinstimul pancreat juic treat anim whole pancrea homogen treat anim show signific increas ca protein content result indic chronic administr reserpin alter secret water protein bicarbon rat pancrea affect sever exocrin gland involv cystic fibrosi find lend support concept anim model human diseas chronic administr reserpin rat shown induc alter salivari pulmonari secret resembl seen patient cystic fibrosi concept anim model propos basi observ pancrea anoth exocrin gland promin involv cystic fibrosi demonstr reserpin administr also induc alter pancreat secret concept anim model would strengthen consider
933	differ cystic fibrosi normal saliva alphaamylas function age sex alphaamylas activ protein concentr cystic fibrosi cf oblig heterozygot h normal n saliva evalu respect genotyp age sex clinic statu factor present cf saliva detect effect salivari amylas activ reaction condit optim competit noncompetit inhibit tri trishydoxymethylaminomethan inhibit amylas activ ki 59 plu minu 10 mm cf factor detect effect either substrat tri bind alphaamylas alphaamylas concentrationand protein content cf saliva bimod distribut thirtysix percent cf patient found amylas hypersecretor amylas concentr 3 sd n mean amylas hypersecret margin correl genet factor parent valu p 0075 clinic statu scwachman score p 0068 hypersecretor 1424 year age group amylas concentr age signific higher cf sampl mean plu minu sd 82 plu minu 37 starch unitsml n 12 n sampl 33 plu minu 17 starch unitesml n 13 measur student ttest p 0001 salivari protein content 14 24yearold cf male elev compar group 157 plu minu 076 n 5 vs 063 plu minu 047 n 20 student ttest p 0005 mean specif activ male saliva drop sharpli age increas 1015 year 200 less 75 starch unitsmg protein mean normal femal specif activ valu essenti constant 97 plu minu 50 n 18 starch unitsmg protein 530 year age cf male specif activ valu decreas similarli n male valu preadolesc adolesc mean cf femal valu peak later 17 year maximum 171 plu minu 58 n 4 significantli higher group 16 20year age rang 63 plu minu 30 n 9 p 0005 data emphas need age sexmatch control studi salivari composit unabl detect effect salivari cf factor enzymat activ alphaamylas hypersecret salivari alphaamylas observ 36 cf patient may reflect alter secretori function basic cf secondari diseas process result decreas secret mucou salivari gland deterior pancreat function
934	biolog activ cystic fibrosi serum ii ultrastructur aspect effect cystic fibrosi sera calcium ionophor a23187 rabbit tracheal explant ultrastructur cytochem observ indic cystic fibrosi cf sera calcium ionophor a23187 induc swell increas size possibl number secondari lysosom increas mucu secret epithelium rabbit tracheal bioassay system extend incub rabbit tracheal explant either cf control sera produc cytotox effect tracheal epithelium termin normal bioassay time period compar ultrastructur studi effect cf sera calcium ionophor a23187 rabbit tracheal bioassay system indic increas membran permeabl calcium may import product ciliari dyskinesia respons cf serum factor rabbit tracheal bioassay system
935	effect saliva cystic fibrosi patient normal subject red blood cell sodium transport saliva whether taken patient cystic fibrosi normal subject caus increas red blood cell na efflux presenc absenc ouabain 1929 compar non saliva control howev signific differ effect cystic fibrosi saliva normal saliva
936	salivari amylas cystic fibrosi marker disord autonom function total serum amylas determin 83 patient cystic fibrosi cf 14 steatorrhea 21 control patient 6 patient shwachman syndrom patient cf steatorrhea therefor lack pancreat function serum level pre postprandi control subject wherea patient without steatorrhea therefor evid pancreat function significantli higher level patient shwachman syndrom significantli lower total serum amylas three patient group patient shwachman syndrom demonstr signific postprandi rise activ salivari isoenzym detect patient shwachman syndrom cf appar absent pancreat function wherea cf patient without steatorrhea salivari pancreat isoenzym result demonstr patient cf increas circul salivari amylas isoenzym wherea patient shwachman syndrom increas probabl reflect autonom hyperstimul salivari secret primari cf unrel state pancreat activ
937	calcium sodium transport process patient cystic fibrosi specif decreas mg2depend ca2adenosin triphosphatas activ erythrocyt membran cystic fibrosi patient calciumatpas activ mg2depend ca2atpas atp phosphohydrolas ec 3613 erythrocyt membran prepar cystic fibrosi cf patient greatli reduc compar erythrocyt membran control subject km calcium found similar two group howev vmax maxim rate activ ca2atpas reduc 50 erythrocyt membran prepar cf patient p less 0001 contrast mg2atpas activ erythrocyt membran cf patient unchang compar control subject differ nakatpas activ erythrocyt membran cf patient compar control patient could observ indic ca2atpas activ note cf erythrocyt part gener membran membranebound enzym alter remain determin whether alter ca2atpas activ directli relat defect calcium transport cell gener phenomenon cf present cell type directli involv secret
938	decreas adenosin 35monophosph respons isoproterenol cystic fibrosi leukocyt leukocyt prepar cystic fibrosi cf patient produc markedli less adenosin 35monophosph camp respons isoproterenol normal cell stimul ratio net isoproterenolstimul accumul camp significantli p 0001 lower mix leukocyt prepar 20 cf patient 29 trial compar 21 normal subject 49 trial signific correl result clinic score differ cf group attribut medic presenc pancreat insuffici cf heterozygot mean stimul ratio mean net isoproterenolstimul camp intermedi betweem normal cf statist signific differ among normal subject cf patient cf heterozygot basal camp prostaglandin e1stimul camp purifi mononuclear cell five normal person seven cf homozygot basal prostaglandin e1stimul camp isoproterenolstimul camp markedli depress p 001 cf cell granulocyt six normal person nine cf patient also basal prostaglandin e1stimul camp isoproterenolstimul camp decreas p 005 cf sampl result clearli demonstr differ normal cf leukocyt camp respons betaadrenerg stimul diminis camp respons betaadrenerg stimul cf probabl relat presenc cf gene may interact genet abnorm produc clinic syndrom cf
939	triglycerid level intralipid infus children cystic fibrosi infus soybean oil emuls intralipid report correct essenti fatti acid efa defici patient cystic fibrosi pancrea articl report immedi effect intralipid infus patient cf attempt ascertain biochem data whether use intralipid report dose free untoward effect six patient cf place protocol call period infus soybean oil emuls contain efa first three patient receiv 2 gmkg bodi weight intralipid fourhour period three patient receiv half dose period first three patient develop symptom pale nausea mild discomfort two three hour infus inform need determin best method correct efa defici children cf
940	late effect nocturn mist tent therapi relat sever airway obstruct children cystic fibrosi evalu longterm effect nocturn mist tent therapi progress airway obstruct children cystic fibrosi cf vari sever two match group consist 24 children cf studi 18 month mist tent therapi 18 month therapi progress airway obstruct measur chang serial measur maxim midexpiratori flow mmef regress equat mmef time obtain individu chang mmef valu without therapi compar patient match sever diseas indic initi mmef valu group whole differ found progress airway obstruct whether patient receiv mist tent therapi therapi fail benefit group children cf earli moder advanc airway obstruct judg initi mmef valu conclud nocturn mist tent therapi neither decreas airway obstruct prevent progress children cf
941	bronchial reactiv cystic fibrosi consider disput regard preval asthma patient cystic fibrosi cf studi 50 patient cf compar respons inhal histamin asthmat children incid posit respons inhal histamin 24 patient cf 90 asthmat patient found correl patient cf histamin respons sever index atopi clinic allerg diseas posit allergen skin test posit respond histamin evenli distribut diseas spectrum cf instead posit respons occur patient whose prechalleng pulmonari function abnorm conclud heighten bronchial reactiv patient cf reflect sever underli lung diseas rather presenc coexist asthma
942	hemorrhag retinopathi patient cystic fibrosi 21yearold woman histori chronic lung diseas secondari cystic fibrosi cf develop acut hemorrhag retinopathi exposur moder high altitud although retin hemorrhag known occur patient cf specul retinopathi case partial relat altitudin chang patient chronic hypoxemia may predispos highaltitud retinopathi much lower altitud
943	influenc cystic fibrot heterozyg serum rat jejunum rat jejunum bioassay shown capabl identifi cystic fibrot homozygot heterozygot therefor would appear great potenti screen test latter suggest cystic fibrosi factor influenc sodium reabsorpt inhibit activ sodium reabsorpt mechan rather inhibit passiv sodium entri cell
944	calcium sodium transport process patient cystic fibrosi 2 mg2 depend ca2 atpas activ fibroblast membran prepar cystic fibrosi patient control mg2depend ca2atpas activ determin membran prepar fibroblast grown skin biopsi cystic fibrosi patient agematch control enzym stimul increas free calcium concentr appar kdiss calcium approxim 45 micron although great deal variat ca2atpas activ observ individu strain signific decreas maxim activ ca2atpas membran prepar fibroblast obtain cystic fibrosi patient compar control p less 005 observ indic decreas ca2 atpas activ gener phenomenon cystic fibrosi found one celltyp decreas ca2atpas activ may number implic may explain manifest diseas
945	cystic fibrosi southern africa includ prepar regist carrier potenti carrier littl publish cystic fibrosi cf white southern africa figur incid exist regist cf patient parent obligatori carrier sibl uncl aunt first cousin potenti carrier compil southern africa degre cooper shown colleagu famili whose address provid possibl reason noncooper discuss number birth date patient rough estim incid republ south africa south west africa rhodesia made three region especi south africa incid like underestim detail avail regist includ number cf patient aliv dead present meconium ileu number affect patient per famili consanguin among parent grandpar frequenc ident surnam encount sibship size regist town district popul rich cf gene mention number potenti carrier determin screen practic detect test devis regist answer number question cf southern africa focus attent diseas region play major catalyt role format southern african cystic fibrosi associ
946	cystic fibrosi compar immotilecilia syndrom studi mucociliari clearanc ciliari ultrastructur clinic pictur ventilatori function patient cystic fibrosi cf investig mucociliari clearanc without stimul terbutalin clinic pictur ventilatori function ultrastructur cilia result compar patient congenit immotil cilia immotilecilia syndrom mucociliari clearanc could demonstr seven cf patient succeed inhal test aerosol ciliari ultrastructur deceas cf patient normal patient immotil cilia syndrom substanti clearanc defect cilia cf patient cough clearanc measur group studi earlier cough effect one patient succeed avoid cough measur faster clearanc got terbutalin got vehicl although younger cf patient tend obstruct lung handicap patient suffer immotilecilia syndrom latter patient discomfort rhiniti sinus otiti cf patient impair mucociliari transport rate henc unlik primari pathogen factor respiratori tract diseas cf patient
947	serum lipoprotein concentr cystic fibrosi two major class lipoprotein low densiti high densiti decreas serum patient cystic fibrosi major apoprotein also decreas sinc essenti fatti acid certain fatsolubl vitamin depend lipoprotein transport serum knowledg lipoprotein level cystic fibrosi patient could prove valuabl understand basi abnorm low serum level fatti acid vitamin ii effect therapi involv molecul
948	enhanc dexamethason resist cystic fibrosi cell potenti use heterozygot detect prenat diagnosi cultur skin fibroblast patient cystic fibrosi cf resist dexamethason toxic normal cell report fibroblast cultur oblig cf heterozygot expos dexamethason intermedi surviv compar normal homozyg cf cell dexamethason surviv test cell four patient undergo amniocentesi cell woman risk produc child cf show signific dexamethason resist similar fibroblast deriv lnown cf homozygot amniot cell specimen show dexamethason sensit similar normal skin fibroblast data suggest dexamethason resist previous observ skin fibroblast may also use prenat diagnosi cf
949	cystic fibrosi decreas conjug excret 14cspermidin free conjug 14cspermidin measur plasma sampl normal individu cystic fibrosi patient within 4 minut 14clabel materi plasma normal individu 70 percent conjug compar detect conjug cystic fibrosi patient patient excret 11 13 percent 14cspermidin urin within 72 hour wherea normal excret 60 76 percent case label materi conjug form
950	pleiotrop drug resist cystic fibrosi fibroblast increas resist cyclic amp previou studi cystic fibrosi cf fibroblast demonstr resist cytotox effect ouabain dexamethason sex hormon dihydrotestosteron 17beta estradiol progesteron show cf fibroblast also exhibit greatli increas resist cytotox effect exogen dibutyryl cyclic amp camp well isoproterenol theophyllin drug known increas endogen level camp cf cell also shown normal amount 3hcamp bind protein kinas well normal amount camp stimul protein kinas activ phosphodiesteras cf cell also found stimul camp degre normal cell find suggest detect protein kinas defici cf cell cf cell thu appear unlik campresist mutant describ other defect protein kinas activ camp regul phosphodiesteras level crossresist cf fibroblast ouabain steroid hormon camp may provid uniqu opportun studi biochem event involv metabol drug well basic biochem defect common human genet diseas
951	misdiagnosi neglect child bleed disord cystic fibrosi report describ child bleed disord secondari vitamin k defici led mistaken diagnosi child neglect eventu correct cystic fibrosi
952	biochem basi cystic fibrosi hypothesi base upon polyelectrolyt mucu evid show patholog cystic fibrosi cf relat mucoid secret consequ question govern viscos mucu examin detail gener agre mucin gel consist polyanion glycoprotein hitherto unidentifi poli cation crosslink protein propos larger amount polyc increas viscos excess caus mucu becom polyc compound known inhibit ductal reabsorpt sodium two princip aspect patholog cf relat mechan mucu globul membran mgm propos cross link protein
953	pu deoxyribonucl acid sputum viscos 100 sputum specimen select patient suffer chronic bronchiti bronchiectasi asthma cystic fibrosi total deoxyribonucl acid dna content relat macroscop type total dri weight yield appar viscos secret 1350 s1 sinc dna may present either fibr within cell onethird specimen contribut form appar viscos assess effect sputum viscos addit dna vitro also studi wherea mucoid mucopurul purul macroscop type signific differ total dna dri weight yield found viscos significantli correl purul similarli concentr either cell fibr correl significantli total dna viscos vitro addit dna sputum caus signific increas viscos reason differ iv vivo vitro effect discuss certain constitu purul sputum tend increas viscos other reduc influenc vari sever diseas studi
954	cystic fibrosi hla 94 children suffer cystic fibrosi abnorm frequenc hla marker b locu observ comparison distribut antigen control seri furthermor hla genotyp seven pair diseas sib incompat hypothesi close linkag cfan autosom recess transmit diseaseand hla
955	signific sweat test chronic pancreat order studi disposit thought latent chronic pancreat investig sweat chlorid concentr 95 normal subject 43 case chronic pancreat 12 case cholelithiasi 15 case peptic ulcer 16 case hepat diseas 23 case diabet mellitu sweat test use method pilocarpin iontophoresi obtain follow result 1 normal subject sweat chlorid concentr inclin rise gradual age childhood adulthood mean valu sweat chlorid concentr 300 meqlit adult 20 year old upper limit 60 meqlit 2 mean valu sweat chlorid concentr 600 meqlit chronic calcifi pancreat valu markedli higher control subject age p less 0001 3 mean valu sweat chlorid concentr cholelithiasi peptic ulcer hepat diseas differ significantli control subject mean valu sweat chlorid concentr diabet mellitu significantli higher control subject p less 001 significantli lower chronic pancreat p less 001 4 suppos case chronic pancreat congenit disposit toward abnorm secret sweat gland epithelium pancreat duct resembl cystic fibrosi disposit lead easili pancreat disord individu expos variou extern factor
956	coexist sickl cell trait cystic fibrosi aim paper report detail clinic patholog observ case cystic fibrosi show wide dissemin intravascular sickl best knowledg case cystic fibrosi associ sickl cell trait report literatur six month old infant diagnos cystic fibrosi sickl cell trait present literatur review coexist
957	mucopolysaccharid bronchial secret children diseas respiratori system nowaday one import medic econom social problem modern civil common symptom diseas regardless etiolog charact klinic manifest morpholog find hypersecret bronchial sputum tracheobronchi mucu produc mucou bronchial gland goblet cell mucu repres physiolog condit 5 micromet thick cover mucou nasopharynx larynx trachea bronchi termin bronchiol protect function mucu cover respos mechan humor barrier also remov inhal particl transport upper part respiratori system spite fact bronchial secret import role protect mechan thermal water exchang respiratori tract secret suffici scrutin mainli children yet
958	ruster corros action palmar sweat sodium chlorid sweat sweat 8 ruster 8 control person examin sodium concentr sweat induc iontophoresi pilocarpin distal forearm case concentr exceed normal upper limit procedur differ found two group way studi fail confirm earlier report elev sodium chlorid concentr sweat ruster propos relationship ruster patient pancreat cystic fibrosi substanti hyperhidrosi palm volar surfac finger present ruster seem main caus corros tendenc patient refer palmar hyperhidrosi found produc corros similar ruster topic applic aluminium chlorid hexahydr 25 solut absolut ethyl alcohol prove effect hyperhidrosi corros tendenc
959	inflammatori middl ear diseas patient cystic fibrosi 111 patient cystic fibrosi cf age 7 month 29 year examin detect inflammatori middl ear diseas 35 histori one attack acut otiti media incid level noncf patient none chronic suppur otiti 4 88 patient abl cooper audiometri hear impair 2 hear loss percept 3 mild fourth case moder sever middl ear pressur measur 108 patient 86 prove normal 15 patient middl ear pressur lower than100 mmh2o indic tubal occlus 7 patient imped minimum lack indic accumul mucu 7 patient 6 secretori otiti media nasal polyp present 32 correl nasal polyp tubal occlus secretori otiti incid inflammatori middl ear diseas cf patient rang noncf patient find varianc previou investig show middl ear patholog 2548
960	precipit antibodi escherichia coli bacteroid fragili ss thetaiotaomicron pseudomona aeruginosa serum normal person cystic fibrosi patient determin mean cross immunoelectrophoresi serum normal person 133 cystic fibrosi patient examin precipitin faecal bacteria e coli b fragili p aeruginosa mean cross immunoelectrophoresi 27 normal sera contain 12 precipitin e coli 16 contain one precipitin b fragili 6 contain one precipitin p aeruginosa sera cystic fibrosi patient significantli increas preval precipitin e coli 76 b fragili 38 p aeruginosa 63 mean number precipitin bacteria 3 rang 112 14 rang 14 16 rang 160 respect increas number precipitin p aeruginosa correl chronic lung infect caus speci poor prognosi wherea associ reveal regard precipitin two bacteri speci increas number precipitin e coli b fragili significantli associ increas number precipitin p aeruginosa suggest associ due immun reaction intestin mucosa result increas absorpt antigen gut
961	exocrin pancreat insuffici small intestin dysfunct protein intoler chanc occurr connect coexist cystic fibrosi cf coeliac diseas cd report eight children odd occur child 12 million 159 million sweden would around 13 million incid cf 13000 cd 11000 coexist two diseas thought chanc although cf might predispos develop cd 10year period 33405 live birth observ three children exocrin pancreat insuffici small intestin dysfunct
962	increas intracrani pressur infant cystic fibrosi letter although mechan propos dr katznelson increas intracrani pressur observ three infant cystic fibrosi cannot discount anoth explan possibl report previous defici vitamin may predispos develop increas intracrani pressur bulg fontanel cystic fibrosi final somewhat difficult understand mark airway obstruct produc increas intracrani pressur could occur preserv arteri blood gase vitamin caroten blood level determin case therefor obvious possibl cannot exclud least two case dr taussig suggest improv intracrani pressur case realli result unknow associ administr vitamin improv pulmonari statu propos fail note clinic observ rise fall bulg fontanel concomitantli increas decreas respiratori obstruct sign question sever airway obstruct clinic revers pictur sever tachypnea poor air entri clear lung field xray overdistend lung small heart appear suggest airway obstruct cf
963	precipit antibodi haemophilu influenza staphylococcu aureu sputum serum patient cystic fibrosi serum sputum sol phase 23 patient cystic fibrosi cf examin occurr titr precipitin haemophilu influenza staphylococcu aureu mean cross immunoelectrophoresi intermedi gel patient four nine h influenza precipitin serum case fewer precipitin sputum averag differ titr antibodi serum sputum antibodi crossreact speci notabl haemophilu genu aureu precipitin gener found higher number serum sputum averag titr precipitin sputum higher serum three precipitin detect sputum serum one aureusspecif precipitin antibodi crossreact speci antibodi often present sputum much higher titr correspond sera antibodi teichoic acid aureu cell wall could demonstr sputum present 22 sera possibl role local pulmonari humor immun respons protect immun patholog lung diseas cf discuss
964	iga igg antibodi surfac antigen pseudomona aeruginosa sputum serum patient cystic fibrosi eleven cystic fibrosi cf patient chronic infect lung mucoid pseudomona aeruginosa present multipl precipitin serum bacterium cf p 10 cf patient without p aeruginosa infect cfp serum sputum sol phase specimen examin antibodi iga igg class surfac antigen p aeruginosa mean indirect immunofluoresc techniqu iga igg antibodi titr demonstr serum sputum cf p patient significantli higher cfp patient p less 001 titr iga antibodi sputum higher serum 3 case indic local pulmonari product specif iga antibodi role demonstr antibodi local pulmonari immun defens mechan possibl patogenesi pulmonari tissu damag cf patient discuss
965	activ complement sputum patient cystic fibrosi 14 cystic fibrosi cf patient chronic infect mucoid p aeruginosa present multipl precipitin serum bacterium cf p 13 cf patient without p aeruginosa infect cfp plasma sputum sol phase examin albumin clq c3c3c c4 c5 mean electroimmunoassay sputum sol phase examin also factor b rocketimmunoelectrophoresi c3c demonstr sputum sol phase significantli frequent p less 001 among cf p patient among cfp patient factor b also demonstr sputum sol phase signific differ frequenc could demonstr cf p cfp patient none result indic local pulmonari product complement factor took place complement activ significantli p less 001 associ inflamm express increas formula see text result show import complement mediat inflamm pathogenesi pulmonari tissu damag patient cf support concept chronic p aeruginosa lung infect immun complex diseas cf patient
966	autoantibodi serum sputum patient cystic fibrosi sera 89 patient cystic fibrosi cf 88 control person examin occurr rheumatoid factor rf igg iga igm class indirect immunofluoresc method latex fixat slide test preval rfigg significantli higher 88 p less 00005 among cf patient among control person 7 differ found two group regard rf iga igm class fiftyf cf patient chronic pseudomona aeruginosa infect lung two precipitin bacteria sera determin cross immunoelectrophoresi cf patient differ 34 cf patient without chronic p aeruginosa infect neither regard preval titer rf posit correl number p aeruginosa precipitin 55 chronic infect cf patient titer iggrf nineteen cf patient examin also rf antinuclear antibodi ana antidna antibodi sputum sol phase correspond sera rf demonstr sputum sol phase 6 patient latex fixat test wherea sera neg test possibl indic local product rf posit reaction ana antidna antibodi found 7 10 sputa respect higher titer correspond sera also suggest local product titer autoantibodi sputum low differ found patient chronic p aeruginosa infect patient without p aeruginosa infect possibl role autoantibodi patogenesi pulmonari tissu damag cf patient discuss
967	chronic obstruct lung diseas chapter deal problem chronic obstruct lung diseas children first consid approach evalu diagnosi manag variou form chronic obstruct lung diseas emphasi histori physic laboratori data brief overview therapeut principl appli form chronic obstruct lung diseas includ second part chapter consist review common diseas produc chronic airway obstruct infanc childhood patient evalu topic discuss includ histori physic examin laboratori studi therapeut principl manag chronic obstruct lung diseas pediatr precursor chronic obstruct lung diseas chronic obstruct lung disord asthma cystic fibrosi bronchopulmonari dysplasia aspir pneumon atelectasi bronchomalacia tracheomalacia immunodefici bronchiectasi chronic bronchiti chronic upper airway obstruct hypoventil examin
968	meconium health diseas meconium first gastrointestin excret normal expel neonat review discuss composit meconium protein lipid steroid sterol bile pigment bile acid glycoprotein miner composit enzym major complic relat meconium seriou includ aspir pneumonia may prove fatal relat cystic fibrosi meconium plug syndrom meconium ileu screen cystic fibrosi also examin
969	effect oral zinc supplement plasma level vitamin retinolbind protein cystic fibrosi oral zinc supplement 100 mg zinc sulfat 8week period 36 patient cystic fibrosi 17 sibl affect vitamin transport system evidenc absenc consist signific quantit chang plasma level vitamin retinolbind protein zinc exogen zinc appear stimul growth exert clinic benefit cystic fibrosi patient lack respons zinc supplement might explain fact group cystic fibrosi subject studi fairli healthi regard clinic statu certain blood paramet includ zinc
970	fecal microflora bile acid children cystic fibrosi fecal fat bile acid rectal microflora studi seven control children three group patient cystic fibrosi cf seven antibiot ten oral cloxacillin six iv tripl therapi cloxacillin gentamycin carbenicillin least 2 week control lower concentr milligram per gram dri stool fat p 0005 vile acid p 0025 cf children antibiot antibiot littl effect fat led strike decreas p 001 bile acid tripl therapi group concomitantli reduc deconjug bile acid p 001 format secondari bile acid p 0005 associ 5fold increas percentag bile acid found aqueou phase stool mark reduct p 0001 anaerob flora log count per gram wet stool children tripl therapi 43 plu minu 19 compar control 98 plu minu 01 cf antibiot 91 plu minu 01 cf cloxacillin 96 plu minu 02 close relationship anaerob flora extent bile acid microbi transform fecal bile acid concentr suggest reduct anaerob flora decreas adsorpt bile acid dietari residu microb favor bile acid absorpt lead decreas fecal loss bile acid cf
971	serum glycineconjug bile acid pediatr hepatobiliari disord measur serum bile acid glycin conjug cholic chenodeoxychol deoxychol lithochol acid radioimmunoassay varieti pediatr hepatobiliari disord show elev neonat hepat syndrom cholestasi hepat extrahepat intrahepat origin measur individu serum bile acid fail differenti variou neonat hepat syndrom one patient cholestasi increas level bile acid observ return normal follow therapi cholestyramin phenobarbit chronic activ hepat serum bile acid valu correl well bilirubin sgot respons therapi corticosteroid data confirm suggest serum cholylglycin chenodeoxycholylglycin level sensit indic disturb hepat function use monitor cours activ therapeut respons variou hepat syndrom rey syndrom protract diarrhea infanc elev serum bile acid detect without associ hyperbilirubinemia provid addit evid disturb hepat function
972	comparison chlorid electrod gravimetr chlorid titrat sweat test chlorid electrod sweat test gravimetr chlorid titrat technic compar two technic gave compar mean valu ogiv equival point overlap patient cystic fibrosi healthi subject singl test either technic unaccept risk falseposit falseneg result test alway done pair statist interpret technic base preval technic variabl two test decreas number undiagnos subject defin probabl cystic fibrosi undiagnos group
973	comparison error due use gauz use filter paper gravimetr chlorid titrat sweat test potenti sourc error gibson cook method sweat test use gauz filter paper collect media describ absolut chlorid content gauz higher filter paper howev variabl chlorid content two insignific complet chlorid elut filter paper requir time elut gauz method determin probabl clinic accept measur base sweat sampl size chlorid determin variabl chlorid collect media also describ
974	cystic fibrosi acut hypoelectrolytemia metabol alkalosi infanc describ two infant previous undiagnos cystic fibrosi electrolyt deplet metabol alkalosi dehydr winter three infant known cf similar manifest develop confirm previou report salt deplet metabol alkalosi occur throughout year northern unit state england metabol alkalosi hypoelectrolytemia infanc explain basi clinic condit cf suspect pediatrician measur serum electrolyt valu promptli consid earli parenter fluid electrolyt therapi prevent measur infant cf persist vomit andor diarrhea
975	deminer cystic fibrosi detect direct photon absorptiometri bone miner content bone width ratio measur patient cystic fibrosi cf use monoenerget photon absorptiometri serial measur radiu ulna made 27 patient cf compar 968 agematch control deminer found 37 boy 63 girl patient age 10 year normal bone miner content nine 15 patient age 13 older deminer p less 01 deminer correl extent weight reduct patient p less 001 patient like deminer adolesc girl knowledg first report bone miner statu children cf result indic sizabl proport patient may deminer without overt ricket
976	psychosoci support adult cystic fibrosi group approach articl describ first timelimit psychosoci support group adult cystic fibrosi cfthe chronolog group trace focus issu import health profession work patient cf issu rais patient member includ doubt compet nonpediatrician adequ treat cf resent toward normal without cf includ health profession desir control mani area live possibl covert ie unrecogn issu role staff risk outcom detail guid other may wish conduct group literatur group medic patient rational benefici effect group given
977	cystic fibrosi adult 75 case review 232 case literatur cystic fibrosi common caus chronic obstruct pulmonari diseas copd pancreat insuffici first three decad life unit state report describ 75 patient cystic fibrosi age 18 47 year review anoth 232 case report literatur 307 patient elev sweat chlorid sodium level prove excel discrimin cystic fibrosi even patient older age group copd present 97 per cent major caus morbid mortal differ copd etiolog progress downhil cours patient punctuat recurr symptomat exacerb chronic bacteri bronchiti caus pseudomona aeruginosa staphyloccocu aureu termin pulmonari insuffici cor pulmonal death copd complic minor hemoptysi 60 per cent massiv hemoptysi 7 per cent pneumothorax 16 per cent problem rare children sinus present examin roentgenograph 48 per cent nasal polyposi pancreat insuffici present 95 per cent patient contrast younger patient seldom symptomat although steatorrhea azotorrhea still massiv intussuscept meconium ileu equival fecal accumul frequent adult 21 per cent rare children requir immedi diagnost therapeut intervent enema diatrizo sodium glycosuria biliari cirrhosi cholelithiasi aspermia among complic height weight usual within lower limit normal 17 per cent men 180 cm height 7 per cent overweight therefor high index suspicion need make diagnosi older patient cystic fibrosi may look quit well
978	genet counsel prenat diagnosi cystic fibrosi letter turner associ cite cystic fibrosi exampl applic judici use genet counsel prenat diagnosi reader unfamiliar genet disord prenat diagnosi genet counsel may taken cystic fibrosi exampl fact rather model intend cystic fibrosi recess disord prenat diagnosi heterozygot detect yet possibl current present inabl detect heterozyg state genet counsel individu famili histori cystic fibrosi frequent mean statist predict given rather precis recurr risk
979	quantit evalu develop exocrin pancrea cystic fibrosi control infant develop exocrin pancrea determin quantit 31 infant cystic fibrosi cf without meconium ileu 29 control infant normal pancrea ratio acinar connect tissu volum 05 32 week postconcept age pca increas linearli 20 52 week pga cystic fibrosi infant without meconium ileu ration 05 35 week pca anddecreas linearli 03 52 week pca volum acinar duct lumen greater cf control infant independ age acinar volum develop exocrin pancrea infant cf without meconium ileu diverg normal pattern consist lack exocrin tissu fullterm birth persist throghout age rang studi cf infant 42 week pca discrimin control basi quantit assess acinar volum
980	compar studi inhal atropin sulfat isoproterenol hydrochlorid cystic fibrosi investig contribut vagal tone obstruct airway diseas cystic fibrosi evalu pulmonari function respons administr 01 mg atropin sulfat per kg bodi weight 005 mg isoproterenol hydrochlorid per kg bodi weight isoton salin control solut administ nebul 3 differ day 10 patient cystic fibrosi singl blind studi dose atropin sulfat isoproterenol hydrochlorid base publish doserespons characterist drug day thorac ga volum airway resist measur volum displac bodi plethysmograph maxim expiratori flowvolum curv perform 15 30 60 min inhal inhal salin group mean valu pulmonari function indic greater airway obstruct 15 30 60 min compar pretreat valu inhal isoproterenol atropin signific improv p 005 note maxim expiratori flow 60 per cent total lung capac specif airway conduct thorac ga volum residu volum inhal atropin also significantli improv maxim expiratori flow 25 per cent vital capac isoproterenol increas mean flow 8 46 per cent baselin decreas thorac ga volum residu volum 11 16 per cent maxim respons 15 30 min atropin increas mean flow 15 77 per cent decreas thorac ga volum residu volum 16 25 per cent maxim effect 30 60 min mean respons atropin express percentag baselin alway greater equal isoproterenol conclud vagal tone may reflect increas irrit receptor activ contribut obstruct pulmonari function cystic fibrosi inhal atropin sulfat decreas pulmonari function abnorm side effect prohibit clinic use
981	pulmonari circul remodel growth diseas 1978 j burn amberson lectur account draw studi young matur lung normal morbid anatom featur normal adapt growth remodel diseas qualit analysi vascular bed develop pulmonari circul right ventricular hypertrophi cor pulmonal remodel diseas experiment studi discuss pulmonari hypertens offer us complex pattern structur function interact begin realiz complex inform normal structur modif remodel growth diseas appropri techniqu avail enabl us formul question due regard anatom precis function implic research lead understand expect control undesir aspect pulmonari hypertens
982	aspergillosi atopi cystic fibrosi fortysix patient cystic fibrosi cf studi colon sensit aspergillu organ fungu cultur 21 37 57 patient produc sputum noncf sputum isol rate 65 sputum hypha seen 95 patient posit cultur sputum eosinophilia accompani colon aspergillu aspergillu precipitin found 37 cf patient posit immedi skin test found 39 atopi defin skin test criteria found 46 find common patient sever diseas p less 005 cf patient predomin mold sensit contrast predomin pollen sensit control group asthmat subject serum ige concentr increas 22 cf patient cf patient increas serum concentr ige like famili histori atopi wheez common atop especi group predomin mold sensit sever diseas four patient fulfil diagnost criteria allerg bronchopulmonari aspergillosi abpa time studi followup fifth patient abpa diagnos studi incid abpa 2yr period cf popul 11
983	maxim expiratori flow postur drainag flow measur maxim expiratori flowvolum mefv curv use evalu efficaci postur drainag improv ventilatori function acut maxim expiratori flowvolum curv obtain 9 cystic fibrosi subject 10 subject chronic bronchiti 5 15 45 min 30min session postur drainag percuss vibrat cough forc vital capac fvc significantli increas 45 min drainag combin group flow high lung volum differ 2 subgroup subject cystic fibrosi demonstr signific increas peak expiratori flow rate 45 min drainag increas forc expiratori volum one sec time interv subject chronic bronchiti decreas peak expiratori flow rate 5 min drainag 45 min return baselin signific chang onesec forc expiratori volum time interv chronic bronchiti subgroup chang flow low lung volum similar 2 subgroup fortyf min drainag increas flow rate near 50 per cent fvc flow near 25 per cent fvc increas 15 45 min drainag studi demonstr postur drainag cough result signific improv flow low lung volum chang flow high lung volum less consist
984	relationship respons exercis allergi patient cystic fibrosi respons treadmil exercis 36 patient cystic fibrosi studi evalu use identifi atopi ten 36 patient cystic fibrosi 28 abnorm respons exercis frequent atop characterist normal exercis respons respons treadmil exercis alon cannot identifi patient atop diseas among cystic fibrosi
985	radioimmunoassay trypsin new aid assess pancreat function review describ develop applic novel test determin level human immunoreact trypsin enzym produc sole pancrea biolog fluid organ specif assay immunoreact trypsin ideal marker pancreat function support result number clinic research investig use assay studi chronic pancreat juvenileonset diabet cystic fibrosi yield much valuabl data expect research lead improv understand condit associ pancrea health diseas
986	endobronchi balloon tamponad hemoptysi patient cystic fibrosi flexibl bronchoscop fogarti balloon irrig cathet use effect manag treat hemoptysi seri patient cystic fibrosi procedur well suit patient prone recurr hemoptysi may also indic inoper patient poor cardiopulmonari reserv
987	antimicrobi suscept rough smooth mucoid coloni type pseudomona isol cystic fibrosi patient minim inhibitori concentr carbenicillin chloramphenicol tetracyclin gentamicin tobramycin trimethoprim sulfamethoxazol determin rough smooth mucoid pseudomona sp isol sputa collect 40 cystic fibrosi patient ninetyfour percent minim inhibitori concentr obtain use mix inocula coloni differ morpholog type fell within one serial dilut resist minim inhibitori concentr obtain coloni type test separ
988	result 10 year screen newborn infant inherit metabol diseas provinc limburg belgium provinc limburg newborn babi screen metabol anomali amino acidopathi sinc 1968 galactosemia sinc 1974 mucoviscidosi sinc 1978 127676 newborn 12 case phenylketonuria 3 inherit anomali meaning polici govern neonat screen necessarili requir good organ put togeth screen data diagnosi treatment followup
989	compar trial manual mechan percuss techniqu gravityassist bronchial drainag patient cystic fibrosi chest physiotherapi still remain one import aspect treatment chest complic cystic fibrosi mechan devic allow patient cystic fibrosi chest physiotherapi great benefit effect manual percuss 14 patient cystic fibrosi use mechan manual percuss physiotherapi studi measur sputum volum fev fvc result mechan percussor good manual percussor therefor would reason older patient use former
990	screen cystic fibrosi newborn meconium analysi 4year routin screen programm cystic fibrosi cf 15 464 specimen examin rais meconium albumin level test strip method electroimmunoassay incid fals posit result 5 per 1000 specimen either test could reduc 90 determin ratio albumin alpha1 trypsin inhibitor ratio 20 consid neg result could reduc zero determin ratio subsequ faecal specimen three 12 meconium specimen infant prove cf gave falseneg result 3 test 9 specimen greater 100 mg album dri weight albumin alpha1trypsin inhibitor ratio greater 30 subsequ faecal specimen ratio 40 176 meconium specimen elsewher uk examin includ 23 infant subsequ prove cf six 23 cf specimen gave falseneg result 17 strongli posit origin meconium serum protein suggest infant cf meconium give falseneg result normal pancreat function birth specif current meconium test therefor cannot improv depend pancreat dysfunct
991	pulmonari candidiasi cystic fibrosi child cystic fibrosi asthma develop pulmonari candidiasi predispos factor patient prolong antibiot therapi highdos corticosteroid intraven catheris diagnosi made lung punctur confirm rapid respons 5fluorocytosin
992	intestin bile salt cystic fibrosi studi patient experiment anim quantit qualit distribut bile salt duoden juic 13 patient cystic fibrosi cf studi test meal effect triolein bovin serum albumin bsa ricinol acid ra absorpt taurochol tca distal ileum rat vivo also studi mean rang total bile salt concentr glycin taurin conjug ratio percentag dihydroxi bile salt patient cf pancreat insuffici 35 1366 mmoll 86 greater 1031 37 1060 compar control valu 74 30160 mmoll 30 1345 61 52 70 respect differ control cf valu statist signific p less 001p less 0001 three 13 cf patient total bile salt concentr less 2 mmoll 8 much higher glycin taurin ratio 8 reduc percentag dihydroxi bile salt 2 patient normal pancreat enzym activ duoden bile salt quantit qualit normal 10 30 mmoll bsa 3 ra 5 mmoll inhibitori effect ileal absorpt tca result show pronounc abnorm duoden juic bile salt cf pancreat insuffici consist broken enterohepat circul ehc abnorm may contribut defect lipid absorpt cf data experiment anim support suggest unhydrolys dietari substrat play role pathophysiolog broken ehc
993	possibl hazard timedreleas aspirin patient pancreat insuffici episod sever small intestin hemorrhag occur cystic fibrosi patient pancreat insuffici receiv time releas aspirin therapi disabl hypertroph pulmonari osteoarthropathi increas acid small intestin content due decreas bicarbon secret observ patient pancreat insuffici may alter lumin environ result mucos eros andor ulcer associ presenc aspirin thu physician awar possibl timedreleas aspirin caus small intestin hemorrhag patient
994	cystic fibrosi brain abscess 21yearold patient cystic fibrosi develop bilater brain abscess due anaerob streptococcu rare associ present interest etiolog studi
995	cystic fibrosi hear loss mucos epithelium middl ear eustachian tube direct continu upper respiratori tract sinc otolaryngolog aspect cystic fibrosi cf domin involv paranas sinus might assum children cf would expect higher usual incid middl ear diseas eighti patient afflict cf audiolog evalu consist hear threshold level 250 8000 hz speech imped audiometri found greater incid conduct sensorineur hear loss patient cf compar normal ageadjust popul
996	vocat develop adjust adolesc cystic fibrosi adolesc cystic fibrosi compar normal adolesc age educ grade sever measur vocat develop adjust cystic fibrosi group age 1216 grade 7 8 9 score lower normal counterpart measur vocat educ plan less realist normal consid limit financi constraint contrast cystic fibrosi group nearli age grade level score significantli higher strength commit vocat choic work valu awar occup inform compar 4 addit handicap group alreadi studi adolesc cystic fibrosi score favor plan work also hold strong work valu compar normal rehabilit program emphas prepar career develop educ vocat plan adolesc still high school
997	pharmacokinet azlocillin children cystic fibrosi 6e1r2oxoimidazolidine1carboxamido2phenylacetamido penicillan acid sodium salt azlocillin securopen given dose 100 200 mgkg bodi weight children cystic fibrosi intraven bolu infect serum halflif 082 012 h lower dose 098 018 h higher dose consequ dose limit elimin kinet due limit renal nonren process elimin upon doubl dose 100 200 mgkg total bodi clearanc drop 1393 510 1h evalu data present public indic dose limit elimin kinet normal situat azlocillin besid serum concentr patient cystic fibrosi consider lower seen healthi state reason faster elimin renal rout cystic fibrosi
998	die children need help control symptom die children often sadli neglect neglect reflect review case note two children die cystic fibrosi within three year girl care consult interv two case introduc concern proper termin care children
999	cystic fibrosi relev famili practition major chang outlook children cystic fibrosi last 20 year provid diagnosi made seriou irrevers lung diseas occur patient expect reach adult life without seriou disabl
1000	inhibit tammhorsfal glycoprotein induct alkalin phosphatas cystic fibrosi fibroblast medium condit normal cell confirm level alkalin phosphatas fibroblast deriv cystic fibrosi patient induc manyfold grow cell presenc tammhorsfal glycoprotein shown normal fibroblast produc cf correct factor markedli inhibit phenomenon observ support previou hypothesi natur metabol defect cystic fibrosi
1001	antibodi respons influenza viru vaccin patient cystic fibrosi patient cystic fibrosi immun subunit influenza vaccin haemagglutinationinhibit hi antibodi respons compar respons young healthi adult signific differ antibodi level reach immun evid impair respons patient group
1002	biolog activ cystic fibrosi serum iii cf serum induc uptak 45ca rabbit tracheal explant cystic fibrosi cf serum isol compon igg fraction produc increas uptak 45ca rabbit tracheal explant compar control serum isol igg fraction heterozygot serum also produc increas uptak 45ca extent cf serum calcium channel blocker d600 inhibit cf serum induc uptak 45ca indic cf serum may act plasma membran produc chang calcium permeabl rabbit tracheal explant
1003	differenti concanavalin bind cystic fibrosi normal liver alphalfucosidas novel techniqu employ demonstr alphal fucosidas purifi cystic fibrosi control liver exhibit differenti bind lectin concanavalin concentr alphach3mannosid necessari prevent 50 bind alphalfucosidas concanavalin consider lower cystic fibrosi enzym 135 vs 333 mm compar result found bind studi done crude supernat alphalfucosidas 8 cystic fibrosi 8 control liver 56 plu minu 04 mm 132 plu minu 34 respect without overlap valu cystic fibrosi control liver result suggest compar lectin bind studi cystic fibrosi normal glycoprotein readili avail tissu might result assay detect cystic fibrosi genotyp
1004	enzym immunoassay albumin aid diagnosi cystic fibrosi newborn human proceed one symptom cystic fibrosi mucoviscidosi pancreat insuffici reduc proteolyt activ gut children diseas result elev concentr protein especi serum albumin meconium featur use diagnosi diseas newborn decid examin util enzym immunoassay measur albumin meconium sampl normal cystic fibrosi infant normal sampl found appar albumin concentr rang 005026 mgg dri wt wherea cystic fibrosi sampl concentr rang 60230 mgg dri wt assay provid cheap rel rapid method differenti cystic fibrosi posit neg meconium sampl
1005	induct alkalin phosphatas cultur human fibroblast comparison normal cell patient cystic fibrosi membran glycoprotein enzym alkalin phosphatas induc cultur human fibroblast dibutyryl cyclic amp sodium butyr serum glycoprotein fetuin tammhorsfal urinari glycoprotein number inhibitor dna synthesi uninduc basal enzym activ increas later stage growth cell becam confluent induct dibutyryl cyclic amp fetuin effect agent ad cell reach stationari phase maxim least two day exposur level induct result addit pair agent dibutyryl cyclic amp nbutyr fetuin addit indic differ mode action inhibitor dna synthesi cytosin arabinosid hydroxyurea methothrex less effect induc bromodeoxyuridin also nondna mediat effect induc extent dibutyryl cyclic amp similar experi sex agematch cell strain deriv patient cystic fibrosi fail detect differ level induct observ normal cell addit combin induct effect tamm horsfal glycoprotein isoproterenol theophyllin similar normal cystic fibrosi cell
1006	plasma membran lipid human diploid fibroblast normal individu patient cystic fibrosi lipid composit isol plasma membran human skin fibroblast describ first time plasma membran number strain fibroblast patient cystic fibrosi match normal isol recent describ procedur analys major phospholipid class cholesterol fatti acid differ quantiti compound detect cell two differ origin fetal calf serum use supplement growth medium contain rel palmitol oleat less stearat membran also consist differ cystic fibrosi normal membran term fatti acid composit individu phospholipid class consist lack chemic chang lipid membran cystic fibrosi cell degre fluoresc polar diphenylhexatrien index fluiditi also unchang
1007	2 theori genet causat human diseas central problem mid20th centuri genet counselor determin place gene origin complex human characterist neural tube defect cleft palat diabet congenit heart diseas short major malform polygen syndrom make bulk call birth defect compar import term genet counsel understand origin incid newli recogn genet heterogen lie behind previous regard simpl singlegen determin diseas topic includ deal genet heterogen phenotyp genotyp genet causat defi simpl analysi sourc variat behavior disord presumpt singlegen causat leschnyhan diseas presumpt sexlink causat aggress presumpt polygen causat alcohol also discuss
1008	bronchial arteri embol control massiv haemoptysi bronchial arteri embol use palli treatment lifethreaten haemoptys surgeri contraind patient present haemoptys complic cystic fibrosi aspergilloma embol control haemoptysi achiev former late recurr haemoptysi latter led asphyxi
1009	new mechan aid physiotherapi cystic fibrosi forc impact frequenc percuss physiotherapist parent children cystic fibrosi analys special test rig incorpor prototyp percussor adult volunt cadav maximum intrathorac pressur could achiev critic frequenc mechan percuss higher reach physiotherapist parent consequ percussor redesign oper optimum frequenc discov percussor press firmli enough chest maximum intrathorac pressur could indic quiver voic continu studi intrathorac pressur obtain mechan manual salford percussor produc higher pressur physiotherapist maintain constantli physiotherapist effort result vari one anoth hospit domiciliari use percussor shown help first stage physiotherapi routin patient cystic fibrosi percussor enabl adolesc adult treat encourag twicedaili effect chest treatment easi appli speed effici enabl parent improv qualiti chest therapi younger children home longterm benefit difficult assess natur diseas
1010	evalu forc expir techniqu adjunct postur drainag treatment cystic fibrosi sixteen patient cystic fibrosi treat convent physiotherapi aid assist result compar produc physiotherapi use forc expir techniqu clear sputum less time convent physiotherapi sputum less time convent physiotherapi second studi show assist improv result obtain patient perform forc expir techniqu find mean patient cystic fibrosi reli help other home treatment may perform effect treatment without help forc expir techniqu might also help patient chronic bronchiti asthma bronchiectasi
1011	die children need help control symptom die children often sadli neglect neglect reflect review case note two children die cystic fibrosi within three year girl care consult interv two case introduc concept proper termin care children two case show ill caus physic emot spiritu pain famili staff retrospect area distress clearli defin either case opportun allevi suffer miss principl control symptom need rememb much distress treatment distress die
1012	nocturn element diet retard growth patient cystic fibrosi combin chronic pulmonari sepsi pancreat insuffici children cystic fibrosi may lead malnutrit describ experi longterm use continu nocturn infus element diet patient cystic fibrosi patient toler longterm nocturn element diet well enabl continu normal everyday activ eat normal meal period nutrit support coincid period increas bodi weight total bodi potassium indic lean bodi mass increas think result show need studi home treatment children cystic fibrosi
1013	lung function abnorm cystic fibrosi chang growth static lung volum vc tlc frc rv elast recoil pressur lung pst1 100 90 60 tlc static lung complianc cst1 specif airway conduct frc level gawtgvex forc expiratori volum first second fev1 maxim expiratori flow vmax 25 50 vc 60 tlc upstream airway conduct gu 60 tlc studi 28 patient cystic fibrosi 5 25 year old period 1 5 year data compar individu normal valu relat bodi height form regress equat express percentag predict valu indic assess airway function vmax low lung volum gu 60 tlc rv rvtlc function paramet consist abnorm among indic character lung elast pst1 60 tlc abnorm gener valu major lung function indic vc tlc frc pst1 declin growth vmax lung volum gu 60 tlc deterior growth probabl due great abnorm paramet alreadi young patient also observ lung function chang significantli period 1 5 year correspond 10 cm increas bodi height howev period lung function improv subject chang 50 case deterior other
1014	role nutrit statu airway obstruct hypoxia abnorm serum lipid composit limit exercis toler children cystic fibrosi studi investig role hypoxia pulmonari mechan nutrit statu serum fatti acid composit limit exercis toler cystic fibrosi twenti children cf carri sever perform two progress exercis test cycl ergomet breath air breath o2 children lower maxim midexpiratori flow rate tend littl respiratori reserv final work load conclud nutrit statu airway obstruct close correl exercis toler cf unlik adult chronic obstruct pulmonari diseas exercis limit dyspnoea occur presenc normal endtid co2 ct 1 leupold w z klin med 40 661 985
1015	one breath time famili teach program children cystic fibrosi found patient cystic fibrosi special peopl overcom appar insurmount odd teach program come basic belief support encourag affect inform focu posit aspect life person cf live well even one breath time
1016	noninvas radionuclid assess right ventricular perform man chapter focus applic radionuclid angiocardiographi assess right ventricular eject fraction relationship right left heart perform demonstr techniqu prior discuss clinic applic function geometri two ventricl review addit firstpass radiotrac techniqu compar radionuclid imag approach right heart firstpass radionuclid angiocardiograph techniqu suitabl clinic applic valid standard reli upon accur reproduc noninvas assess right left ventricular perform alreadi appli studi patient cardiopulmonari diseas futur direct includ earlier evalu myocardi infarct applic children adult varieti congenit cardiac abnorm primarili affect right heart assess effect physiolog stress upon right ventricular function background valuabl clinic investig insight becom avail come year
1017	vitro suscept pseudomona four betalactamantibiot ampicillin cephalothin carbenicillin piperacillin four aminoglycosid kanamycin amikacin gentamicin tobramycin colimycin 97 welldefin strain pseudomona isol sputum patient cystic fibrosi cf minimum inhibitori concentr mic sever antibiot determin broth dilut method major strain resist ampicillin cephalothin moder suscept carbenicillin 70 100 microgramml highli suscept piperacillin 100 25 microgramml 88 625 microgram 60 312 microgramml pharmacolog properti piperacillin compar carbenicillin expect sputum level drug adequ treat pseudomona pulmonari infect lowest concentr test 078 microgramml 3 strain suscept kanamycin 855 amikacin 95 gentamicin 98 tobramycin 80 colimycin regard clinic attain concentr 989 strain suscept gentamicin tobramycin 979 amikacin 969 colimycin 886 piperacillin 38 carbenicillin 257 kanamycin 123 ampicillin 1 cephalothin
1018	echocardiograph profil longterm cardiac chang cystic fibrosi echocardiograph studi assess heart children cystic fibrosi shown chang occur right ventricl also left ventricl aorta compar normal echocardiogram could success perform 34 37 patient thick right ventricular anterior wall dimens right ventricular caviti abnorm even patient mild diseas nation institut health nih score sever diseas 85 greater larger older children lower nih score disproportion larger right ventricular anterior wall caviti thick septal wall thick left ventricular posterior wall aortic dimens increas sever diseas dimens left ventricular caviti popul slightli significantli smaller normal systol diastol throughout cours diseas studi demonstr echocardiographi effect noninvas mean assess longterm chang children cystic fibrosi chang occur side heart appear worsen diseas progress
1019	lymphocyt acidhydrolas respons mitogen cystic fibrosi present studi compar level seri cultur lymphocyt acidhydrolas enzym cystic fibrosi homozygot heterozygot control compar effect three differ mitogen level studi effect cf vs control serum cultur medium observ provid entir new interpret appar chang occur lymphocyt enzym cultur lymphocyt mitogen suggest serum factor present cystic fibrosi serum mimic mitogen regard lymphocyt acidhydrolas total protein present higher concentr lymphocyt cultur 48 hour without mitogen cf homozyg heterozyg serum present cultur media appear result cf serum factor mitogenlik activ prevent loss cell protein cultur respons cellular protein mitogen blunt cf serum present cultur media either cell protein alreadi maxim stimul cf serum factor factor block modifi action mitogen lymphocyt protein content phenomenon use detect cf heterozygos appear reflect genet abnorm caus cystic fibrosi
1020	measur region lung function tetrapolar electr imped plethysmographi studi demonstr clinic feasibl atraumat measur dynam region lung function tetrapolar electr imped plethysmographi eip pediatr age group tetrapolar electrod system use abil detect local baselin pulsatil imped chang minim electrod tissu imped interfer uniform current distribut studi perform 4 children 4 15 year old variou pulmonari diseas present inform obtain region ventil pulsatil perfus eip found agre close pulmonari ventil perfus scan one case eip detect pulsatil perfus abnorm appar nonpulsatil perfus scan demonstr cineangiographi conclud tetrapolar eip provid safe reliabl region inform ventil perfus diseas lung atraumat approach technic suitabl use children
1021	evalu singlebreath diffus capac asthma cystic fibrosi explain singlebreath carbon monoxid diffus capac dsb averag elev 163 asthmat subject 175 patient cystic fibrosi simul elev ten normal subject perform test dsb inspiratori obstruct result 18 percent increas dsb correct pulmonari volum inhal bronchodil drug associ relief obstruct fall correct dsb 31 asthmat subject chang either obstruct correct dsb 17 patient cystic fibrosi suggest elev dsb asthma cystic fibrosi partli due maxim inspir obstruct airway requir abnorm neg intrathorac pressur increas pulmonari capillari blood volum therebi increas dsb
1022	echocardiograph abnorm patient cystic fibrosi echograph studi undertaken evalu left lv right ventricular rv function 30 patient cystic fibrosi echograph record pulmonari aortic valv echogram permit measur phase right left ventricular systol ratio lv preeject periodlv eject time lpeplvet shorten lv intern dimens sid employ reflect lv function rv preeject periodrv eject time rpeprvet excel correl pulmonari arteri diastol pressur rpeprvet two echograph measur right ventricular wall rvw intern dimens rvd compar pulmonari function test clinic score rpeprvet correl well percent vital capacityvc r 073 percent residu volum rvol r 072 clinic score r 077 multilinear regress rpeprvet rvd rvw improv correl vc r 080 rvol r 082 clinic score r 084 patient overt right heart failur exhibit elev rpeprvet mean 048 compar patient right heart failur mean 33 mark diminut lv function present two patient varieti cardiovascular abnorm demonstr echograph valuabl assess degre cardiac involv patient cystic fibrosi
1023	respons bronchial provoc exercis children cystic fibrosi ten fifteen cystic fibrosi children posit skin prick test common antigen gave immedi bronchial reaction antigen inhal five also gave late reaction howev one gave histori asthma antigen commonli elicit posit skin reaction cystic fibrosi patient aspergillu fumigatu six children test antigen bronchial respons vari two neg one gave immedi reaction three gave dual immedi late reaction none children show characterist pattern respons exercis seen asthmat patient initi rise peak expiratori flow rate follow fall greater 14 rest level two patient show abnorm rise peak expiratori flow rate exercis pattern describ previous cystic fibrosi result suggest bronchial allergi immedi late complet explain suscept asthma factor includ perhap type bronchial reactiv shown bronchoconstrict exercis may requir howev major children test bronchial allergi anti allergi therapi inhal sodium cromoglyc may place manag select patient cystic fibrosi
1024	ige mediat hypersensit pancreat extract pe parent cystic fibrosi cf children exposur pancreat extract pe four parent cystic fibrosi cf children develop immedi hypersensitivitylik symptom ie rhinoconjunct asthma andor anaphylaxi ige pe demonstr subject skin test leucocyt histamin releas radioallergosorb test rast serum precipit antibodi found bronchial challeng caus immedi asthmat respons delay asthmat respons hypersensit pneumonitislik reaction occur respons antigen pe induc asthma unknown trypsin fail inhibit perast therefor respons subject caution exercis use pe skin test bronchial challeng subject suspect hypersensit pe certain measur found use prevent occurr symptom four subject
1025	studi erythrocyt fatti acid adenosinetriphosphatas acetylcholinesteras cystic fibrosi 1 proport satur polyunsatur fatti acid measur erythrocyt cystic fibrosi cf patient along two membran bound enzym atpas acetylcholinesteras linol acid found significantli decreas arachidon acid increas cf patient proport satur fatti acid significantli differ control adenosinetriphosphatas activ found reduc acetylcholinesteras cf patient
1026	measur 4hydroxyphenylacet aciduria screen test smallbowel diseas evalut measur urinari 4hydroxyphenyl acet acid potenti screen method smallbowel diseas bacteri overgrowth syndrom 360 unselect acut ill infant children control data obtain 120 healthi children age 15 15 year gener medic practic 48 healthi infant age one five year local day nurseri 150 healthi babi age less one eight day compar data 300 acut ill hospit babi children rang age less one day 15 year without clinic evid small bowel diseas bacteri overgrowth syndrom falseneg result 2 falseposit result observ among 10 patient whose urinari excret analyt consid abnorm patient giardia lamblia infest ileal resect blind loop diseas small intestin associ bacteri overgrowth conclud measur 4hydroxyphenylacet acid excret use screen diseas
1027	qualiti sweat test perform diagnosi cystic fibrosi sweat test correctli perform appear reliabl result found unreli half time 84 small commun hospit assess reason inexperienc untrain technician infrequ test perform use unstandard equip lack appropri standard behoov clinic laboratori director reexamin standard procedur use recommend cystic fibrosi foundat physician made awar current situat send patient laboratori perform test reliabl
1028	secret betanacetylglucosaminidas isoenzym cultur cystic fibrosi fibroblast secret lysosom enzym betanacetylglucosaminidas ec 32130 normal cystic fibrosi fibroblast compar contrast earlier report differ found either rate secret molecular form enzym secret normal fibroblast cultur cultur initi patient cystic fibrosi b isoenzym betan acetylglucosaminidas cystic fibrosi fibroblast convert neg charg form preincub 3 h ph 50 37 degre c enzym normal fibroblast unaffect treatment
1029	glycosidas serum cystic fibrosi patient studi eight glycosidas serum sampl 72 cystic fibrosi patient 85 cystic fibrosi parent 34 healthi diseas control signific elev mean alphaglucosidas level found cystic fibrosi patient glycosidas show signific chang mean alphaglucosidas level oblig heterozygot control individu moreov alphaglucosidas level cystic fibrosi patient correl degre clinic impair measur schwachman score
1030	carboxypeptidas b activ cultur skin fibroblast relationship cystic fibrosi enzym activ hippuryllarginin studi cultur skin fibroblast control cystic fibrosi patient enzym lysosom distribut acid optimum ph 45 littl activ present ph 70 dithiothreitol requir full activ kinet thiol activ differ control cystic fibrosi enzym properti lysosom distribut enzym indic carboxypeptidas b substrat affin thermol ph stabil fall rise activ subcultur cyclic pattern activ serial passag level activ similar control cystic fibrosi enzym
1031	decreas sialic acid alter bind lectin purifi alpha 2macroglobulin patient cystic fibrosi purifi prepar plasma alpha 2macroglobulin patient cystic fibrosi shown normal amount total hexos much 40 decreas sialic acid content bind prepar concanavalin wheatgerm agglutinin markedli reduc compar normal valu control intermedi valu found oblig heterozygot result suggest possibl alter carbohydr moieti alpha 2macroglobulin cystic fibrosi presum due defect posttransl process
1032	abnorm distribut alphalfucosidas cystic fibrosi decreas activ serum activ alphalfucosidas decreas serum cystic fibrosi patient compar agematch control result combin elev activ skin fibroblast support concept abnorm intracellular extracellular distribut alphalfucosidas cystic fibrosi
1033	electrolyt norepinephrin level blood patient cystic fibrosi young adult cystic fibrosi good excel condit reduc plasma sodium chlorid elev plasma potassium compar group healthi young adult control subject blood pressur also lower patient cystic fibrosi howev plasma norepinephrin dopaminebetahydroxylas respons stand isometr hand grip normal cystic fibrosi patient
1034	primari amniot fluid cell skin fibroblast liver alphalfucosidas relat cystic fibrosi cultur skin fibroblast primari amniot fluid cell alphal fucosidas doubl optimum ph 50 60 alphalfucosidas larg bound singl peak deaecellulos ph 66 sucros densiti isoelectr focus reveal seven compon pi valu 49 52 54 58 61 65 71 appar km valu 77500 mumol higher 57 mumol unfocus enzym liver skin fibroblast amniot fluid cell alphalfucosidas separ two peak gel filtrat peak one activ stabl low ph thermost 50 degre c peak two peak appar km 52 mumol apart differ proport peak separ gel filtrat result three tissu similar properti alphalfucosidas studi similar control cystic fibrosi liver skin fibroblast
1035	allergi cystic fibrosi fortyfour patient cystic fibrosi sixtyseven parent thirtynin control compar regard immedi cutan hypersensit total specif serum ige serum igg4 concentr patient increas prick test reaction specif ige aspergillu fumigatu develop reaction fumigatu correl sever diseas signific differ serum total ige specif ige igg4 concentr skin test reactiv compar patient parent control
1036	heterozygot advantag cystic fibrosi mosquito test test demonstr prefer mosquito sting control oppos oblig heterozygot cystic fibrosi prove neg heterozygot advantag caus lower malari incid carrier south west africa must work malari parasit advers affect serum factor remain test
1037	defici serum carboxypeptidas blike anaphylatoxin inactiv carboxypeptidas n activ sera patient cystic fibrosi serum 95 patient cystic fibrosi 47 control subject without cystic fibrosi analyz carboxypeptidas blike activ presenc optim concentr co2 ion hippurylllysin serum fourteen cystic fibrosi patient steatorrhea therefor minim pancreat dysfunct patient cystic fibrosi control compar age serum carboxypeptidas blike activ significantli decreas cystic fibrosi patient includ cystic fibrosi patient without steatorrhea significantli low valu found male femal cystic fibrosi patient compar control similar sex although valu unaffect age control popul valu older patient cystic fibrosi significantli lower valu younger patient correl obtain serum carboxypeptidas blike activ pulmonari hepat function serum carboxypeptidas blike activ therefor fall progress diseas may limit abil degrad circul peptid older patient cystic fibrosi defici serum carboxypeptidas blike activ less like howev factor develop earli manifest diseas
1038	falseposit 111inlabel leukocyt scan cystic fibrosi falseposit 111inlabel leukocyt scan obtain girl cystic fibrosi infect focal accumul 111in activ abdomen mark pulmonari uptak surgic explor postmortem examin reveal abdomin abnorm abnorm activ appar due swallow sputum contain label leukocyt broader clinic implic discuss
1039	studi oligosaccharid unit mucu glycoprotein meconium normal infant case cystic fibrosi meconium ileu 1 mucu glycoprotein meconium normal infant infant cystic fibrosi meconium ileu studi 2 wherea normal meconium contain 50 proteinbound carbohydr meconium cystic fibrosi contain 10 3 glycopolypeptid prepar mucu glycoprotein oligosaccharid unit materi releas fraction fraction rang wide size composit 4 fraction cystic fibrosi specimen significantli higher content fucos normal specimen
1040	pseudomona aeruginosa infect pathogenesi therapi infect gramneg bacillu pseudomona aeruginosa less common infect escherichia coli klebsiella pneumonia proteu sp howev mortal associ pseudomona sepsi exce found commonli isol gramneg bacilli consider margin explan exist increas virul pseudomona includ secret toxic exoproduct high degre antibiot resist precis reason unfavor clinic experi organ uncertain current interest pseudomona infect partli due everincreas number immunosuppress granulocytopen patient seen clinic practic organ pathogenesi clinic present burn patient nosocomi infect immunosuppress patient cystic fibrosi therapi discuss
1041	lipid cystic fibrosi certain aspect symptomatolog cystic fibrosi bear resembl essenti fatti acid defici fed group patient essenti fatti acid oral sinc intraven administr practic method long term treatment result studi vari although respons note patient consist clinic chang seen everi patient oral efa therapi effect chang sputum cultur one year efa sweat sodium concentr lower one patient clinic aspect studi small promis result suggest role efa care cf whether efa factor etiolog cf mere manifest malabsorpt requir investig
1042	obstruct respiratori pathway evalu method function examin lung develop patient cystic fibrosi 28 patient cystic fibrosi age 524 year valu maximum expiratori flow rate vmax lower volum level assess well specif conduct respiratori pathway gawtgv vital capac vc total lung capac tlc residu volum rv function residu capac frc rvtlc frctlc ratio onesecond forc expir vital capac fev1 evalu obstruct respiratori pathway markedli frequent abnorm valu vmax rv rvtlc ratio find reveal almost patient cf alreadi initi examin obstruct peripher respiratori pathway hyperinfl lung repeat measur valu lung function 15 patient cystic fibrosi period 15 year patient increas height 10 cm averag valu deterior averag howev individu variabl investig valu period comprehens treatment provid countri prevent patient cf deterior obstruct respiratori pathway period investig
1043	prenat diagnosi cystic fibrosi letter far know test prenat diagnosi cystic fibrosi yet shown reliabl sever experiment studi prenat diagnosi cystic fibrosi carri defici proteas activ assay 4methylumbelliferyl guanidinobenzo activ site titrant serin proteas report plasma cultiv skin fibroblast patient cystic fibrosi anoth prenat diagnost test cystic fibrosi involv observ resist patient skin fibroblast dexamethason synthet glucocorticoid toxic comparison normal fibroblast specif induct alkalin phosphatas tamm horsfal glycoprotein isoproterenol theophyllin record skinderiv fibroblast affect patient
1044	clinic pharmacolog paediatr hospit despit critic role play clinic pharmacologist three canada special paediatr role paediatr clinic pharmacologist promot safer effect drug use research teach servic discuss well contribut clinic pharmacolog
1045	proteas defici plasma patient cystic fibrosi reduc reaction 4methylumbelliferylguanidinobenzo plasma patient cystic fibrosi proteas activ plasma assay use 4 methylumbelliferylguanidinobenzo assay modifi carri reaction presenc absenc benzamidin competit inhibitor trypsinlik proteas paramet assay describ detail use assay earlier demonstr defici proteas activ plasma patient cystic fibrosi confirm activ correct nonspecif hydrolysi 4 methylumbelliferylguanidinobenzo benzamidin express nanomol 4methylumbelliferon releas per millilit plasma standard condit activ plasma activ chloroformellag acid 1272 231 7 control 704 117 11 oblig heterozygot 487 166 12 patient cystic fibrosi ident result obtain unactiv plasma use data demonstr judici use specif inhibitor benzamidin might use assay low level proteas activ crude system
1046	evalu long term tobramycin therapi patient cystic fibrosi advanc pulmonari diseas nine cystic fibrosi patient chronic bronchopulmonari infect sever damag lung invad pseudomona aeruginosa eleven cours prolong tobramycin treatment 5 mgkgday four 16 week administ pulmonari symptom improv better qualiti life achiev one patient object paramet chest xray pulmonari function test chang lesser extent one patient pseudomona erad sputum reappear discontinu therapi rest patient pseudomona significantli suppress replac pathogen four patient show rise antibodi titr candida two aspergillu fumigatu nephrotox side effect observ vestibular function revers impair one patient without correspond clinic symptom bacteri resist tobramycin observ therapi
1047	cystic fibrosi decreas thermost alphamannosidas crude extracellular fluid patient carrier wish demonstr abnorm thermost found crude extracellular fluid alphamannosidas extens studi involv sever leaki hydrolas way indic observ thermol exploit develop urgent need simpl diagnost tool cystic fibrosi
1048	relationship clinic condit radiograph find pulmonari function patient cystic fibrosi clinic radiolog find quantifi special score 36 patient cystic fibrosi compar lung function measur includ ratio rvtlc fevvc arteri blood gase rest exercis although respiratori function test found correl well pulmonari find score chest radiograph score distinct three sever group possibl vector calcul blood gase pao2paco2diagram rest exercis thu measur po2 pco2 rest exercis appear help adjuv routin spirometri individu apprais degre lung involv perform care level
1049	complement cystic fibrosi quantit function assess made classic altern pathway complement activ sera 23 patient cystic fibrosi classic pathway function similarli patient control measur ch50 titr altern pathway function initi patient sera incub inulin equal control determin cleavag factor b c3 consumpt termin compon factor b howev readili activ patient control sera rapid alter factor b lead acceler extens activ termin complement compon via altern pathway assess c3 cleavag consumpt termin compon thu complement defici found import easili activ factor b undefin
1050	substanc p plasma level pregnanc variou clinic disord use radioimmunoassay immunoreact sp isp measur plasma 162 hospit patient variou disord plasma 67 pregnant women pregnanc isp undetect 40 women compar 12 hospit patient mean isp plasma level pregnanc 378 46 sem compar 771 49 sem pgml hospit patient result support earlier observ base bioassay suggest blood pregnant women contain higher concentr spinactiv factor hospit patient elev level isp found patient chronic leukaemia one patient basaloid carcinoma anu one patient toxic liver damag pancreat insuffici correl found thyroid function isp plasma level isp plasma level variou gastrointestin disord similar found normal subject
1051	effect serum patient pancreat diseas short circuit current rat jejunum short circuit current rat jejunum bioassay first employ attempt discern cystic fibrosi cf serum factor evalu use sera patient pancreat diseas data suggest pancreat diseas specif genet diabet alcohol pancreat also present serum factor factor reduc short circuit current rat jejunum effect similar cf serum factor larg number sera presum normal subject also exhibit signific reduct short circuit current fals posit repres yet defin mechan howev decreas likelihood observ effect mere due pancreat destruct detail procedur equip specif bioassay system includ
1052	defect cellular immun gramneg bacteria cystic fibrosi patient vitro lymphocyt respons pseudomona aeruginosa found impair cystic fibrosi patient advanc clinic diseas respons klebsiella pneumonia serratia marcescen proteu mirabili studi similar group cystic fibrosi patient normal individu cystic fibrosi patient found unrespons pseudomona also unrespons klebsiella serratia proteu respons staphylococcu aureu impair cystic fibrosi patient postul vitro lymphocyt respons sever gram neg bacteria requir function lymphocyt subpopul may impair cystic fibrosi patient
1053	high dosag tobramycin treatment children cystic fibrosi bacteriolog effect clinic ototox bacteriolog effect chemotherapi mucoid strain pseudomina aeruginosa lower respiratori tract patient cystic fibrosi report comparison effect high dose tobramycin 10 mgkg24 h given alon combin carbenicillin show signific differ favour combin therapi 745 initi success cours patient recolon within one month fiftythre patient examin audiometr vestibular test one patient possibl regist transient high tone hear impair 8000 hz bilater might attribut tobramycin treatment conclud high dose tobramycin treatment children adolesc normal kidney function impli minim clinic risk advers ototox effect even repeat cours treatment nephrotox sideeffect found materi
1054	immotilecilia syndrom ciliari diseas purpos review present evid disord believ caus defect cilia review data occurr abnorm cilia evid form respons environment insult cilium human ciliat structur immotilecilia syndrom inborn ciliari diseas cystic fibrosi acquir disord ciliat structur discuss ciliari activ vital loss caus great deal discomfort greatest problem relat lower respiratori tract also site cilia bodi strike certain degre clearanc maintain lung absenc motil cilia cough hawk mechan
1055	cystic fibrosi cystic fibrosi hereditari disord affect infant children adolesc young adult genet influenc sign symptom diagnost test nutrit manag diet therapi respiratori infect growth retard discuss
1056	tobramycin ototox repeat cours high dosag treatment children cystic fibrosi fiftythre patient cystic fibrosi treat larg dose tobramycin sulphat 10 mgkg24 h patient receiv averag 32 cours last 10 14 day patient examin audiometr vestibular test one patient 10yearold girl found transient high tone loss 8000 hz bilater might attribut tobramycin treatment patient normal kidney function high dose tobramycin treatment children normal kidney function give minim clinic risk advers ototox effect even repeat cours treatment
1057	round tabl discussiontreat lower respiratori tract infect cotrimoxazol one thousand patient acut chronic chest infect treat combin trimethoprim sulphamethoxazol patient may divid four group result summaris present much work publish elsewher
1058	epidemiolog cystic fibrosi review three main reason advanc degre ignor confus surround epidemiolog measur incid preval cystic fibrosi cf rel recent recognit cf specif diseas entiti wide rang clinic manifest present multisystem diseas great natur variat sever involv variou organ past difficulti establish diagnosi base sound laboratori evid larg due lack screen test gain wide accept among diagnostician inaccuraci perform interpret sweat test addit factor number methodolog defici question assumpt sever paper review may noteworthi two set author whose research design close match aim provid multipl ascertain case crosscheck valid arriv nearli estim incid particular disord 13700 13800 respect issu select diagnost criteria one import implic epidemiolog studi cystic fibrosi particularli diseas like cf spectrum clinic manifest sever involv broad estim incid vari accord criteria case ascertain includ greater degre uniform standard employ previou studi necessari comparison meaning made good ground regard estim cf incid minimum confirm figur particularli research design ensur multipl ascertain case identifi higher estim made sever sourc error respond bia gener hospit data wider popul multipl ascertain patient recognis
1059	impact grief retrospect studi famili function follow loss child cystic fibrosi impact death cystic fibrosi child subsequ famili function evalu retrospect studi 16 famili find similar report anoth model fatal childhood ill leukemia high incid emot medic problem parent unexpectedli high incid 716 incomplet mourn ie mainten child room shrine weekli grave visit six month sibl less difficulti adjust loss report sibl leukem children suggest prolong cours diseas hopeless prognosi prepar famili child death also retard mourn process famili may need counsel ensur mourn complet
1060	synthesi hemoglobin aic relat minor hemoglobin erythrocyt vitro studi regul factor influenc hemoglobin hbaic synthesi intact erythrocyt studi vitro incub cell lyse hemoglobin separ isoelectr focus polyacrylamid slab gel quantit microdensitometri hbaic increas time glucos concentr 5500 mm incub temperatur 4 degrees37 degre c low temperatur allow prolong incub minim hemolysi 4 degre c hbaic increas linearli time 6 wk incub highest glucos concentr hbaic compris 50 total hemoglobin insulin 1 01 muml affect hbaic synthesi vitro addit glucos galactos mannos fructos serv precursor hbaic good substrat hexokinas 2deoxyglucos poor hexokinas substrat 3omethylglucos better precursor hbaic synthesi glucos suggest enzymat phosphoryl glucos requir hbaic synthesi autoradiographi erythrocyt incub 32pphosphat show incorpor radioact hbaia1 hbaia2 hbaib aic acetyl hba gener incub acetylsalicyl migrat anod hbaic clearli separ erythrocyt patient insulinopen diabet mellitu synthes hbaic rate control incub ident glucos concentr likewis rate hbaic synthesi erythrocyt patient cystic fibrosi congenit spherocytosi parallel control erythrocyt cord blood hbc sickl cell anemia patient incub elev concentr glucos fetal hb hbc sickl hb decreas wherea hemoglobin focus isoelectr point near expect correspond glycosyl deriv appear proportion increas amount
1061	serotyp antibiot suscept pseudomona aeruginosa isol singl sputa cystic fibrosi patient phenotyp character pseudomona aeruginosa singl sputum sampl 21 typic cystic fibrosi patient indic high frequenc heterogen among isol basi differ antibiot resist coloni morpholog pigment serotyp two isol differ stabl suscept carnecillin gentamycin streptomycin tetracyclin chloramphenicol sulfamethoxazol plu trimethoprim detect 38 sputa differ gener independ mucoid state strain antigen group determin difco type set show two serolog distinct strain present 1021 sputum specimen nonmucoid deriv mucoid isol almost alway retain antibiot suscept serotyp parent strain data suggest cystic fibrosi patient may cocolonizedcoinfect differ strain p aeruginosa frequent gener believ altern phenotyp distinct strain singl patient might aris phenotyp dissoci singl infect strain frequenc multipl phenotyp distinct p aeruginosa isol obtain cystic fibrosi patient import select multipl isol sputum cultur antimicrobi suscept test assess adequ suscept organ antibiot therapi cystic fibrosi recommend sever coloni distinguish coloni type p aeruginosa pool antibiogram
1062	dietari problem associ care chronic sick children dietari problem associ care chronic sick children consid two broad head first problem children diet essenti part treatment chronic disord second nutrit complic may occur children chronic diseas diet specif role treatment thu often neglect consid later stage manag mani problem cours common situat paper review briefli difficulti illustr specif exampl attempt made describ discuss treatment particular disord
1063	inborn error metabol need sugar inborn error metabol condit bodi fail metabolis certain chemic due inherit enzym defici inborn error metabol consid paper affect metabol dietari nutrient requir manipul carbohydr intak case need sugar either sourc energi energysuppli nutrient suppress control hypoglycaemia vital import inborn error protein metabol includ phenylketonuria maplesyrup urin diseas organ acidaemia hyperammonaemia inborn error fat metabol includ abetalipoprotinaemia type lipoproteinlipas defici lymphangiectasia inborn error carbohydr metabol includ diabet galactosaemia fructosaemia glucose6phosph defici type glycogen storag diseas inborn error multipl nutrient includ cystic fibrosi dietari carbohydr psycholog consider dental cari examin
1064	therapeut possibl pseudomona infect acut pseudomona infect requir treatment antibiot produc bactericid effect use gentamicin tobramycin sisomicin polymyxin b resist strain amikacin indic addit carbenicillin ticarcillin carfenicillin azocillin never given alon combin prepar drug chloramphenicol tetracyclin streptomycin though effect vitro avoid chemotherapi may complement passiv immun either hyperimmun specif gama globulin hyperimmun plasma programmat item combin treatment activ immun especi toxoid vaccin chronic process perhap except urinari infect suitabl antibiot therapi reason effect polyval vaccin develop appropri strain certain infect caus mucou strain frequent encount cystic fibrosi vaccin prepar strain sinc distinct function antigen characterist
1065	multipl isol pseudomona aeruginosa differ antimicrobi suscept pattern patient cystic fibrosi clinic isol pseudomona aeruginosa patient cystic fibrosi studi effort determin uniqu characterist infect strain elucid pattern colon 413 patient studi 81 chronic infect p aeruginosa patient p aeruginosa never occasion isol better clinic condit chronic infect patient isol classifi six morpholog varieti classic rough mucoid gelatin dwarf enterobact patient two varieti multipl varieti individu serotyp often differ antibiot suscept determin disk minim inhibitori concentr method differ appar mucoid strain compar nonmucoid strain nonmucoid strain compar one anoth studi antibiot suscept perform morpholog differ type p aeruginosa obtain patient cystic fibrosi
1066	summari workshop infect patient cystic fibrosi cystic fibrosi current common fatal hereditari diseas caucasian race lack effect oral antibiot pseudomona aeruginosa preclud either system treatment suppress outpati set chronic pseudomona bronchiti typic seen cf patient central role infect particularli pseudomona infect sequenc event lead respiratori failur death cf current avail inform regard pathogenesi infect caus p aeruginosa emphas discuss workshop infect patient cf sponsor nation institut allergi infecti diseas bethesda md januari 9 10 1979 ct 1 cassino rjj pediatr re 14 1212 980 2 fick rb j immunol meth 38 103 980 3 bannatyn rm antimicrob agent chemoth 20 493 981 4 mark mi j pediatr 98 173 981 5 oboyl cp ir j med sci 150 286 981 6 hoibi n acta paediatr scand suppl 301 1982 75 982 7 schofield dh drug intel clin pharm 18 153 984 8 suter j infect di 149 523 984 9 jewett cv j pediatr 106 669 985 10 suter j infect di 153 902 986
1067	sulfhydrylmedi depress ciliari activ advers effect acetylcystein although nacetyllcystein mucomyst effect mycolyt numer investig fail demonstr consist improv pulmonari mechan follow use order determin whether benefici mucolyt activ might counterbalanc deleteri direct effect cilia studi effect activ ciliat epithelium ferret tracheal organ cultur system nacetyllcystein consist caus progress timedepend ciliostasi concentr clinic employ complet ciliari paralysi within 8 hr effect partial revers remov drug control prepar retain full ciliari activ 3 12 week order determin activ site nacetyl cystein molecul investig ciliostat effect five chemic analog isomolar nacetyllalanin ciliostat indic necess sulfhydryl group activ ciliostasi independ isomer structur acetyl chain length evidenc similar ciliostat effect lcystein dcystein 2mercaptoethylamin nacetyllhomocystein conclud nacetyllcystein induc partial revers ciliostasi tracheal epithelium via sulfhydryl group prolong use drug may impair mucociliari clearanc
1068	adult cystic fibrosi new therapeut challeng primari care physician articl examin reason prolong surviv individu cystic fibrosi well discuss pathogenesi diagnosi treatment multisystem diseas reason improv prognosi cf multipl improv antibiot therapi earli diagnosi special care center aggress treatment regimen present primari care physician new challeng patient popul requir coordin effort health care team includ specialist nurs therapist etc achiev effect therapi truli multisystem diseas
1069	cystic fibrosi northern ireland retrospect studi cystic fibrosi northern ireland 1961 1971 incid 1 1857 livebirth compar figur great britain republ ireland
1070	cutan necrot venul patient cystic fibrosi palpabl purpura note occur late cours patient cystic fibrosi skin biopsi specimen show necrot venul character perivenular infiltr compos neutrophil leukocyt fibrin hypogranul mast cell endotheli cell necrosi circul immun complex detect recurr pulmonari infect chronic administr therapeut agent provid sourc potenti antigen
1071	hla determin famili one member cystic fibrosi letter attempt identifi carrier state cystic fibrosi cf make prenat diagnosi cf unsuccess one approach problem look associ known genet marker locu cf gener studi look frequenc hla type patient cf fail demonstr strong associ attempt look linkag hla haplotyp cf famili one affect member segreg hla affect sibpair vari littl expect although sampl size small unlik close linkag exist hla loci cf locu
1072	episod arthriti children cystic fibrosi five children 2 10 year age cystic fibrosi develop transient episod arthriti although polyarticular distribut one joint might involv attack laboratori radiolog evid juvenil chronic arthriti present perman joint limit note
1073	failur thrive anemia anasarca 5monthold white girl admit infant intens care unit jackson memori hospit accord mother babi usual state health one week admiss began spit feed lower extrem becam puffi vomit increas frequenc occur everi meal eventu babi refus feed diarrhea ultim famili physician consult recommend admit hospit fourth day develop renal failur anuria rise creatinin concentr despit adequ fluid intak periton dialysi begun howev soon becam hypotherm develop pulmonari edema die hour later discuss case present
1074	bronchial hyperreact cystic fibrosi letter mitchel cowork conclud bronchial hyperreact common cystic fibrosi cf differ asthma data interest agre conclus one interpret data suggest common revers compon patient group perhap common denomin mechan certain problem baselin measur withhold medic seem conclus mitchel et al may well support felt justifi studi patient low baselin fev forc expiratori volum one second sinc subject bronchial respons methacholin remain stabl even moder fluctuat initi specif airway conduct sever diseas feel withhold drug longer period would affect comparison although might common underli mechan bronchial hyperreact asthma cystic fibrosi data show number differ two group patient although differ would exclud common mechan bronchial hyperreact two diseas exist differ lead caution conclud common underli mechan bronchial hyperreact two diseas
1075	peror test pancreat insuffici 4nacetylltyrosylaminobenzo acid children cystic fibrosi report examin stimul pancreat secret use 4nacetylltyrosylaminobenzo acid children cystic fibrosi control urinari excret 4aminobenzo acid amount 548 117 196 lower limit normal six hour 747 108 405 eight hour children cystic fibrosi mean valu 56 sixhour test 137 eighthour test valu significantli differ comparison control may assum 4nacetylltyrosylaminobenzo acid 4nbenzoylltyrosylaminobenzo acid suitabl indirect determin exocrin pancreat secret children
1076	effect cimetidin maldigest cystic fibrosi ten patient 6 27 year age sever pancreat exocrin insuffici due cystic fibrosi studi determin whether cimetidin would improv dietari fat nitrogen absorpt constant diet consum oral pancreat enzym administ addit cimetidin 150 200 mg taken oral onehalf hour meal signficantli reduc fecal fat excret 253 29 173 21 gm24 hour fecal nitrogen excret 45 06 34 05 gm24 hour p less 005 lower dose cimetidin result less signific reduct steatorrhea azotorrhea cimetidin may use adjunct oral pancreat enzym therapi patient cystic fibrosi continu steatorrhea azotorrhea enzym therapi alon
1077	normal neutrophil monocyt chemotaxi patient cystic fibrosi promin role infect clinic cours cystic fibrosi led consider investig possibl immun defici patient leukotaxi circul phagocyt cell abil gener chemotact factor import host defens bacteri invas properti investig patient clinic stabl cystic fibrosi determin possess dysfunct inflammatori respons would predispos sever infect
1078	bronchial arteri embol cystic fibrosi techniqu longterm result sever bronchial hemorrhag 13 patient cystic fibrosi treat cathet embol bronchial arteri indic either excess bleed persist sever day bleed seriou enough interfer pulmonari drainag recur week month followup rang one 30 month cessat major bleed achiev 12 13 patient 93 although 5 13 patient 40 recurr minor hemoptysi neurolog major complic encount howev potenti risk approach present limit patient lifethreaten bleed carri experienc angiograph
1079	reliabl sweat test cystic fibrosi letter report huff huang arey call attent heterogen cystic fibrosi fact properli perform sweat test normal borderlin rang rule cystic fibrosi may occur approxim 1 patient classifi cystic fibrosi confirm origin impress sweat test reliabl 98 99 one must pay close attent clinic pictur famili histori especi pulmonari gastrointestin find provid ration treatment accept evid diseas document issu report fals posit sweat test canadian patient mauriac syndrom author list varieti condit report yield elev sweat electrolyt manner collect greatli influenc result patient transient abnorm sweat electrolyt sodium valu consist higher chlorid valu perhap find sodium valu excess chlorid abnorm rang suggest fals posit test
1080	25hydroxycholecalciferol level patient cystic fibrosi assess statu circul vitamin cystic fibrosi patient investig determin serum level 25hydroxycholecalciferol major patient cf pancreat insuffici level 25ohd within normal rang clinic symptom patholog sign result defici vitamin e patient cf repeatedli document contrast paradox lack vitamin defici sign observ cf patient especi puzzl sinc ricket commonli associ form steatorrhea specul ricket formerli rare report associ cf perhap voraci appetit select absorpt vitamin via lymphat without requir esterif individu spare clinic ricket
1081	reduc serum 25hydroxyvitamin concentr disord miner metabol patient cystic fibrosi vitamin miner metabol studi 21 adolesc young adult cystic fibrosi result compar 21 match control cf patient maintain standard multivitamin supplement combin pancreat enzym replac despit supplement rel control subject cf patient 36 reduct serum 25 hydroxyvitamin concentr slight signific reduct serum calcium concentr evid calcium malabsorpt secondari hyperparathyroid 14 decreas bone mass measur photon absorpt techniqu current accept mode pancreat enzym replac vitamin supplement often inadequ maintain normal miner homeostasi cf patient addit measur may requir reduc risk clinic signific osteopenia concomit prolong surviv cf
1082	serum concentr 25hydroxyvitamin 2425dihydroxyvitamin patient cystic fibrosi steatorrhea preval gastrointestin manifest cystic fibrosi although defici vitamin e k describ patient diseas vitamin defici ricket rare report major form vitamin cholecalciferol vitamin d3 produc ultraviolet irradi 7dehydrocholesterol skin ergocalciferol vitamin d2 product plant ergosterol studi vitamin statu patient cystic fibrosi measur serum concentr major circul metabolit vitamin 25hydroxyvitamin 2425dihydroxyvitamin mean serum concentr total 25ohd 25ohd3 2425oh2d 25ohd325ohd ratio patient cystic fibrosi similar valu record control subject present studi demonstr serum concentr major metabolit vitamin patient cystic fibrosi similar healthi subject
1083	atyp cystic fibrosi pancrea normal level sweat chlorid minim pancreat lesion paper present addit evid variabl independ involv sweat gland cystic fibrosi case report infant girl die age 9 year progress pulmonari diseas present case indic fatal cystic fibrosi variant thereof exist normal level sweat chlorid pulmonari diseas develop independ function abnorm sweat gland
1084	noninvas evalu ventricular function cystic fibrosi cardiac function 21 patient cystic fibrosi studi use radionuclid mmode echocardiographi patient mean age 132 year rang 4 27 wide rang clinic pulmonari function abnorm mean shwachmankulczycki score 621 decreas right ventricular eject fraction found 13 18 patient 72 addit four patient abnorm septal motion echo left ventricular eject fraction abnorm rest four patient 19 addit four patient borderlin low lvef lv preeject period eject time ratio increas significantli ie worsen lv perform deterior sk score chest radiograph score forc expiratori volum 1 second three eight patient normal lvef rest abnorm respons supin bicycl exercis lvef fell two patient unchang one thu evid lv dysfunct observ seven 21 33 patient four rest three exercis
1085	aminoglycosid clearanc patient cystic fibrosi letter util patient individu pharmacokinet profil plan monitor aminoglycosid therapi often note appear extrem rapid elimin rate gentamicin patient cystic fibrosi patient cystic fibrosi significantli greater renal total clearanc without cystic fibrosi observ could extend drug aminoglycosid normal subject renal secret would prove intrigu evid possibl primari renal defect patient
1086	placebocontrol trial cephalexin therapi ambulatori manag patient cystic fibrosi effect oral administr cephalexin evalu doubleblind placebocontrol crossov studi 17 patient mild moder pulmonari diseas due cystic fibrosi two year fourmonth period cephalexin altern fourmonth placebo period thu patient serv control subject fungal vulvovagin occur two patient cephalexin therapi 2 year studi rate colon mucoid strain pseudomona aeruginosa increas diseas sever deterior patient initi colon p aeruginosa shortterm cours sputum culturespecif antibiot improv cours patient mild moder pulmonari diseas due cystic fibrosi treatment cephalexin decreas frequenc respiratori ill respiratori ill requir antibiot hospit respiratori ill patient initi colon staphylococcu aureu andor haemophilu influenza also reduc colon organ improv weight gain 16 17 patient associ period cephalexin therapi pulmonari function test remain stabl improv 10 14 patient diseas sever improv patient colon p aeruginosa
1087	fals posit sweat test malnutrit mauriac syndrom mauriac syndrom characteris hepatomegali glycogen infiltr liver retard sexual matur short statur diabet children report first exampl mauriac syndrom patient clinic malnourish edemat transient fals posit sweat test malnourish children posit sweat test repeat sweat test malnourish state revers would elimin error diagnosi cystic fibrosi
1088	cystic fibrosi two black children sickl cell anemia sickl cell anemia cystic fibrosi frequent lethal inherit diseas black white popul respect occurr diseas individu report literatur report present two patient pose question concern possibl clinic implic simultan occurr diseas
1089	cystic fibrosi malnutrit cystic fibrosi specif diseas entiti known associ malnutrit almost half centuri import malnutrit diseas process remain unknown much inform specif nutrit defici cf supplement children cf includ extra energi fat carbohydr form linol acid absorb hydrolyz protein fatsolubl vitamin vitamin e water emuls vitamin b12 probabl b vitamin vitamin c trace miner routin measur nutrit statu particularli children growth failur made regular interv includ threeday diet record simultan 72hour stool fat determin fat malabsorpt control pancreat enzym use antacid cimetidin consid true role nutrit patient cf known appropri studi complet
1090	preatherosclerot aortic lesion cystic fibrosi patient cystic fibrosi fat malabsorpt provid experiment model evalu hypothesi lowfat intak may prevent atherosclerosi studi frequenc extent aortic precursor lesion fatti streak earli fibromusculoelast lesion late fibromusculoelast lesion found autopsi diseas well patient debilit disord appar impair fat absorpt fatti streak less common cystic fibrosi group late fibromusculoelast lesion signific differ frequenc length thick earli fibromusculoelast lesion find suggest fat may respons progress initi fibromusculoelast precursor lesion support concept earli restrict dietari fat may prevent delay otherwis modifi atherosclerosi adult
1091	pabatest diagnosi exocrin pancreat insuffici letter also found signific differ 6hour urinari paba recoveri healthi control cf patient overlap rang good correl fecal chymotrypsin activ stress use test age group studi group healthi newborn infant howev result quit differ paba recoveri smaller show greater variat overlap result cf patient occur clear test applic newborn infant perform describ manner one possibl explan physiolog limit glomerular filtrat rate newborn infant could delay paba excret
1092	brain abscess cystic fibrosi brain abscess recent consid complic cystic fibrosi three patient report fourth cite literatur patient young adult advanc pulmonari diseas bacteria involv mouth organ found sputum cultur one patient resist present previous given antibiot patient cystic fibrosi surviv adulthood risk develop brain abscess appear increas
1093	meconium ileu laparotomi without resect anastomosi enterostomi 14 yr 1965 1978 49 infant present shortli birth intestin obstruct due impact meconium three patient fibrocyst diseas eight patient cure gastrografin enema 18 patient complic includ associ atresia volvulu andor periton variou oper done includ resect either primari anastomosi enterostomi varieti forego twentythre babi simpl uncompl form meconium ileu eleven underw resect six patient die twelv patient treat laparotomi ileotomi pursestr sutur prolong irrig use acetylcystein group one succumb latter cours manag recommend patient simpl uncompl meconium ileu involv resect enterostomi primari anastomosi
1094	effect histamin metiamid cystic fibrosi factor electrophysiolog properti frog gastric mucosa proceed total activ transport cl ion across frog gastric mucosa consid net cl flux serosa mucosa h ssc shortcircuit current term express micromol cm2 hr1 net chlorid flux hogben 1955 durbin heinz 1958 may divid two fraction acid one equival acid secret electromot one account gastric electromot forc chang scc accordingli use partial index activ chlorid pump experi design investig effect histamin metiamid h2 receptor antagonist cystic fibrosi cf noncf plasma paramet use frog isol gastric mucosa scc resist mucos prepar measur mean automat scc apparatu de jesu 1977 h ion secret measur ph meter result obtain express mean chang delta plu minu se mean histamin 104 n 10 show initi increas scc 3694 plu minu 295 microa cm2 parallel small increas h output 0045 plu minu 0003 micromol cm2 hr1 initi increas scc follow drop steadyst level 2362 plu minu 223 microa cm2 also larg increas h secret 226 plu minu 022 micromol cm2 hr1 result support work rehm 1961 histamin effect first cl pump h secret metiamid 104 n 12 caus drop scc 2016 plu minu 232 microa cm2 also reduc acid secret 221 plu minu 014 micromol cm2 hr1 thu suggest effect cl pump well h secret signific differ shown p 0001 cf noncf plasma result cf plasma n 8 increas scc 1725 plu minu 294 microa cm2 h secret 238 plu minu 043 micromol cm2 hr1 noncf plasma caus slight increas scc 517 plu minu 11 microa cm2 littl effect h secret 034 plu minu 001 micromol cm2 hr1 n 8 effect cf plasma cl h mechan interest sinc cystic fibrosi abnorm increas cl na sweat patient di sant agnes darl perera 1953
1095	chronic ligat submandibular salivari duct rabbit possibl model cystic fibrosi proceed schulz 1969 show rais na concentr sweat children suffer cystic fibrosi due defect na reabsorpt duct epithelium somewhat surprisingli transepitheli potenti differ pd normal control na transport also reduc chronic ligat salivari duct rabbit submandibular gland fraser smaje 1978 pd unaffect ligat gland may use model aspect cystic fibrosi would like report similar cystic fibrosi duct ligat lead goblet cell hyperplasia also occur salivari gland cystic fibrosi lev spicer 1965 section salivari duct 6 microm thick taken 60 microm interv duct ligat 1 5 week contralater control follow fixat immers ligat result increas lumin diamet distens previous convolut epithelium signific chang epitheli surfac area number cell layer appear increas howev prolifer goblet cell mucu cell stain alcian blue ph 1 indic presenc sulphomucin mean goblet cell densiti rose 762 plu minu 473 mm2 mean plu minu se mean n 6 control 114 plu minu 496 ligat duct transepitheli na flux duct reduc 101 plu minu 079 nmole cm2 sec1 16 plu minu 084 pd remain 22 mv similar result previous report signific correl degre diminut na transport densiti goblet cell posit correl r 090 number goblet cell control contralater ligat duct
1096	sweat test letter agre sweat test frequent perform reliabl wonder clinic chemist singl respons hospit laboratori still direct pathologist profession clinic chemist addit laboratori know mani hospit clinic chemistri laboratori test perform properli furthermor pediatr committe american associ clinic chemistri work review articl journal clinic chemistri regard correct way sweat test run clearli clinic chemist lack interest
1097	sweat test cystic fibrosi letter major issu lack interest clinic chemist actual perform test neither pathologist clinic chemist likelihood actual perform test rather medic technologist technician carri actual procedur major part role educ laboratori administr ensur peopl adequ train task test meet high enough perform standard provid clinic relev answer
1098	immunoreact serum trypsin diseas pancrea immunoreact serum trypsin measur doubl antibodi radioimmunoassay normal subject patient variou diseas pancrea normal rang 115350 ngml geometr mean 212 ngml trypsin found serum total duodenopancreatectomi 75 patient cystic fibrosi patient pancrea carcinoma chronic pancreat reduc serum trypsin level 10 100 ngml measur remain 25 cystic fibrosi one third patient chronic pancreat serum trypsin increas 70017000 ngml patient acut pancreat acut phase chronic pancreat absent reduc serum trypsin reliabl indic total partial exocrin pancreat insuffici wherea consider increas serum trypsin concentr indic acut pancreat
1099	differenti patholog nasal polyp cystic fibrosi atopi nineteen nasal polyp 13 patient examin histolog nine polyp seven cystic fibrosi cf patient could posit identifi triad observ delic bare visibl basement membran surfac epithelium without submucos hyalin lack extens infiltr eosinophil giemsa stain preponder acid mucin gland cyst polyp surfac mucou blanket alcian blueperiod acid schiff stain two polyp two patient cf atopi show characterist find cf without modif eight polyp four atop patient without cf identifi revers triad chang extens thicken epitheli basement membran extens submucosa irregular hyalin membran high stromal eosinophil count mainli neutral mucin mucou gland cyst mucou blanket hyperplast mucou gland mucou cyst variabl size focal metaplasia surfac epithelium acid mucin goblet cell consid nonspecif lesion
1100	sensit trypsin assay driedblood specimen screen procedur earli detect cystic fibrosi immunoreactivetrypsin assay use small driedblood spot diamet 125 mm therefor suitabl incorpor establish neonat screen scheme blood specimen neonat cystic fibrosi trypsin level greater control subject thu confirm earlier find trypsin level normal sever older patient cystic fibrosi
1101	detect cystic fibrosi plasma hydrolas letter dr hosli mr hosli report differenti thermol plasma alphamannosidas plasma acid phosphatas allow discrimin normal peopl cystic fibrosi carrier patient repeat experi pay special attent technic detail given hosliss paper separ seri experi use larger volum plasma assay perform either without nonfluoresc paraffin oil case blood sampl process exactli outlin hosli vogt paper signific differ heat stabil plasma alphamannosidas acid phosphatas three group
1102	dri blood spot screen cystic fibrosi letter measur immunoreact trypsin irt activ dri blood spot sampl found abnorm high level infant cystic fibrosi cf agre crossley et al test deserv investig screen cf newborn low valu 94 week infant consist find children low pancreat enzym output increas irt result restrict first month life remain prove whether older cf patient residu pancreat enzym secret inde continu increas irt level irt test would also deserv investig tool use conjunct stool pancreat enzym activ smaller centr problem inaccur sweat test
1103	age depend serum angiotensinconvert enzym activ letter examin age depend serum angiotensinconvert enzym sace activ healthi control found age depend control older 20 year 20 much increas sace valu feel inappropri evalu sace activ patient 20 year old diagnost criteria determin adult dr romer colleagu report high activ sace 3 patient 10 chronic granulomat diseas cgd conclud cgd associ increas level sace unfortun romer et al studi adequ paedeatr age control group mean valu compar primarili 5 children cystic fibrosi recent studi confirm earlier observ children age 19 year definit higher mean sace valu adult cysticfibrosi patient use comparison sinc tend lower sace level compar age control opinion patient cgd accord data publish romer et al show increas sace level age
1104	methylumbelliferylguanidinobenzo reactiv proteas prenat diagnosi cystic fibrosi letter sever reason supernat fraction amniot fluid often use prenat detect inborn error metabol earli pregnanc bulk protein amniot fluid deriv matern circul obscur critic contribut fetu need prenat diagnosi 10 30 amniot fluid significantli contamin matern blood enzym question present blood 4methylumbelliferyl guanidinobenzo mugb proteas distort diagnost conclus reason examin variat mugb proteas heterogen collect amniot fluid signific differ titr individu week second trimest observ 104 secondtrimest amniot fluid pregnanc abnorm outcom also investig mean four group significantli differ normal rang similar yet opportun examin amniot fluid known case cystic fibrosi diagnosi cystic fibrosi could probabl refin coupl amnioticfluid proteas titrat isoelectr focus polyacrylamid gel
1105	screen cystic fibrosi letter cysticfibrosi children usual either sever lung diseas mild steatorrhea sever maldigest lesser pulmonari problem therefor measur serumproteas cysticfibrosi patient control see support follow hypothesi sinc lack antitrypsin associ lung damag plasmatrypsin excess antitrypsin might respons lung damag cystic fibrosi gener proteas trypsin level measur spectrophotometr use modif method erlang kojowski cohen result show signific differ proteas trypsin level cysticfibrosi patient control differ result crossley et al may explain differ measur techniqu use trypsin level measur spectrophotometr radioimmunoassay
1106	serumangiotensinconvertingenzym chronic granulomat diseas letter studi serumangiotensinconvertingenzym sace sarcoidosi granulomat disord measur sace 10 randomli chosen consecut patient chronic granulomat diseas cgd famili member 5 children cystic fibrosi sever chronic pulmonari involv sace level patient cgd differ significantli normal control famili member patient cystic fibrosi preliminari studi show cgd associ increas level sace
1107	driedblood spot screen cystic fibrosi newborn serumimmunoreactivetrypsin irt measur children cystic fibrosi cf varieti control first month life cf children rais serumirt dri bloodspot assay irt establish potenti screen test cf newborn
1108	serumimmunoreactivetrypsin concentr cystic fibrosi letter measur immunoreact trypsin irt concentr 32 patient establish cystic fibrosi 16 parent heterozygot patient cf 29 patient 91 6 parent 38 abnorm trypsin concentr found 3 29 patient abnorm irt concentr supranorm data suggest low irt concentr excel index diminish pancreat reserv cf serumirt concentr would use diagnost test fact cf patient birth invari high irt concentr fall age progress diseas alli fact heterozygot high concentr support previou suggest uncontrol hypersecret zymogen granul basic cellular defect cf
1109	methylumbelliferylguanidinobenzo reactiv proteas amniot fluid possibl marker cystic fibrosi letter previou studi laboratori demonstr signific differ extent proteas reactiv mugb 4methylumbelliferyl guanidinobenzo sensit activ site titrant mani serin proteas plasma cultiv skin fibroblast patient cystic fibrosi cf oblig heterozygot control compar observ potenti valu amniot fluid prenat detect cystic fibrosi studi extend human amniot fluid obtain amniocentesi done intrauterin detect genet fetal abnorm amnioticfluid sampl obtain woman subsequ deliv babi cf show much reduc level mugb reactiv similar rel defici observ plasma cultiv skin fibroblast patient cf observ suggest amnioticfluid proteas activ may use marker prenat detect cf
1110	plasma hydrolas cystic fibrosi letter dr hosli esther vogt report alphamannosidas acid phosphatas activ cystic fibrosi plasma assay ph 54 abnorm thermolabil 41 degre 365 degre c respect level residu activ heat inactiv clearli distinguish cf patient cf carrier normal subject repeat experi ident condit found differ three group
1111	detect cystic fibrosi homozygot heterozygot plasma letter dr hosli esther vogt base diagnosi heterozygot homozygot cystic fibrosi thermal stabil plasma extracellular fluid alphamannosidas andor phosphatas activ assay ph 54 activ alphamannosidas plasma ph composit one acid alphamannosidas ph optimum 425 intermedi alphamannosidas ph optimum 56 60 contribut activ measur ph 54 two form alphamannosidas structur genet distinct differ kinet thermost therefor total alphamannosidas activ ph 54 physicochem properti activ depend upon rel proport two type alphamannosidas sampl proport two form vari wide normal plasma especi plasma children although data hosli vogt suggest total alphamannosidas ph 54 differ significantli control cf heterozygot cf homozygot show whether proport acid intermedi alphamannosidas chang increas proport thermolabil intermedi alphamannosidas cf would manifest decreas thermost alphamannosidas ph 54 altern mutat normal stabl acid alphamannosidas lead less stabl form would also reflect decreas stabil activ ph 54 especi proport acid alphamannosidas increas cf situat also consid possibl explan observ addit one favour hosli vogt
1112	arginin esteras amniot fluid possibl marker cystic fibrosi letter follow rao nadler report decreas arginin activ blood patient cystic fibrosi tri appli find prenat diagnosi cystic fibrosi therefor interest report use 4methylumbelliferylrhoguanidinobenzo mugb assay arginin esteras activ amniot fluid result mugb similar brock haywood substanti higher walsh nedler sampl amniot fluid incub mugb assay prophearg4methylcoumarinyl7amid ppamca show less 20 activ similarli treat control sampl incub mugb activ arginin esteras toward ppamca amniot fluid cultur amniot fluid cell much greater toward cbzargamc level activ high enough warrant investig use antenat diagnosi
1113	detect cystic fibrosi homozygot heterozygot plasma evid accumul indic basic defect cystic fibrosi interfer format recognit marker hydrolyt enzym result hydrolas leak extracellular space display abnorm thermol heat inactiv plasma alphamannosidas 41 degre c plasma phosphatas 365 degre c enzym assay ph 54 possibl differenti normal peopl cystic fibrosi carrier patient
1114	differenti incorpor 3hthymidin dna cultur skin fibroblast deriv patient cystic fibrosi control tritiat thymidin 3htdr incorpor dna fibroblast deriv subject cystic fibrosi cf control studi scintil count autoradiographi 3htdr incorpor 24 hour postseed significantli less p 0005 cf strain comparison cell control percentag label fibroblast significantli differ two strain p 01 cell cycl time durat phase studi mitot select scintil count techniqu differ cell cycl time cf control fibroblast howev durat synthet phase significantli p 0005 longer cf subject
1115	anim model cystic fibrosi pulmonari clearanc staphylococcu aureu mice treat reserpin sinc demonstr chronic administr reserpin rat produc cflike alter studi lung resist bacteri infect anim treat reserpin mice balbc inbr strain inject subcutan differ dose reserpin 7 day submit infect aerosol contain staphylococcu aureu nebul chamber pair expos anim individu valu unclear bacteria ratio ubr 4 hour obtain reserpin anim show signific increas ubr valu compar control mice p 005 p 001 depend dose suggest impair lung antibacteri defens although pharmacolog dose reserpin produc catecholamin deplet conclud action upon nervou system caus cflike respons detect conclus observ ubr decreas lend support concept reserpin induc cf anim model
1116	increas resist influenza possibl sourc heterozygot advantag cystic fibrosi cystic fibrosi common lethal semileth genet diseas caucasian central european origin among inherit autosom recess trait frequenc approxim 10 time expect recurr mutat alon decreas sialic acid content observ cell surfac glycoprotein cystic fibrosi fibroblast numer solubl glycoprotein prepar cystic fibrosi homozygot sialic acid residu cell surfac glycoconjug play essenti role bind infect myxovirus paramyxovirus includ caus pandem influenza suggest increas resist virus confer similar quantit smaller alter sialoglycoconjug structur cystic fibrosi heterozygot may provid select advantag maintain high frequenc cystic fibrosi gene caucasian popul
1117	pathogenesi cystic fibrosi possibl import alter epitheli surfac topographi pathogenesi cystic fibrosi cf consid lie disturb behavior secret particularli mucin exocrin gland propos alter surfac topographi form number distribut microvilli bleb epitheli cell line duct could impair distribut lead retent mucu lead clinic phenotyp scan electronmicroscopi human epitheli suspens cultur offer opportun evalu role plasmalemma topographi cf
1118	alkalin phosphatas induct cystic fibrosi fibroblast letter lysosom acid hydrolas alkalin phosphatas cooper intracellular digest natur polym stimulu induct enzym retent kind polym insid cell stimulu longlast strong polym intracellularli retain lack digest enzym previou paper demonstr alkalin phosphatas aip induct tamm horsfal glycoprotein discrimin fibroblast cf homozygot one hand normal cf carrier hand hypothesi propos explain observ predict effici induc mixtur sinc develop use present studi first writer familiar ultramicrotechniqu carri doubl blind studi 20 fibroblast cultur french patient find demonstr reproduc aip induct method use particularli underlin import employ present ultramicrotechniqu success aip induct like amniot fluid cell behav like skin fibroblast test prove induct alkalin phosphatas provid use techniqu prenat diagnosi cystic fibrosi
1119	improv surviv patient cystic fibrosi surviv 320 patient born 1958 cystic fibrosi manag depart thorac medicin gastroenterolog royal children hospit melbourn review eighti per cent patient surviv 11 year age 64 18 year patient manag 1973 1977 91 surviv 12 year age 80 17 year age period 79 patient surviv 16 year diagnosi forti four per cent 240 patient current manag signific perman lung diseas 9 advanc diseas
1120	alkalin phosphatas induct cystic fibrosi fibroblast letter hosli publish hypothesi relat primari caus cystic fibrosi cf base observ level alkalin phosphatas alp cfderiv skin fibroblast fibroblast deriv normal individu could increas severalfold grow cell presenc urinari glycoprotein tammhorsfal protein thp howev abl show adelaid chang induct level alp activ cfderiv skin fibroblast grown presenc local prepar thp appear ident cell cultur condit use hosli thu appear condit current employ laboratori diagnost discrimin fibroblast cf homozygot normal individu
1121	shortterm effect chest physiotherapi lung function test children cystic fibrosi chest physiotherapi import part treatment program children cystic fibrosi control studi effect 27 children cystic fibrosi 20 chronic sputum produc 7 nonsputum produc studi hospit serial lung function test 3 consecut day 1st day physiotherapi perform twice 2nd day physiotherapi perform 3rd day two period physiotherapi preced inhal bronchodil rimiterol lung function test includ peak flow forc vital capac fvc forc expiratori volum 1 sec fev10 residu volum total lung capac ratio measur begin day similar interv throughout 3 day sputum volum cough frequenc note day 1 day 3 physiotherapi result signific improv peak flow sputum produc howev fvc fev10 improv physiotherapi also improv control day physiotherapi perform suggest physiotherapi may effect remov sputum central larg airway result improv peak flow littl ad effect peripher airway whose airflow improv day normal activ signific effect shown non sputum produc although trend toward improv peak flow bronchodil physiotherapi may benefici patient demonstr signific reduct airflow obstruct formal test bronchodil respons may lessen benefici effect physiotherapi without posit respons studi illustr import examin differ method chest physiotherapi find way improv sputum clearanc ct 1 gotz eur j respir di 61 122 980
1122	effect four physiotherapi schedul pulmonari function children cystic fibrosi 17 children group cystic fibrosi cf effect follow treatment schedul pulmonari function studi random order 4 consecut day 1 clap postur drainag cp 2 cp inhal aerosol 5 ml 20 nacetylcystein monaghan ultrason devic 3 2 addit 05 mg isoprenalin aerosol 4 3 ippb devic ad nebul treatment start 930 last 1 h pulmonari function measur prior 30 min treatment 900 1100 respect 8 children group b cf sever compar previou group pulmonari function measur 900 1100 without physiotherapi follow pulmonari function measur includ evalu result vc fvc fev1 tlc bodi box tlc helium dilut tlcbbtlche rvbb rvhe maxim expiratori flow 60 tlbbb 25 fvc maxim midexpiratori flow airway conduct techniqu determin care control initi valu reproduc children group b mean valu pulmonari function equal 900 1100 group none treatment schedul caus signific improv mean pulmonari function valu children howev pulmonari function improv other deterior signific find discuss
1123	relationship clinic condit chest radiograph find respiratori function test cystic fibrosi explor 44 children suffer cystic fibrosi predomin pulmonari involv follow particular cours ill 30 patient averag period 4 year impress enorm variabl pulmonari symptomatolog children question aros whether clinic impress support find thorax radiograph result lung function test blood ga measur rest exercis clinic point view possibl make classif sever pulmonari aspect diseas larg rang score valu clear distinct sever could possibl larg group patient compar interindividu comparison cumul evalu clinic score chest radiograph lung function test indispens continu followup examin allow one notic time progress lung involv degen chang
1124	new percuss aid cystic fibrosi patient paper report first part comprehens research programm aim develop mechan aid enabl patient cystic fibrosi give satisfactori physiotherapi percussor use patient parent rel portabl lightweight domiciliari trial show effect percuss could selfadminist front chest lesser extent side chest percussor found accept adolesc patient especi girl earli breast develop research work complet result system develop enabl patient treat satisfactori chest percuss five prefer posit postur drainag
1125	mechan autogen drainag studi flow volum curv 1977 demonstr effici autogen drainag two bronchorrh children need bronchographi diagnost purpos demonstr made possibl thank radiocinematograph studi bronchographi examin also show inefficaci cough object present studi analyz physiolog mechan autogen drainag children older five method simpl effici effort onset excess expir need complet autogen drainag exhaust perform long time indispens sinc progress secret slow
1126	intestin lactas defici newborn cystic fibrosisdietari consequ problem proper diet children infant cystic fibrosi continu discuss paper deal diet cf infant younger one year basic view diet close normal babi diet possibl partli ensur normal growth develop partli avoid extra work famili cf infant infant suffer cf given lactosefre diet reach age one year weight increas rapidli cf patient given tradit cf diet low fat high protein furthermor necessari give increas amount calori infant given lactosefre diet receiv addit fatsolubl vitamin
1127	ultrastructur bronchial epithelium children cystic fibrosi ultrastructur bronchial epithelium 3 children cystic fibrosi describ 2 develop squamou metaplasia mani sign patholog alter epitheli cell observ third patient sever injur pseudostratifi epithelium remnant ciliari border preserv
1128	recent research cystic fibrosi review emphas posit accomplish cystic fibrosi research puzzl recent develop promis one major unresolv question mainten lethal gene high frequenc perhap heterozygot advantag past longer oper present noth known chromosom local trait except chromosom morpholog normal autosom sex link correl blood group major hla loci one import achiev past mani year understand rel well pathogenesi clinic manifest cf yet unknown inherit basic defect metabol error cf give rise two main anomali electrolyt defect exocrin sweat gland mucou secret abnorm result tissu cultur studi often conflict dispar seem consensu fibroblast affect basic metabol error manner respond abnorm differ experiment circumst virtual investig found anomali biolog fluid cf although use differ approach method abnorm function autonom nervou system close associ exocrin gland alway attract explan gener exocrinopathi cf search genet anim model cf led interest find
1129	relev second messeng cystic fibrosi water electrolyt macromolecular secret affect cystic fibrosi regul neurotransmitt autonom nervou system stimul cell bind alphaadrenerg betaadrenerg cholinerg receptor therefor genet disturb cyclic 35adenosin monophosph camp respons could eventu explain manifold express labil biochem chang observ cf special tissu cultur character betareceptor cultur fibroblast cf patient normal control investig isoproterenol prostaglandin e1medi camp respons use defin cultur condit signific differ found two phenotyp basal camp valu except one cell line cf strain 25 180 increas camp content differ highli signific p 00025 statist signific differ respons neither attribut differ dose timerespons curv differenti camp escap cultur medium sinc cf cell synthes camp control respons isoproterenol prostaglandin e1 alter might respons observ phenomenon probabl locat proxim adenyl cyclas cell border intra extracellular space
1130	trace element malabsorpt exocrin pancreat insuffici paper present preliminari result metabol balanc studi iron zinc manganes absorpt retent children cystic fibrosi shwachman syndrom malabsorpt zinc iron manganes exocrin pancreat insuffici demonstr earli studi possibl relationship associ featur cf briefli discuss indic area research relationship establish form trace element supplement consid
1131	prostaglandin cystic fibrosi investig two aspect prostaglandin function cystic fibrosi respons platelet pge1 concentr pge2 pgealpha sweat low concentr pge1 less effect platelet agglutin cf patient heterozygot normal differ observ high pg concentr use sweat pge2 pgealpha concentr similar normal cf patient heterozygot sweat pge2 concentr proport nacl level cf control children heterozygot
1132	oper definit cystic fibrosi recent one us suggest new hypothesi concern basic defect cystic fibrosi purpos present paper review model critic discuss eventu diagnost applic extens studi collect experiment data contribut five major argument favour proposit cf may enzym recognit site mutant fibroblast cultur three genotyp separ follow way cf homozygot leaki alkalin phosphatas a1p lysosom hydrolasesa1p tammhorsfal glycoprotein thp induc cf heterozygot leaki a1p lysosom hydrolasesa1p thp induc normal control leaki a1p lysosom enzymesa1p thp induc except second doubleblind studi thp induct well leakag analysi seem statist unequivoc strongli support hypothesi concern basic defect cf
1133	alphaglucosidas cystic fibrosi studi present serum level sever acid glycosidas normal cystic fibrosi subject level alphaglucosidas found serum cf patient significantli higher normal heterozygot increas alphaglucosidas directli relat clinic graviti diseas level glycosidas studi cf patient normal rang
1134	postprandi total serum bile acid concentr cystic fibrosi recent year sever worker report singl 2hour postprandi total serum bile acid tsba concentr varieti liver diseas state sensit index derang liver function convent serum liver function test observ seem us provid challeng situat assess tsba concentr cystic fibrosi distribut result cf patient mean tsba concentr 270 micromol agematch control mean concentr 199 micromol show wider rang cf group statist analysi howev two group show signific differ mani factor affect size distribut bile acid pool cf consider factor may go way toward explain rather unspectacular tsba result
1135	cystic fibrosi gene ige igg4 decid survey geograph defin popul cystic fibrosi patient parent live avon counti england examin oblig heterozygot parent would abl assess influenc cf gene without presenc diseas increas immedi hypersensit fumigatu cf patient parent increas sensit probabl igemedi secondari effect lung damag evid cf gene produc generalis increas skin reactiv atopi serum ige serum igg4 heterozygot therefor like develop asthma
1136	bronchial reactiv children cystic fibrosi recurr chronic bronchopulmonari diseas effort standard evalu bronchial reactiv perform investig threshold dosag acetylcholineinduc bronchospasm patient variou recurr chronic bronchopulmonari diseas significantli decreas threshold valu acetylcholin thu increas bronchial reactiv could proven patient cystic fibrosi comparison healthi children caus bronchial hyperreact patient cf may due proteas deriv leucocyt purul sputum furthermor investig influenc terbutalin bronchial obstruct induc acetylcholin patient bronchial asthma cystic fibrosi group compar especi regard degre initi bronchial obstruct
1137	increas serum tsh respons trh cystic fibrosi aim present studi reassess peripher pattern thyroid function subject cystic fibrosi special refer respons thyrotropinreleas hormon trh stimul cf patient basal level serum t4 t3 tbg within normal rang mean valu cf patient control children significantli differ cf patient correl tsh respons area basal level serum t4 grade accord shwachman kulczycki found relat therapi basal condit data show complet normal pattern serum concentr t4 t3 tbg tsh subject cf absenc iodid therapi thyroid statu examin patient cf special receiv iodid therapi drug enhanc impair thyroid function
1138	factor influenc frequenc cystic fibrosi south west africa drift chanc effect small commun consanguin result south west africa high cystic fibrosi incid isol commun gener ago europ eg bad gastein congress held surround alpin peak could result gene enrich togeth increas fertil heterozygot could still respons cf seen wherev european live today
1139	effect cystic fibrosi noncyst fibrosi plasma electrophysiolog respons isol frog gastric mucosa altern method assay cystic fibrosi factor could electrophysiolog respons isol live tissu abil frog gastric mucosa secret hydrochlor acid maintain neg potenti differ well known potenti differ across secretori mucosa nutrient serosa side coupl properti transport chlorid hydrogen ion electrochem gradient could therefor serv use model investig induc chang presenc cf noncf plasma result obtain short circuit current h secret respons presenc cf whole plasma show signific increas compar control find show presenc cf plasma whole plasma fraction b mark increas activ transport cl h effect cf plasma increas net cl flux import consid elev electrolyt sweat cf patient deserv investig
1140	fatti acid supplement cystic fibrosi elliott work togeth previou work sever author report low essenti fatti acid concentr serum lipid patient cystic fibrosi stimul us make pilot studi treat older cf patient intralipid 1 year found side effect treat older cf patient intralipid 1 year hand object benefit limit today confus ie slight signific improv renal sodium excret oral sodium load found relev specul
1141	bronchial provoc test cystic fibrosi patient cystic fibrosi higher incid posit skin prick test normal may result defect antigen handl mucos surfac aim investig bronchial allergi group children cf posit skin test studi 15 children age 7 16 year mild moder respiratori diseas 1 child gave histori wheez associ chest infect studi support hypothesi clinic asthma product bronchial allergi bronchol respons bronchial provoc aspergillu suggest allergi antigen may play part pathogenesi lung diseas patient cf ct 1 davi pb sem respir med 6 261 985 2 darga pediatr pulmonol 2 82 986
1142	local immun statu cystic fibrosi focus studi concentr immunoglobulin lysozym lactoferrin antiproteolyt fraction acut phase protein bronchial secret children variou pulmonari diseas especi cystic fibrosi secretori iga decreas studi group patient chronic recurr infect respiratori tract compar group healthi children group character infect lower part respiratori tract increas lysozym level result obtain group cf children similar obtain group bronchiectasi chronic bronchiti suggest observ differ characterist chronic infect rather cf although cf well bronchiectasi massiv bacteri infect result increas concentr immunoglobulin antiproteolyt fraction acut phase protein result seen group somewhat differ differ may indic differ reactiv infect respiratori tract cf comparison patient bronchiectasi seem conceiv among children cf low siga chronic respiratori tract infect occur earlier igg respons perman exposit varieti antigen less vigor present result rais also possibl bacteri infect cf stimul defenc mechan extent bronchiectasi
1143	complement activ pulmonari inflamm cf patient studi examin whether biolog activ c3 subsequ pulmonari inflamm take place lung patient cystic fibrosi plasma complement c3 level normal eleven patient c3 split product c3c group 14 patient suffer chronic infect mucoid strain pseudomona aeruginosa 2 group 14 cf patient without p aeruginosa infect differ signific p 0002 comparison albumin ratio 13 patient c3 split product c3c remain 15 patient show signific higher ratio former group p 001 averag 41 versu 14 per cent significantli higher albumin ratio demonstr patient c3c sputum sol phase support concept complementinduc inflamm subsequ transud plasma protein patient studi thu show complementmedi inflammatori reaction may play import role pathogenesi pulmonari tissu damag patient cf even plasma c3 level normal support concept chronic p aeruginosa lung infect immun complex diseas cf patient
1144	protein iga secretori iga igg electrolyt paramet parotid gland function children cystic fibrosi studi parotid gland function children cystic fibrosi investig parotid saliva specimen 18 patient compar result control group 12 healthi children age sex furthermor children bronchial asthma chronic bronchiti examin flow rate parotid protein output without stimul nearli four group patient cf protein output stimul significantli lower increas level sodium observ stimul secret unstimul saliva well cf children found signific higher output sodium stimul parotid saliva unstimul parotid saliva igg output gland stimul found slightli reduc patient cf comparison healthi children output gland iga stimul observ strongli reduc group cf group bronchial asthma decreas output gland secretori iga stimul demonstr cf bronchial asthma comparison healthi person increas sodium concentr parotid saliva may caus similar way electrolyt abnorm sweat cf patient name decreas net reabsorpt sodium due result increas electrolyt output decreas immunoglobulin output parotid gland suppos molecular magnitud play role disturb
1145	precipit antibodi e coli b fragili p aeruginosa cf patient normal person determin mean cross immunoelectrophoresi wallwork cowork propos increas absorpt antigen take place across mucos membran gut respiratori tract possibl due transient defect product secretori iga consequ hypothesi one would expect cystic fibrosi patient produc pronounc antibodi respons intestin bacteri flora present work therefor carri investig antibodi respons cf patient normal person escherichia coli bacteroid fragili present gut larg number respiratori pathogen p aeruginosa significantli higher preval precipitin 3 bacteri speci found cf patient compar normal person preval precipitin bacteria increas significantli age regard p aeruginosa precipitin preval number significantli higher cf patient subsequ succumb compar cf patient still aliv correl antibodi respons prognosi patient found regard e coli b fragili consid hypothesi wallwork cowork concern increas absorpt antigen gut seem attract suppos increas absorpt antigen gut flora occur predominantli cf patient p aeruginosa lung infect pronounc antibodi respons p aeruginosa
1146	screen cystic fibrosi newborn 8year period programm screen cystic fibrosi conduct extens part wale screen method use base detect high level albumen greater 20 mg meconium cours investig sever differ test use high incid falseneg result 34 detect protein meconium ideal screen test satisfactori present avail newborn period rel simplic low cost absenc direct involv parent patient high yield posit case use wider scale may justifi
1147	sulphat glycoprotein pancrea sever report indic presenc abnorm high amount sulphat mucou gland patient cystic fibrosi bear fact mind suspect abnorm oversulph strongli anion glycoprotein might involv pathogenesi cf present studi carri determin whether sulphat bloodgroup substanc occur normal pancreat tissu distribut sulphat exocrin part pancrea coincid distribut bloodgroup substanc previous observ fluoresc microscopi therefor find like sulphat bloodgroup substanc associ glycoprotein molecul sinc bloodgroup substanc demonstr mani secret man sinc high amount sulphat found mucou gland cf mechan possibl mani locat may thu offer explan multiorgan involv cf
1148	evalu meconium lactas test detect cystic fibrosi newborn recent antonowicz et al propos simpl test cystic fibrosi could use verifi boehringermannheim meconium test result thu reduc falseposit incid test base detect lactas activ meconium lactas test may valu confirmatori test use bmmec test although specif studi good previous report
1149	two children cystic fibrosi myocardi fibrosi usual cardiac affect cystic fibrosi secondari progress affect lung cor pulmonal rare case babi young children show primari sever cardiac affect caus myocardi fibrosi could recent observ two case clinic case present discuss babi young children cardiac insuffici caus cardiomyopathi might first present symptom cf therefor children cardiomyopathi unknown origin cf suspect sweat test perform rapidli progress cardiac insuffici respond poorli treatment rhythm disturb typic correct earli diagnosi import earli genet counsel
1150	chemic comparison normal cystic fibrosi meconium quantit qualit analysi carbohydr split enzym meconium specimen 200 normal prematur 5 cystic fibrosi newborn analyz level sever glycosidas consider scatter activ found three group studi evid relat scatter blood groupspecif b h substanc found alphaglucosidas acid glycosidas found elev cf serum fibroblast elev cf meconium extract includ low albumin content
1151	use abus antibiot includ manag pulmonari manifest cystic fibrosi individu collect opinion express antibiot among frequent prescrib drug unit state probabl also mani countri adopt mani increas longev cystic fibrosi patient strongli relat antibiot usag never document adequ principl tri follow use antibiot cf patient outlin
1152	longterm tobramycin therapi patient cystic fibrosi advanc pulmonari diseas aim clinic studi find prolong tobramycin therapi prevent rapid deterior cystic fibrosi patient eleven cours treatment given nine patient eight markedli improv physic activ gain weight howev four patient clinic improv correl improv radiogram pseudomona erad sputum four patient therapi reappear three end therapi clinic improv neglig side effect suggest treatment exacerb pyocyaneu bronchopneumonia prolong tobramycin therapi dosag higher 5 mgkgday strict control tobramycin blood level awar side effect
1153	bioavail oral antibiot cystic fibrosi present investig design assess absorpt disposit cystic fibrosi patient two commonli use antibiot aminopenicillin epicillin cephalexin ospexin pharmacokinet paramet epicillin patient cf normal control differ number aspect differ found maxim plasma concentr could account manifold increas renal clearanc drug data support idea patient cf exhibit unusu larg rapid renal clearanc certain penicillin
1154	progress screen sinc dresden meet 1977 new develop interest special field screen cystic fibrosi ideal screen test cf avail today bm test meconium test wide use mani technic psycholog methodolog problem remain solv test endors without reserv
1155	diagnos cystic fibrosi adult letter gordeuk et al state cystic fibrosi may first diagnos adulthood feel condit grave genet prognost implic must diagnos special caution age group particular sweat test main diagnost tool use children must interpret adult light possibl agerel increas normal sweatelectrolyt concentr factor may affect assay although gener accept normal sweat sodium chlorid concentr higher adult children clear agreement upper limit normal rang adult volum sweat produc test may also substanti effect electrolyt valu diagnosi cystic fibrosi adult attempt thu made base diagnosi elev sweatelectrolyt valu clinic impress also pancreaticfunct data
1156	mitochondri calcium uptak oxygen consumpt cystic fibrosi report exocrin gland secretori anomali cystic fibrosi increas calcium ion concentr cf secret import cellular ca stimulussecret coupl led us studi cellular ca cf report data ca uptak studi mitochondri microsom fraction isol skin fibroblast subject cf age sex passag numbermatch control mitochondria cf cell accumul ca control cell also describ subsequ studi show increas mitochondri electron transport activ measur oxygen uptak whole cell cell subject cf oblig heterozygot one hypothesis mechan link alter mitochondri ca cf fibroblast major sign associ diseas data suggest electron transport system cf oblig heterozygot fibroblast activ respect control condit studi appar central role ca sever pathogenet pathway cf data report mitochondri ca capac oxygen consumpt increas cf suggest organel suitabl focu cf investig
1157	cystic fibrosi erron sweat test make diagnosi cystic fibrosi requir clinic suspicion sweat test physician today awar main clinic featur pulmonari pancreat involv suspect diagnosi earlier past year accuraci sweat test crucial factor confirm diagnosi present case illustr point main purpos paper serv remind sweat test often less accur frequent perform princip pitfal sweat test present seem use chlorid electrod appli skin without assur adequ amount sweat present
1158	cystic fibrosi diseas unknown caus author look diseas affect two everi 2000 newborn children diseas caus childhood chronic pulmonari diseas western world author tell cystic fibrosi research trust help parent affect children
1159	prone immers physic exercis therapi three children cystic fibrosi pilot studi prone immers physic exercis therapi use success physic rehabilit middleag adult moder sever chronic obstruct pulmonari diseas purpos pilot project evalu effect pipe therapi children cystic fibrosi three children cf two boy age 6 14 year one girl age 15 year voluntarili particip experiment train program patient perform individu group exercis three time week altern day 28 consecut week intens approxim 75 percent aerob capac durat exercis gradual increas 15 3 x 5 minut 60 3 x 20 minut minut rest period exercis constant two minut pipe train result increas physic work capac maxim oxygen consumpt three subject curious chang accompani train bradycardia
1160	anemia hypoproteinemia edema infant cystic fibrosi patient cystic fibrosi encount present anemia hypoproteinemia edema failur thrive blood transfus result improv symptom recur week correct diagnosi made appropri therapi institut patient show sign improv account case illustr import consid diagnosi cystic fibrosi child malnutrit
1161	pyridin scale clinic measur olfactori threshold quantit reevalu serial dilut pyridin water employ measur olfactori detect threshold patient experiment precaut describ improv precis accuraci method exist data sensit hyposm patient confirm sensit normal subject hyperosm patient believ substanti overestim earlier public routin clinic applic revis pyridin odor threshold test discuss author experi averag cystic fibrosi patient slightli hyposm case pituitari tumor accompani 100000fold hyperosmia
1162	cystic fibrosi adult autopsi studi annot catalog clinic patholog observ adult popul cf present spectrum diseas broad diagnosi usual requir demonstr abnorm multipl system tissu germ layer found involv cf correl clinic patholog observ suggest manifest essenti episod focal popul characterist abnorm recogn pathologist focal biliari cirrhosi distinct obstruct lesion male genit tract prolong staphylococc pseudomona colon respiratori secret obstruct bronchopulmonari diseas form pancreat atrophi usual present
1163	invit review techniqu scope electronprob xray analysi patholog purpos articl review briefli techniqu applic electronprob xray analysi studi interest pathologist dealt principl xray fluoresc spectrometri capabl limit energi dispers xray analysi equip specimen prepar method electronprob xray analysi discuss applic electronprob xray analysi includ miner deposit lung intranuclear bismuth inclus gold deposit tissu natur haemosiderin copper wilson diseas calcium mitochondria surgic implant foreign bodi eye wound specif v kossa method calcium cytochem local acid phosphatas chromaffin argentaffin reaction transfer antigen materi macrophag lymphocyt diagnosi cystic fibrosi electronprob xray analysi nail
1164	genet aspect pediatr lung diseas sever genet diseas describ affect lung usual least case pediatr age group four disord discuss select wither high frequenc demonstr varieti way genet factor influenc diseas cystic fibrosi one common metabol disord inherit autosom recess trait immotil cilia syndrom includ kartagen syndrom singl gene disord involv structur abnorm cilia asthma common disord children genet compon alpha1antitrypsin defici inherit protein defici commonli caus obstruct lung diseas adult occasion affect children
1165	perspect cystic fibrosi would seem earli diagnosi cystic fibrosi institut aggress treatment program widespread irrevers lung damag occur may greatli prolong surviv individu predict time diagnosi imposs number factor consid togeth enabl clinician place patient number broadli defin risk group definit characterist group would help physician assess counsel followup patient cystic fibrosi address articl heterogen cystic fibrosi sex differ present age diagnosi pulmonari function radiolog assess project futur discuss
1166	increas heparin bind cystic fibrosi reflect alter glycoprotein biosynthesi serum protein bind heparin contribut ph 557 heparin bind capac human serum glycoprotein cystic fibrosi serum found 27 higher fucos methylpentos content 27 lower sialic acid content 31 lower hexos content compar heparin precipit serum glycoprotein normal control subject hexosamin content heparinprecipit serum glycoprotein result preliminari investig indic alter carbohydr composit serum glycoprotein may affect significantli heparin bind capac
1167	chronic reserpin rat anim model cystic fibrosi acut effect isoproterenol pilocarpin upon pulmonari lavag fluid lung lavag sampl rat treat chronic fashion reserpin mean increas 133 170 120 total protein lipid carbohydr content respect compar untreat control anim valu express term bodi weight acut singl ip inject betaadrenerg agent isoproterenol 10 mg increas glycoprotein content pulmonari lavag fluid control rat approxim 1519 910 reserpin treat rat contrast pilocarpin 10 mg administ manner caus 15 increas total protein carbohydr lipid content lavag sampl control rat increas constitu lavag sampl reserpin treat rat 98 102 80 respect increas total carbohydr content lavag sampl treat anim associ chang percent distribut neutral sugar amino sugar sialic acid ratio variou sugar compon chang lavag sampl control reserpin treat rat upon stimul either pilocarpin isoproterenol increas total lipid content fround lavag sampl treat rat probabl result increas phospholipid decreas phospholipid content occur lavag sampl reserpin treat rat upon stimul opposit observ control anim chronic treatment rat reserpin thu appear induc enhanc product glycoprotein airway interfer phospholipid metabol lung addit drug treatment enhanc secretori respons pilocarpin comparison respons control anim enhanc respons hypersecret glycoprotein quantit one seem involv alter ratio distribut variou sugar compon disturb secretori function respiratori tract target organ promin involv cystic fibrosi cf togeth alter exocrin gland resembl cf patient make reserpin treat rat use model studi possibl pathogenet mechan cf experiment anim model cf develop chronic administr reserpin rat found chang protein content lung lavag sampl addit morpholog secretori alter salivari gland pancrea analysi organ composit lung lavag sampl show protein carbohydr lipid content significantli increas chronic reserpin administr respons stimul pilocarpin enhanc treat anim compar untreat control rat therefor appear chronic reserpin administr caus hypersecret glycoprotein chang lipid metabol respiratori tract rat conjunct previou find exocrin gland effect lung function make reserpin treat rat use tool studi patholog disturb seen major exocrin gland affect cf
1168	alter polyamin metabol cystic fibrosi children cystic fibrosi excret elev urinari level three polyaminesputrescin spermidin spermin heterozygot parent excret intermedi concentr polyamin level significantli differ level normal control patient cystic fibrosi administ tracer amount 14cspermidin excret 1113 radiolabel within 72 hr wherea normal control excret 6076 radiolabel within 72 hr spermin excret posit correl increas patholog assess nation institut health nih clinic score wherea urinari putrescin spermidin level neg correl increas patholog
1169	chronic reserpin rat model cystic fibrosi na transport inhibitori effect submaxillari saliva retrograd perfus assay rat parotid gland use investig effect salivari secret control reserpinetr rat na reabsorpt result demonstr submaxillari saliva treat anim caus 69 inhibit na reabsorpt accompani 28 reduct volum saliva secret 22 reduct flow rate contrast submaxillari saliva control rat caus 6 inhibit na reabsorpt 6 reduct volum 5 reduct flow rate parotid saliva reserpinetr rat also inhibit na reabsorpt extent 39 caus 38 reduct volum 33 reduct flow parotid saliva control rat inhibit na reabsorpt extent 27 caus 4 6 reduct salivari volum flow rate inhibit na reabsorpt reduct salivari volum flow rate caus submaxillari saliva reserpinetr rat either abolish significantli reduc saliva previous heat 100 degre c frozen thaw kept glass tube 4 degre c 24 hr result indic saliva reserpinetr rat compar effect assay system saliva cystic fibrosi cf patient support use anim model diseas
1170	evid specif effect serum patient cystic fibrosi sodiumdepend glucos transport rat jejunum sera patient cystic fibrosi pancrea cf normal human sera assay abil inhibit sodium depend glucos transport rat brushbord membran vesicl fresh cf age sexmatch control sera inhibitori compar physiolog salin inhibit cf serum 44 13 mean sd final serum concentr 67 67 34 10 serum 68 28 20 serum ratio inhibit cf sera compar control sera 100 078 093 67 10 20 serum concentr respect although slightli greater inhibit cf serum observ concentr 10 probabl signific differ could detect concentr 20 serum glucos transport presenc serum sensit phlorizin indic residu glucos transport proceed sodiumdepend glucos transport system find suggest cf serum specif inhibit sodiumdepend glucos transport system intravesicular space access glucos reduc presenc cf control serum fresh cf serum 14 time effect fresh control serum p less 001 presenc substanti vesicl shrink activ control serum indic activ cannot consid specif cf
1171	alter intracellular calcium fibroblast patient cystic fibrosi heterozygot import intracellular calcium ca secret transmembran ion movement led us studi ca cell patient cystic fibrosi cf lethal genet exocrinopathi skin fibroblast patient cf oblig heterozygot hz age sexmatch control c use match pair experi measur 45ca exchang efflux cell time cf cell line hz cell line exhibit increas 45ca exchang compar respect control p less 0005 magnitud differ approxim 30 reduc cell wash lanthanum chlorid exchang period differ like attribut alter capac one intracellular ca sequest organel evid explan seen 45ca efflux experi cf cell retain higher percent initi 0time 45ca c cell late efflux period p less 005 find alter ca pool size cf particularli hz cell suggest alter ca metabol relat basic gene defect cf
1172	anomal alpha 2macroglobulinproteas complex cystic fibrosi decreas uptak complex fibroblast cultur immunochem function properti control cystic fibrosi cf alpha 2macroglobulin alpha 2m compar cross immunoelectrophoresi ouchterloni doubl diffus reveal qualit differ two alpha 2m prepar trypsinesteras activ assay bapna substrat presenc excess sti gave similar ratio total activ alpha 2m alpha 2mtrypsin complex equal stabl variou experiment condit maintain constant sti noninhibit esteras activ normal cfalpha 2mtrypsin complex taken normal human fibroblast similar extent four hour period signific differ observ uptak alpha 2m untreat sera examin uptak alpha 2m cf sera alway lower pool control sera despit larg variat mix control cf serum affect normal uptak serum compon taken normal extent intracellular degrad cf alpha 2m half life 20 28 hour compar well normal half life 22 hour work need done natur interact alpha 2m proteas reason explan molecular natur abnorm behavior sought
1173	inhibitori effect cystic fibrosi serum pseudomona phagocytosi rabbit human alveolar macrophag report present experiment observ indic presenc inhibitori activ cystic fibrosi cf serum impair phagocytosi pseudomona aeruginosa rabbit well human alveolar macrophag 49 patient serum sampl studi 40 consist show greater equal 60 inhibit 3 show inhibit 6 rang 2060 inhibit pseudomona phagocytosi parallel studi phagocytosi aureu marcescen found inhibit cf serum mix cf serum normal serum could overcom inhibitori effect indic presenc inhibitori factor rather lack necessari compon inhibitori activ lost upon exposur serum glass upon freez serum upon heat 56 degre c 30 minut
1174	serum ciliotox activ mutant mice hereditari alter resembl cystic fibrosi serum ciliotox activ sca describ cystic fibrosi cf studi mutant mice hereditari alter resembl inherit diseas test develop detect sca biolog fluid mean natur vibratil system consist incub mous sperm differ cf serum dilut control condit order determin sperm translat cessat time stct sperm activ cessat time sact find studi similar obtain author employ altern system decid appli method mice serum sera obtain male femal 3 4wkold mice dba2jcri c57bl6jbgj balbc inbr strain sca investig affect homozygot sibl use control male 8 16wkold balbc mice employ sperm donor signific differ found cricri mice dba2jcri strain stct sact determin 110 serum dilut conclud mous sperm system sensit enough detect sca biolog fluid human be likewis test mous sperm allow us detect sca cricri mice turn mutat possibl anim model cf
1175	bind 125ilabel proteinas plasma protein cystic fibrosi sampl plasma serum 53 cystic fibrosi cf patient 90 rel cf patient 159 control incub porcin bovin 125itrypsin electrophores polyacrylamid gel autoradiograph individu main bind protein 125itrypsin shown alpha 2macroglobulin alpha 2m use method analysi differ electrophoret migrat 125itrypsinalpha 2m complex observ cf control individu howev trypsin bind igg observ 80 cf patient 30 mother 3 control two patient affect pancreat trypsin bind immunoglobulin call tbig specif tb1gg refer g class experiment evid indic bind trypsin igg occur fab portion molecul tb1gg must antibodi probabl induc exogen trypsin ingest daili cf patient patient affect chronic pancreat antibodi porcin pancreat elastas observ use analysi frequent tb1g
1176	serum salivari amylas cystic fibrosi letter found cystic fibrosi cf patient pancreat insuffici pi statist lower total serum amylas level normal subject valu still within normal rang although found absolut amount salivari amylas serum patient cf pi normal subject percent contribut consider higher found pancrea contribut approxim 23 total serum amylas cf patient pi valu similar 34 amount found kamaryt et al also found davidson et al cf patient without pi higher total serum amylas valu normal subject thu feel davidson et al misinterpret result previou studi fact feel davidson et al essenti confirm previou work suggest cf patient pancreat insuffici increas salivari amylas reason yet unknown experi shown inde pancreat portion first increas decreas patient cf appar normal pancreat function progress time toward pancreat insuffici howev chang serum amylas valu patient cf averag due chang pancreat contribut serum express mean highli significantli differ normal abnorm pancreat function second import point paper mean variat occur serum sampl patient cf total amylas valu within normal test rang serum salivari isoamylas normal patient cf pi higher serum salivari percent
1177	develop improv tracheal explant bioassay detect ciliari dyskinesia factor cystic fibrosi serum tracheal ring explant system use 25 cystic fibrosi cf serum display obviou ciliostasi hamster rabbit guinea pig explant measur decreas ciliari activ 24 hr incub serum differenti respons cf serum rel normal serum greatli increas use explant maintain 2472 hr minim essenti medium mem 10 hors serum select basi optim ciliari activ vigor bioassay system guinea pig tracheal explant incub 25 normal serum would produc essenti chang rel ciliari activ score 242 possibl 300 wherea cf serum result 86 decreas score 33 scan electron microscop observ indic explant display cfciliostat effect signific accumul mucou ciliat epitheli surfac biochem viabil assay dehydrogenas activ show cytonecrosi cf serumtr tissu compar standard explant 10 hors serum mem control explant 25 normal human serum
1178	laser lightscatt spectroscopi preliminari result bioassay cystic fibrosi factor effect 7 cystic fibrosi sera 4 normal sera investig 37 cultur ciliat epithelium rabbit trachea serum introduc rose cultur chamber concentr 10 volum frequenc ciliari beat monitor laser lightscatt spectroscopi result show respons cilia sera well character laser light scatter preliminari evid suggest earli increas frequenc ciliari beat follow rapid arrest ciliari activ sensit characterist respons produc cystic fibrosi serum normal serum
1179	cystic fibrosi serum effect short circuit current rat jejunum sera 100 subject test presenc cystic fibrosi cf factor util short circuit current rat jejunum bioassay compar mean percent decreas short circuit current presum normal group differ homozyg cf group p 0001 heterozyg group p 005 two cf genotyp statist differ p 0004 howev larg overlap among three group limit assay util guid factor purif well clinic use
1180	detect cystic fibrosi protein isoelectr focus serum letter sever cystic fibrosi research group independ attempt reproduc isoelectr focus work wilson et al protocol employ lkb mulitphor electrofocus apparatu wilson et al although fix stain polyacrylamid gel perform boil water bath 30 min 10 11 sera patient cf cystic fibrosi protein band directli identifi two independ observ sera nine oblig heterozygot individu cfp band note seven eight instanc observ respect sera 26 normal control individu cfp band observ two instanc result would support view cfp band inde directli identifi ct heterozygot homozygot sera without recours photograph imag enhanc frequenc occurr similar report previous
1181	cystic fibrosi protein confirm diagnost marker detect heterozygot carrier signific relat futur screen propos primari defect alpha 2macroglobulin fact alpha2macroglobulin cystic fibrosi cda made fibroblast monocyt point fact marker cf protein valu detect cf gene antenat screen cfp cfcda isoelectr focus radioimmunoassay conjunct quantit function capac a2m could distinguish fetu homozyg one heterozyg cf gene
1182	serum factor cystic fibrosi correl clinic paramet relationship activ cystic fibrosi serum ciliari dyskinesia factor detect rabbit tracheal bioassay clinic statu patient investig children 124 year old cystic fibrosi signific correl found amount serum factor activ age clinic statu assess schwachman score pulmonari function vital capac function residu capac total lung capac residu volum maximum breath capac maxim midinspiratori flow maxim midexpiratori flow blood ga level pco2 po2 activ show signific relationship serum galactosyltransferas activ children cystic fibrosi
1183	intraven linol acid supplement children cystic fibrosi ten children cf match pair infus either intralipid 10 glucos doubl blind basi everi week one year although statist significantli greater gain height weight studi year compar previou year test group group improv expect cumul data analysi show greater improv intralipid group 23 possibl 45 point compar glucos group 2 point p less 02 studi indic need better defin role nutrit pathophysiolog cf meanwhil recommend children cf plasma linol acid level measur least yearli level low appropri supplement given
1184	chest roentgenogram cystic fibrosi new score system roentgenogram score system present use evalu followup patient cystic fibrosi system shown reproduc observ correl significantli result pulmonari function test shwachmankulczycki score shortterm evalu morbid
1185	neg effect oral fatti acid supplement sweat chlorid cystic fibrosi essenti fatti acid supplement oral safflow oil 1 gmkgday 11 cystic fibrosi patient age 6 month 14 year one year produc signific chang sweat chlorid concentr meqlit sweat rate gmminm2 addit vitamin e 10 mgkgday safflow oil effect sweat chlorid concentr rate compar placebo clinic improv could detect compar control group result support previou report effect fatti acid supplement sweat electrolyt concentr cystic fibrosi
1186	hypoelectrolytemia metabol alkalosi infant cystic fibrosi record children tucson area diagnos cystic fibrosi cf age 12 month review ascertain preval metabol alkalosi major present manifest cf five eleven infant 46 cf diagnos 1 12 month age initi seen hypokalemia hypochloremia metabol alkalosi unassoci mark dehydr hyperpyrexia major pulmonari andor gastrointestin symptom two infant repeat episod metabol alkalosi one infant episod metabol alkalosi occur diagnosi cf postul chronic loss sweat electrolyt togeth mild gastrointestin respiratori ill may predispos infant cystic fibrosi sever electrolyt acidbas disturb lack shock hyperpyrexia togeth appar chronic electrolyt loss differenti metabol alkalosi heat prostrat syndrom acut complic cystic fibrosi quantit sweat test part evalu infant unexplain metabol alkalosi serum electrolyt assess regularli infant cystic fibrosi hot weather month
1187	multifoc myocardi necrosi fibrosi pancreat diseas children review 2000 autopsi children 16 case extens necrosi scar fibrosi myocardium found lesion involv mainli left ventricl spare endocardium pericardium coronari vessel necrot fibrot heart lesion found close associ variou pancreat diseas cystic fibrosi 11 case pancreat lipomatosi 2 case extens small bowel resect 3 case 2 associ acut interstiti pancreat explain unexpect associ two hypothes put forth 1 lack absorpt present undetermin substanc indispens correct trophic myocardium 2 releas blood proteolyt enzym consecut activ phlogist substanc kinin
1188	vitamin e stand propos clinician gener understand littl physiolog known tocopherol abl recogn circumst caus low tocopherol level understand provid physiolog replac therapi accept respons protect patient uncontrol experiment use tocopherol tocopherol physiolog tocopherol pharmacolog tocopherol defici therapi defici state pharmacolog dose tocopherol discuss patient prolong fat malabsorpt prematur infant receiv iron must given vitamin e use tocopherol therapi bronchopulmonari dysplasia retrolent fibroplasia promis unproven use control studi research role vitamin e human physiolog enter rapidgrowth phase
1189	metabol alkalosi infant cystic fibrosi letter diagnos six cystic fibrosi infant 1 year age four document episod hypoelectrolytemia sever metabol alkalosi addit data support previou hypothesi chronic sweat electrolyt deplet frequent previous recogn caus sever metabol derang infant cystic fibrosi especi live humid dri hot climat
1190	evalu forc expir techniqu adjunct postur drainag critic often level forc expir techniqu fet increas may even produc bronchospasm impress use forc expir combin period relax diaphragmat breath aggrav bronchospasm shorten postur drainag session two group patient studi 24 cystic fibrosi evalu use fet independ mean postur drainag 20 asthmat patient assess effect fet bronchospasm studi indic forc expir techniqu increas effici postur drainag increas airway obstruct techniqu appli medic surgic condit postur drainag modifi form postur drainag indic
1191	rapid procedur larg scale purif elastas cathepsin g human sputum procedur describ permit rapid isol larg amount elastas cathepsin g purul sputum procedur involv 1 digest sputum dnase 2 extract insolubl residu remain 1 nacl ph 8 3 affin chromatographi sepharosebound trasylol 4 separ two enzym chromatogrphi cmsephadex start 500 g sputum possibl isol 175 mg two enzym within 7 10 day activ site titrat indic enzym least 97 pure disc gel electrophoresi presenc absenc sd amino acid sequenc ntermin region support conclus elastas cathepsin g isol sputum ident enzym isol directli leukocyt human blood
1192	mitrochondri nadh dehydrogenas cystic fibrosi shown skin fibroblast patient cystic fibrosi cf carrier cf heterozygot hz consum o2 control mitochondri electron transport inhibitor rotenon ad cell rel inhibit o2 consumpt cf greater hz greater control p less 0005 comparison rotenon specif inhibit nadh dehydrogenas nadh acceptor oxidoreductas ec 16993 enzym energyconserv site 1 mitochondri electron transport system activ kinet enzym system studi fibroblast homogen nadh dehydrogenas activ equal cell three genotyp ph 80 affin enzym substrat cf greater hz control ph 86 affin cf greater hz control p less 0005 differ ph optima genotyp without except 86 cf 83 hz 80 control hz control line distinguish unequivoc blind test basi differ ph optima purifi mitochondri prepar reveal ph optima ident found whole cell homogen data suggest mutant gene respons cf express complex mitochondri nadh dehydrogenas system
1193	cystic fibrosi potenti manag manipul secretori process affect exocrin gland ten year ago demonstr chronic administr isoproterenol rat result structur function chang salivari gland similar seen exocrin gland patient cystic fibrosi recent began studi cellular pathophysiolog gland manag achiev pharmacolog control abnorm demonstr administr betaadrenerg antagonist anim result correct electrolyt abnorm similar seen sweat gland patient cystic fibrosi two exampl manipul secretori process exocrin gland experiment anim demonstr feasibl approach therapi patient cystic fibrosi
1194	chang pattern genet counsel cystic fibrosi center chang life expect cystic fibrosi patient stimul interest assess understand util genet inform adult cf patient may affect cope mechan present studi design obtain inform area expect effect genet counsel might develop enlarg group patient knowledg genet attitud concern reproduct attitud toward prenat diagnosi attitud toward carrier identif studi report 25 male 15 femal proven cystic fibrosi
1195	cystic fibrosisit surgic present seri 62 case cystic fibrosi present transvaal memori hospit children johannesburg 10year period 19681978 15 patient requir surgic treatment 17 complic diseas meconium ileu rectal prolaps intussuscept ethmoid commonest surgic present portal hypertens bronchial obstruct nasal polyposi also experienc basic defect unknown treatment today still direct toward usual unpredict secondari consequ
1196	chemotherapi chronic infect mucoid pseudomona aeruginosa lower airway patient cystic fibrosi bacteriolog effect chemotherapi pseudomona aeruginosa psae lung patient cystic fibrosi review 5year period 49 children adult treat 190 cours differ antibiot mucoid strain psae disappear 720 cours combin tobramycin carbenicillin employ tobramycin given alon bacteriolog effect 266 cours colimycin alon combin carbenicillin effect 18 patient receiv subsequ cours tobramycin combin tobramycin carbenicillin signific differ favour combin therapi found also case mani precipitin psae serum 745 initi success cours patient recolon psae within 1 month nephrotox ototox side effect demonstr spite high dose tobramycin 10 mgkg24 h emmploy repeat cours
1197	protein bronchial secret children chronic pulmonari diseas relat clinic diagnosi bronchial secret 207 children suffer variou pulmonari diseas 15 healthi control test concentr iga igg lactoferrin lysozym result obtain suggest mani case chronic lung diseas children level lactoferrin immunoglobulin especi secretori iga low sever infect cystic fibrosi bronchiectas signific increas igg concentr observ
1198	protein bronchial secret children chronic pulmonari diseas ii relat bronchoscop bronchograph examin concentr immunoglobulin lactoferrin lysozym compar bronchial secret obtain children variou chronic lung diseas igg lactoferrin lysozym secretori iga concentr shown increas chronic inflammatori respons
1199	kill fibroblast dexamethason dibutyryl adenosin 35monophosph valid test cystic fibrosi assay base count total cell colonyform cell use demonstr neither dexamethason dibutyryl adenosin 35monophosph cyclic amp kill human fibroblast varieti condit result contradict previou studi show dexamethason dibutyryl cyclic amp kill higher percentag fibroblast normal human individu cystic fibrosi
1200	prematur senesc cultur skin fibroblast subject cystic fibrosi cultur skin fibroblast subject cystic fibrosi exhibit normal popul doubl time earli passag 13 cumul popul doubl cystic fibrosi line doubl slowli control ceas doubl 19 weekli passag control line continu doubl 27 passag prematur senesc note cell subject cystic fibrosi reconcil controversi observ cell doubl report literatur data present demonstr experi cystic fibrosi cell late passag may gener mislead result sinc differ control line may ascrib gener senil chang rather specif result cystic fibrosi genotyp
1201	cystic fibrosi adolesc young adult earli diagnosi cystic fibrosi better manag patient childhood increas number surviv adult life main problem requir continu medic care older cystic fibrosi patient persist often progress chest diseas reason cystic fibrosi clinic adolesc young adult start western infirmari 1975 paper present observ 13 patient attend 1975 1977 eleven patient aliv well shown evid deterior period ten school regular employ optimum medic supervis possibl give young adult cystic fibrosi worthwhil exist
1202	implic cystic fibrosi health servic afflict psychosoci literatur cystic fibrosi cf critic review major methodolog shortcom includ anecdot natur find overemphasi neg consequ diseas lack suitabl theoret framework avenu futur research suggest
1203	cystic fibrosi diagnosi treatment prognosi review intend present brief summari import area concept cystic fibrosi relev clinic practic indic remain controversi offer opinion base relev literatur clinic experi cleveland cystic fibrosi center sweat test test pancreat function test pulmonari function genet famili histori diagnosi infertil diagnost factor role circul factor diagnosi heterozygot detect prenat diagnosi miscellan factor lead diagnosi neonat screen gener observ diagnosi cf examin philosophi treatment physic measur antimicrobi therapi aerosol therapi role hospit therapeut program drug therapi treatment cor pulmonal respiratori failur specif pulmonari complic discuss enzym replac obstruct phenomena glucos intoler treatment sweat defect psychosoci therapi prognosi also consid
1204	distal splenoren shunt decompress portal hypertens children cystic fibrosi apart sound physiolog basi distal splenoren shunt compar portacav shunt convent central splenoren shunt two import reason think use type shunt especi advantag children portal hypertens secondari cystic fibrosi firstli thick fibrot retroperiton area porta hepati portacav shunt construct avoid make distal splenoren shunt easier oper secondli notwithstand rel smallsiz vessel wide anastomosi construct high flow rate therefor minim chanc shunt thrombosi
1205	cystic fibrosi review investig mucociliari inhibitor recent found cystic fibrosi mucociliari inhibitor urin homozygot heterozygot normal recent studi attempt compar rel concentr cfmi materi homozygot heterozygot unit inhibit reflect concentr cfmi serum tissu cultur medium fraction heterozygot close onehalf fraction homozyg sourc purif cfmi gener monospecif antibodi prepar answer becom avail question whether normal counterpart cfmi whether quantit cfmi use heterozygot detect prenat diagnosi cystic fibrosi
1206	small airway diseas children test best test claim detect small airway diseas evalu children fiftytwo subject normal 30 cystic fibrosi cf 35 asthma select basi normal spirometri inform consent obtain parent test undertaken measur maximum expiratori flow volum curv breath air heliumoxygen mixtur singl breath nitrogen washout curv lung volum except normal subject measur arteri oxygen tension close volum normal children cf asthma wherea slope alveolar plateau abnorm 83 maximum expiratori flow rate 50 total lung capac reduc 65 maximum midexpiratori flow rate 57 residu volum increas 51 result test abnorm less 50 children evid suggest lung diseas patchi children mild cf interv phase asthma test detect specif patholog process small airway reflect consequ small airway abnorm may vari diseas well differ diseas one test alon appear use togeth contribut understand function abnorm present individu
1207	detect lectin blood cystic fibrosi homozygot heterozygot theoriz cystic fibrosi may diseas plasma factor lectinlik activ stimul mucu secret caus precipit mucu glycoprotein incident affect lymphocyt cultur confirm theori plan search addit lectinlik activ cf serum experi suggest lectinlik substanc cf blood requir igm redbloodcellagglutin activ thu differ agglutin titer observ cf homozygot heterozygot igm limit factor igm concentr differ appreci subject suspect cf homozygot larger pool free lectin blood heterozygot quantit free lectin pool may distinguish two phenotyp excess free lectin may account sign symptom cf wherea lesser amount may theoret advantag heterozygot
1208	defici essenti fatti acid vitamin e cystic fibrosi 25 children 13 male 12 femal cystic fibrosi age 6 month 16 year 24 match control total serum vitamin e level fatti acid pattern serum cholesterol ester phospholipid triglycerid demonstr compar control 102 024 mgdl total serum vitamin e level significantli decreas patient cystic fibrosi 030 026 mgdl p less 001 signific differ compar fatti acid pattern serum ester fraction group differ seen best cholesterol ester fraction fraction linol acid show trend decreas cystic fibrosi patient compar control group possibl influenc height veloc level essenti fatti acid discuss
